OA17636A - Benzimidazolone derivatives as bromodomain inhibitors - Google Patents
Benzimidazolone derivatives as bromodomain inhibitors Download PDFInfo
- Publication number
- OA17636A OA17636A OA1201500387 OA17636A OA 17636 A OA17636 A OA 17636A OA 1201500387 OA1201500387 OA 1201500387 OA 17636 A OA17636 A OA 17636A
- Authority
- OA
- OAPI
- Prior art keywords
- mmol
- dimethylisoxazol
- alkyl
- benzo
- heteroaryl
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 42
- 102000001805 Bromodomains Human genes 0.000 title claims abstract description 20
- 108050009021 Bromodomains Proteins 0.000 title claims abstract description 20
- 239000003112 inhibitor Substances 0.000 title abstract description 30
- 150000008641 benzimidazolones Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 196
- 102100015500 BRD4 Human genes 0.000 claims abstract description 25
- 101700009767 BRD4 Proteins 0.000 claims abstract description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 83
- 125000001072 heteroaryl group Chemical group 0.000 claims description 65
- -1 -S(0)o-2Ra Inorganic materials 0.000 claims description 63
- 125000003118 aryl group Chemical group 0.000 claims description 56
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 48
- 229910003813 NRa Inorganic materials 0.000 claims description 42
- 229910003827 NRaRb Inorganic materials 0.000 claims description 42
- 201000010099 disease Diseases 0.000 claims description 40
- 229910052736 halogen Inorganic materials 0.000 claims description 39
- 125000000623 heterocyclic group Chemical group 0.000 claims description 39
- 150000002367 halogens Chemical class 0.000 claims description 38
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 32
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 30
- 229910004664 ORa Inorganic materials 0.000 claims description 28
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000001624 naphthyl group Chemical group 0.000 claims description 15
- 229910004755 ORb Inorganic materials 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000004043 oxo group Chemical group O=* 0.000 claims description 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 125000000172 C5-C10 aryl group Chemical group 0.000 claims description 9
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000001118 alkylidene group Chemical group 0.000 claims description 7
- 125000004429 atoms Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 210000002784 Stomach Anatomy 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 201000009251 multiple myeloma Diseases 0.000 claims description 3
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims description 2
- 210000004556 Brain Anatomy 0.000 claims description 2
- 210000000481 Breast Anatomy 0.000 claims description 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims description 2
- 210000003169 Central Nervous System Anatomy 0.000 claims description 2
- 210000003679 Cervix Uteri Anatomy 0.000 claims description 2
- 210000001072 Colon Anatomy 0.000 claims description 2
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 210000003734 Kidney Anatomy 0.000 claims description 2
- 210000004185 Liver Anatomy 0.000 claims description 2
- 210000004072 Lung Anatomy 0.000 claims description 2
- 210000001672 Ovary Anatomy 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 210000002307 Prostate Anatomy 0.000 claims description 2
- 210000000664 Rectum Anatomy 0.000 claims description 2
- 210000003491 Skin Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 124
- 230000000694 effects Effects 0.000 abstract description 5
- 230000000051 modifying Effects 0.000 abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 333
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 186
- 238000006243 chemical reaction Methods 0.000 description 185
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 172
- 235000019439 ethyl acetate Nutrition 0.000 description 139
- 239000011541 reaction mixture Substances 0.000 description 117
- 239000000243 solution Substances 0.000 description 91
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 72
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 72
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 68
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 67
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 63
- 239000012267 brine Substances 0.000 description 61
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 60
- 238000004007 reversed phase HPLC Methods 0.000 description 57
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 56
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 53
- 239000012044 organic layer Substances 0.000 description 53
- 238000000746 purification Methods 0.000 description 53
- 239000002904 solvent Substances 0.000 description 53
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 description 50
- 229910052938 sodium sulfate Inorganic materials 0.000 description 48
- 230000002829 reduced Effects 0.000 description 45
- 239000007787 solid Substances 0.000 description 45
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 44
- 239000008079 hexane Substances 0.000 description 44
- 238000003756 stirring Methods 0.000 description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
- 238000004128 high performance liquid chromatography Methods 0.000 description 38
- 239000000047 product Substances 0.000 description 38
- 238000010898 silica gel chromatography Methods 0.000 description 35
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 34
- 239000012043 crude product Substances 0.000 description 32
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
- 235000011152 sodium sulphate Nutrition 0.000 description 30
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 238000004166 bioassay Methods 0.000 description 26
- 238000003818 flash chromatography Methods 0.000 description 25
- 239000000543 intermediate Substances 0.000 description 25
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 25
- 239000000463 material Substances 0.000 description 25
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 25
- 239000000843 powder Substances 0.000 description 25
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- 239000003054 catalyst Substances 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 238000004293 19F NMR spectroscopy Methods 0.000 description 23
- 239000007832 Na2SO4 Substances 0.000 description 23
- 125000004432 carbon atoms Chemical group C* 0.000 description 23
- 210000004027 cells Anatomy 0.000 description 23
- 238000000034 method Methods 0.000 description 23
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
- 239000003960 organic solvent Substances 0.000 description 21
- 230000027455 binding Effects 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 18
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 17
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 17
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 16
- YNMUSSIWYDKWBG-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(=O)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(=O)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C YNMUSSIWYDKWBG-UHFFFAOYSA-N 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 12
- 229960004132 diethyl ether Drugs 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 102100015262 MYC Human genes 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 238000007792 addition Methods 0.000 description 11
- 238000010511 deprotection reaction Methods 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- VRLSARGDMZKGFM-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-(6-methylquinolin-5-yl)-1,3-dihydrobenzimidazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2C)=C(NC(=O)N2)C2=C1 VRLSARGDMZKGFM-UHFFFAOYSA-N 0.000 description 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 10
- NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 10
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 10
- 238000002953 preparative HPLC Methods 0.000 description 10
- 239000011877 solvent mixture Substances 0.000 description 10
- ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 1,2-dimethoxyethane;hydrate Chemical compound O.COCCOC ZWNCJCPLPUBNCZ-UHFFFAOYSA-N 0.000 description 9
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 8
- UTICYFGULAXWJU-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(I)=C(N)C([N+]([O-])=O)=C1 Chemical compound CC1=NOC(C)=C1C1=CC(I)=C(N)C([N+]([O-])=O)=C1 UTICYFGULAXWJU-UHFFFAOYSA-N 0.000 description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 125000005842 heteroatoms Chemical group 0.000 description 8
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 8
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 229960001866 silicon dioxide Drugs 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- CVLHETBAROWASE-UHFFFAOYSA-N 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-oxazole Chemical compound CC1=NOC(C)=C1B1OC(C)(C)C(C)(C)O1 CVLHETBAROWASE-UHFFFAOYSA-N 0.000 description 7
- GMXSJDCLHSOVEP-UHFFFAOYSA-N 5-(3,5-dimethyl-1,2-oxazol-4-yl)-7-(6-methylquinolin-5-yl)-3H-1,3-benzoxazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2C)=C(OC(=O)N2)C2=C1 GMXSJDCLHSOVEP-UHFFFAOYSA-N 0.000 description 7
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 7
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 7
- 102000004965 antibodies Human genes 0.000 description 7
- 108090001123 antibodies Proteins 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 7
- 230000001131 transforming Effects 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 6
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 6
- JBASLVFAGSTZOD-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(I)=C(N(C)C(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(I)=C(N(C)C(=O)N2)C2=C1 JBASLVFAGSTZOD-UHFFFAOYSA-N 0.000 description 6
- HBJKQTGDJCBOPF-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(I)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(I)=C(NC(=O)N2)C2=C1 HBJKQTGDJCBOPF-UHFFFAOYSA-N 0.000 description 6
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 235000011150 stannous chloride Nutrition 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- 108091005573 Bromo- and Extra-Terminal domain (BET) family Proteins 0.000 description 5
- FRSICXAEAHREAL-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC=C(N)C([N+]([O-])=O)=C1 Chemical compound CC1=NOC(C)=C1C1=CC=C(N)C([N+]([O-])=O)=C1 FRSICXAEAHREAL-UHFFFAOYSA-N 0.000 description 5
- 102100016347 H4-16 Human genes 0.000 description 5
- 101710017531 H4C15 Proteins 0.000 description 5
- 101710007269 H4C7 Proteins 0.000 description 5
- 101700032126 H4Y Proteins 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 101710007262 HHF2 Proteins 0.000 description 5
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 5
- SQGYOTSLMSWVJD-UHFFFAOYSA-N Silver nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 125000001979 organolithium group Chemical group 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 5
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Chemical compound CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 4
- UODINHBLNPPDPD-UHFFFAOYSA-N 2-bromo-5-fluoropyridine Chemical compound FC1=CC=C(Br)N=C1 UODINHBLNPPDPD-UHFFFAOYSA-N 0.000 description 4
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- YRDKTZNIAALYFS-UHFFFAOYSA-N N=1C(OCC)=CC(C(=O)C=2N(C3=CC=CC=C3N=2)C(=O)OC(C)(C)C)=CC=1C=1C(C)=NOC=1C Chemical compound N=1C(OCC)=CC(C(=O)C=2N(C3=CC=CC=C3N=2)C(=O)OC(C)(C)C)=CC=1C=1C(C)=NOC=1C YRDKTZNIAALYFS-UHFFFAOYSA-N 0.000 description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 238000006069 Suzuki reaction reaction Methods 0.000 description 4
- AXZWODMDQAVCJE-UHFFFAOYSA-L Tin(II) chloride Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- OKRROXQXGNEUSS-UHFFFAOYSA-M imidazole-1-carboxylate Chemical compound [O-]C(=O)N1C=CN=C1 OKRROXQXGNEUSS-UHFFFAOYSA-M 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CNTWHKAWJCAEIJ-UHFFFAOYSA-N (6-methylquinolin-5-yl)boronic acid Chemical compound N1=CC=CC2=C(B(O)O)C(C)=CC=C21 CNTWHKAWJCAEIJ-UHFFFAOYSA-N 0.000 description 3
- AOEFTUSVNBYYEB-UHFFFAOYSA-L 3-chloro-2H-pyridin-2-ide;dichloropalladium Chemical compound Cl[Pd]Cl.ClC1=CC=CN=[C-]1 AOEFTUSVNBYYEB-UHFFFAOYSA-L 0.000 description 3
- WNECQYUVCXQNBR-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-[hydroxy-(6-methylpyridin-2-yl)-pyridin-2-ylmethyl]-1,3-dihydrobenzimidazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=C(C)C=CC=2)=C(NC(=O)N2)C2=C1 WNECQYUVCXQNBR-UHFFFAOYSA-N 0.000 description 3
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- CEVPFDIRLBBGJV-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=CC2=C(C=O)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=CC2=C(C=O)C=C1C=1C(C)=NOC=1C CEVPFDIRLBBGJV-UHFFFAOYSA-N 0.000 description 3
- JNDHGJZADJICHL-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(=O)C=2C=CC=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(=O)C=2C=CC=CC=2)C=C1C=1C(C)=NOC=1C JNDHGJZADJICHL-UHFFFAOYSA-N 0.000 description 3
- GBUBJSKYYVJPGW-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(O)C=2N=CC(F)=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(O)C=2N=CC(F)=CC=2)C=C1C=1C(C)=NOC=1C GBUBJSKYYVJPGW-UHFFFAOYSA-N 0.000 description 3
- MUYLAUXSHDSQKZ-UHFFFAOYSA-N C1CC1C1=NOC(C2CC2)=C1 Chemical compound C1CC1C1=NOC(C2CC2)=C1 MUYLAUXSHDSQKZ-UHFFFAOYSA-N 0.000 description 3
- SUIKLEVHUWXQMT-UHFFFAOYSA-N C=1C=2NC(=O)NC=2C(C(=O)OC)=CC=1C=1C(C)=NOC=1C Chemical compound C=1C=2NC(=O)NC=2C(C(=O)OC)=CC=1C=1C(C)=NOC=1C SUIKLEVHUWXQMT-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 101700013321 LOXL2 Proteins 0.000 description 3
- 102100015591 LOXL2 Human genes 0.000 description 3
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Substances BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 3
- BHAZBDKBTKDRNG-UHFFFAOYSA-N N1=CC=CC2=C(Br)C(C)=CC(Cl)=C21 Chemical compound N1=CC=CC2=C(Br)C(C)=CC(Cl)=C21 BHAZBDKBTKDRNG-UHFFFAOYSA-N 0.000 description 3
- PYVDXLKXDIWVLZ-UHFFFAOYSA-N N1=CC=CC2=C(Br)C(C)=CC(F)=C21 Chemical compound N1=CC=CC2=C(Br)C(C)=CC(F)=C21 PYVDXLKXDIWVLZ-UHFFFAOYSA-N 0.000 description 3
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 201000001320 atherosclerosis Diseases 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- 230000001973 epigenetic Effects 0.000 description 3
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 3
- RGVZMPONLYFINH-UHFFFAOYSA-N nitronium;tetrafluoroborate Chemical compound O=[N+]=O.F[B-](F)(F)F RGVZMPONLYFINH-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrugs Drugs 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- WJVGSDPTLNDYHR-UHFFFAOYSA-N (2,4-dimethylpyrazol-3-yl)boronic acid Chemical compound CC=1C=NN(C)C=1B(O)O WJVGSDPTLNDYHR-UHFFFAOYSA-N 0.000 description 2
- RIZYBSMDFJDHOI-UHFFFAOYSA-N (2-methylnaphthalen-1-yl)boronic acid Chemical compound C1=CC=CC2=C(B(O)O)C(C)=CC=C21 RIZYBSMDFJDHOI-UHFFFAOYSA-N 0.000 description 2
- BHMAGGNQKVLKSV-UHFFFAOYSA-N (2-phenylpyridin-3-yl)boronic acid Chemical compound OB(O)C1=CC=CN=C1C1=CC=CC=C1 BHMAGGNQKVLKSV-UHFFFAOYSA-N 0.000 description 2
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 2
- HRVRAYIYXRVAPR-UHFFFAOYSA-N 1,3,4,5-tetrahydro-1-benzazepin-2-one Chemical compound N1C(=O)CCCC2=CC=CC=C21 HRVRAYIYXRVAPR-UHFFFAOYSA-N 0.000 description 2
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 2
- ZBNZAJFNDPPMDT-UHFFFAOYSA-N 1H-imidazole-5-carboxamide Chemical compound NC(=O)C1=CNC=N1 ZBNZAJFNDPPMDT-UHFFFAOYSA-N 0.000 description 2
- ZNOVTXRBGFNYRX-UHFFFAOYSA-N 2-[[4-[(2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-UHFFFAOYSA-N 0.000 description 2
- GSKMWMFOQQBVMI-UHFFFAOYSA-N 2-bromo-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Br)N=C1 GSKMWMFOQQBVMI-UHFFFAOYSA-N 0.000 description 2
- BZUUVQCSPHPUQA-UHFFFAOYSA-N 2-bromo-5-chloropyridine Chemical compound ClC1=CC=C(Br)N=C1 BZUUVQCSPHPUQA-UHFFFAOYSA-N 0.000 description 2
- CZZGLPOYHNAIBA-UHFFFAOYSA-N 2-bromo-7-fluoroquinoline Chemical compound C1=CC(Br)=NC2=CC(F)=CC=C21 CZZGLPOYHNAIBA-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- IPSHOAWCCYABTN-UHFFFAOYSA-N 3-bromo-2-(4-fluorophenyl)pyridine Chemical compound C1=CC(F)=CC=C1C1=NC=CC=C1Br IPSHOAWCCYABTN-UHFFFAOYSA-N 0.000 description 2
- HMGDWEMULHSXRY-UHFFFAOYSA-N 4-[bis(5-fluoropyridin-2-yl)-hydroxymethyl]-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1,3-dihydrobenzimidazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC(F)=CC=2)C=2N=CC(F)=CC=2)=C(NC(=O)N2)C2=C1 HMGDWEMULHSXRY-UHFFFAOYSA-N 0.000 description 2
- LTSBWJRAUCGPKD-UHFFFAOYSA-N 4-bromo-2-chloro-N-(2,2,2-trifluoroethyl)aniline Chemical compound FC(F)(F)CNC1=CC=C(Br)C=C1Cl LTSBWJRAUCGPKD-UHFFFAOYSA-N 0.000 description 2
- ZCWBZRBJSPWUPG-UHFFFAOYSA-N 4-bromo-2-nitroaniline Chemical compound NC1=CC=C(Br)C=C1[N+]([O-])=O ZCWBZRBJSPWUPG-UHFFFAOYSA-N 0.000 description 2
- NBROUSPITUKLCY-UHFFFAOYSA-N 5-bromo-6-methyl-1H-quinolin-2-one Chemical compound N1C(=O)C=CC2=C(Br)C(C)=CC=C21 NBROUSPITUKLCY-UHFFFAOYSA-N 0.000 description 2
- 108010085273 Adenosine A2B receptor Proteins 0.000 description 2
- 102000007470 Adenosine A2B receptor Human genes 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 102100014217 BRDT Human genes 0.000 description 2
- 101700074072 BRDT Proteins 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N Benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- SORYEWGTSZGERP-UHFFFAOYSA-N BrC1=C(C2CC2)N(C)N=C1C1CC1 Chemical compound BrC1=C(C2CC2)N(C)N=C1C1CC1 SORYEWGTSZGERP-UHFFFAOYSA-N 0.000 description 2
- DHKJYHWXVQQSQV-UHFFFAOYSA-N BrC=1C(C2CC2)=NOC=1C1CC1 Chemical compound BrC=1C(C2CC2)=NOC=1C1CC1 DHKJYHWXVQQSQV-UHFFFAOYSA-N 0.000 description 2
- CVZWNZJSZZABHT-UHFFFAOYSA-N C1=C(C(=O)OC)C(NC)=C(N)C=C1C1=C(C)ON=C1C Chemical compound C1=C(C(=O)OC)C(NC)=C(N)C=C1C1=C(C)ON=C1C CVZWNZJSZZABHT-UHFFFAOYSA-N 0.000 description 2
- VQIGXSFVOHRHGQ-UHFFFAOYSA-N C1=C(N)C(C(=O)OC)=CC(C2=C(ON=C2C)C)=C1F Chemical compound C1=C(N)C(C(=O)OC)=CC(C2=C(ON=C2C)C)=C1F VQIGXSFVOHRHGQ-UHFFFAOYSA-N 0.000 description 2
- FSZCJNGCVKSQRJ-UHFFFAOYSA-N C1=C([N+]([O-])=O)C(N(C(=O)C(F)(F)F)CC)=C(I)C=C1C1=C(C)ON=C1C Chemical compound C1=C([N+]([O-])=O)C(N(C(=O)C(F)(F)F)CC)=C(I)C=C1C1=C(C)ON=C1C FSZCJNGCVKSQRJ-UHFFFAOYSA-N 0.000 description 2
- HCSLRGRUOOHCCW-UHFFFAOYSA-N C1=C([N+]([O-])=O)C(NC)=C(C(=O)OC)C=C1C1=C(C)ON=C1C Chemical compound C1=C([N+]([O-])=O)C(NC)=C(C(=O)OC)C=C1C1=C(C)ON=C1C HCSLRGRUOOHCCW-UHFFFAOYSA-N 0.000 description 2
- KKZVVQIJRJOMHV-UHFFFAOYSA-N C1=C([N+]([O-])=O)C(NC)=C(I)C=C1C1=C(C)ON=C1C Chemical compound C1=C([N+]([O-])=O)C(NC)=C(I)C=C1C1=C(C)ON=C1C KKZVVQIJRJOMHV-UHFFFAOYSA-N 0.000 description 2
- ZOGUQDDYZZPSBO-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=CC2=C(C(=O)C=2N=CC(F)=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=CC2=C(C(=O)C=2N=CC(F)=CC=2)C=C1C=1C(C)=NOC=1C ZOGUQDDYZZPSBO-UHFFFAOYSA-N 0.000 description 2
- GCQUDOJDROTMSI-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(=O)C=2C(=CC=CC=2F)F)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(=O)C=2C(=CC=CC=2F)F)C=C1C=1C(C)=NOC=1C GCQUDOJDROTMSI-UHFFFAOYSA-N 0.000 description 2
- NWOPAQMXOXMNHB-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(=O)C=2N=CC(F)=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(=O)C=2N=CC(F)=CC=2)C=C1C=1C(C)=NOC=1C NWOPAQMXOXMNHB-UHFFFAOYSA-N 0.000 description 2
- OOEBJXPZTUKGDY-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(O)(C=O)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(O)(C=O)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C OOEBJXPZTUKGDY-UHFFFAOYSA-N 0.000 description 2
- CAAOKDLQXCLGRY-UHFFFAOYSA-N C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C(O)(C(O)CC)C1=CC=CC=N1 Chemical compound C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C(O)(C(O)CC)C1=CC=CC=N1 CAAOKDLQXCLGRY-UHFFFAOYSA-N 0.000 description 2
- UDBGKZIENVUCMQ-UHFFFAOYSA-N C=1C=CC(OCC)(C(=O)C=2N(C3=CC=CC=C3N=2)C(=O)OC(C)(C)C)NC=1C=1C(C)=NOC=1C Chemical compound C=1C=CC(OCC)(C(=O)C=2N(C3=CC=CC=C3N=2)C(=O)OC(C)(C)C)NC=1C=1C(C)=NOC=1C UDBGKZIENVUCMQ-UHFFFAOYSA-N 0.000 description 2
- PVNGTVOMBJZDFO-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=CC=CC=2)=C(N)C(N)=C1F Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=CC=CC=2)=C(N)C(N)=C1F PVNGTVOMBJZDFO-UHFFFAOYSA-N 0.000 description 2
- LZXPLZXFDMVPHR-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)C(F)(F)F)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)C(F)(F)F)=C(NC(=O)N2)C2=C1 LZXPLZXFDMVPHR-UHFFFAOYSA-N 0.000 description 2
- VRCXPXARBVDRSZ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C(=NC=C(N)C=2)C2CC2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C(=NC=C(N)C=2)C2CC2)=C(NC(=O)N2)C2=C1 VRCXPXARBVDRSZ-UHFFFAOYSA-N 0.000 description 2
- RXWPLARHUOQOSM-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3C=CC=2C)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3C=CC=2C)=C(NC(=O)N2)C2=C1 RXWPLARHUOQOSM-UHFFFAOYSA-N 0.000 description 2
- HKZNTABNBUFOKC-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(Cl)=C(OC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(Cl)=C(OC(=O)N2)C2=C1 HKZNTABNBUFOKC-UHFFFAOYSA-N 0.000 description 2
- HWHCDCCIBQHNPY-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(I)=C(NC(=O)C(F)(F)F)C([N+]([O-])=O)=C1 Chemical compound CC1=NOC(C)=C1C1=CC(I)=C(NC(=O)C(F)(F)F)C([N+]([O-])=O)=C1 HWHCDCCIBQHNPY-UHFFFAOYSA-N 0.000 description 2
- KGFSLNXOUHPSEK-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(N)=C(N)C(C(O)(C=2N=CC=CC=2)C=2N=CC=CC=2)=C1 Chemical compound CC1=NOC(C)=C1C1=CC(N)=C(N)C(C(O)(C=2N=CC=CC=2)C=2N=CC=CC=2)=C1 KGFSLNXOUHPSEK-UHFFFAOYSA-N 0.000 description 2
- PXQZBSURLZSXJE-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(N)=C(N)C(C(O)=O)=C1 Chemical compound CC1=NOC(C)=C1C1=CC(N)=C(N)C(C(O)=O)=C1 PXQZBSURLZSXJE-UHFFFAOYSA-N 0.000 description 2
- WOPRZMFHWUIZBU-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC=C(NCC(F)(F)F)C(Cl)=C1 Chemical compound CC1=NOC(C)=C1C1=CC=C(NCC(F)(F)F)C(Cl)=C1 WOPRZMFHWUIZBU-UHFFFAOYSA-N 0.000 description 2
- 101700046984 CDK20 Proteins 0.000 description 2
- AHOXXHGZNRYWOV-UHFFFAOYSA-N CNC1=C(C(=O)OC)C=C(Br)C=C1[N+]([O-])=O Chemical compound CNC1=C(C(=O)OC)C=C(Br)C=C1[N+]([O-])=O AHOXXHGZNRYWOV-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 210000003483 Chromatin Anatomy 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L Copper(II) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- QBILHYZNJQKJIR-UHFFFAOYSA-N FC(F)(F)CN1C(=O)C=CC2=C(Br)C(C)=CC=C21 Chemical compound FC(F)(F)CN1C(=O)C=CC2=C(Br)C(C)=CC=C21 QBILHYZNJQKJIR-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000003964 Histone deacetylases Human genes 0.000 description 2
- 108090000353 Histone deacetylases Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- JXDYKVIHCLTXOP-UHFFFAOYSA-N Isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N Isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JKYHIVJMELHHLU-UHFFFAOYSA-N N1=CC=CC2=C(Br)C(OC(F)(F)F)=CC=C21 Chemical compound N1=CC=CC2=C(Br)C(OC(F)(F)F)=CC=C21 JKYHIVJMELHHLU-UHFFFAOYSA-N 0.000 description 2
- OFRUBKQMWVUMQE-UHFFFAOYSA-N N1C(=O)CCCC2=C(Br)C(C)=CC=C21 Chemical compound N1C(=O)CCCC2=C(Br)C(C)=CC=C21 OFRUBKQMWVUMQE-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N Potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 239000007759 RPMI Media 1640 Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M Sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010047461 Viral infection Diseases 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- AVRHUDAVFSMYSM-UHFFFAOYSA-N [O-][N+](=O)C1=C(N)C(C(=O)OC)=CC(C2=C(ON=C2C)C)=C1F Chemical compound [O-][N+](=O)C1=C(N)C(C(=O)OC)=CC(C2=C(ON=C2C)C)=C1F AVRHUDAVFSMYSM-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229920002892 amber Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- BLFJCJKTSCOLEY-UHFFFAOYSA-N cinnoline-3-carboxylic acid Chemical compound C1=CC=C2N=NC(C(=O)O)=CC2=C1 BLFJCJKTSCOLEY-UHFFFAOYSA-N 0.000 description 2
- 239000012045 crude solution Substances 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- PUJFWFKWWCVKMO-UHFFFAOYSA-N methyl 2-(methylamino)-3-nitrobenzoate Chemical compound CNC1=C(C(=O)OC)C=CC=C1[N+]([O-])=O PUJFWFKWWCVKMO-UHFFFAOYSA-N 0.000 description 2
- PGXWDLGWMQIXDT-UHFFFAOYSA-N methylsulfinylmethane;hydrate Chemical compound O.CS(C)=O PGXWDLGWMQIXDT-UHFFFAOYSA-N 0.000 description 2
- 101700034118 myca Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 229940013123 stannous chloride Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- 239000012414 tert-butyl nitrite Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin dichloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- BDNGENSUAQQEKF-UHFFFAOYSA-N (2,4-dimethylpyridin-3-yl)boronic acid Chemical compound CC1=CC=NC(C)=C1B(O)O BDNGENSUAQQEKF-UHFFFAOYSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-AIECOIEWSA-N (2R,3R,4R,5S,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-AIECOIEWSA-N 0.000 description 1
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2S)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 description 1
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- PWWYQZOIPIJRJV-UHFFFAOYSA-N 1,2-dihydrophthalazine Chemical compound C1=CC=C2CNN=CC2=C1 PWWYQZOIPIJRJV-UHFFFAOYSA-N 0.000 description 1
- BWASJRFNPJXAGT-UHFFFAOYSA-L 1,3-bis[2,6-di(propan-2-yl)phenyl]-4,5-dihydroimidazole;3-chloropyridine;dichloropalladium Chemical compound Cl[Pd]Cl.ClC1=CC=CN=C1.CC(C)C1=CC=CC(C(C)C)=C1N1CCN(C=2C(=CC=CC=2C(C)C)C(C)C)[CH]1 BWASJRFNPJXAGT-UHFFFAOYSA-L 0.000 description 1
- UEMGWPRHOOEKTA-UHFFFAOYSA-N 1,3-difluorobenzene Chemical compound FC1=CC=CC(F)=C1 UEMGWPRHOOEKTA-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- WPDRTZQNLRNDMG-UHFFFAOYSA-N 1-bromopyrrolidine Chemical compound BrN1CCCC1 WPDRTZQNLRNDMG-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- CIQJWKNJDQKPPO-UHFFFAOYSA-N 1-chloropiperidine Chemical compound ClN1CCCCC1 CIQJWKNJDQKPPO-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 1
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 1
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 1
- SLMHHOVQRSSRCV-UHFFFAOYSA-N 2,3-dibromopyridine Chemical compound BrC1=CC=CN=C1Br SLMHHOVQRSSRCV-UHFFFAOYSA-N 0.000 description 1
- LWTIGYSPAXKMDG-UHFFFAOYSA-N 2,3-dihydro-1H-imidazole Chemical compound C1NC=CN1 LWTIGYSPAXKMDG-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- JCCCMAAJYSNBPR-UHFFFAOYSA-N 2-Ethylthiophene Chemical class CCC1=CC=CS1 JCCCMAAJYSNBPR-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-Methylpyridine Chemical class CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- PZBCKZWLPGJMAO-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
- JWTZSVLLPKTZJP-UHFFFAOYSA-N 2-bromo-6-chloropyridine Chemical compound ClC1=CC=CC(Br)=N1 JWTZSVLLPKTZJP-UHFFFAOYSA-N 0.000 description 1
- SOHDPICLICFSOP-UHFFFAOYSA-N 2-bromo-6-methylpyridine Chemical compound CC1=CC=CC(Br)=N1 SOHDPICLICFSOP-UHFFFAOYSA-N 0.000 description 1
- RIYFONBSYWACFF-UHFFFAOYSA-N 2-bromoethylcyclopropane Chemical compound BrCCC1CC1 RIYFONBSYWACFF-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-M 2-carboxy-6-propylphenolate Chemical class CCCC1=CC=CC(C([O-])=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-M 0.000 description 1
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical class CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- DNNVRTZJRKIUFK-UHFFFAOYSA-N 3,4-dihydroquinoline Chemical compound C1=CC=C2N=CCCC2=C1 DNNVRTZJRKIUFK-UHFFFAOYSA-N 0.000 description 1
- AKUSZFPCJFNRSZ-UHFFFAOYSA-N 3,4-dimethyl-1,2-oxazole Chemical class CC1=CON=C1C AKUSZFPCJFNRSZ-UHFFFAOYSA-N 0.000 description 1
- JUSFANSTBFGBAF-IRXDYDNUSA-N 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=C3N=C(N=C(C3=CC=2)N2[C@H](COCC2)C)N2[C@H](COCC2)C)=C1 JUSFANSTBFGBAF-IRXDYDNUSA-N 0.000 description 1
- YNUXSEIVRGFEKY-UHFFFAOYSA-N 3-bromo-2-(3-fluorophenyl)pyridine Chemical compound FC1=CC=CC(C=2C(=CC=CN=2)Br)=C1 YNUXSEIVRGFEKY-UHFFFAOYSA-N 0.000 description 1
- FQAWBGAIOYWONH-UHFFFAOYSA-N 3-chloroperoxybenzoic acid Chemical compound OC(=O)C1=CC=CC(OOCl)=C1 FQAWBGAIOYWONH-UHFFFAOYSA-N 0.000 description 1
- PWRBCZZQRRPXAB-UHFFFAOYSA-N 3-chloropyridine Chemical compound ClC1=CC=CN=C1 PWRBCZZQRRPXAB-UHFFFAOYSA-N 0.000 description 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- DVUSLCKIKIVCNW-UHFFFAOYSA-N 4,6-bis(3,5-dimethyl-1,2-oxazol-4-yl)-3-methyl-1H-benzimidazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C2=C(ON=C2C)C)=C(N(C)C(=O)N2)C2=C1 DVUSLCKIKIVCNW-UHFFFAOYSA-N 0.000 description 1
- XZGDIRZQQDDVFC-UHFFFAOYSA-N 4-[(5-chloropyridin-2-yl)-hydroxy-pyridin-2-ylmethyl]-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1,3-dihydrobenzimidazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=CC(Cl)=CC=2)=C(NC(=O)N2)C2=C1 XZGDIRZQQDDVFC-UHFFFAOYSA-N 0.000 description 1
- CDNMDRUIGNHEMR-VKAVYKQESA-N 4-[(5Z)-4-amino-5-(7-methoxyindol-2-ylidene)-1H-imidazo[5,1-f][1,2,4]triazin-7-yl]cyclohexane-1-carboxylic acid Chemical compound N1=C2C(OC)=CC=CC2=C\C1=C(C1=C(N)N=CNN11)\N=C1C1CCC(C(O)=O)CC1 CDNMDRUIGNHEMR-VKAVYKQESA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- INMZDDDQLHKGPF-UHFFFAOYSA-N 4-bromo-2-chloroaniline Chemical compound NC1=CC=C(Br)C=C1Cl INMZDDDQLHKGPF-UHFFFAOYSA-N 0.000 description 1
- IDCPJMXIWPFVIX-UHFFFAOYSA-N 4-bromo-5,7-difluoroquinoline Chemical compound BrC1=CC=NC2=CC(F)=CC(F)=C21 IDCPJMXIWPFVIX-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- WCUCENNZJXVTMB-UHFFFAOYSA-N 4-iodo-3-methylisoquinoline Chemical compound C1=CC=CC2=C(I)C(C)=NC=C21 WCUCENNZJXVTMB-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- RWRUXQOYBCUTRH-UHFFFAOYSA-N 5,7-bis(3,5-dimethyl-1,2-oxazol-4-yl)-3H-1,3-benzoxazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C2=C(ON=C2C)C)=C(OC(=O)N2)C2=C1 RWRUXQOYBCUTRH-UHFFFAOYSA-N 0.000 description 1
- AGSLHFQPWVSWHT-UHFFFAOYSA-N 5,7-dibromo-3H-1,3-benzoxazol-2-one Chemical compound BrC1=CC(Br)=C2OC(=O)NC2=C1 AGSLHFQPWVSWHT-UHFFFAOYSA-N 0.000 description 1
- KCDOZXUXDIQQHG-UHFFFAOYSA-N 5-(3,5-dimethyl-1,2-oxazol-4-yl)-4-fluoro-7-[hydroxy(dipyridin-2-yl)methyl]-1,3-dihydrobenzimidazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=CC=CC=2)=C(NC(=O)N2)C2=C1F KCDOZXUXDIQQHG-UHFFFAOYSA-N 0.000 description 1
- LMWJSCUJKDFDNC-UHFFFAOYSA-N 5-(3,5-dimethyl-1,2-oxazol-4-yl)-7-(2-phenylpyridin-3-yl)-3H-1,3-benzoxazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C=2C(=NC=CC=2)C=2C=CC=CC=2)=C(OC(=O)N2)C2=C1 LMWJSCUJKDFDNC-UHFFFAOYSA-N 0.000 description 1
- JYQLOTBEOJCYPK-UHFFFAOYSA-N 5-[6-(3,5-dimethyl-1,2-oxazol-4-yl)-2-oxo-1,3-dihydrobenzimidazol-4-yl]-1-methyl-3,4-dihydroquinolin-2-one Chemical compound CN1C(=O)CCC2=C1C=CC=C2C(C=1NC(=O)NC=1C=1)=CC=1C=1C(C)=NOC=1C JYQLOTBEOJCYPK-UHFFFAOYSA-N 0.000 description 1
- UZQOAKHXPRHASO-UHFFFAOYSA-N 5-bromo-1-methyl-4-phenylpyrazole Chemical compound CN1N=CC(C=2C=CC=CC=2)=C1Br UZQOAKHXPRHASO-UHFFFAOYSA-N 0.000 description 1
- BFZMLKFSKFFWCY-UHFFFAOYSA-N 5-bromo-1-methylpyrazole-4-carbonitrile Chemical compound CN1N=CC(C#N)=C1Br BFZMLKFSKFFWCY-UHFFFAOYSA-N 0.000 description 1
- FGCDNBKKAKAWDF-UHFFFAOYSA-N 5-bromo-4-methyl-1-phenylpyrazole Chemical compound BrC1=C(C)C=NN1C1=CC=CC=C1 FGCDNBKKAKAWDF-UHFFFAOYSA-N 0.000 description 1
- PXVJXLQVOGNYMR-UHFFFAOYSA-N 5-bromo-7-chloro-3H-1,3-benzoxazol-2-one Chemical compound ClC1=CC(Br)=CC2=C1OC(=O)N2 PXVJXLQVOGNYMR-UHFFFAOYSA-N 0.000 description 1
- KWKUFZDSKWVPRI-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)-3-methyl-4-(6-methylquinolin-5-yl)-1H-benzimidazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2C)=C(N(C)C(=O)N2)C2=C1 KWKUFZDSKWVPRI-UHFFFAOYSA-N 0.000 description 1
- QTAFEHGNOVONQR-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-(2-phenylpyridin-3-yl)-1,3-dihydrobenzimidazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C=2C(=NC=CC=2)C=2C=CC=CC=2)=C(NC(=O)N2)C2=C1 QTAFEHGNOVONQR-UHFFFAOYSA-N 0.000 description 1
- FXHZDSDHEWEYPI-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-[(5-fluoropyridin-2-yl)-hydroxy-(2,4,6-trifluorophenyl)methyl]-1,3-dihydrobenzimidazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC(F)=CC=2)C=2C(=CC(F)=CC=2F)F)=C(NC(=O)N2)C2=C1 FXHZDSDHEWEYPI-UHFFFAOYSA-N 0.000 description 1
- ZCEXVMXLJMGVMO-UHFFFAOYSA-N 6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-[hydroxy(dipyridin-2-yl)methyl]-1,3-dihydrobenzimidazol-2-one Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=CC=CC=2)=C(NC(=O)N2)C2=C1 ZCEXVMXLJMGVMO-UHFFFAOYSA-N 0.000 description 1
- PYRLDVVMVBKTTQ-UHFFFAOYSA-N 6-(trifluoromethoxy)quinoline Chemical compound N1=CC=CC2=CC(OC(F)(F)F)=CC=C21 PYRLDVVMVBKTTQ-UHFFFAOYSA-N 0.000 description 1
- MIOQBSPUPLFYHC-UHFFFAOYSA-N 6-bromo-N,N-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC(Br)=N1 MIOQBSPUPLFYHC-UHFFFAOYSA-N 0.000 description 1
- LYEPZCPAEZKSKN-UHFFFAOYSA-N 6-bromo-N-methylpyridin-2-amine Chemical compound CNC1=CC=CC(Br)=N1 LYEPZCPAEZKSKN-UHFFFAOYSA-N 0.000 description 1
- BKLJUYPLUWUEOQ-UHFFFAOYSA-N 6-bromopyridin-2-amine Chemical compound NC1=CC=CC(Br)=N1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N Acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N Anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- CUFNKYGDVFVPHO-UHFFFAOYSA-N Azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N BEZ235 Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
- 102100015499 BRD2 Human genes 0.000 description 1
- 101700003936 BRD2 Proteins 0.000 description 1
- 102100015498 BRD3 Human genes 0.000 description 1
- 101700008396 BRD3 Proteins 0.000 description 1
- 102100009312 BTK Human genes 0.000 description 1
- 101700058566 BTK Proteins 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N Baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 229950000971 Baricitinib Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N Benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N Bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KETNMRPDYGLFLI-UHFFFAOYSA-N BrC1=CC(N)=CN=C1C1CC1 Chemical compound BrC1=CC(N)=CN=C1C1CC1 KETNMRPDYGLFLI-UHFFFAOYSA-N 0.000 description 1
- 229910014263 BrF3 Inorganic materials 0.000 description 1
- SODRECDKCZSAEI-UHFFFAOYSA-M Br[Mg]CC1CC1 Chemical compound Br[Mg]CC1CC1 SODRECDKCZSAEI-UHFFFAOYSA-M 0.000 description 1
- XMQJZUCPWLSQIF-UHFFFAOYSA-N C1=C(I)C(NCC)=C(N)C=C1C1=C(C)ON=C1C Chemical compound C1=C(I)C(NCC)=C(N)C=C1C1=C(C)ON=C1C XMQJZUCPWLSQIF-UHFFFAOYSA-N 0.000 description 1
- WUNCYUVHHWBGAJ-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(=O)C=2N=CC(Cl)=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(=O)C=2N=CC(Cl)=CC=2)C=C1C=1C(C)=NOC=1C WUNCYUVHHWBGAJ-UHFFFAOYSA-N 0.000 description 1
- WSXNQYHDWROIQI-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(=O)N(C)OC)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(=O)N(C)OC)C=C1C=1C(C)=NOC=1C WSXNQYHDWROIQI-UHFFFAOYSA-N 0.000 description 1
- BKKINQQQDUDAKB-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(O)(C=2N=CC=CC=2)C=2N=C(Cl)C=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(O)(C=2N=CC=CC=2)C=2N=C(Cl)C=CC=2)C=C1C=1C(C)=NOC=1C BKKINQQQDUDAKB-UHFFFAOYSA-N 0.000 description 1
- WEHCERUXQMAXSC-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(O)(C=2N=CC=CC=2)C=2N=CC(F)=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(O)(C=2N=CC=CC=2)C=2N=CC(F)=CC=2)C=C1C=1C(C)=NOC=1C WEHCERUXQMAXSC-UHFFFAOYSA-N 0.000 description 1
- FGBRTDLCQOJVGG-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(O)C=2N=CC(=CC=2)C(F)(F)F)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(O)C=2N=CC(=CC=2)C(F)(F)F)C=C1C=1C(C)=NOC=1C FGBRTDLCQOJVGG-UHFFFAOYSA-N 0.000 description 1
- BZUYUHJEAGFGES-UHFFFAOYSA-N C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(O)C=2N=CC=NC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2N(C(=O)OC(C)(C)C)C(OCC)=NC2=C(C(O)C=2N=CC=NC=2)C=C1C=1C(C)=NOC=1C BZUYUHJEAGFGES-UHFFFAOYSA-N 0.000 description 1
- PEBVBNWVSLNXLN-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(O)(C(C)CC)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(O)(C(C)CC)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C PEBVBNWVSLNXLN-UHFFFAOYSA-N 0.000 description 1
- FTYTWTJALSPRQG-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(O)(C2CCC2)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(O)(C2CCC2)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C FTYTWTJALSPRQG-UHFFFAOYSA-N 0.000 description 1
- UEESXEIBSORWND-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(O)(C2CCCCC2)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(O)(C2CCCCC2)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C UEESXEIBSORWND-UHFFFAOYSA-N 0.000 description 1
- LXWCDSUJRMHCEP-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(O)(C=2C=CC=CC=2)C=2N=C3C=CC=CC3=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(O)(C=2C=CC=CC=2)C=2N=C3C=CC=CC3=CC=2)C=C1C=1C(C)=NOC=1C LXWCDSUJRMHCEP-UHFFFAOYSA-N 0.000 description 1
- ZIWRFSKOYHOZHK-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(O)(C=2N=CC=CC=2)C=2N=C(Cl)C=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(O)(C=2N=CC=CC=2)C=2N=C(Cl)C=CC=2)C=C1C=1C(C)=NOC=1C ZIWRFSKOYHOZHK-UHFFFAOYSA-N 0.000 description 1
- HBQDZVNRUVZFAK-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(O)(C=2N=CC=CC=2)C=2N=C3C=C(F)C=CC3=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(O)(C=2N=CC=CC=2)C=2N=C3C=C(F)C=CC3=CC=2)C=C1C=1C(C)=NOC=1C HBQDZVNRUVZFAK-UHFFFAOYSA-N 0.000 description 1
- OQYSYPAKNJAGNU-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(O)(C=2N=CC=CC=2)C=2N=C3C=CC=CC3=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(O)(C=2N=CC=CC=2)C=2N=C3C=CC=CC3=CC=2)C=C1C=1C(C)=NOC=1C OQYSYPAKNJAGNU-UHFFFAOYSA-N 0.000 description 1
- RWYFEGWASRUGSL-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(O)(CC(C)(C)C)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(O)(CC(C)(C)C)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C RWYFEGWASRUGSL-UHFFFAOYSA-N 0.000 description 1
- DKRFOFAEDKIUKZ-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C(O)(CCC2CC2)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C(O)(CCC2CC2)C=2N=CC=CC=2)C=C1C=1C(C)=NOC=1C DKRFOFAEDKIUKZ-UHFFFAOYSA-N 0.000 description 1
- LHLLVZWUIGBEGR-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(C=2N(N=CC=2C=2C=CC=CC=2)C)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(C=2N(N=CC=2C=2C=CC=CC=2)C)C=C1C=1C(C)=NOC=1C LHLLVZWUIGBEGR-UHFFFAOYSA-N 0.000 description 1
- PDKNFLGDDSIRDR-UHFFFAOYSA-N C1=C2NC(OCC)=NC2=C(I)C=C1C=1C(C)=NOC=1C Chemical compound C1=C2NC(OCC)=NC2=C(I)C=C1C=1C(C)=NOC=1C PDKNFLGDDSIRDR-UHFFFAOYSA-N 0.000 description 1
- CRGXIJDBSHMTOC-UHFFFAOYSA-N C1=CC=C2N(C)C(=O)CCC2=C1Br Chemical compound C1=CC=C2N(C)C(=O)CCC2=C1Br CRGXIJDBSHMTOC-UHFFFAOYSA-N 0.000 description 1
- AHFFKOYZRVZTOT-UHFFFAOYSA-N C1=CC=C2N=C(C(F)F)C(C)=C(I)C2=C1 Chemical compound C1=CC=C2N=C(C(F)F)C(C)=C(I)C2=C1 AHFFKOYZRVZTOT-UHFFFAOYSA-N 0.000 description 1
- GFUMSAIYQIUTSD-UHFFFAOYSA-N C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C(C)C1=CC=C(F)C=C1 Chemical compound C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C(C)C1=CC=C(F)C=C1 GFUMSAIYQIUTSD-UHFFFAOYSA-N 0.000 description 1
- LGACQOFKXRXSEM-UHFFFAOYSA-N C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C(O)(C(=O)CC)C1=CC=CC=N1 Chemical compound C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C(O)(C(=O)CC)C1=CC=CC=N1 LGACQOFKXRXSEM-UHFFFAOYSA-N 0.000 description 1
- AMQXFAHQTBACHU-UHFFFAOYSA-N C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C(O)(CC)C1=CC=CC=N1 Chemical compound C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C(O)(CC)C1=CC=CC=N1 AMQXFAHQTBACHU-UHFFFAOYSA-N 0.000 description 1
- QMJIEVSDFPOCAQ-UHFFFAOYSA-N C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C1=C(C)C=NN1C1CCCCO1 Chemical compound C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C1=C(C)C=NN1C1CCCCO1 QMJIEVSDFPOCAQ-UHFFFAOYSA-N 0.000 description 1
- HYJGWQDYGITPOR-UHFFFAOYSA-N C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C1=CC(NC(=O)C)=CN=C1C1CC1 Chemical compound C=1C(C2=C(ON=C2C)C)=CC=2NC(=O)NC=2C=1C1=CC(NC(=O)C)=CN=C1C1CC1 HYJGWQDYGITPOR-UHFFFAOYSA-N 0.000 description 1
- KNEWMCNHJKVRMD-UHFFFAOYSA-N C=1C=2NC(=O)N(C)C=2C(C(=O)OC)=CC=1C=1C(C)=NOC=1C Chemical compound C=1C=2NC(=O)N(C)C=2C(C(=O)OC)=CC=1C=1C(C)=NOC=1C KNEWMCNHJKVRMD-UHFFFAOYSA-N 0.000 description 1
- NBIVJWFZNGOIQK-UHFFFAOYSA-N C=1C=2NC(=O)NC=2C(C(=O)C(C)C)=CC=1C=1C(C)=NOC=1C Chemical compound C=1C=2NC(=O)NC=2C(C(=O)C(C)C)=CC=1C=1C(C)=NOC=1C NBIVJWFZNGOIQK-UHFFFAOYSA-N 0.000 description 1
- MSAVGTAFEWQGSO-UHFFFAOYSA-N C=1C=2NC(=O)NC=2C(C(O)(C(C)C)C(C)C)=CC=1C=1C(C)=NOC=1C Chemical compound C=1C=2NC(=O)NC=2C(C(O)(C(C)C)C(C)C)=CC=1C=1C(C)=NOC=1C MSAVGTAFEWQGSO-UHFFFAOYSA-N 0.000 description 1
- VFBDNJZCMAMWNQ-UHFFFAOYSA-N C=1C=2NC(=O)NC=2C(C(O)(CC)CC)=CC=1C=1C(C)=NOC=1C Chemical compound C=1C=2NC(=O)NC=2C(C(O)(CC)CC)=CC=1C=1C(C)=NOC=1C VFBDNJZCMAMWNQ-UHFFFAOYSA-N 0.000 description 1
- JWBMTAUDWQSERU-UHFFFAOYSA-N CC1=NNC(=C1C1=CC(=CC=2NC=NC=21)C=1C(=NOC=1C)C)C Chemical compound CC1=NNC(=C1C1=CC(=CC=2NC=NC=21)C=1C(=NOC=1C)C)C JWBMTAUDWQSERU-UHFFFAOYSA-N 0.000 description 1
- UXAYJMFCZYEVEG-UHFFFAOYSA-N CC1=NOC(=C1C=1C=C(C2=C(NC=N2)C=1)C=1C(=NC=CC=1)C1=CC(=CC=C1)F)C Chemical compound CC1=NOC(=C1C=1C=C(C2=C(NC=N2)C=1)C=1C(=NC=CC=1)C1=CC(=CC=C1)F)C UXAYJMFCZYEVEG-UHFFFAOYSA-N 0.000 description 1
- SZPHYHXFLNOQBE-UHFFFAOYSA-N CC1=NOC(C)=C1C(C=C1[N+]([O-])=O)=CC(I)=C1NC1CC1 Chemical compound CC1=NOC(C)=C1C(C=C1[N+]([O-])=O)=CC(I)=C1NC1CC1 SZPHYHXFLNOQBE-UHFFFAOYSA-N 0.000 description 1
- LSLHICBMVKQVMP-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(B2OC(C)(C)C(C)(C)O2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(B2OC(C)(C)C(C)(C)O2)=C(NC(=O)N2)C2=C1 LSLHICBMVKQVMP-UHFFFAOYSA-N 0.000 description 1
- FZWQUXWVBSRXHR-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(=C)C=2C=CC(F)=CC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(=C)C=2C=CC(F)=CC=2)=C(NC(=O)N2)C2=C1 FZWQUXWVBSRXHR-UHFFFAOYSA-N 0.000 description 1
- RMFSAQLOGHZBLW-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C2CCCC2)C2CCCC2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C2CCCC2)C2CCCC2)=C(NC(=O)N2)C2=C1 RMFSAQLOGHZBLW-UHFFFAOYSA-N 0.000 description 1
- AYNSBUYGSFEMAZ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C2OCCCC2)C=2N=CC=CC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C2OCCCC2)C=2N=CC=CC=2)=C(NC(=O)N2)C2=C1 AYNSBUYGSFEMAZ-UHFFFAOYSA-N 0.000 description 1
- SQCDBKSDBLNGJN-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C=2C=C(C=CC=2)C(F)(F)F)C=2N=CC=CC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2C=C(C=CC=2)C(F)(F)F)C=2N=CC=CC=2)=C(NC(=O)N2)C2=C1 SQCDBKSDBLNGJN-UHFFFAOYSA-N 0.000 description 1
- MFPINLKTDIPKRZ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C=2C=C(F)C=C(F)C=2)C=2N=CC(F)=CC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2C=C(F)C=C(F)C=2)C=2N=CC(F)=CC=2)=C(NC(=O)N2)C2=C1 MFPINLKTDIPKRZ-UHFFFAOYSA-N 0.000 description 1
- JEYMJXQBKOIOTI-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC(F)=CC=2)C=2C(=CC(F)=C(F)C=2)F)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC(F)=CC=2)C=2C(=CC(F)=C(F)C=2)F)=C(NC(=O)N2)C2=C1 JEYMJXQBKOIOTI-UHFFFAOYSA-N 0.000 description 1
- UZSNFLIOYAFNOD-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC(F)=CC=2)C=2N=C(C=CC=2)C(F)(F)F)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC(F)=CC=2)C=2N=C(C=CC=2)C(F)(F)F)=C(NC(=O)N2)C2=C1 UZSNFLIOYAFNOD-UHFFFAOYSA-N 0.000 description 1
- XXSOIJWCLGRKKN-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC(F)=CC=2)C=2N=CC=NC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC(F)=CC=2)C=2N=CC=NC=2)=C(NC(=O)N2)C2=C1 XXSOIJWCLGRKKN-UHFFFAOYSA-N 0.000 description 1
- YBYYXBWGSMVTPH-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2C(=C(C)N=C(Br)C=2)F)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2C(=C(C)N=C(Br)C=2)F)=C(NC(=O)N2)C2=C1 YBYYXBWGSMVTPH-UHFFFAOYSA-N 0.000 description 1
- CSZWRLOCHYNFKD-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=C(N)C=CC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=C(N)C=CC=2)=C(NC(=O)N2)C2=C1 CSZWRLOCHYNFKD-UHFFFAOYSA-N 0.000 description 1
- LLYDHNGZZUXZLW-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=C3C=CC=CC3=CC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=C3C=CC=CC3=CC=2)=C(NC(=O)N2)C2=C1 LLYDHNGZZUXZLW-UHFFFAOYSA-N 0.000 description 1
- YKTKNLHHSJPCCQ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=CC(F)=CC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)(C=2N=CC=CC=2)C=2N=CC(F)=CC=2)=C(NC(=O)N2)C2=C1 YKTKNLHHSJPCCQ-UHFFFAOYSA-N 0.000 description 1
- PMHMIULFCKNIDJ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)C2NCCC2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)C2NCCC2)=C(NC(=O)N2)C2=C1 PMHMIULFCKNIDJ-UHFFFAOYSA-N 0.000 description 1
- WQIZJHSQTVSDHC-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C(O)C=2N=CC(=CC=2)C(F)(F)F)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C(O)C=2N=CC(=CC=2)C(F)(F)F)=C(NC(=O)N2)C2=C1 WQIZJHSQTVSDHC-UHFFFAOYSA-N 0.000 description 1
- FBLOOJBVSRDCOR-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C2=C(N(C)N=C2C2CC2)C2CC2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C2=C(N(C)N=C2C2CC2)C2CC2)=C(NC(=O)N2)C2=C1 FBLOOJBVSRDCOR-UHFFFAOYSA-N 0.000 description 1
- HGOZLVVDIBVUJY-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C(=CC=NC=2)C2CC2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C(=CC=NC=2)C2CC2)=C(NC(=O)N2)C2=C1 HGOZLVVDIBVUJY-UHFFFAOYSA-N 0.000 description 1
- BXXBUEAIMQMNSS-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C(=CN(C)N=2)C2CC2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C(=CN(C)N=2)C2CC2)=C(NC(=O)N2)C2=C1 BXXBUEAIMQMNSS-UHFFFAOYSA-N 0.000 description 1
- QSXVSCFNHPEEFI-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C(=NC=C(Br)C=2)C2CC2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C(=NC=C(Br)C=2)C2CC2)=C(NC(=O)N2)C2=C1 QSXVSCFNHPEEFI-UHFFFAOYSA-N 0.000 description 1
- AWZMSLHFJOHYRZ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C(=NC=CC=2C2CC2)C2CC2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C(=NC=CC=2C2CC2)C2CC2)=C(NC(=O)N2)C2=C1 AWZMSLHFJOHYRZ-UHFFFAOYSA-N 0.000 description 1
- PHDFIBRNNCGAFI-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C(=[N+]([O-])C=CC=2)C2CC2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C(=[N+]([O-])C=CC=2)C2CC2)=C(NC(=O)N2)C2=C1 PHDFIBRNNCGAFI-UHFFFAOYSA-N 0.000 description 1
- XJHKKAZGAFFHMC-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=C(Cl)C=CC=C3N=CC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=C(Cl)C=CC=C3N=CC=2)=C(NC(=O)N2)C2=C1 XJHKKAZGAFFHMC-UHFFFAOYSA-N 0.000 description 1
- JIJKQPFCBBZFBJ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=C(F)C=C(F)C=C3N=CC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=C(F)C=C(F)C=C3N=CC=2)=C(NC(=O)N2)C2=C1 JIJKQPFCBBZFBJ-UHFFFAOYSA-N 0.000 description 1
- DPRLJCTUGGDCOB-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=C(F)C=CC(F)=C3N=CC=2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=C(F)C=CC(F)=C3N=CC=2)=C(NC(=O)N2)C2=C1 DPRLJCTUGGDCOB-UHFFFAOYSA-N 0.000 description 1
- UTEQNDOENLCXHL-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3C=NC=2C)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3C=NC=2C)=C(NC(=O)N2)C2=C1 UTEQNDOENLCXHL-UHFFFAOYSA-N 0.000 description 1
- MAKWJGUBODKFLO-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3N=CC=2C(F)(F)F)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3N=CC=2C(F)(F)F)=C(NC(=O)N2)C2=C1 MAKWJGUBODKFLO-UHFFFAOYSA-N 0.000 description 1
- BGDQFYPBFSREAS-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3N=CC=2C(F)F)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3N=CC=2C(F)F)=C(NC(=O)N2)C2=C1 BGDQFYPBFSREAS-UHFFFAOYSA-N 0.000 description 1
- JZMRECXTXYZXPS-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3N=CC=2C)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3N=CC=2C)=C(NC(=O)N2)C2=C1 JZMRECXTXYZXPS-UHFFFAOYSA-N 0.000 description 1
- CYDYYKXXKRLBQZ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3N=CC=2Cl)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3N=CC=2Cl)=C(NC(=O)N2)C2=C1 CYDYYKXXKRLBQZ-UHFFFAOYSA-N 0.000 description 1
- CSTJHRCILXZSEO-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3[N+]([O-])=CC=2C)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CC=C3[N+]([O-])=CC=2C)=C(NC(=O)N2)C2=C1 CSTJHRCILXZSEO-UHFFFAOYSA-N 0.000 description 1
- BXZGXEHNSDBUFD-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C(Cl)=CC=2C)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C(Cl)=CC=2C)=C(NC(=O)N2)C2=C1 BXZGXEHNSDBUFD-UHFFFAOYSA-N 0.000 description 1
- MJLSYEVTIHWHAM-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C(F)=CC=2C)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C(F)=CC=2C)=C(NC(=O)N2)C2=C1 MJLSYEVTIHWHAM-UHFFFAOYSA-N 0.000 description 1
- RHUOKHUEZSAQMU-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2C(F)(F)F)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2C(F)(F)F)=C(NC(=O)N2)C2=C1 RHUOKHUEZSAQMU-UHFFFAOYSA-N 0.000 description 1
- BPJIFKWHAPJCNO-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2C)=C(NC(=O)N2)C2=C1Cl Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2C)=C(NC(=O)N2)C2=C1Cl BPJIFKWHAPJCNO-UHFFFAOYSA-N 0.000 description 1
- KXRGELHPAACJEE-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2C)=C(NC(=O)N2)C2=C1F Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2C)=C(NC(=O)N2)C2=C1F KXRGELHPAACJEE-UHFFFAOYSA-N 0.000 description 1
- GSRGYVSFUXNLIZ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2OC(F)(F)F)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C3=CC=CN=C3C=CC=2OC(F)(F)F)=C(NC(=O)N2)C2=C1 GSRGYVSFUXNLIZ-UHFFFAOYSA-N 0.000 description 1
- SIRFIERNPXFMFX-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C=3C=CC(=O)N(C)C=3C=CC=2C)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C=3C=CC(=O)N(C)C=3C=CC=2C)=C(NC(=O)N2)C2=C1 SIRFIERNPXFMFX-UHFFFAOYSA-N 0.000 description 1
- WKOBAOIDWYZZFX-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2C=3C=CC(=O)N(CC(F)(F)F)C=3C=CC=2C)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2C=3C=CC(=O)N(CC(F)(F)F)C=3C=CC=2C)=C(NC(=O)N2)C2=C1 WKOBAOIDWYZZFX-UHFFFAOYSA-N 0.000 description 1
- BKHGKKXSNIAMIL-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(C=2N(N=CC=2C=2C=CC=CC=2)C)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(C=2N(N=CC=2C=2C=CC=CC=2)C)=C(NC(=O)N2)C2=C1 BKHGKKXSNIAMIL-UHFFFAOYSA-N 0.000 description 1
- JNUWKMAPHHOALC-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(Cl)=C(NC(=O)N2)C2=C1F Chemical compound CC1=NOC(C)=C1C1=CC(Cl)=C(NC(=O)N2)C2=C1F JNUWKMAPHHOALC-UHFFFAOYSA-N 0.000 description 1
- BRVNCNVMTSCIBB-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(I)=C(Br)C([N+]([O-])=O)=C1 Chemical compound CC1=NOC(C)=C1C1=CC(I)=C(Br)C([N+]([O-])=O)=C1 BRVNCNVMTSCIBB-UHFFFAOYSA-N 0.000 description 1
- FOUJWIZSDDVGCP-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(N)=C(N)C(S(=O)(=O)NC2CCCC2)=C1 Chemical compound CC1=NOC(C)=C1C1=CC(N)=C(N)C(S(=O)(=O)NC2CCCC2)=C1 FOUJWIZSDDVGCP-UHFFFAOYSA-N 0.000 description 1
- IRDCGYNLXVIMTM-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC(S(=O)(=O)NC2CCCC2)=C(NC(=O)N2)C2=C1 Chemical compound CC1=NOC(C)=C1C1=CC(S(=O)(=O)NC2CCCC2)=C(NC(=O)N2)C2=C1 IRDCGYNLXVIMTM-UHFFFAOYSA-N 0.000 description 1
- CFLWGTLYBLLOCD-UHFFFAOYSA-N CCN1N=CC(C)=C1Br Chemical compound CCN1N=CC(C)=C1Br CFLWGTLYBLLOCD-UHFFFAOYSA-N 0.000 description 1
- ZYSQXACMTRMRLO-UHFFFAOYSA-N CN(C)C1=CC=CC(C(O)(C=2N=CC=CC=2)C=2C=3NC(=O)NC=3C=C(C=2)C2=C(ON=C2C)C)=N1 Chemical compound CN(C)C1=CC=CC(C(O)(C=2N=CC=CC=2)C=2C=3NC(=O)NC=3C=C(C=2)C2=C(ON=C2C)C)=N1 ZYSQXACMTRMRLO-UHFFFAOYSA-N 0.000 description 1
- MNYCZJWCVWYGEI-UHFFFAOYSA-M CN1C(NC2=C1C(=CC=C2)C(=O)[O-])=O Chemical compound CN1C(NC2=C1C(=CC=C2)C(=O)[O-])=O MNYCZJWCVWYGEI-UHFFFAOYSA-M 0.000 description 1
- IEPKZENETNKYCW-UHFFFAOYSA-N CN1N=CC(C=2C=CC=CC=2)=C1B1OC(C)(C)C(C)(C)O1 Chemical compound CN1N=CC(C=2C=CC=CC=2)=C1B1OC(C)(C)C(C)(C)O1 IEPKZENETNKYCW-UHFFFAOYSA-N 0.000 description 1
- FSYZXXZXJHEMJU-UHFFFAOYSA-N CNC1=CC=CC(C(O)(C=2N=CC=CC=2)C=2C=3NC(=O)NC=3C=C(C=2)C2=C(ON=C2C)C)=N1 Chemical compound CNC1=CC=CC(C(O)(C=2N=CC=CC=2)C=2C=3NC(=O)NC=3C=C(C=2)C2=C(ON=C2C)C)=N1 FSYZXXZXJHEMJU-UHFFFAOYSA-N 0.000 description 1
- 101700004039 CUBN Proteins 0.000 description 1
- ZVHNDZWQTBEVRY-UHFFFAOYSA-N CYT387 Chemical compound C1=CC(C(NCC#N)=O)=CC=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 ZVHNDZWQTBEVRY-UHFFFAOYSA-N 0.000 description 1
- JHLNERQLKQQLRZ-UHFFFAOYSA-N Calcium silicate Chemical compound [Ca+2].[Ca+2].[O-][Si]([O-])([O-])[O-] JHLNERQLKQQLRZ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- WDECIBYCCFPHNR-UHFFFAOYSA-N Chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N Cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N Copper(I) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N DME dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 241001319200 Ebo Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N EtOAc EtOAc Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 101700001948 F2R Proteins 0.000 description 1
- GKIBRPVSHRWCSQ-UHFFFAOYSA-N FC(F)(F)[Mg]CC Chemical compound FC(F)(F)[Mg]CC GKIBRPVSHRWCSQ-UHFFFAOYSA-N 0.000 description 1
- QRUQXDJOFUVORV-UHFFFAOYSA-N FC=1C=2NC(=O)NC=2C(C(=O)OC)=CC=1C=1C(C)=NOC=1C Chemical compound FC=1C=2NC(=O)NC=2C(C(=O)OC)=CC=1C=1C(C)=NOC=1C QRUQXDJOFUVORV-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N Fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N Fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- GKDRMWXFWHEQQT-UHFFFAOYSA-N Fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 1
- 229950005309 Fostamatinib Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 208000005017 Glioblastoma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108060003497 HAUS7 Proteins 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- SCLHWLIAPUBZBG-UHFFFAOYSA-N IC1=CC=CC2=C1NC(N2)=O Chemical compound IC1=CC=CC2=C1NC(N2)=O SCLHWLIAPUBZBG-UHFFFAOYSA-N 0.000 description 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N Indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N Indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N Isobenzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 102000008986 Janus Human genes 0.000 description 1
- 108050000950 Janus Proteins 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 101710009221 LD Proteins 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N Lestaurtinib Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- 229950001845 Lestaurtinib Drugs 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- ANYSGBYRTLOUPO-UHFFFAOYSA-N Lithium tetramethylpiperidide Chemical compound [Li]N1C(C)(C)CCCC1(C)C ANYSGBYRTLOUPO-UHFFFAOYSA-N 0.000 description 1
- 102100003436 MAP3K5 Human genes 0.000 description 1
- 102100016823 MAPK1 Human genes 0.000 description 1
- 102100006844 MMP9 Human genes 0.000 description 1
- 101700067851 MMP9 Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N MeCN acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LMMITLHJIWHUDR-UHFFFAOYSA-N N1=CC=CC2=C(Br)C(C(F)(F)F)=CC=C21 Chemical compound N1=CC=CC2=C(Br)C(C(F)(F)F)=CC=C21 LMMITLHJIWHUDR-UHFFFAOYSA-N 0.000 description 1
- MTLHKIBATNRNEF-UHFFFAOYSA-N N1C(=O)C=CC2=C(Cl)C(C(F)(F)F)=CC=C21 Chemical compound N1C(=O)C=CC2=C(Cl)C(C(F)(F)F)=CC=C21 MTLHKIBATNRNEF-UHFFFAOYSA-N 0.000 description 1
- ISUKOMCZWYUGTN-UHFFFAOYSA-N N1C(=O)CCC2=C(Br)C(C)=CC=C21 Chemical compound N1C(=O)CCC2=C(Br)C(C)=CC=C21 ISUKOMCZWYUGTN-UHFFFAOYSA-N 0.000 description 1
- VSSBYTJNALDTLD-UHFFFAOYSA-N NC1=C(N)C(C(=O)N(C)OC)=CC(C2=C(ON=C2C)C)=C1 Chemical compound NC1=C(N)C(C(=O)N(C)OC)=CC(C2=C(ON=C2C)C)=C1 VSSBYTJNALDTLD-UHFFFAOYSA-N 0.000 description 1
- HDEOYNKLIAGGFJ-UHFFFAOYSA-N NC1=C(N)C(C(=O)OC)=CC(C2=C(ON=C2C)C)=C1 Chemical compound NC1=C(N)C(C(=O)OC)=CC(C2=C(ON=C2C)C)=C1 HDEOYNKLIAGGFJ-UHFFFAOYSA-N 0.000 description 1
- MVANPFSDXYZVBD-UHFFFAOYSA-N NC1=C(N)C(C(=O)OC)=CC(C2=C(ON=C2C)C)=C1F Chemical compound NC1=C(N)C(C(=O)OC)=CC(C2=C(ON=C2C)C)=C1F MVANPFSDXYZVBD-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N O-Phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N Oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 229950010131 PUROMYCIN Drugs 0.000 description 1
- HWXVIOGONBBTBY-ONEGZZNKSA-N Pacritinib Chemical compound C=1C=C(C=2)NC(N=3)=NC=CC=3C(C=3)=CC=CC=3COC\C=C\COCC=2C=1OCCN1CCCC1 HWXVIOGONBBTBY-ONEGZZNKSA-N 0.000 description 1
- 229950011410 Pacritinib Drugs 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N Panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- UXPOJVLZTPGWFX-UHFFFAOYSA-N Pentafluoroethyl iodide Chemical compound FC(F)(F)C(F)(F)I UXPOJVLZTPGWFX-UHFFFAOYSA-N 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- XDJOIMJURHQYDW-UHFFFAOYSA-N Phenalene Chemical compound C1=CC(CC=C2)=C3C2=CC=CC3=C1 XDJOIMJURHQYDW-UHFFFAOYSA-N 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- RDOWQLZANAYVLL-UHFFFAOYSA-N Phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical compound C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N Pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N Pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N Pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- BBEAQIROQSPTKN-UHFFFAOYSA-N Pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N Pyridine-N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N Quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 229960000329 Ribavirin Drugs 0.000 description 1
- 208000010157 Sclerosing Cholangitis Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N Sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N Sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N Tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N Tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N TosMIC Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- VPAYJEUHKVESSD-UHFFFAOYSA-N Trifluoroiodomethane Chemical compound FC(F)(F)I VPAYJEUHKVESSD-UHFFFAOYSA-N 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- MQMKRQLTIWPEDM-UHFFFAOYSA-N XL147 Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC2=NSN=C2C=C1 MQMKRQLTIWPEDM-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N Xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- PLWIGERSUIOLRS-UHFFFAOYSA-M [Br-].CCC([Mg+])CC Chemical compound [Br-].CCC([Mg+])CC PLWIGERSUIOLRS-UHFFFAOYSA-M 0.000 description 1
- PAVBFVDIWOBMCX-UHFFFAOYSA-M [Br-].FC(F)(F)CC[Mg+] Chemical compound [Br-].FC(F)(F)CC[Mg+] PAVBFVDIWOBMCX-UHFFFAOYSA-M 0.000 description 1
- UKRKJOQTJHREDX-UHFFFAOYSA-M [Br-].[Mg+]CCC1CC1 Chemical compound [Br-].[Mg+]CCC1CC1 UKRKJOQTJHREDX-UHFFFAOYSA-M 0.000 description 1
- GROGEABZCKQTJW-UHFFFAOYSA-M [Cl-].[Mg+]C1CCCC1 Chemical compound [Cl-].[Mg+]C1CCCC1 GROGEABZCKQTJW-UHFFFAOYSA-M 0.000 description 1
- WMJMABVHDMRMJA-UHFFFAOYSA-M [Cl-].[Mg+]C1CCCCC1 Chemical compound [Cl-].[Mg+]C1CCCCC1 WMJMABVHDMRMJA-UHFFFAOYSA-M 0.000 description 1
- DUVKJGRTGPRRGL-UHFFFAOYSA-N [O-]B[O-] Chemical class [O-]B[O-] DUVKJGRTGPRRGL-UHFFFAOYSA-N 0.000 description 1
- CZLUBUZXGJJRNV-UHFFFAOYSA-L [O-]C(=O)C1=CC=CC2=C1N=CN2C([O-])=O Chemical compound [O-]C(=O)C1=CC=CC2=C1N=CN2C([O-])=O CZLUBUZXGJJRNV-UHFFFAOYSA-L 0.000 description 1
- 230000001594 aberrant Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 101700005476 ail Proteins 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 201000004384 alopecia Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001638 boron Chemical class 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- BSHICDXRSZQYBP-UHFFFAOYSA-N dichloromethane;palladium(2+) Chemical compound [Pd+2].ClCCl BSHICDXRSZQYBP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002222 downregulating Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 1
- YFXCNIVBAVFOBX-UHFFFAOYSA-N ethenylboronic acid Chemical compound OB(O)C=C YFXCNIVBAVFOBX-UHFFFAOYSA-N 0.000 description 1
- 125000006437 ethyl cyclopropyl group Chemical group 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N ethylene glycol monomethyl ether Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical class C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- BKUUBJVRXLTPMT-UHFFFAOYSA-M magnesium;2-methanidyl-2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].CC(C)(C)[CH2-] BKUUBJVRXLTPMT-UHFFFAOYSA-M 0.000 description 1
- WSHFRLGXCNEKRX-UHFFFAOYSA-M magnesium;butane;bromide Chemical compound [Mg+2].[Br-].CC[CH-]C WSHFRLGXCNEKRX-UHFFFAOYSA-M 0.000 description 1
- VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- KCEZKHRRFNEJGO-UHFFFAOYSA-N methyl 2-amino-5-bromo-4-fluorobenzoate Chemical compound COC(=O)C1=CC(Br)=C(F)C=C1N KCEZKHRRFNEJGO-UHFFFAOYSA-N 0.000 description 1
- VEKYKLDXYNUERO-UHFFFAOYSA-N methyl 2-fluoro-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1F VEKYKLDXYNUERO-UHFFFAOYSA-N 0.000 description 1
- PMXSNEURQGNVGW-UHFFFAOYSA-N methyl 4-chlorocinnoline-3-carboxylate Chemical compound C1=CC=CC2=C(Cl)C(C(=O)OC)=NN=C21 PMXSNEURQGNVGW-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- GQONLASZRVFGHI-UHFFFAOYSA-M phenylmagnesium chloride Chemical compound Cl[Mg]C1=CC=CC=C1 GQONLASZRVFGHI-UHFFFAOYSA-M 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- QHXLIQMGIGEHJP-UHFFFAOYSA-N picoline - borane complex Substances [B].CC1=CC=CC=N1 QHXLIQMGIGEHJP-UHFFFAOYSA-N 0.000 description 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- OFPTZWGZSRJCOT-MSPNRCMCSA-M potassium;2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-d Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O OFPTZWGZSRJCOT-MSPNRCMCSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000000541 pulsatile Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- HREHOXSRYOZKNT-UHFFFAOYSA-N quinolin-2-ylmethanol Chemical compound C1=CC=CC2=NC(CO)=CC=C21 HREHOXSRYOZKNT-UHFFFAOYSA-N 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- 108010091666 romidepsin Proteins 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 108091006090 transcriptional activators Proteins 0.000 description 1
- 108091006091 transcriptional repressors Proteins 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CWLNAJYDRSIKJS-UHFFFAOYSA-N triethoxymethoxyethane Chemical compound CCOC(OCC)(OCC)OCC CWLNAJYDRSIKJS-UHFFFAOYSA-N 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of formula (I)
Description
BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS
[0001] This application claims the benefits of U.S. Provisional Application 61/805,995, filed on March 28, 2013, and U.S. Provisional Application 61/860,230, filed on July 30, 2013, both of which are incorporated herein by reference in their entireties.
FIELD
[0002] This application relates to chemical compounds which may inhibit or otherwise modulate the activity of a bromodomain-containing protein, including bromodomaincontaining protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds.
BACKGROUND
[0003] The bromodomain and extraterminal (BET) family of proteins (BET proteins) are readers of the epigenetic code that couple acétylation of lysine residues on histones to changes in chromatin structure and gene expression. The BET family includes BRD2, BRD3, BRD4, and BRDT, ail of which are widely expressed across diverse tissues, with the exception of the BRDT, whose expression is restricted to the testes. See Wu, S. Y. & Chiang, C M., J. Biol. Chem., 282: 13141-13145 (2007). Each BET family member contains tandem bromodomains in the N-terminal régions that specifically bind acelyated lysine residues in histones H3 and H4. Id. Once bound to histones, BET proteins recruit protein complexes that modulate gene transcription either directly, such as transcriptional activators or repressors, or indirectly such as chromatin remodeling complexes. BRD4 is the most well studied member ofthe BET family and is known to preferentially recognize tetra-acelyated histone H4 epigenetic marks. See Filippakopoulos, P., et al., Cell, 149: 214-231 (2012). BRD4 recruits the p-TEFb complex to nucléosomes, which in turn phosphorylâtes the C- terminal tail of RNA polymerase II and increases the transcriptional élongation of neighboring genes. See Yang, Z., et al., Mol. CellBiol., 28: 967-976 (2008); Urano, E., et al., FEBS Lett., 582: 40534058 (2008).
[0004] The epigenetic code, including histone acétylation, is highly perturbed in many pathological disease states, resulting in the aberrant expression of genes that control cell fate, cell différentiation, cell survival, and inflammatory processes. See, e.g., Cohen, I., et al., Genes Cancer, 2: 631-647 (2011); Brooks, W.H., et al., J. Autoimmun., 34: J207-219 (2010); Wierda, R.J., et al., J. Cell Mol. Med., 14: 1225-1240 (2010); Shirodkar, A.V. & Marsden, P.A., Curr. Opin. Cardiol., 26: 209-215 (2011); Villeneuve, L.M., et al., Clin. Exp.
Pharmacol. Physiol., 38: 401-409 (2011). BET proteins including BRD4 hâve been identified as important mediators of altered gene expression profiles found in numerous diseases including cancer, diabètes, obesity, atherosclerosis, cardiovascular and rénal disorders, and viral infection. See Muller, S., et al., Expert Rev. Mol. Med., 13: e29 (2011); Zhou, M., et al., J. Virol., 83: 1036-1044 (2009); Chung, C.W., et al., J. Med. Chem., 54: 3827-3838 (2011). For example, MYC has been implicated in the majority of human cancers and BET proteins hâve been identified as regulatory factors of c-Myc; inhibition of BET, including BRD4, has been shown to downregulate MYC transcription. See Delmore, J.E., et al. Cell, 146, 904-17 (2011); Lovén, J. et al., Cell, 153, 320-34 (2013). Inhibitors and modulators of BET proteins, including BRD4, are therefore needed.
SUMMARY
[0005] One aspect provides for a compound of Formula (I)
wherein
Rla and Rlb are each independently Ci-Cô alkyl, Ci-Cô alkoxy, Ci-Cô haloalkyl, Ci-Ce haloalkoxy, Ci-Cô hydroxyalkyl, C3-C6 cycloalkyl, or CH2-C3-C6 cycloalkyl;
R2a and R2b are each independently H or halogen;
R3 is
C5-C10 aryl, C5-C10 heteroaryl, or C5-C10 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or
-S(O)2NHR4, wherein R4 is Ci-Cô alkyl or C3-C7 cycloalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or a moiety of the formula
wherein
R6 is H, OH, or halogen; and R7 and R8 are each independently Ci-Cô alkyl, C2-Cô alkenyl, C2-Cô alkynyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, Cs-Ci2 aryl, C5-Ci2 heteroaryl, or Cs-Ci2 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or
R6 is H, Ci-Cô alkyl, C2-Cô alkenyl, C2-Cô alkynyl, C3-Cô cycloalkyl, phenyl, naphthyl, or C3-Ci2 heteroaryl; and R7 and R8 together form a Ci-Cô alkylidene group having a double bond with the carbon to which each of R6, R7, and R8 are bound wherein each of the Ci-Cô alkyl, C2-Cô alkenyl, C2-Cô alkynyl, -C3-Cô cycloalkyl, phenyl, naphthyl, or C3-Ci2 heteroaryl groups is optionally substituted with from 1 to 5 R20 groups;
X is N-Q, or O;
Q is H, Ci-C3 alkyl, Ci-C3 haloalkyl, benzyl or substituted benzyl;
each R20 is independently Ci-Cô alkyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, C3-Cô heterocyclic, C5-C12 aryl, C5-Ci2 heteroaryl, halogen, oxo, -ORa, -C(O)Ra, C(O)ORa, -C(0)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, S(O)0-2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2, wherein each Ci-C6 alkyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, C3-Cô heterocyclic, C5-Ci2 aryl, C5-C12 heteroaryl is optionally substituted with from one to fîve halogen, oxo, -ORa, C(O)Ra, -C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, NRaC(O)ORb, -S(0)o-2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or-NO2;
each Ra and Rb is independently H; or Ci-Cô alkyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, C3-Cô heterocyclic, Cs-Ci2 aryl, C5-C12 heteroaryl, each of which is optionally substituted with from one to fîve R21; or Ra and Rb together with the atoms to which they are attached form a heterocycle, and;
each R21 is independently Ci-Cô alkyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, C3-Cô heterocyclic, Cs-Ci2 aryl, C5-C12 heteroaryl, or halogen;
or a pharmaceutically acceptable sait thereof.
[0006] Another aspect provides for a compound selected from the group consisting the title comounds listed in Examples 1 to 201.
[0007] Another aspect provides for a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier.
[0008] Another aspect provides for a use of a compound of Formula (I), or a pharmaceutically acceptable sait thereof, in therapy. Such aspects include use of a compound of Formula (I), or a pharmaceutically acceptable sait thereof, for the treatment of a subject having a disease or condition responsive to the inhibition of a bromodomain-containing protein; and use of a compound of Formula (I), or a pharmaceutically acceptable sait thereof, for the manufacture of a médicament for the treatment of a human having a disease or condition responsive to the inhibition of a bromodomain-containing protein. Another aspect provides for a method of treating a subject having a disease or condition responsive to the inhibition of a bromodomain-containing protein, comprising administering a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable sait thereof. In some aspects, the bromodomain-containing protein is BRD4. In some aspects, the disease or condition is an autoimmune disease, an inflammatory disease, a neurodegenerative disease, a cancer, a cardiovascular disorder, a rénal disorder, a viral infection, or obesity. In certain embodiments, the disease or condition is chosen from rheumatoid arthritis, osteoarthritis, atherosclerosis, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, asthma, chronic obstructive airways disease, pneumonitis, dermatitis, alopecia, nephritis, vasculitis, atherosclerosis, Alzheimer’s disease, hepatitis, primary biliary cirrhosis, sclerosing cholangitis, diabètes (including type I diabètes), acute rejection of transplanted organs, lymphomas, multiple myelomas, leukemias, neoplasms and solid tumors. In some aspects the disease or condition is a solid tumor of the colon, rectum, prostate, lung, pancréas, liver, kidney, cervix, stomach, ovaries, breast, skin, brain, méningés, or central nervous system (including a neuroblastoma or a glioblastoma). In some aspects, the disease or condition is a lymphoma. In some aspects, the disease or condition is a B-cell lymphoma. In some aspects, the disease or condition is Burkitt’s lymphoma. In some aspects, the disease or condition is diffuse large B-cell lymphoma. In some aspects, the disease or condition is multiple myeloma. In some aspects the disease or condition is a carcinoma. In some aspects the disease or condition is NUT midline cardinoma. In some aspects the subject is a human.
[0009] Another aspect provides for a method of downregulating or decreasing MYC transcription in a subject, comprising administering to the subject a compound of Formula (I). Another aspect provides for a method of treating a disease or condition in a subject in which activation of MYC is implicated, comprising administering to the subject a compound of Formula (I).
[0010] In some aspects, the compound is administered intravenously, intramuscularly, parenterally, nasally, or orally. In one aspect, the compound is administered orally.
[0011] Also provided is a method of inhibiting a bromodomain in a subject, comprising providing to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically or a pharmaceutically acceptable sait thereof acceptable sait thereof. Also provided is a method of inhibiting a bromodomain in a cell, comprising providing to the cell a compound of Formula (I). It is understood that providing to the cell may be accomplished by administering the compound to the subject. Also provided is a method of inhibiting a bromodomain, comprising contacting the bromodomain with a compound of Formula (I), or a pharmaceutically acceptable sait thereof.
[0012] Also provided is the use of a compound of Formula (I), or a pharmaceutically acceptable sait thereof, in the manufacture of a médicament for the treatment of a disease or condition responsive to bromodomain inhibition.
[0013] Also provided are kits that include a compound of Formula (I), or a pharmaceutically acceptable sait thereof. In one aspect, the kit further includes instructions for use. In one aspect, a kit includes a compound of Formula (I), or a pharmaceutically acceptable sait thereof, and instructions for use of the compounds in the treatment of the diseases or conditions described above.
[0014] Also provided are articles of manufacture that include a compound of Formula (I), or a pharmaceutically acceptable sait thereof. In one embodiment, the container may be a vial, jar, ampoule, preloaded syringe, or an intravenous bag.
DETAILED DESCRIPTION
[0015] Described herein are compounds of Formula (I), which include compounds of Formulae (la) and (Ib), compositions and formulations containing such compounds, and methods of using and making such compounds.
[0016] One aspect of the current disclosure relates to compounds of Formula (I)
wherein
Rla and Rlb are each independently Ci-Cô alkyl, Ci-Cô alkoxy, Ci-Cf, haloalkyl, Ci-Ce haloalkoxy, Ci-Cô hydroxyalkyl, C3-C6 cycloalkyl, or CH2-C3-C6 cycloalkyl;
R2a and R2b are each independently H or halogen;
R3 is
C5-C10 aryl, C5-C10 heteroaryl, or C5-C10 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or
-S(O)2NHR4, wherein R4 is Ci-Cô alkyl or C3-C7 cycloalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or a moiety of the formula
R6
wherein
R6 is H, OH, or halogen; and R7 and R8 are each independently Ci-Ce alkyl,
C2-C6 alkenyl, C2-C6 alkynyl, C3-Cô cycloalkyl, Ci-Ce heteroalkyl, C5-C12 aryl, C5-C12 heteroaryl, or C5-C12 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or
R6 is H, Ci-Cô alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, phenyl, naphthyl, or C3-C12 heteroaryl; and R7 and R8 together form a Ci-Cô alkylidene group having a double bond with the carbon to which each of R6, R7, and R8 are bound wherein each of the Ci-Ce alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C3-C6 cycloalkyl, phenyl, naphthyl, or C3-C12 heteroaiyl groups is optionally substituted with from 1 to 5 R20 groups;
X is N-Q, or O;
Q is H, C1-C3 alkyl, C1-C3 haloalkyl, benzyl or substituted benzyl;
each R20 is independently Ci-Câ alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, halogen, oxo, -ORa, -C(O)Ra, C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, S(0)o-2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2, wherein each Ci-C6 alkyl, C3-C6 cycloalkyl, Ci-Ce heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, C(O)Ra, -C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, NRaC(O)ORb, -S(0)o-2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2;
each Ra and Rb is independently H; or Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, each of which is optionally substituted with from one to five R21; or Ra and Rb together with the atoms to which they are attached form a heterocycle, and;
each R21 is independently Ci-Cë alkyl, C3-C6 cycloalkyl, Ci-Ce heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, or halogen;
or a pharmaceutically acceptable sait thereof
[0017] One subset of compounds of Formula (I) relates to compounds of Formula (la)
N-O
H3i
H
CH3 (la) wherein
R3 is
C5-C10 aryl, C5-C10 heteroaryl, or C5-C10 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or
-S(O)2NHR4, wherein R4 is Ci-Cô alkyl or C3-C7 cycloalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or a moiety of the formula
wherein
R6 is H, OH, or halogen; and R7 and R8 are each independently Ci-Cô alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C5-C12 aryl, C5-C12 heteroaryl, or C5-C12 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or
R6 is H, Ci-Cô alkyl, Cî-Cô alkenyl, C2-Cô alkynyl, C3-C6 cycloalkyl, phenyl, naphthyl, or C3-C12 heteroaryl; and R7 and R8 together form a Ci-Cô alkylidene group having a double bond with the carbon to which each of R6, R7, and R8 are bound wherein each of the Ci-Cô alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C3-C6 cycloalkyl, phenyl, naphthyl, or C3-C12 heteroaryl groups is optionally substituted with from 1 to 5 R20 groups;
Q is H, C1-C3 alkyl, C1-C3 haloalkyl, benzyl or substituted benzyl;
each R20 is independently Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, halogen, oxo, -ORa, -C(O)Ra, C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, S(0)o-2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2, wherein each Ci-C6 alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, C(O)Ra, -C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, NRaC(O)ORb, -S(O)0-2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2;
each Ra and Rb is independently H; or Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, each of which is optionally substituted with from one to five R21; or Ra and Rb together with the atoms to which they are attached form a heterocycle, and;
each R21 is independently Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, or halogen;
or a pharmaceutically acceptable sait thereof.
[0018] Another subset of compounds ofFormula (I) relates to compounds of Formula (lb)
wherein
R3 is
C5-C10 aryl, C5-C10 heteroaryl, or C5-C10 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or
-S(O)2NHR4, wherein R4 is Ci-Cô alkyl or C3-C7 cycloalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or a moiety of the formula
wherein
R6 is H, OH, or halogen; and R7 and R8 are each independently Ci-Cô alkyl, C2-C6 alkenyl, Cî-Cô alkynyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, C5-C12 aryl, C5-C12 heteroaryl, or C5-C12 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or
R6 is H, Ci-Cô alkyl, C2-Cô alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, phenyl, naphthyl, or C3-C12 heteroaryl; and R7 and R8 together form a Ci-Cô alkylidene group having a double bond with the carbon to which each of R6, R7, and R8 are bound wherein each of the Ci-Cô alkyl, C2-Cô alkenyl, C2-Cô alkynyl, -C3-C6 cycloalkyl, phenyl, naphthyl, or C3-Ci2 heteroaryl groups is optionally substituted with from 1 to 5 R20 groups;
each R20 is independently Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, halogen, oxo, -ORa, -C(O)Ra, C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, S(0)o-2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2, wherein each Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, C(O)Ra, -C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, NRaC(O)ORb, -S(0)o-2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2;
each Ra and Rb is independently H; or Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-Ci2 aryl, Cs-Ci2 heteroaryl, each of which is optionally substituted with from one to five R21; or Ra and Rb together with the atoms to which they are attached form a heterocycle, and;
each R21 is independently Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, Cs-Ci2 aryl, Cs-Ci2 heteroaryl, or halogen;
or a pharmaceutically acceptable sait thereof.
[0019] In some compounds of Formula (I), Rla and Rlb are each independently Ci-Cô alkyl. In some compounds of Formula (I), Rla and Rlb are each independently methyl, ethyl, or propyl. In some compounds of Formula (I), Rla and Rlb are different. In some compounds of Formula (I), Rla and Rlb are the same. In some compounds of Formuala (I), Rla and Rlb are both methyl.
[0020] In some compounds of Formula (I), R2a and R2b are both H. In some compounds of Formula (I), R2a and R2b are both halo. In some compounds of Formula (I), one of R2a and R2b is H and the other is halo. In some compounds of Formula (I), the halo is -F or -Cl.
[0021] In some compound of Formula (I), X is N-Q.
[0022] In some compounds of Formula (I) or (la), Q is H, C1-C3 alkyl, or C1-C3 haloalkyl.
[0023] In some compounds of Formula (I), (la) or (Ib), R3 is C5-C10 aryl, C5-C10 heteroaryl, or C5-C10 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups.
[0024] In some compounds of Formula (I), (la) or (Ib), R3 is phenyl, oxetanyl, tetrahydrofuranyl, furanyl, tetrahydrothiophenyl, thiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, dioxolanayl, oxazolyl, thiazolyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyranyl, pyridinyl, piperidinyl, dioxanyl, morpholinyl, thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, triazinyl, indolizinyl, indolyl, isoindolyl, indolinyl, chromenyl, benzofuranyl, benzothiophenyl, dihydrobenzothiophenyl, indazolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, imidazo[l,2-a]pyridinyl, purinyl, quinolinyl, quinolizinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, indenyl, naphthalenyl, or azulenyl, each of which is optionally substituted with from 1 to 5 R20 groups.
[0025] In some compounds of Formula (I), (la) or (Ib), R3 is a moiety of the formula wherein R6 is H, OH, or halogen; and R7 and R8 are each independently Ci-Cô alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, Ci-Cf, heteroalkyl, C5-C12 aryl, C5-C12 heteroaryl, or C5-C12 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups. In some comounds, R6 is OH. In some compounds, R7 and R8 are each independently Ci-Ce alkyl, C3-C6 cycloalkyl, Ci-Ce heteroalkyl, C5-C12 aryl, C5-C12 heteroaryl, or C5-C12 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups. In some compounds of Formula (I), (la) or (Ib), R7 and R8 are each independently Ci-Cô alkyl, Ce aryl or Cô heteroaryl, each of which is optionally substituted with from 1 to 5 R20 groups. In some compounds, R7 and R8 are each independently Ce aryl or Ce heteroaryl (e.g. a pyridyl), each of which is optionally substituted with from 1 to 5 R20 groups. In some compounds of Formula (I), (la) or (Ib), R7 and R8 are each independently Ci-Ce alkyl, each of which is optionally substituted with from 1 to 5 R20 groups.
[0026] Other non-limiting examples of R3 include the following:
Br
NH2
O
F
[0027] Additional non-limiting examples of R3 include the following:
compounds:
compounds:
[0030] Unless defmed otherwise, ail technical and scientific terms used herein hâve the same meaning as commonly understood by one of ordinary skill in the art. It must be noted that as used herein and in the appended claims, the singular forms a, and, and the include plural referents unless the context clearly dictâtes otherwise. Thus, e.g., reference to the compound includes a plurality of such compounds and reference to the assay includes reference to one or more assays and équivalents thereof known to those skilled in the art, and so forth.
[0031] A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates a point of attachment of a group. A dashed line indicates an optional bond. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written. For instance, the group “-SO2CH2-” is équivalent to “-CH2SO2-” and both may be connected in either direction. The prefix “Cu.v” indicates that the following group has from u to v carbon atoms, one or more of which, in certain groups (e.g. heteroalkyl, heteroaryl, heteroarylalkyl, etc.), may be replaced with one or more heteroatoms or heteroatomic groups. For example, “Ci-6 alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms.
[0032] Also, certain commonly used alternative chemical names may or may not be used. For example, a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc., may also be referred to as an “alkylene” group or an “alkylenyl” group, an “arylene” group or an “arylenyl” group, respectively.
[0033] “Alkyl” refers to any group derived from a linear or branched saturated hydrocarbon. Alkyl groups include, but are not limited to, methyl, ethyl, propyls such as propan-1-yl, propan-
2-yl (iso-propyl), butyls such as butan-l-yl, butan-2-yl (sec-butyl), 2-methyl-propan-l-yl (iso-butyl), 2-methyl-propan-2-yl (t-butyl), pentyls, hexyls, octyls, decyls, and the like. Unless otherwise specified, an alkyl group has from 1 to about 10 carbon atoms, for example from 1 to 10 carbon atoms, for example from 1 to 6 carbon atoms, for example from 1 to 4 carbon atoms.
[0034] “Alkenyl” refers to any group derived from a straight or branched hydrocarbon with at least one carbon-carbon double bond. Alkenyl groups include, but are not limited to, ethenyl (vinyl), propenyl (allyl), 1-butenyl, 1,3-butadienyl, and the like. Unless otherwise specified, an alkenyl group has from 2 to about 10 carbon atoms, for example from 2 to 10 carbon atoms, for example from 2 to 6 carbon atoms, for example from 2 to 4 carbon atoms.
[0035] “Alkynyl” refers to any group derived from a straight or branched hydrocarbon with at least one carbon-carbon triple bond and includes those groups having one triple bond and one double bond. Examples of alkynyl groups include, but are not limited to, ethynyl (-C^CH), propargyl (-ClfrCYCH), (£)-pent-3-en-l-ynyl, and the like. Unless otherwise specified, an alkynyl group has from 2 to about 10 carbon atoms, for example from 2 to 10 carbon atoms, for example from 2 to 6 carbon atoms, for example from 2 to 4 carbon atoms.
[0036] “Aryl” refers to any group derived from one or more aromatic rings, that is, a single aromatic ring, a bicyclic or a multicyclic ring system. Aryl groups include, but are not limited to, those groups derived from acenaphthylene, anthracene, azulene, benzene, chrysene, a cyclopentadienyl anion, naphthalene, fluoranthene, fluorene, indane, perylene, phenalene, phenanthrene, pyrene and the like.
[0037] “Arylalkyl” (also “aralkyl”) refers to any combination of one or more aryl groups and one or more alkyl groups. Arylalkyl groups include, but are not limited to, those groups derived from benzyl, tolyl, dimethylphenyl, 2-phenylethan-l-yl, 2-naphthylmethyl, phenylmethylbenzyl, 1,2,3,4-tetrahydronapthyl, and the like. An arylalkyl group comprises from 6 to about 30 carbon atoms, for example the alkyl group can comprise from 1 to about carbon atoms and the aryl group can comprise from 5 to about 20 carbon atoms.
[0038] “Cycloalkyl” refers to a cyclic alkyl group. A cycloalkyl group can hâve one or more cyclic rings and includes fùsed and bridged groups. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, methylcycloproyl (cyclopropylmethyl), ethylcyclopropyl, and the like.
[0039] “Halo” and “halogen” refer to fluoro, chloro, bromo and iodo.
[0040] “Haloalkyl” refers to an alkyl wherein one or more hydrogen atoms are each replaced by a halogen. Examples include, but are not limited to, -CHzCl, -CH2F, -CHfeBr, -CFCIBr, -CH2CH2Cl, -CH2CH2F, -CF3, -CH2CF3, -CH2CCl3, and the like, as well as alkyl groups such as perfluoroalkyl in which ail hydrogen atoms are replaced by fluorine atoms.
[0041] “Heteroalkyl” refers to an alkyl in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatom or heteroatomic group. Heteroatoms include, but are not limited to, N, P, O, S, etc. Heteroatomic groups include, but are not limited to, -NR-, -O-, -S-, -PH-, -P(O)2-, -S(O), -S(O)2-, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or cycloheteroalkyl. The term “heteroalkyl” includes heterocycloalkyl (a cyclic heteroalkyl group), alkyl-heterocycloalkyl (a linear or branched C1-C6 alkyl group attached to a cyclic heteroalkyl group), and the like. Heteroalkyl groups include, but are not limited to, -OCH3, CH2OCH3, -SCH3, -CH2SCH3, -NRCH3, -CH2NRCH3, and the like, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted. A heteroalkyl group comprises from 1 to about 10 carbon and hetero atoms, e.g., from 1 to 6 carbon and hetero atoms.
[0042] “Heteroaryl” refers to an aryl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatom or heteroatomic group, as defined above. Heteroaryl groups include, but are not limited to, groups derived from acridine, benzoimidazole, benzothiophene, benzofùran, benzoxazole, benzothiazole, carbazole, carboline, cinnoline, furan, imidazole, imidazopyridine, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like.
[0043] “Heteroarylalkyl” refers to an arylalkyl group in which one or more carbon atoms (and any associated hydrogen atoms) are independently replaced with the same or different heteroatoms or heteratomic groups, as defined above. Heteroarylalkyl groups include, but are not limited to, groups derived from heteroaryl groups with alkyl substituents (e.g. methylpyridines, ethylthiophenes, methylthiazoles, dimethylisoxazoles, etc.), hydrogenated heteroaryl groups (dihydroquinolines, e.g. 3,4-dihydroquinoline, dihydroisoquinolines, e.g. 1,2-dihydroisoquinoline, dihydroimidazole, tetrahydroimidazole, etc.), indoline, isoindoline, isoindolones (e.g. isoindolin-1-one), isatin, dihydrophthalazine, quinolinone, spiro[cyclopropane-l,l'-isoindolin]-3'-one, and the like.
[0044] “Heterocycle,” “heterocyclic,” and “heterocyclyl” refer to a single saturated or partially unsaturated non-aromatic ring or a non-aromatic multiple-ring System with at least one heteroatom or heteroatomic group, as defined above. Heterocycles include, but are not limited to, groups derived from azetidine, aziridine, imidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, quinuclidine, N-bromopyrrolidine, N-chloropiperidine, and the like.
[0045] The term pharmaceutically acceptable with respect to a substance refers to that substance which is generally regarded as safe and suitable for use without undue toxicity, irritation, allergie response, and the like, commensurate with a reasonable benefit/risk ratio.
[0046] “Pharmaceutically acceptable sait” refers to a sait of a compound that is pharmaceutically acceptable and that possesses (or can be converted to a form that possesses) the desired pharmacological activity of the parent compound. Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, fùmaric acid, glucoheptonic acid, gluconic acid, lactic acid, maleic acid, malonic acid, mandelic acid, methanesulfonic acid, 2-napththalenesulfonic acid, oleic acid, palmitic acid, propionic acid, stearic acid, succinic acid, tartaric acid, p-toluenesulfonic acid, trimethylacetic acid, and the like, and salts formed when an acidic proton présent in the parent compound is replaced by either a métal ion, e.g., an alkalî métal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as diethanolamine, triethanolamine, N-methylglucamine and the like. Also included in this définition are ammonium and substituted or quaternized ammonium salts. Représentative non-limiting lists of pharmaceutically acceptable salts can be found in S.M. Berge et al., J. Pharma Sci., 66(1),
1-19 (1977), and Remington: The Science and Practice of Pharmacy, R. Hendrickson, ed., 21 st édition, Lippincott, Williams & Wilkins, Philadelphia, PA, (2005), at p. 732, Table 38-5, both of which are hereby incorporated by reference herein.
[0047] “Subject” and “subjects” refers to humans, domestic animais (e.g., dogs and cats), farm animais (e.g., cattle, horses, sheep, goats and pigs), laboratory animais (e.g., mice, rats, hamsters, guinea pigs, pigs, rabbits, dogs, and monkeys), and the like.
[0048] “Treating” and “treatment” of a disease include the following:
(1) preventing or reducing the risk of developing the disease, i.e., causing the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the disease but does not yet expérience or display symptoms of the disease, (2) inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms, or (3) relieving the disease, i.e., causing régression of the disease or its clinical symptoms.
[0049] “Effective amount” refers to an amount that may be effective to elicit the desired biological, clinical, or medical response, including the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment. The effective amount will vary depending on the compound, the disease and its severity and the âge, weight, etc., of the subject to be treated. The effective amount can include a range of amounts.
[0050] It it understood that combinations of chemical groups may be used and will be recognized by persons of ordinary skill in the art. For instance, the group “hydroxyalkyl” would refer to a hydroxyl group attached to an alkyl group. A great number of such combinations may be readily envisaged.
[0051] Provided are also compounds in which from 1 to n hydrogen atoms attached to a carbon atom may be replaced by a deuterium atom or D, in which n is the number of hydrogen atoms in the molécule. As known in the art, the deuterium atom is a nonradioactive isotope of the hydrogen atom. Such compounds exhibit may increase résistance to metabolism, and thus may be useful for increasing the half-life of the compounds when administered to a mammal. See, e.g., Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci., 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogen atoms hâve been replaced by deuterium.
[0052] Compounds of a given formula described herein encompasses the compound disclosed and ail pharmaceutically acceptable salts, stereoisomers, tautomers, solvatés, and deuterated forms thereof, unless otherwise specified.
[0053] The pharmaceutical compositions of compounds of Formual (I) (including compounds of Formulae (la) and (Ib)) may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an arteryinserted cylindrical polymer.
[0054] In one aspect, the compounds described herein may be administered orally. Oral administration may be via, for example, capsule or enteric coated tablets. In making the pharmaceutical compositions that include at least one compound of Formula (I), or a pharmaceutically acceptable sait, ester, prodrug, or solvaté thereof, the active ingrédient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingrédient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, élixirs, suspensions, émulsions, solutions, syrups, aérosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight ofthe active compound, soft and hard gelatin capsules, stérile injectable solutions, and stérile packaged powders.
[0055] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, stérile water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnésium stéarate, and minerai oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
[0056] The compositions that include at least one compound of Formula (I), or a pharmaceutically acceptable sait, ester, prodrug, or solvaté thereof, can be formulated so as to provide quick, sustained or delayed release of the active ingrédient after administration to the subject by employing procedures known in the art. Controlled release drug delivery Systems for oral administration include osmotic pump Systems and dissolutional Systems containing polymer-coated réservoirs or drug-polymer matrix formulations. Examples of controlled release Systems are given in U.S. Patent Nos. 3,845,770; 4,326,525; 4,902,514; and 5,616,345. Another formulation for use in the methods of the présent invention employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the présent invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
[0057] The compositions may, in some embodiments, be formulated in a unit dosage form. The term “unit dosage forms” refers to physically discrète units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient (e.g., a tablet, capsule, ampoule). The compounds are generally administered in a pharmaceutically effective amount. In some embodiments, for oral administration, each dosage unit contains from about 10 mg to about 1000 mg of a compound described herein, for example from about 50 mg to about 500 mg, for example about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg. In other embodiments, for parentéral administration, each dosage unit contains from 0.1 to 700 mg of a compound a compound described herein. It will be understood, however, that the amount of the compound actually administered usually will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the âge, weight, and response of the individual subject, and the severity of the subject’s symptoms.
[0058] In certain embodiments, dosage levels may be from 0.1 mg to 100 mg per kilogram of body weight per day, for example from about 1 mg to about 50 mg per kilogram, for example from about 5 mg to about 30 mg per kilogram. Such dosage levels may, in certain instances, be useful in the treatment of the above-indicated conditions. In other embodiments, dosage levels may be from about 10 mg to about 2000 mg per subject per day. The amount of active ingrédient that may be combined with the vehicle to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms may contain from 1 mg to 500 mg of an active ingrédient.
[0059] Frequency of dosage may also vary depending on the compound used and the particular disease or condition treated. In some embodiments, for example, for the treatment of an autoimmune and/or inflammatory disease, a dosage regimen of 4 times daily or less is used. In some embodiments, a dosage regimen of 1 or 2 times daily is used. It will be understood, however, that the spécifie dose level for any particular subject will dépend upon a variety of factors including the activity of the spécifie compound employed, the âge, body weight, general health, sex, diet, time of administration, route of administration, and rate of excrétion, drug combination and the severity of the particular disease in the subject undergoing therapy.
[0060] For preparing solid compositions such as tablets, the principal active ingrédient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of Formula (I), or a pharmaceutically acceptable sait, ester, prodrug, or solvaté thereof. When referring to these preformulation compositions as homogeneous, the active ingrédient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
[0061] The tablets or pills of the compounds described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodénum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
[0062] Kits that include a compound of Formula (I), or a pharmaceutically acceptable sait, thereof, and suitable packaging are provided. In one embodiment, a kit further includes instructions for use. In one aspect, a kit includes a compound of Formula (I), or a pharmaceutically acceptable sait thereof, and instructions for use of the compounds in the treatment of the diseases or conditions described herein.
[0063] Articles of manufacture that include a compound of Formula (I), or a pharmaceutically acceptable sait thereof, in a suitable container are provided. The container may be a vial, jar, ampoule, preloaded syringe, and intravenous bag.
[0064] Compounds of Formula (I) may be combined with one or more additional anti-cancer or anti-inflammatory agents, including any of the following. Various kinase inhibitors are being used and are being developed to treat various cancers. For example, the activiation of the phosphatidylinositol 3-kinase (PI3K) pathway is observed in human cancer, and agents inhibiting PI3K are being investigated or developed as potential anti-cancer drugs and for the use in anti-cancer thérapies. Additional kinase inhibitors include inhibitors of spleen tyrosine kinase (Syk) and Janus kinase (JAK). Other agents inhibiting related pathways are also of interest as anti-cancer or anti-inflammatory agents, including agents inhibiting the Ras/Raf/MEK/ERK pathway and the PI3K/PTEN/Akt/mTOR pathway. As described herein, such inhibitors include agents that inhibit ail subclasses of a target (e.g. PI3K alpha, beta, delta and gamma), agents that inhibit primarily one subclass, and agents that inhibit a subset of ail subclasses. Compounds of Formula (I) may also be combined with one or more additional anti-cancer or anti-inflammatory agents including inhibitors or antagoniste of lysyl oxidase-like 2 (LOXL2), and inhibitors or antagoniste of adenosine A2B receptor.
[0065] In various aspects, compounds of Formula (I) may be combined with one or more kinase inhibitors. Examples of kinase inhibitors include PI3K inhibitors, Syk inhibitors and J AK inhibitors.
[0066] Examples of PI3K inhibitors include Compound A, Compound B, and Compound C:
(Compound A)
(Compound B)
(Compound C).
[0067] Additional examples ofPI3K inhibitors include XL147, BKM120, GDC-0941,
BAY80-6946, PX-866, CH5132799, XL756, BEZ235, and GDC-0980.
[0068] Inhibitors of mTOR include OSI-027, AZD2014, and CC-223.
[0069] Inhibitors of AKT include MK-2206, GDC-0068 and GSK795.
[0070] Examples of Syk inhibitors include compound D:
(Compound D).
[0071] Additional Syk inhibitors include R788 (fostamatinib), R-406 (tamatinib), and
PRT062607.
[0072] Examples of J AK inhibitors include Compound E:
(Compund E).
[0073] Additional JAK inhibitors include Ruxolitinib, Tofacitinib, Baricitinib, CYT387,
Lestaurtinib, Pacritinib, and TGI01348.
[0074] In other aspects, compounds of Formula (I) may be combined with one or more inhibitors or modulators (e.g. antagonists) of LOXL2, adenosine A2B receptor, MMP-9, ASK1, BTK, mTOR, HD AC, and MEK.
[0075] In other aspects, compounds of Formula (I) may be combined with one or more components of CHOP therapy (cyclophosphamide, Adriamycin, Vincristine, Prednisolone).
[0076] In other aspects, compounds of Formula (I) may be combined with one or more of ribavirin and interferon.
[0077] In other aspects, compounds of Formula (I) may be combined with one or more agents that activate or reactivate latent human immunodeficiency virus (HIV). For example, compounds of Formula (I) may be combined with a histone deacetylase (HDAC) inhibitor (listed above) or a protein kinase C (PKC) activator. For example, compounds of Formula (I) may be combined with romidepsin or panobinostat.
EXAMPLES
[0078] General Methods. Synthesis of certain compounds, and intermediates used to préparé compounds, is detailed in the following sections. Compound numbers are listed for convenience.
[0079] Ail operations involving moisture and/or oxygen sensitive materials were conducted under an atmosphère of dry nitrogen in pre-dried glassware. Unless noted otherwise, materials were obtained from commercially available sources and used without further purification.
[0080] Flash chromatography was performed on an Isco Combiflash Companion using RediSep Rf silica gel cartridges by Teledyne Isco. Thin layer chromatography was performed using precoated plates purchased from E. Merck (silica gel 60 PF254, 0.25 mm) and spots were visualized with long-wave ultraviolet light followed by an appropriate staining reagent.
[0081] Nuclear magnetic résonance (“NMR”) spectra were recorded on a Varian 400 MHz résonance spectrometer. IH NMR chemical shifts are given in parts per million (δ) downfield from tetramethylsilane (“TMS”) using TMS or the residual solvent signal (CHC13 = δ 7.24, DMSO = δ 2.50) as internai standard. IH NMR information is tabulated in the following format: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet), coupling constant(s) (J) in Hertz, number of protons. The prefix app is occasionally applied in cases where the true signal multiplicity was unresolved and br indicates the signal in question was broadened.
[0082] The compounds were named using ChemBioDraw Ultra Version 12.0.
[0083] LCMS analysis was performed using a PE SCIEX API 2000 spectrometer with a Phenomenex Luna 5 micron C18 column.
[0084] Preparatory HPLC was performed on a Gilson HPLC 215 liquid handler with a
Phenomenex column (Gemini 10 □„ C18,110A) and a UV/VIS 156 detector.
[0085] When production of starting materials is not particularly described, the compounds are known or may be prepared analogously to methods known in the art or as disclosed in the Examples. One of skill in the art will appreciate that synthetic méthodologies described herein are only représentative of methods for préparation of the compounds described herein, and that other known methods and variants of methods described herein may be used. The methods or features described in various Examples may be combined or adapted in various ways to provide additional ways of making the compounds described herein.
[0086] Methods for obtaining the novel compounds described herein will be apparent to those of ordinary skill in the art, procedures described in, for example, the reaction schemes and examples below, and in the references cited herein.
EXAMPLES
[0087] Methods for obtaining the novel compounds described herein will be apparent to those of ordinary skill in the art, with suitable procedures being described, for example, in the reaction schemes and examples below, and in the references cited herein.
Scheme 1
X
ΛΛ/V
I (a)
Formula (A)
[0088] The compound of Formula (1-a) can be prepared by Suzuki coupling of a compound of commercially available compound of Formula (a) to commercially available isoxazole boronic acid ester shown above in the presence of a base. Substituents X in compound (a) may be any appropriate leaving group (e.g., Cl, Br, I, OTf). Suitable catalysts may include palladium catalysts, such as (l,3-bis(2,6-diisopropylphenyl)imidazolidene)(3-chloropyridyl) palladium(II) dichloride (Peppsi-iPr). Suitable bases may include, for example, césium carbonate or l,8-diazobicycloundec-7-ene. Suitable solvents may include a combination of organic solvents and water, including, for example, 1,4-dioxane, THF, dimethoxyethane or dimethylformamide and water. The reaction is carried out in an appropriate solvent under nitrogen, at an elevated température of about 70°C to 150°C, for about 30 seconds to 5 hours.
When the reaction is substantially complété, the reaction is allowed to cool to room température. The reaction mixture can be partitioned between an aqueous phase and an organic phase. The aqueous phase is discarded, and the organic phase concentrated under reduced pressure, and the residue is purified by reverse phase high-performance liquid chromatography, eluting with an appropriate solvent mixture such as acetonitrile and water, 10 to isolate compounds of Formula (A).
[0089] Another exemplary method of preparing compounds of Formula (B) is shown in Reaction Scheme No. 2.
Br
jvw
I
Scheme 2
Step 1 - Préparation of Formula (B-l)
[0090] The compound of Formula (B-l) can be prepared by Suzuki coupling of a compound of commercially available compound chloro-bromo substituted aromatic heterocycle which may bear an additional heteroaryl ring as shown above as two variable attachment bonds to commercially available isoxazole boronic acid ester shown above in the presence of a base. Suitable catalysts may include palladium catalysts, such as [l,l'-Bis(diphenylphosphino) ferrocene] dichloropalladium(II). Suitable bases may include, for example, césium carbonate or l,8-diazobicycloundec-7-ene. Suitable solvents may include a combination of organic solvents and water, including, for example, 1,4-dioxane, THF, dimethoxyethane or dimethylformamide and water. The reaction is carried out in an appropriate solvent under nitrogen, at an elevated température of about 70°C to 150°C, for about 30 seconds to 5 hours. When the reaction is substantially complété, the reaction is allowed to cool to room température. The reaction mixture can be partitioned between an aqueous phase and an organic phase. The aqueous phase is discarded, and the organic phase concentrated under reduced pressure, and the residue is purified by reverse phase high-performance liquid chromatography, eluting with an appropriate solvent mixture such as acetonitrile and water, to isolate compounds of Formula (B-l). The compound of Formula (B-l) may also be purified by other conventional means, such as silica gel chromatography.
Step 2 - Préparation of Formula (B-2)
[0091] The compound of Formula (B-2) can be prepared by Suzuki coupling of a compound of Formula (B-l) to commercially available boronic acid dérivatives bearing substituent R3 as defined in the spécification for compounds of Formula (I). Suitable catalysts may include palladium catalysts, such as (l,3-bis(2,6-diisopropylphenyl)imidazolidene)(3-chloropyridyl) palladium(II) dichloride (Peppsi-iPr). Suitable bases may include, for example, césium carbonate or l,8-diazobicycloundec-7-ene. Suitable solvents may include a combination of organic solvents and water, including, for example, 1,4-dioxane, THF, dimethoxyethane or dimethylformamide and water. The reaction is carried out in an appropriate solvent under nitrogen, at an elevated température of about 70°C to 150°C, for about 30 seconds to 5 hours. When the reaction is substantially complété, the reaction is allowed to cool to room température. The reaction mixture can be partitioned between an aqueous phase and an organic phase. The aqueous phase is discarded, and the organic phase concentrated under reduced pressure, and the residue is purified by reverse phase high-performance liquid chromatography, eluting with an appropriate solvent mixture such as acetonitrile and water, to isolate compounds of Formula (B-2).
[0092] Another exemplary method of preparing compounds of Formula (C-2) is shown in Reaction Scheme No. 3.
Scheme 3
Formula (C-2)
Step 1 - Préparation of Formula (C-l)
[0093] An appropriate carbony-delivering reagent is reacted with the compound of Formula (C-l) (with substituent Q as either H or methyl) in an appropriate solvent, and allowed to react for a period of time such as 1-5 hours at an elevated température of 80-150 °C. Appropriate solvents include organic solvents such as tetrahydrofuran. When the reaction is substantially complété, the compound of (C-l) is isolated by removal of solvent under vacuum and purification by conventional means, such as recrystallization or trituration in an appropriate solvent mixture, such as hexanes and ethyl acetate.
Step 2 - Préparation of Formula (C-2)
[0094] The compound of Formula (C-2) can be prepared by Suzuki coupling of a compound of Formula (C-l) to boronic acid shown above in the presence of a base. As shown above, boronic acid is substituted with carbon-linked phenyl, naphthyl, or heteroaryl R3 group as defined in the spécification for compounds of Formula (I). It should be understood that boronate esters, or other appropriate boron complexes (i.e. -BF3K salts, etc.) may also be used in place of a boronic acid. Suitable catalysts may include palladium catalysts, such as ( 1,3-bis(2,6-diisopropylphenyl)imidazolidene)(3-chloropyridyl) palladium(II) dichloride (Peppsi-iPr). Suitable bases may include, for example, césium carbonate or 1,8diazobicycloundec-7-ene. Suitable solvents may include a combination of organic solvents and water, including, for example, 1,4-dioxane, THF, dimethoxyethane or dimethylformamide and water. The reaction is carried out in an appropriate solvent under nitrogen, at an elevated température of about 70°C to 150°C, for about 30 seconds to 5 hours. When the reaction is substantially complété, the reaction is allowed to cool to room température.
[0095] The reaction mixture can be partitioned between an aqueous phase and an organic phase. The aqueous phase is discarded, and the organic phase concentrated under reduced pressure, and the residue is purified by reverse phase high-performance liquid chromatography, eluting with an appropriate solvent mixture such as acetonitrile and water, to isolate compounds of Formula (C-2). Altematively, the compound of Formula (C-2) may be purified by other conventional means, such as silica gel chromatography or recrystallization.
[0096] When the reactions described herein are substantially complété, the reaction may be allowed to cool to room température. The reaction mixture can then be concentrated and purified by any suitable method, including for example, chromatography on silica gel or préparative HPLC to obtain the compound of Formulas (I), (la), and (Ib), including each of the compounds in the examples provided below.
Step 3: Préparation of Formula (C1-C5)
[0097] The compound of Formula (C-4, C-5 and C-6) can be prepared as follows: Reacting (C-l) with and appropriate carbonyl source as described previously affords (C-2). (C-2) is then reacted with metalated alkyl or aryl reagents (e.g. but not limited to Li or Mg) to symmetrical carbinols (C-4), or converted to Weinreb amide (C-3) followed by reaction with metalated alkyl and aryl reagents to afford ketone (C-5). Ketone (C-5) can then we reacted again with metalated alkyl and aryl reagents to afford asymmetric carbinol (C-6).
[0098] Alternatively, compounds above can be prepared by converting (C-l) to the corresponding 2-alkoxy-benzimidazole (C-7), which is then further converted to (C-4) including (C-6) using methods above.
Scheme 3
O-N
(C^)
[0099] The following examples are included to demonstrate certain preferred embodiments. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute certain preferred modes for its practice. However, those of skill in the art should, in light of the présent disclosure, appreciate that many changes can be made in the spécifie embodiments which are disclosed, and still obtain a like or similar results without department from the spirit and the scope of the invention.
[00100] The following abbreviations are used in the Examples below:
DME 1,2-dimethoxy ethane
DMF dimethylformamide
EtOAc ethyl acetate
Hepes 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid mCPBA meta chloroperbenzoic acid
MeCN acetonitrile
NBS N-bromosuccinimide
Peppsi-iPr (or PEPPSI iPr or PEPPSI™-iPr)
(l,3-bis(2,6-diisopropylphenyl)imidazolidene)(3chloropyridyl)palladium(II) dichloride | |
PdChdppf | [1,1 -Bis(diphenylphosphino) ferrocene]dichloropalladium (II) |
POC13 | phosphoryl chloride |
rf | rétention factor |
TEA | triethylamine |
TFA | trifluoroacetic acid |
THF | tetrahydrofuran |
Example 1
N-cyclopentyl-6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazole-4sulfonamide
CDI, TEA
[00101] 2,3 -Diamino-N-cyclopentyl-5 -(3,5-dimethylisoxazol-4-yl)benzenesulfonamide (58 mg, 0.17 mmol) was dissolved in DMF (2 mL). To the solution was added CDI (360 mg, 4 mmol) and TEA (1 mL). The reaction was heated at 150°C in microwave for lOh. The solvent was evaporated and the residue was purified by préparative HPLC (0-100% CH3CN/H2O) to afford N-cyclopentyl-6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lHbenzo[d]imidazole-4-sulfonamide.
[00102] C17H20N4O4S. 377.0 (M+l). ‘H NMR (400MHz, CD3OD) δ 7.34 (s, IH), 7.18 (s, IH), 3.63-3.58 (m, IH), 2.41 (s, 3H), 2.25 (s, 3H), 1.70-1.60 (m, 4 H), 1.49-1.31 (m, 4H).
Example 2
6-(3,5-dimethyIisoxazol-4-yI)-4-(6-methylquinolin-5-yl)-lH-benzo[d]imidazol-2(3H)-one
PEPPSI-iPr (5 mol%)
N-O
^NH
O
NfljCOs dioxane
H2O
[00103] 6-(3,5-Dimethylisoxazol-4-yl)-4-iodo-1 H-benzo [d]imidazol-2(3H)-one (38.9 mg, 0.11 mmol) was treated with 6-methylquinolin-5-ylboronic acid (30.9 mg, 0.165 mmol,
1.5 equiv.), 2M-Na2CO3 (aq) (1 mL) in the presence of PEPPSI iPr (3.7 mg, 0.0055 mmol, 0.05 equiv) in 1,4-dioxane (3 mL) at 150°C for 20 min in microwave reactor (Biotage, Optimizer). To the reaction mixture were added water (30 mL) and EtOAc (70 mL). The whole was filtered through Celite (3 g) and then organic layer was separated from the filtrate.
The organic layer was washed with brine (30 mL) and dried over NaîSCU The solvent was removed under a reduced pressure to give a crude product. The crude product was purified by a préparative HPLC (5-95% acetonitrile: water with 0.05% trifluoroacetic acid, on a Phenomenex Luna Cl8 column) and a silica gel chromatography (MeOH:CH2C12 = 3:97-10:90) to give 6-(3,5-dimethylisoxazol-4-yl)-4-(6-methylquinolin-5-yl)-lHbenzo[d]imidazol-2(3H)-one.
[00104] 6-(3,5-dimethylisoxazol-4-yl)-4-(6-methylquinolin-5 -yl)-1Hbenzo[d]imidazol-2(3H)-one: C22H18N4O2. MS. m/z 371.1 (M+l). XH NMR (MeOH-iA) δ
9.15 (d, J= 5.3 Hz, IH), 8.58 (t, J= 8.7 Hz, IH), 8.58 (d, J= 9.0 Hz, IH), 8.22 (d, J= 9.0 Hz, IH), 7.95 (dd, J= 8.7, 5.3 Hz, IH), 7.20 (d, J= 1.5 Hz, IH), 6.95 (d, J= 1.5 Hz, IH), 2.46 (s, 3H), 2.45 (s, 3H), 2.30 (s, 3H).
Example 3
4,6-bis(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazoI-2(3H)-one
N-O
O
[00105] 4,6-bis(3,5 -dimethy lisoxazol-4-yl)-1 H-benzo[d]imidazol-2(3H)-one was synthesized using 3,5-dimethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoxazole and Cs2CO3 in a similar fashion as 6-(3,5-dimethylisoxazol-4-yl)-4-(6-methylquinolin-5-yl)-lHbenzo[d]imidazol-2(3H)-one (Example 2).
[00106] C17H16N4O3. MS. 325.1 (M+l). *H NMR (MeOH-cA) δ 7.04 (d, J = 1.5 Hz,
IH), 6.87 (dd, J= 1.5 Hz, IH), 2.43 (s, 3H), 2.35 (s, 3H), 2.27 (s, 3H), 2.20 (s, 3H).
Example 4
6-(3,5-dimethylisoxazoI-4-yl)-4-(2-phenylpyridin-3-yl)-lH-benzo[d]imidazoI-2(3H)-one
[00107] 6-(3,5-dimethylisoxazol-4-yl)-4-(2-phenylpyridin-3-yl)-lH-benzo[d]imidazol2(3H)-one was synthsized using 2-phenylpyridin-3-ylboronic acid and CS2CO3 in a similar fashion as 6-(3,5 -dimethylisoxazol-4-yl)-4-(6-methylquinolin-5 -yl)-1 H-benzo [d]imidazol2(3H)-one (Example 2).
C23H18N4O2. MS. 383.1 (M+l). *H NMR (MeOH-dT) δ 8.89 (dd, J = 5.7, 1.5 Hz, IH), 8.60 (dd, J= 7.9, 1.5 Hz, IH), 8.04 (dd, J= 7.9, 5.7 Hz, IH), 7.51 - 7.39 (m, 5H), 6.98 (d, J= 1.5
Hz, IH), 6.75 (d, J= 1.5 Hz, IH), 2.19 (s, 3H), 2.03 (s, 3H).
Example 5
4-(3,5-dimethyl-lH-pyrazol-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-
2(3H)-one
O
[00108] 4-(l,4-dimethyl-lH-pyrazol-5-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one was synthsized using 3,5-dimethyl-4-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)-lH-pyrazole and CS2CO3 in a similar fashion as 6-(3,5-dimethylisoxazol
4-yl)-4-(6-methylquinolin-5-yl)-lH-benzo[d]imidazol-2(3H)-one (Example 2).
[00109] CnHnNsCh. MS. 324.1 (M+l). *H NMR (MeOEkA) δ 7.51 (s, IH), 7.11 (d, J= 1.5 Hz, IH), 6.92 (d, J= 1.5 Hz, IH), 3.74 (s, 3H), 2.43 (s, 3H), 2.28 (s, 3H), 2.00 (s, 3H).
Example 6
5-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2i3-dihydro-lH-benzo[d]imidazoI-4-yl)-l-methyl-
3,4-dihydroquinoIin-2(lH)-one
Step 1: Préparation of l-methyl-5-(4,4,5,5-tetramethyl-E3,2-dioxaborolan-2-yl)-3,4dihydroquinolin-2( 1 H)-one
[00110] 5 -bromo-l-methyl-3,4-dihydroquinolin-2(lH)-one (171.4 mg, 0.714 mmol) was treated with 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (272.0 mg, 1.071 mmol, 1.5 equiv.), KOAc (210.2 mg, 2.142 mmol, 3.0 equiv) in the presence of PdChdppf (26.1 mg, 0.0357 mmol, 0.05 equiv) in DMSO (4 mL) at 100°C for 20 min in a micro wave reactor. To the reaction mixture was added water (30 mL) and EtOAc (70 mL). The mixture was filtered through Celite (3 g) and then organic layer was separated from the filtrate. The organic layer was washed with brine (30 mL) and dried over Na2SO4. The solvent was removed under a reduced pressure to give a crude product. The crude product was purified by a préparative HPLC (5-95% acetonitrile: water with 0.05% trifluoroacetic acid, on a Phenomenex Luna Cl8 column) and a silica gel chromatography (MeOH:CH2Cl2 = 3:97-10:90) to give l-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4dihydroquinolin-2(lH)-one (117.2 mg). CieH22BNO3. MS. m/z 389.1 (M+l).
Step 2: Préparation of 5-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-4-yl)-l-methyl-3,4-dihydroquinolin-2(lH)-one
[00111] 5-(6-(3,5 -dimethylisoxazol-4-yl)-2-oxo-2,3 -dihydro-1 H-benzo [d]imidazol-45 yl)-l-methyl-3,4-dihydroquinolin-2(lH)-one was synthsized using l-methyl-5-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(lH)-one and CS2CO3 in a similar fashion as 6-(3,5-dimethylisoxazol-4-yl)-4-(6-methylquinolin-5-yl)-lH-benzo[d]imidazol2(3H)-one (Example 2).
[00112] 5-(6-(3,5-dimethylisoxazol-4-yI)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-410 yl)-l-methyl-3,4-dihydroquinolin-2(lH)-one: C22H20N4O3. MS. m/z 389.1 (M+l). 'HNMR (MeOH-tA) δ 7.41 (t, J= 8.0 Hz, IH), 7.24 (dd, J= 8.0, 1.1 Hz, IH), 7.11 (dd, J= 8.0, 1.1 Hz, IH), 7.02 (d, J= 1.5 Hz, IH), 6.84 (d, J = 1.5 Hz, IH), 3.42 (s, 3H), 2.88 - 2.64 (m, 2H),
2.64 - 2.46 (m, 2H), 2.42 (s, 3H), 2.27 (s, 3H).
Example 7
5-(3,5-dimethylisoxazoI-4-yl)-l-methyl-7-(6-methylquinolin-5-yl)-lH-benzo[d]imidazoi2(3H)-one
Step 1: Préparation of4-(3,5-dimethylisoxazol-4-yl)-2-iodo-N-methyl-6-nitroaniline
Mel, Οδ2θθ3
DMF
[00113] Into a flask containing 4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6-nitroaniline (1000 mg, 2.78 mmol, 1 equiv) is added DMF (15 mL, 0.2 M) before adding césium carbonate (1.4 gm, 4.17 mmol, 1.5 equiv.) and idomethane (260 pL, 4.17 mmol, 1.5 equiv). After an hour, the reaction was quenched with water and the reaction was partitioned between 5 water and ethyl acetate. The organic layer was washed with brine and dried over sodium sulfate. Purification was carried out by flash column chromatography to fumish 4-(3,5dimethylisoxazol-4-yl)-2-iodo-N-methyl-6-nitroaniline (615 mg, 60 %).
[00114] LCMS (m/z+1)373.85. ’HNMR (400 MHz, cdch) δ 7.81 (t, J= 3.0 Hz, IH),
7.70 (d, J= 2.1 Hz, IH), 2.97 (s, 3H), 2.40 (d, J= 16.8 Hz, 3 H), 2.26 (d, J= 14.2 Hz, 3H).
Step 2: Préparation of4-(3,5-dimethylisoxazol-4-yl)-6-iodo-Nl-methylbenzene-L2-diamine
SnCI2, EtOH
[00115] Into a microwave vial containing 4-(3,5-dimethylisoxazol-4-yl)-2-iodo-Nmethyl-6-nitroaniline (610 mg, 1.64 mmol, 1 equiv) is added EtOH (12mL, 0.25M) and tin (II) chloride (622 mg, 3.28 mmol, 2 equiv). The reaction was heated for 30 min at 110°C. The 15 reaction was then stirred in 2N NaOH solution for 20 minutes before being partitioned between water and ethyl acetate. The organic layer was washed with brine and dried over sodium sulfate. Purification was carried out by flash column chromatography to fùrnish 4(3,5-dimethylisoxazol-4-yl)-6-iodo-Nl-methylbenzene-l,2-diamine.
[00116] LCMS (m/z +1) 344.02.
Step 3: Préparation of 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-l-methyl-lH-benzo[d]imidazol2(3H)-one
CDI, THF
[00117] Into a flask containing 4-(3,5-dimethylisoxazol-4-yl)-6-iodo-Nlmethylbenzene-l,2-diamine (299 mg, 0.87mmol, 1 equiv) is added THF (8 mL, 0.1 M) and CDI (282 mg, 1.74 mmol, 2 equiv). The reaction was heated for 2 hr at 120°C. The reaction was then concentrated in vacuo and the solid triturated with diethyl ether before being air dried to fumish 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-l-methyl-lH-benzo[d]imidazol-2(3H)one as a light yellow solid.
[00118] LCMS (m/z +1) 370.00.
Step 4: Préparation of 5-(3,5-dimethylisoxazol-4-yl)-l-methyl-7-(6-methylquinolin-5-yl)lH-benzo[d]imidazol-2(3H)-one
[00119] To a microwave vial containing 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-lmethyl-lH-benzo[d]imidazol-2(3H)-one (40 mg, 0.11 mmol, 1 equiv.) was added 3,5- 6methylquinoIin-5-ylboronic acid (51 mg, 0.27 mmol, 2.5 equiv.), CS2CO3 (141 mg, 0.43 mmol, 4 equiv.) and PEPPSI™-IPr catalyst (8 mg, 0.02 mmol, 0.1 equiv.) and dissolved in
DME-H2O (20 mL, 0.2 M, 2/1, v/v). The mixture was heated to 140C. After 2 hr, the reaction was complété. After cooling, the reaction was extracted with EtOAc and washed with water and saturated NH4CI. After drying with MgSCU, it was fîltered and concentrated to dryness. Purification was carried out by reverse phase HPLC to furnish 5-(3,5-dimethylisoxazol-4-yl)l-methyl-7-(6-methylquinolin-5-yl)-lH-benzo[d]imidazol-2(3H)-one.
[00120] LCMS (m/z +1) 385.23. JH NMR (400 MHz, cd3od) δ 8.82 (d, J= 4.3 Hz, IH), 8.09 (d, J= 8.7 Hz, IH), 7.82 (t, J= 7.1 Hz, 2H), 7.47 (dd, J= 8.5, 4.3 Hz, IH), 7.17 (d, J = 1.6 Hz, IH), 6.82 (d, J = 1.6 Hz, IH), 2.53 (s, 3H), 2.42 (s, 3H), 2.33 (s, 3H), 2.27 (s, 3H).
Example 8
7-(l,4-dimethyl-lH-pyrazol-5-yl)-5-(3,5-dimethyIisoxazol-4-yl)-l-methyI-lHbenzo [d] imidazol-2(3H)-one
N-O
[00121] To a microwave vial containing 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-lmethyl-lH-benzo[d]imidazol-2(3H)-one (40 mg, 0.11 mmol, 1 equiv.) was added 1,4dimethyl-lH-pyrazol-5-ylboronic acid (72 mg, 0.32 mmol, 3 equiv.), CS2CO3 (141 mg, 0.43 mmol, 4 equiv.) and PEPPSI™-IPr catalyst (8 mg, 0.02 mmol, 0.1 equiv.) and dissolved in DME-H2O (20 mL, 0.2 M, 2/1, v/v). The mixture was heated to 140°C. After 1 hr, the reaction was complété. After cooling, the reaction was extracted with EtOAc and washed with water and saturated NH4CI. After drying with MgSÛ4, it was fîltered and concentrated to dryness. Purification was carried out by reverse phase HPLC to furnish 7-(l,4-dimethyl-lHpyrazol-5-yl)-5-(3,5-dimethylisoxazol-4-yl)-l-methyl-lH-benzo[d]imidazol-2(3H)-one.
[00122] LCMS (m/z +1) 338.19. Ή NMR (400 MHz, cd3od) δ 7.44 (s, IH), 7.15 (d, J = 1.6 Hz, IH), 6.88 (d, J= 1.6 Hz, IH), 3.65 (s, 3H),.90 (s, 3H), 2.42 (s, 3H), 2.27 (s, 7H), 1.95 (s, 3H).
Example 9
7-(1,4-dimethyl-1 H-py razol-5-yl)-5-(3,5-dimethyiisoxazoI-4-yl)-1 -methyl-1Hbenzo [d] imidazol-2(3H)-one
[00123] To a microwave vial containing 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-lmethyl-lH-benzo[d]imidazol-2(3H)-one (40 mg, 0.11 mmol, 1 equiv.) was added 3,5Dimethylisoxazole-4-boronic acid pinacol ester (72 mg, 0.32 mmol, 3 equiv.), CS2CO3 (141 mg, 0.43 mmol, 4 equiv.) and PEPPSI™-IPr catalyst (8 mg, 0.02 mmol, 0.1 equiv.) and dissolved in DME-H2O (20 mL, 0.2 M, 2/1, v/v). The mixture was heated to 140°C. After 1 hr, the reaction was complété. After cooling, the reaction was extracted with EtOAc and washed with water and saturated NILCl. After drying with MgSO4, it was filtered and concentrated to dryness. Purification was carried out by reverse phase HPLC to fumish 7( 1,4-dimethyl-1 H-pyrazol-5-yl)-5-(3,5-dimethylisoxazol-4-yl)-1 -methyl-1H15 benzo[d]imidazol-2(3H)-one.
[00124] LCMS (m/z +1) 339.15. 'HNMR (400 MHz, cd3od) δ 7.09 (d, J= 1.6 Hz, IH), 6.81 (d, J= 1.6 Hz, IH) 3.11 (d, J= 14.5 Hz, 3H), 2.41 (s, 3H), 2.35-2.23 (m, 6H),
2.15 (s, 3H).
Example 10
5,7-bis(3,5-dimethylisoxazoI-4-yI)benzo[d]oxazoI-2(3H)-one
[00125] 5,7-Dibromobenzo[d]oxazol-2(3H)-one (100.0 mg, 0.341 mmol) was treated with 3,5-dimethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoxazole (304.7 mg, 1.366 mmol, 4.0 equiv.), 2M-Na2CÜ3 (aq) (1 mL) in the presence of PEPPSI-IPr (11.6 mg, 0.017 mmol, 0.05 equiv) in 1,4-dioxane (3 mL) at 150°C for 10 min in microwave reactor To the reaction mixture were added water (30 mL) and EtOAc (70 mL). The mixture was fdtered through Celite (3 g) and then organic layer was separated from the filtrate. The organic layer was washed with brine (30 mL) and dried over Na2SO4. The solvent was removed under a reduced pressure to give a crude product. The crude product was purified by a préparative HPLC (5-95% acetonitrile: water with 0.05% trifluoroacetic acid, on a Phenomenex Luna C18 column) and a silica gel column chromatography (MeOH:CH2Cl2 = 3:97-10:90) to give
5,7-bis(3,5-dimethylisoxazol-4-yl)benzo[d]oxazol-2(3H)-one.
[00126] C17H15N3O4. MS. m/z 326.0 (M+l). Ή NMR (MeOH-tA) δ 7.08 (s, IH), 7.01 (s, IH), 2.433 (s, 3H), 2.430 (s, 3H), 2.28 (s, 3H), 2.27 (s, 3H).
Example 11
5-(3,5-dimethylisoxazol-4-yl)-7-(6-methylquinolin-5-yl)benzo[d]oxazol-2(3H)-one
Step 1:
PdCI2dppf (5 mol%)
KOAc
DMSO
[00127] 5-Bromo-7-chlorobenzo[d]oxazol-2(3H)-one (100.0 mg, 0.4025 mmol) was treated with 3,5-dimethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoxazole (89.8 mg, 0.4025 mmol, 1.0 equiv.), DBU (183.8 mg, 1.2075 mmol, 3.0 equiv.) in the presence of PdCfdppf (14.7 mg, 0.02015 mmol, 0.05 equiv) in DMSO (3 mL) and water (1 mL) at
120°C for 1 h in an oil bath. To the reaction mixture were added water (30 mL) and EtOAc (70 mL). The mixture was filtered through Celite (3 g) and then organic layer was separated from the filtrate. The organic layer was washed with brine (30 mL) and dried over Na2SO4. The solvent was removed under a reduced pressure to give a crude product. The crude product was purified by a préparative HPLC (5-95% acetonitrile: water with 0.05% trifluoroacetic acid, on a Phenomenex Luna C18 column) and a silica gel column chromatography (hexane:EtOAc = 1:1) to give 7-chloro-5-(3,5-dimethylisoxazol-4yl)benzo[d]oxazol-2(3H)-one.
[00128] Ci2H9C1N2O3. MS. m/z 265.0 (M-l), 267.0 (M+l).
Step 2:
N-O
PEPPSI-iPr (5 mol%)
Cs20O^ dioxane
H2O
[00129] 7-Chloro-5-(3,5-dimethylisoxazol-4-yl)benzo[d]oxazol-2(3H)-one (20.8 mg, 0.0786 mmol) was treated with 6-methylquinolin-5-ylboronic acid (44.1 mg, 0.2358 mmol,
3.0 equiv.), CS2CO3 (153.7 mg, 0.4716 mmol, 6.0 equiv.) in the presence of PEPPSI iPr (2.9 mg, 0.00393 mmol, 0.05 equiv) in 1,4-dioxane (3 mL) and water (1 mL) at 150°C for 1 h in a microwave reactor. To the reaction mixture were added water (30 mL) and EtOAc (70 mL). The mixture was filtered through Celite (3 g) and then organic layer was separated from the filtrate. The organic layer was washed with brine (30 mL) and dried over Na2SO4. The solvent was removed under a reduced pressure to give a crude product. The crude product was purified by a préparative HPLC (5-95% acetonitrile: water with 0.05% trifluoroacetic acid, on a Phenomenex Luna C18 column) to give 5-(3,5-dimethylisoxazol-4-yl)-7-(6methylquinolin-5-yl)benzo[d]oxazol-2(3H)-one.
[00130] C22H17N3O3. MS. m/z 372.1 (M+l). *H NMR (MeOH-^) δ 9.16 (d, J= 5.3
Hz, IH), 8.69 (d, J= 8.7 Hz, IH), 8.28 (d, 8.9 Hz, IH), 8.21 (d, J= 8.9 Hz, IH), 7.97 (dd,
J= 8.'7, 5.3 Hz, IH), 7.27 (d, J = 1.6 Hz, IH), 7.07 (d, J = 1.6 Hz, IH), 2.49 (s, 3H), 2.45 (s, 3H), 2.30 (s, 3H)
Example 12
5-(3,5-dimethylisoxazol-4-yl)-7-(2-phenylpyridin-3-yl)benzo[d]oxazol-2(3H)-one
The title compound was synthsized using 2-phenylpyridin-3-ylboronic acid in a similar fashion with 5-(3,5-dimethylisoxazol-4-yl)-7-(6-methylquinolin-5-yl)benzo[d]oxazol-2(3H)one (Example 11).
[00131] C23H17N3O3. MS. 384.1 (M+l). Ή NMR (MeOH-^) δ 8.02 (dd, J = 5.4, 1.5
Hz, IH), 7.68 (dd, J= 8.0, 1.5 Hz, IH), 7.10 (dd, 8.0, 5.4 Hz, IH), 6.67 - 6.55 (m, 5H), 6.21 (d, J= 1.6 Hz, IH), 5.97 (d, J= 1.6 Hz, IH), 1.35 (s, 3H), 1.19 (s, 3H).
Example 13 and
Example 14 (R) -6-(3,5-dimethylisoxazol-4-yl)-4-(6-methylquinolin-5-yl)-lH-benzo[d]imidazol-2(3H)one and (S) -6-(3,5-dimethyIisoxazol-4-yl)-4-(6-methyIquinolin-5-yl)-lH-benzo[d]imidazol-2(3H)one
O-N
O-N
[00132] (R)-6-(3,5 -Dimethylisoxazol-4-yl)-4-(6-methylquinolin-5-yl)-1Hbenzo[d]imidazol-2(3H)-one and (S)-6-(3,5-dimethylisoxazol-4-yl)-4-(6-methylquinolin-5yl)-lH-benzo[d]imidazol-2(3H)-one were obtained by resolving the racemate (Example 2) by supercritical fluid chromatography on a chiral column (25% MeOH with 0.1% v/v TFA on an SFC Chiralpak AD-H column.)
[00133] First eluting compound: (R)-6-(3,5-dimethylisoxazol-4-yl)-4-(6methylquinolin-5-yl)-lH-benzo[d]imidazol-2(3H)-one. C22H18N4O2. 371.1 (M+l). SFC rétention time 3.525 min (Chiralpak AD-H 250mm x 10mm, 16 mL/min, 10 minute run time, 10 40 °C column oven, 10 MPa back-pressure limiter). ’H NMR spectra identical to racemic compound.
[00134] Second eluting compound: (S)- 6-(3,5-dimethylisoxazol-4-y 1)-4-(6methylquinolin-5-yl)-lH-benzo[d]imidazol-2(3H)-one. C22H18N4O2. 371.1 (M+l). SFC rétention time 4.992 min (Chiralpak AD-H 250mm x 10mm, 16 mL/min, 10 minute run time, 15 40 °C column oven, 10 MPa back-pressure limiter). ’H NMR spectra identical to racemic compound.
Example 15
6-(3,5-dimethylisoxazol-4-yl)-4-(2,4-dimethyIpyridin-3-yl)-lH-benzo[d]imidazol-2(3H)- one
[00135] 6-(3,5-Dimethylisoxazol-4-yl)-4-(2,4-dimethylpyridin-3-yl)-lHbenzo[d]imidazol-2(3H)-one was synthsized using 2,4-dimethylpyridin-3-ylboronic acid and
CS2CO3 in a similar fashion as Example 11.
[00136] C19H18N4O2. MS. m/z 335.1 (M+l). Ή NMR (MeOH-J4) δ 8.65 (d, J= 6.2
Hz, IH), 7.93 (d,J=6.2Hz, IH), 7.16 (d, J= 1.5 Hz, IH), 6.92 (d, 1.5 Hz, IH), 2.52 (s,
3H), 2.43 (s, 3H), 2.40 (s, 3H), 2.27 (s, 3H).
Example 16
4-(6-(3,5-dimethyIisoxazol-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)cinnoline-
3-carboxylic acid
PdCI2dppf DBU
DMSO, H2O 110°C
[00137] 6-(3,5-dimethylisoxazol-4-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)lH-benzo[d]imidazol-2(3H)-one (100.0, 0.282 mmol) and 5-bromo-8-chloro-6methylquinoline (94.0 mg, 0.422 mmol) was treated with PdChdppf-ŒLCh (20.6 mg, 0.028 mmol) in the presence of l,8-diazabicycloundec-7-ene (DBU, 300.0 mg, 1.971 mmol, 7.0 equiv) in DMSO (1 mL) and water (1 mL). The reaction mixture was heated at 110°C for 12 min in oil bath. The reaction mixture was injected into Gilson préparative HPLC to give 4-(6(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3 -dihydro-1 H-benzo[d]imidazoI-4-yI)cinnoline-3 carboxylic acid.
[00138] C21H15N5O4. MS. m/z 402.0 (M+l). !H NMR (400 MHz, Methanol-^) Ô 8.67 (d, J= 8.8 Hz, IH), 8.09 (t, J = 8.8 Hz, IH), 7.92 (d, J= 8.8 Hz, IH), 7.70 (d, J= 8.8 Hz, IH), 7.17 (s, IH), 6.96 (s, IH), 2.44 (s, 3H), 2.29 (s, 3H).
Example 17
6-(3,5-dimethylisoxazol-4-yl)-4-(3-methylisoquinolin-4-yl)-lH-benzo[d]imidazol-2(3H)one
PdCI2dppf DBU
DMSO, H2O 110°C
[00139] Synthesized in a similar fashion as that of Example 16.
[00140] C22Hi8N4O2. MS. m/z 371.1 (M+l). *H NMR (400 MHz, Methanol-J4) δ 9.26 (s, IH), 8.16 (d, 8.6 Hz, IH), 7.70 (t, 8.6 Hz, IH), 7.64 (t, J = 8.6 Hz, IH), 7.42 (d,J=
8.6 Hz, IH), 2.50 (s, 3H), 2.45 (s, 3H), 2.29 (s, 3H).
Example 18
6-(3,5-dimethyIisoxazol-4-yl)-4-(2-methylnaphthalen-l-yI)-lH-benzo[d]imidazol-2(3H)- one
N-O
O
[00141] In a 2-5 mL Smith Process Vial, 6-(3,5-dimethylisoxazol-4-yl)-4-iodo-lHbenzo[d]imidazol-2(3H)-one (100.0 mg 0.282 mmol), (2-methylnaphthalen-l-yl)boronic acid (176.0 mg, 0.946 mmol, 3.36 equiv), PEPPSI-iPr (19.2 mg, 0.028 mmol, 0.1 equiv) and CS2CO3 (337.0 mg, 1.126 mmol, 4 equiv) were placed. The mixture was suspended in 1,4dioxane (1.5 mL) and water (0.5 mL) under N2. The mixture was heated at 150°C for 75 min using microwave reactor (Biotage Optimizer). After an aqueous work up, the crude product was purified by a silica-gel column chromatography (hexane / EtOAc 20:80) to give 6-(3,5dimethylisoxazol-4-yl)-4-(2-methylnaphthalen-1 -yl)- lH-benzo[d]imidazol-2(3H)-one.
[00142] C23H19N3O2. MS. m/z 370.1 (M+l). Ή NMR (400 MHz, Methanolé) δ 7.88 (d, J = 8.6 Hz, 2H), 7.50 (d, J - 8.6 Hz, IH), 7.45 - 7.38 (m, IH), 7.38 - 7.33 (m, 2H), 7.10 (s, IH), 6.82 (s, IH), 2.43 (s, 3H), 2.28 (s, 6H).
Example 19
4-(2-(difluoromethyl)-3-methyIquinolin-4-yI)-6-(3,5-dimethyIisoxazol-4-yl)-lHbenzo [d] imidazol-2(3H)-one
DMSO, H2O
MW, 120°C
PdCI2dppf DBU
[00143] The title compound was synthesized in a similar fashion as that of Example
17.
[00144] C23H17FN4O2. MS. m/z 421.1 (M+l). *H NMR (400 MHz, Methanol-ûk) δ
8.18 (d, J = 9.0 Hz, IH), 7.83 - 7.74 (m, IH), 7.63 - 7.57 (m, IH), 7.45 (d, J - 9.4 Hz, IH), 7.23 - 6.87 (m, 2H), 2.47 - 2.40 (m, 6H), 2.30 (s, 3H).
Example 20
Préparation of 4-chloro-5-(3,5-dimethylisoxazol-4-yl)-7-(6-methylquinolin-5-yl)-lHbenzo [d] imidazol-2(3H)-one
[00145] In 0.5 -2 mL Smith Process Vial, the intermediate (25.0 mg, 0.067 mmol) and
NCS (36.3 mg, 0.135 mmol) were dissolved into THF (2 mL). The mixture was heated at 80
°C for 2 h in an oil bath. The reaction mixture was directly injected into Gilson préparative HPLC (5-95% acetonitrile: water with 0.05% trifluoroacetic acid, on a Phenomenex Luna Cl8 column) to give the desired product.
[00146] C19H18N4O2. MS. m/z 405.1 (M+l), 407.1 (M+2+1). JH NMR (400 MHz,
Methanol-^) δ 9.25 - 9.05 (d, J= 5.8 Hz, IH), 8.47 - 8.40 (m, IH), 8.30 (d, J= 9.0 Hz, IH),
8.20 (d, J= 9.0 Hz, IH), 7.96 - 7.90 (m, IH), 7.19 (s, IH), 2.40 (s, 3/2H), 2.39 (s, 3/2H), 2.38 (s, 3/2H), 2.34 (s, 3/2H) 2.21 (s, 3/2H), 2.19 (s, 3/2H).
Example 21
5-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)-6-methyl- l-(2,2,2-trifluoroethyl)quinolin-2(lH)-one
Step 1 :
[00147] 5-Bromo-6-methylquinolin-2(lH)-one (103.5 mg, 0.435 mmol) was suspended into DMF (3 mL). To the suspension, was added NaH (17.4 mg 60% in minerai oil) at room température. After 2 h stirring, CF3CH2OTf (201.8 mg, 0.869 mmol) was added into the mixture at room température. The reaction mixture was stirred for 2 h at the same température. The reaction mixture was quenched with water (30 mL). The whole was extracted with AcOEt (30 mL x 3). Organic layer was washed with brine (30 mL) and dried over Na2SÛ4. The solvent was removed under a reduced pressure to give the crude product. Gilson PHPLC purification gave 5-bromo-6-methyl-l-(2,2,2-trifluoroethyl)quinolin-2(lH)one.
[00148] ]H NMR (400 MHz, Methanol-^) δ 8.41 (d, J= 10.0 Hz, IH), 7.58 (s, 2H),
6.77 (d, J= 10.0 Hz, IH), 5.20 (q, J= 8.7 Hz, 2H), 2.52 (d, J= 1.0 Hz, 3H).
Step 2:
PEPPSI-iPr
OS2CO3 dioxane, H2O
MW, 150°C
[00149] In a 2-5 mL Smith Process Vial, the boronic acid pinacol ester (29.0 mg 0.82 mmol), the bromide (26.1 mg, 0.082 mmol, 1 equiv), PEPPSI-iPr (2.8 mg, 0.004 mmol, 0.05 equiv) and CS2CO3 (53.2 mg, 0.163 mmol, 2 equiv) were placed. The mixture was suspended in 1,4-dioxane and water under N2. The mixture was heated at 150°C for 20 min using microwave reactor (Biotage Optimizer). To the mixture were added EtOAc (70 mL) and water (30 mL). The whole was filtered through Celite (3 g) and the filtrate was washed with brine (30 mL), dried over Na2SO4 and concentrated under a reduced pressure. Obtained crude material was purified by Gilson préparative HPLC to give the desired product (23.0 mg, 60%).
[00150] C24H19F3N4O3. MS. m/z 469.1 (M+l). ΉNMR (400 MHz, Methanol-^) δ
7.70 (d, J= 92 Hz, IH), 7.67 (d, J= 92 Hz, IH), 7.52 (d, J= 10.0 Hz, IH), 7.12 (s, IH),
6.82 (s, IH), 6.60 (d, J= 10.0 Hz, IH), 5.26 (q, J= 13.3 Hz, 2H), 2.43 (s, 3H), 2.28 (s, 3H),
2.20 (s, 3H).
Example 22
5-(6-(3,5-dimethylisoxazoI-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)-l,6- dimethylquinolin-2(lH)-one
Step 1 :
/k | Br^ Λ | |
ll Ί | KHMDS | T| |
Mel | _ il 1 | |
ILnh | THF 0°C to rt | rrfN |
0 | 0 |
[00151] 5-bromo-6-methylquinolin-2(lH)-one (500.0 mg, 2.1 mmol) in THF (10 mL) was treated with KHMDS (2.31 mL, 2.31 mmol, 1.1 equiv) at 0°C for 15 min. To the reaction mixture was added Mel (0.26 mL 596.2 mg, 4.2 mmol, 2 equiv) was added into the mixture at 0°C. The reaction mixture was allowed to warm up to room température and stirred for ovemight at the same température to form a précipitation. The précipitation was filtered off using a glass filter. The filtrate was concentrated and purified by a silica-gel column chromatography (hexane / EtOAc 50:50 to 0:100) to give 5-(6-(3,5-dimethylisoxazol-4-yl)-2oxo-2,3 -dihydro-1 H-benzo[d]imidazol-4-yl)-1,6-dimethylquinolin-2( 1 H)-one as colorless crystals.
[00152] CnHioBrNO. MS. m/z 469.1 (M+l).
Step 2:
O
[00153] 5-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4yl)-l,6-dimethylquinolin-2(lH)-one was synthesized in a similar fashion as that of Example 21.
[00154] C23H20N4O3. MS. m/z 401.1 (M+l). Ή NMR (400 MHz, Methanol-ûU) δ 7.68 (d, J= 9.6 Hz, IH), 7.63 (d, J= 9.6 Hz, IH), 7.45 (d, 9.6 Hz, IH), 7.11 (s, IH), 6.80 (s,
IH), 6.58 (d, 9.6 Hz, IH), 3.80 (s, 3H), 2.43 (s, 3H), 2.28 (s, 3H), 2.20 (s, 3H).
Example 23
4-(3,5-dicyclopropyl-lH-pyrazol-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo [d] imidazoI-2(3H)-one
N-O
PEPPSI-iPr
CS2CO3 dioxane, H2O
MW, 150°C
[00155] The compound of Example 23 was synthesized in a similar fashion as that of Example 22.
[00156] C21H21N5O2. MS. m/z 376.1 (M+l). ’H NMR (400 MHz, Methanol-ûk) δ 7.05 (s, IH), 6.95 (s, IH), 2.33 (s, 3H), 2.28 (s, 3H), 1.86-1.76 (m, 2H), 1.00-0.90 (m, 4H), 0.870.78 (m, 4H).
Example 24
4-(3,5-dicyclopropyl-l-methyl-lH-pyrazol-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one
Step 1:
NaH Mel
DMF rt
[00157] 4-Bromo-3,5-dicyclopropyl-l-methyl-lH-pyrazole (50.0 mg, 0.22 mmol) was dissolved into DMF (3 mL). To the solution, was added NaH (17.6 mg 60% in minerai oil,
0.44 mmol, 2 equiv) at room température. After 30.min stirring, Mel (62.5 mg, 0.44 mmol, 2 equiv) was added into the mixture at room température. The reaction mixture was stirred for min at the same température. The reaction mixture was quenched with water (30 mL). The whole was extracted with AcOEt (30 mL x 3). Organic layer was washed with brine (30 mL) and dried over NaiSCU. The solvent was removed under a reduced pressure to give the crude product. A silica-gel column chromatography (hexane / EtOAc 87:13 to 70:30) purification gave 4-bromo-3,5-dicyclopropyl-l-methyl-lH-pyrazole (51.8 mg, 97.6%).
[00158] CioHi3BrN2. MS. m/z 241.0 (M-l+1), 243.0 (M+l+1).
Step 2:
N-O
PEPPSI-iPr
CS2OO3 dioxane, H2O
MW, 150°C
[00159] 4-(3,5-dicyclopropyl-l-methyl-lH-pyrazol-4-yl)-6-(3,5-dimethylisoxazol-4yl)-lH-benzo[d]imidazol-2(3H)-one was synthesized in a similar fashion as that of Example 10 21.
[00160] C23H20N4O3. MS. m/z 390.1 (M+l). *H NMR (400 MHz, Methanol-rf4) δ 6.98 (s, IH), 6.85 (s, IH), 3.87 (s, 3H), 2.43 (s, 3H), 2.27 (s, 3H), 1.88-1.80 (m, IH), 1.69-1.60 (m, IH), 1.00-0.60 (m, 6H), 0.38-0.28 (m, 2H).
Example 25
6-(3,5-dimethylisoxazol-4-yl)-4-(2-(4-fluorophenyl)pyridin-3-yl)-lH-benzo[d]imidazol-
2(3H)-one
Step 1:
dioxane, H2O
MW, 80°C
Pd(PPh3)4
Na2CO3
[00161] In a 2-5 mL Smith Process Vial, 2,3-dibromopyridine (300.0 mg, 1.266 mmol), 4-fluorophenyl boronic acid (177.2 mg, 1.266 mmol, 1 equiv) and Pd(PPh3)4 (73.2 mg, 0.063 mmol, 0.05 equiv) were placed. The mixture was suspended in 1,4-dioxane (3 mL) and 2M-Na2CO3 (1 mL) under a nitrogen atmosphère. The mixture was heated at 80°C for 10 5 min using the microwave reactor. To the mixture were added EtOAc (70 mL) and water (30 mL). The whole was filtered through Celite (3 g) and the filtrate was washed with brine (30 mL), dried over Na2SO4 and concentrated under a reduced pressure. Obtained crude material was purified by Gilson préparative HPLC to give 3-bromo-2-(4-fluorophenyl)pyridine.
[00162] CnH7BrFN. MS. m/z 241.0 (M-l+1), 243.0 (M+l+1).
Step 2:
PEPPSI-iPr CS20O3 | N-O | F ιΓί AA |
dioxane, H2O | /¼. JU. HN J | Ίι n |
MW, 150°C | V—NH | O |
oz |
[00163] This transformation wsa performed in a similar fashion as that of Example 21.
[00164] C23Hi7FN4O2. MS. m/z 401.1 (M+l). ‘H NMR (400 MHz, Methanol-iZt) δ
8.68 (dd, 1H,J =4.8, 1.6 Hz), 7.77 (dd, IH, J =8.0, 1.6 Hz), 7.55 (dd, IH, J = 8.0, 4.6 Hz),
7.42-7.35 (m, 2H), 7.00 (t, 2H, J = 8.0 Hz), 6.92 (d, IH, J = 1.0 Hz), 6.65 (d, IH, J = 1.0
Hz), 2.20 (s, 3H), 2.05 (s, 3H).
Example 26
6-(3,5-dimethylisoxazol-4-yl)-4-(2-(3-fluorophenyl)pyridin-3-yl)-lH-benzo[d]imidazol-
2(3H)-one
Step 1:
+
B(OH)2 dioxane, H2O
MW, 80°C
Pd(PPh3)4
Na2CO3
[00165] 3 -Bromo-2-(3-fluorophenyl)pyridine was synthesized in a similar fashion with
3-bromo-2-(4-fluorophenyl)pyridine. CnHîBrFN. MS. m/z 241.0 (M-l+1), 243.0 (M+l+1).
Step 2:
PEPPSI-iPr
CS2CO3 dioxane, H2O
MW, 150°C
N-O
O
F
[00166] This transformation wsa performed in a similar fashion as that of Example 21.
[00167] C23H17FN4O2. MS. m/z 401.1 (M+l). *HNMR (400 MHz, Methanolé) δ
8.70 (dd, IH, J = 4.8, 1.6 Hz), 7.98 (dd, IH, J = 8.0, 1.6 Hz), 7.57 (dd, IH, J = 8.0, 4.8 Hz), 7.30-7.22 (m, IH), 7.17-7.10 (m, 2H), 7.06-6.96 (m, IH), 6.93 (d, IH, J = 1.0 Hz), 6.68 (d, IH, J = 1.0 Hz), 2.21 (s, 3H), 2.06 (s, 3H).
Example 27
4-(3,5-dicyclopropylisoxazol-4-yI)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazoI-
2(3H)-one
Step 1:
[00168] l,3-Dicyclopropylpropane-l,3-dione (300.0 mg, 1.971 mmol) and hydroxylamine hydrochloride (162.0 mg, 2.365 mmol, 2 equiv) were heated at 100°C in
DMSO (1 mL) in oil bath. After the reaction completed, the reaction mixture was directly injected into Gilead préparative HPLC to give 4-bromo-3,5-dicyclopropylisoxazole.
[00169] C9H11ON. MS. m/z 228.0 (M-l+1), 230.0 (M+l+1).
Step 2:
[00170] 3,5-Dicyclopropylisoxazole (70.0 mg, 0.469 mmol) was treated with NBS (167.0 mg, 0.938 mmol, equiv) in CH2CI2 at room température for 12 h. The solvent was removed under a reduced pressure and the residue was directly loaded onto a silica gel column chromatography (hexane EtOAc 87:13) to give 4-bromo-3,5-dicyclopropylisoxazole.
[00171] C9HioBrON. MS. m/z 228.0 (M-l+1), 230.0 (M+l+1).
Step 3 :
N-O
dioxane, H2O
MW, 150°C
PEPPSI-iPr
CS2CO3
[00172] This transformation wsa performed in a similar fashion as that of Example 21.
[00173] C21H20N4O3. MS. m/z 377.1 (M+l). Ή NMR (400 MHz, Methanol-^) δ 7.05 (d, IH, J = 1.0 Hz), 6.95 (d, IH, J - 1.0 Hz), 2.43 (s, 3H), 2.28 (s, 3H), 1.90 (quin, IH, J =
6.4 Hz), 1.60 (quin, IH, J = 6.4 Hz), 1.01 (d, 4H, J = 6.4 Hz), 0.91 (d, 4H, J = 6.4 Hz).
Example 28
6-(3,5-dimethylisoxazol-4-yl)-4-(8-fluoro-6-methylquinolin-5-yl)-lH-benzo[d]imidazoI10
2(3H)-one
Step 1 :
[00174] 3,5-Dicyclopropylisoxazole (70.0 mg, 0.469 mmol) was treated with NBS (167.0 mg, 0.938 mmol, 2 equiv) in CH2CI2 at room température for 12 h. The solvent was removed under a reduced pressure and the residue was directly Ioaded onto a silica gel column chromatography (hexane EtOAc 87:13) to give 5-bromo-8-fluoro-6-methylquinoline (68.7 mg, 64.2%).
[00175] CçHioBrON. MS. m/z 239.9 (M-l+1), 241.9 (M+l+1).
Step 2:
PEPPSI-iPr
CS2CO3 dioxane, H2O
MW, 150°C
[00176] This transformation wsa performed in a similar fashion as that of Example 21.
[00177] C22H17FN4O2. MS. m/z 398.1 (M+l). *H NMR (400 MHz, Methanol-i/4) δ
8.93 (d, IH, J = 4.0 Hz), 8.08 (d, IH, J = 8.0 Hz), 7.70 (d, IH, J = 11.2 Hz), 7.67 (dd, IH, J = 8.0, 4.0 Hz), 7.15 (d, IH, J = 1.0 Hz), 6.88 (d, IH, J = 1.0 Hz), 2.43 (s, 3H), 2.38 (s, 3H), 2.28 (s, 3H).
Example 29
-(3,5-dicyclopropyl-l-(2,2,2-trifluoroethyl)-lH-pyrazol-4-yl)-6-(3,5-dimethylisoxazol-4yl)-lH-benzo[d]imidazol-2(3H)-one
Step 1:
[00178] 4-Bromo-3,5-dicyclopropyl-1 -(2,2,2-trifluoroethyI)-1 H-pyrazole was synthesized in a similar fashion with 5-bromo-6-methyl-1 -(2,2,2-trifluoroethyl)quinolin2(lH)-one. CiiHi2BrF3N2. MS. m/z 309.0 (M-l+1), 311.0 (M+l+1).
Step 2:
N-O
PEPPSI-iPr
CS2OO3 dioxane, H2O
MW, 150°C
[00179] This transformation was performed in a similar fashion as that of Example 21.
[00180] C23H22F3N5O2. MS. m/z 458.1 (M+l). Ή NMR (400 MHz, Methanol-i/4) δ
7.00 (d, IH, J = 1.0 Hz), 6.85 (d, IH, J = 1.0 Hz), 4.95 (q, 2H, J - 9.6 Hz), 2.43 (s, 3H),
2.27 (s, 3H), 1.90-1.81 (m, IH), 1.66-1.61 (m, IH), 1.40-1.26 (m, 2H), 0.94-0.68 (m, 6H), 0.42-0.32 (m, 2H).
Example 30
6-(6-(3,5-dimethylisoxazoI-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yI)-7-methyI-
4,5-dihydro-1 H-benzo [b] azepin-2(3H)-one
Step 1:
[00181] 5-Bromo-6-methyl-3,4-dihydroquinolin-2(lH)-one (477.7 mg, 1.998 mmol) was treated with NaN3 (194.8 mg, 0.938 mmol, 1.5 equiv) in MeSCEH (3 g) at 0°C to room température for 1 h. The mixture was neutralized with NaHCCh and extracted with EtOAc (30 mL x 3). The organic layer was washed with brine (30 mL) and dried over Na2SÛ4. The solvent was removed under a reduced pressure and the crude product was recrystallized from EtOAc (10 mL) to give 6-bromo-7-methyl-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one.
[00182] CnHi2BrON. MS. m/z 254.0 (M-l+1), 256.0 (M+l+1).
Step 2:
[00183] This transformation was performed in a similar fashion as that of Example 21.
[00184] C23H22N4O3. MS. m/z 403.1 (M+l). Ή NMR (400 MHz, Methanol-ίΑ) δ 8.93 (d, IH, ./ = 4.0 Hz), 7.24 (d, IH, J= 8.0 Hz), 7.04 (d, IH, J= 8.0 Hz), 7.03 (d, IH, J= 1.0
Hz), 6.73 (d, IH, 1.0 Hz), 2.60-2.22 (m, 4H), 2.41 (s, 3H), 2.26 (s, 3H), 2.05 (s, 3H), 2.04-1.94 (m, 3H).
Example 31
6-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)-7-methyl-
4,5-dihydro-1 H-benzo [b] azepin-2(3H)-one
Step 1:
[00185] 6-Bromo-7-methyl-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one (100.0 mg,
1.998 mmol) was treated with NaH (18.9 mg, 0.472 mmol, 1.2 equiv) in DMF (3 mL) at 0°C to room température for 30 min. To the mixture was added Mel (111.7 mg, 0.787 mmol, 2 equiv). The mixture was stirred at to room température for 1 h The mixture was quenched with water and extracted with EtOAc (30 mL x 3). The organic layer was washed with brine (30 mL) and dried over Na2SO4. The solvent was removed under a reduced pressure and the crude product was purified by a silica-gel column chromatography (hexane ! EtOAc 87:13 to
50:50) to give 6-bromo-l,7-dimethyl-4,5-dihydro-lH-benzo[b]azepin-2(3H)-one (88.5 mg, 83.9%).
[00186] Ή NMR (400 MHz, CDC13) δ 7.16 (d, IH, J= 8.0 Hz), 7.03 (d, IH, J=8.0
Hz), 3.32 (s, 3H), 2.43 (s, 3H), 2.40-1.90 (broad, 6H).
Step 2:
N-O
PEPPSI-îPr CS2CO3 | N-O XX r^ïl i | |
dioxane, H2O | Tl^ | |
MW, 150°C | ^r-NH | |
° / | N- |
O
[00187] This transformation wsa performed in a similar fashion as that of Example 21.
[00188] C24H24N4O3. MS. m/z 417.1 (M+l). JH NMR (400 MHz, Methanol-tZj) δ 7.34 (d, IH, 8.0 Hz), 7.30 (d, IH, J= 8.0 Hz), 7.04 (d, 1 H, J = 1.0 Hz), 6.73 (broad, IH), 3.36 (s, 3H), 2.60-2.20 (m, 4H), 2.41 (s, 3H), 2.26 (s, 3H), 2.07 (s, 3H).
Example 32
4-(8-chloro-6-methylquinolin-5-yI)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-
2(3H)-one
Step 1 :
[00189] 5-Bromo-8-chloro-6-methylquinoline was synthesized in a similar fashion, using 5-bromo-8-fluoro-6-methylquinoline.
CioHsCIN. MS. m/z 258.0 (M-l+1), 256.1 (M+l+1), 260.0 (M+l+2).
Step 2:
[00190] A mixture of 6-(3,5-Dimethylisoxazol-4-yl)-4-(4,4,5,5-tetramethyl-l,3,2dioxaborolan-2-yl)-lH-benzo[d]imidazol-2(3H)-one (100.0, 0.282 mmol) and 5-bromo-8chloro-6-methylquinoline (72.2 mg, 0.282 mmol) was treated with PdChdppf-CHzCk (20.9 mg, 0.028 mmol) in the presence of l,8-Diazabicycloundec-7-ene (DBU, 204.0 mg, 1.34 mmol, 4.76 equiv) in DMSO (0.2 mL) and water (0.2 mL). The reaction mixture was heated at 120°C in oil bath. The reaction mixture was diluted with THF (3 mL) and purified by Gilson préparative HPLC to give 4-(8-chloro-6-methylquinolin-5-yl)-6-(3,5dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one
[00191] C22H17CIN4O2. *H NMR (400 MHz, MethanoW4) δ 8.97 (d, IH, J = 4.8, 1.6
Hz), 8.08 (d, IH, J = 8.0 Hz), 8.09 (dd, IH, J = 9.6, 1.6 Hz), 8.08 (s, 1H),7.66 (dd, IH, J =
9.6, 4.8 Hz), 7.16 (d, IH, J = 1.0 Hz), 6.89 (d, IH, J = 1.0 Hz), 2.44 (s, 3H), 2.36 (s, 3H),
2.28 (s, 3H).
Example 33
6-(3,5-dimethylisoxazol-4-yl)-4-((7-fluoroquinolin-2-yl)(hydroxy)(phenyl)methyl)-lHbenzo[d]imidazol-2(3H)-one
Step 1 :
O-N
O
[00192] 7er/-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4(methoxy(methyl)carbamoyl)-lH-benzo[d]imidazole-l -carboxylate was dissolved in THF (3 mL). To the solution was added a solution of phenyl magnésium chloride (2M in THF, 0.508 mmol, 0.254 mmol) at -78°C. after the addition, the reaction was allowed to warm up to room température. The reaction was stirred for 17 hat the same température. The reaction mixture was quenched with water (30 mL). The whole was extracted with AcOEt (30 mL x 3). Organic layer was washed with brine (30 mL) and dried over Na2SÛ4. The solvent was removed under a reduced pressure to give the crude product. The crude product was purified by a silica gel column chromatography (hexane: EtOAc, 7:1 to 3:1) to give tert-butyl 415 benzoyl-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazole-l-carboxylate.
[00193] C26H27N3O5. MS. m/z 462.2 (M+l).
Step 2:
[00194] To a solution of 7-fluoro-2-bromoquinoline (54.1 mg) in THF (2 mL) was added BuLi (1.6 M, 0.25 mL) at -78°C. After 5 min, a solution of phenyl ketone (60.0 mg) in THF (1 mL) was added at-78°C. The reaction was immediately allowed to warm up to room température and stirred for 30 min. The reaction mixture was quenched with water (30 mL). The whole was extracted with AcOEt (30 mL x 3). Organic layer was washed with brine (30 mL) and dried over Na2SO4. The solvent was removed under a reduced pressure to give the crude product. The crude product was treated with TFA to cleave the Boc group. The crude product was purified by a silica gel column chromatography (hexane: EtOAc, 7:1 to 3:1) to give tert-butyl 4-benzoyl-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-1 H-benzo[d]imidazole-1 carboxylate.
[00195] C26H27N3O5. MS. m/z 509.2 (M+l).
Step 3 :
[00196] Tert-butyl 4-benzoyl-6-(3,5 -dimethyli soxazol-4-yl)-2-ethoxy-1Hbenzo[d]imidazole-l -carboxylate (18.0 mg) was dissolved into EtOH (2 mL) and 4M HCl/dioxane (2 mL) The solution was heated at 70°C for 30 min. The reaction mixture was quenched with water (30 mL). The whole was extracted with EtOAc (30 mL x3). Combined organic layers were washed with brine (50 mL). The solvent was removed under a reduced pressure to give a crude product. The crude product was purified by a a silica gel column chromatography (hexane: EtOAc, 7:1 to 3:1) to give tert-butyl 4-benzoyl-6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazole-l-carboxylate.
[00197] C28H21FN4O3. MS. m/z 481.1 (M+l). 'H NMR (400 MHz, Methanol-t/4) δ
8.31 (1, J= 8.7 Hz, IH), 8.13 (dd, J= 9.2, 5.3 Hz, IH), 7.67 - 7.56 (m, 3H), 7.40-7.25 (m, 5H), 6.98 (d, J= 1.6 Hz, IH), 6.61 (d, 1.6 Hz, IH), 2.28 (s, 3H), 2.11 (s, 3H).
Example 34
6-(3,5-dimethylisoxazoI-4-yl)-4-(hydroxy(phenyl)(quinolin-2-yl)methyl)-lHbenzo [d] imidazoI-2(3H)-one
[00198] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy- lH-benzo[d]imidazol-4yl)(phenyl)(quinolin-2-yl)methanol was synthesized in the similar fashion with tert-butyl 4benzoyl-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazole-l-carboxylate. C30H26N4O3. MS. m/z 491.2 (M+l).
[00199] 6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(phenyl)(quinolin-2-yl)methyl)-lHbenzo[d]imidazol-2(3H)-one was synthesized in the similar fashion as that of Example 33.
C28H22N4O3. MS. m/z 463.1 (M+l). ). Ή NMR (400 MHz, Methanol-^) δ 8.30 (d, J= 8.6
Hz, IH), 8.09 (d, J= 8.6 Hz, IH), 7.93 (d, J= 8.6 Hz, IH), 7.77 (ddd, J= 8.6, 7.0, 1.2 Hz,
IH), 7.61 (ddd, J= 8.6, 7.0, 1.2 Hz, IH), 7.54 (d, J= 8.6 Hz, IH), 7.40-7.26 (m, 5H), 6.98 (d, 15 J = 1.5 Hz, IH), 6.61 (d, J= 1.5 Hz, IH), 2.27 (s, 3H), 2.10 (s, 3H).
Example 35
6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(pyridin-2-yl)(quinolin-2-yI)methyl)-lHbenzo [d] imidazol-2(3H)-one
[00200] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy- lH-benzo[d]imidazol-4-yl)(pyridin-
2-ylXquinolin-2-yl)methanol was synthesized in the similar fashion with tert-butyl 4benzoyl-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazole-l-carboxylate. C29H25N5O3. MS. m/z 492.2 (M+l).
[00201] 6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(pyridin-2-yl)(quinolin-2yl)methyl)-lH-benzo[d]imidazol-2(3H)-one was synthesized in the similar fashion as that of Example 33.
C28H22N4O3. MS. m/z 463.1 (M+l). ). Ή NMR (400 MHz, Methanol-tA) δ 8.78 (dd, J = 6.6, 1.0 Hz, IH), 8.66 (d, J= 8.8 Hz, IH), 8.47 (td, J= 8.8, 1.0 Hz, IH), 8.15 - 8.03 (m, 3H),
8.00 - 7.83 (m, 3H), 7.76 (t, J= 8.0 Hz, IH), 7.07 (d, J= 1.0 Hz, IH), 6.46 (d, J= 1.0 Hz,
IH), 2.22 (s, 3H), 2.04 (s, 3H).
Example 36
6-(3,5-dimethylisoxazol-4-yl)-4-((7-fluoroquinolin-2-yl)(hydroxy)(pyridin-2-yl)methyl)ΙΗ-benzo [d] imidazol-2(3H)-one
Step 1:
[00202] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(7fluoroquinolin-2-yl)(pyridin-2-yl)methanol was synthesized in the similar fashion with tertbutyl 4-benzoyl-6-(3,5 -dimethy lisoxazol-4-yl)-2-ethoxy- ΙΗ-benzo [d]imidazole-1 carboxylate.
[00203] C29H24FN5O3. MS. m/z 510.2 (M+l).
Step 2:
[00204] 6-(3,5-dimethylisoxazol-4-yl)-4-((7-fluoroquinolin-2-yl)(hydroxy)(pyridin-215 yl)methyl)-lH-benzo[d]imidazol-2(3H)-one was synthesized in the similar fashion as that of
Example 33.
C27H20FN5O3. MS. m/z 482.1 (M+l). 'H NMR (400 MHz, Methanol-<A) δ 8.52 (ddd, J= 4.9,
1.8, 0.9 Hz, IH), 8.26 (dd, J= 8.9, 0.8 Hz, IH), 8.04 (dd, J= 9.2, 5.3 Hz, IH), 7.84 (td, J=
7.8, 1.8 Hz, IH), 7.76 (d, 7.8 Hz, IH), 7.72 (d, J = 7.8 Hz, IH), 7.59 (dd, J= 8.9, 1.8 Hz,
IH), 7.54 (d, J= 8.9, 0.8 Hz, IH), 7.33 (ddd, J= 7.5, 4.9, 1.2 Hz, IH), 6.96 (d, J= 1.6 Hz, IH), 6.72 (d, J= 1.6 Hz, IH), 2.28 (s, 3H), 2.11 (s, 3H).
Example 37
6-(3,5-dimethylisoxazoI-4-yl)-4-((5-fluoropyridin-2-yl)(hydroxy)(pyridin-2-yl)methyl)ΙΗ-benzo [d] imidazol-2(3H)-one
[00205] To isopropyl magnésium chloride (1.32 mL, 2.64 mmol, 2 M in THF) in toluene (4mL) was added 2-bromo-5-fluoropyridine (388 mg, 2.05 mmol) in toluene (1 mL). After 3.5 hours the Grignard solution (1 mL, 0.65 mmol) was added to tert-butyl 6-(3,5dimethylisoxazol-4-yl)-2 ethoxypicolinoyl-lH-benzo[d]imidazole-l-carboxylate (60 mg, 0.13 mmol) in a 1:1 mixture of toluene/2-methyl-THF(6 mL) at 0°C and the mixture was allowed to warm to 20°C. After 16 hours, the reaction was quenched with saturated NH4Cl(aq) (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SO4, and concentrated in vacuo. The resulting residue (100 mg) was submitted to deprotection directly.
[00206] To 100 mg crude tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-((5fluoropyridin-2-yl)(hydroxy)(pyridin-2-yl)methyl)-lH-benzo[d]imidazole-1 -carboxylate (100 mg) in éthanol (3 mL) was added hydrochloric acid (0.2 mL, 0.8 mmol, 4 M in 1,4-dioxane).
The mixture was heated to 70°C for 0.5 hours and then concentrated in vacuo. Purification by reverse-phase HPLC (25-50% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini C18
5μ) afforded the TFA sait of 6-(3,5-dimethylisoxazol-4-yl)-4-((5-fluoropyridin-2yl)(hydroxy)(pyridin-2-yl)methyl)-lH-benzo[d]imidazol-2(3H)-one as a light yellow solid.
[00207] C23H18FN5O3. 432.1 (M+H). *HNMR (400 MHz, ûk-acetonitrile) δ 10.72 (s,
IH), 9.80 (s, IH), 8.6 (m, IH), 7.87 (m, IH), 7.75 (m, IH), 7.62 (m,lH), 6.87 (s, IH), 6.51 (s, IH), 2.30 (s, 3H), 2.11 (s, 3H). 19F NMR (376 MHz, ^-acetonitrile) δ -74.7, -130.95.
Example 38
4-((2,6-difluorophenyI)(5-fIuoropyridin-2-yI)(hydroxy)methyI)-6-(3,5-dimethyIisoxazol-
4-yI)- ΙΗ-benzo [d] imidazol-2(3H)-one
[00208] To l-bromo-2,4-difluorobenzene (0.02 ml, 0.16 mmol) in THF (0.52 mL) at 78°C was added w-butyllithium (0.12 mL, 0.18 mmol, 1.6 M in hexanes). After 30 minutes, tert-butyl 6-(3,5 -dimethyIisoxazol-4-yl)-2-ethoxy-4-(5 -fluoropicolinoy 1)-1Hbenzo[d]imidazole-l-carboxylate (50 mg, 0.10 mmol) in THF (1 mL) was added drop-wise to the reaction. After 60 minutes, the reaction was warmed, quenched with saturated NH4Cl(aq) (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SO4, and concentrated in vacuo. To the crude residue in éthanol (3.5 mL) was added hydrochloric acid (0.35 mL, 1.4 mmol, 4 M in 1,4-dioxane) and the mixture was heated to 70°C in a microwave reactor for 45 minutes. Purification by reverse-phase HP LC (40-50% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini Cl8 5μ) gave the trifluoroacetate sait of 4-((2,6difluorophenyl)(5-fluoropyridin-2-yl)(hydroxy)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one as a white solid.
[00209] C24H17F3N4.O3. 467.03 (M+H). XH NMR (400 MHz, tè-acetonitrile) δ 8.74 (s,
IH), 8.65 (s, IH), 8.49 (s, IH), 7.55 (m, IH), 6.95 (m, 3H), 6.70 (s, IH), 2.35 (s, 3H), 2.22 (s,
3H). 19F NMR (377 MHz, ri3-acetonitrile) δ -77, -107, -131.
Example 39
4-((2,4-difluorophenyl)(5-fluoropyridin-2-yl)(hydroxy)methyl)-6-(3,5-dimethylisoxazol-
4-yl)-lH-benzo[d]imidazol-2(3H)-one
[00210] In a synthetic process following that described for Example 40, reaction of tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-(5 -fluoropicolinoyl)-1 H-indole-1 carboxylate (50 mg, 0.13 mmol) with the organolithium species resulting from metal-halogen exchange with l-bromo-2,4-difluorobenzene in diethyl ether gave, after silica gel chromatography, 4-((2,4-difluorophenyl)(5-fluoropyridin-2-yl)(hydroxy)methy 1)-6-(3,510 dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one as a white solid.
[00211] C24H17F3N4O3. 467.1 (M+H). ’H NMR (400 MHz, ί/3-acetonitrile) δ 8.68 (s,
IH), 8.49 (s, IH), 7.56 (m, IH), 7.45 (m, IH), 7.12 (m, IH), 6.99 -6.89 (m, 3H), 6.50 (s, IH), 5.56 (s, IH), 2.29 (s, 3H), 2.12 (s, 3H). 19F NMR (377 MHz, ^-acetonitrile) δ -105, -111,132.
Example 40
4-((3,5-difluorophenyl)(5-fluoropyridin-2-yl)(hydroxy)methyl)-6-(3,5-dimethylisoxazol-
4-yl)-lH-benzo[d]imidazol-2(3H)-one
[00212] In a synthetic process following that described for Example 40, reaction of tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-(5-fluoropicolinoyl)-1 H-indole-1 carboxylate (50 mg, 0.13 mmol) with the organolithium species resulting from métal halogen exchange of l-bromo-3,5-difluorobenzene in diethyl ether gave, after purification of final material by reverse-phase HPLC (40-50% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini C18 5μ) the trifluoroacetate sait of 4-((3,5-difluorophenyl)(5-fluoropyridin-2yl)(hydroxy)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one as a white solid.
[00213] C24H17F3N4O3. 467.1 (M+H). IH NMR (400 MHz, tfc-DMSO) δ 10.73 (s,
IH), 9.76 (s, IH), 8.52 (m, IH), 7.77 (m, IH), 7.09 (m, IH), 6.92 (s, IH), 6.33 (s, IH), 2.25 (s, 3H), 2.07 (s, 3H). 19F NMR (377 MHz, tfc-DMSO) δ -75, -111, -130.
Example 41
4-((2,5-difluorophenyl)(5-fluoropyridin-2-yl)(hydroxy)methyl)-6-(3,5-dimethylisoxazol-
4-yl)- ΙΗ-benzo [d] imidazol-2(3H)-one
[00214] In a synthetic process following that described for Example 40, reaction of tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-(5-fluoropicolinoyl)-lH-indole-lcarboxylate (50 mg, 0.13 mmol) with the organolithium species resulting from métal halogen exchange of l-bromo-2,5-difluorobenzene in diethyl ether gave after purification of final material by reverse-phase HPLC (40-50% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini Cl8 5μ) the trifluoroacetate sait of 4-((2,5-difluorophenyl)(5-fluoropyridin-2yl)(hydroxy)methyl)-6-(3,5-dimethylisoxazol-4-y 1)-1 H-benzo [d]imidazol-2(3 H)-one as a white solid.
[00215] C24Hi7F3N4O3. 466.9 (M+H). Ή NMR (400 MHz, ^-DMSO) δ 10.74 (s, IH),
9.87 (s, IH), 8.48 (m, IH), 7.75 (m, IH), 7.64 (m, IH), 7.30 (s, IH), 7.21-7.07 (m, 3H), 6.86 (s, IH), 6.38 (s,lH), 2.26 (s, 3H), 2.07 (s, 3H). ’9F NMR (377 MHz, rf6-DMSO) δ -76, -114, 120, -130.
Example 42
6-(3,5-dimethylisoxazol-4-yl)-4-((5-fluoropyridin-2-yl)(hydroxy)(2,4,5trifluorophenyl)methyl)-lH-benzo[d]imidazol-2(3H)-one
[00216] In a synthetic process following that described for Example 40, reaction of tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-(5-fluoropicolinoyl)-lH-indole-lcarboxylate (50 mg, 0.13 mmol) with the organolithium species resulting from métal halogen exchange of l-bromo-2,4,5-trifluorobenzene in diethyl ether gave, after purification of final material by reverse-phase HPLC (40-50% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini C18 5μ), the trifluoroacetate sait of 6-(3,5-dimethylisoxazol-4-yl)-4-((5fluoropyridin-2-yl)(hydroxy)(2,4,5-trifluorophenyl)methyl)-lH-benzo[d]iniidazol-2(3H)-one as a white solid.
[00217] C24H16F4N4O:}. 485.12 (M+H). ’H NMR (400 MHz, ôfe-acetonitrile), 8.69 (s,
IH), 8.49 (s,lH), 7.59 (m, IH), 7.13 (m, IH), 6.98 (s, IH), 6.52 (m, IH), 2.29 (s, 3H), 2.13 (s, 3H). ’9F NMR (377 MHz, ^-acetonitrile) δ -77, -110, -137, -135, -145.
Example 43
6-(3,5-dimethylisoxazoI-4-yl)-4-((5-fluoropyridin-2-yl)(hydroxy)(pyrazm-2-yl)methyl)1 H-benzo [d] imidazoI-2(3H)-one
[00218] In a synthetic process following that described for Example 40, reaction of tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-(5-fluoropicolinoyl)-lH-indole-lcarboxylate (50 mg, 0.13 mmol) with the organolithium species resulting from deprotonoation of pyrazine by LiTMP in THF (using the literature method described in J. Org. Chem. 1995, 60, 3781-3786.) Following final deprotection, the combined organics were washed with water (30 mL) and brine (30 mL), and dried over Na2SO4. Purification by flash chromatography (0-100% hexanes/ethyl acetate) gave 6-(3,5-dimethylisoxazol-4-yl)-4-((5fluoropyridin-2-yl)(hydroxy)(pyrazin-2-yl)methyl)-1 H-benzo[d]imidazol-2(3H)-one as a white solid.
[00219] C22H17FN6O3. 433.1 (M+H). IH NMR (400 MHz, d3-acetonitrile), 8.88 (s,
IH), 8.56-8.44 (m,3H), 7.72 (m, IH), 7.61 (m, IH), 6.97 (s, IH), 6.57 (m, IH), 2.29 (s, 3H), 2.13 (s, 3H). 19F NMR (377 MHz, dh-acetonitrile) δ -130.
Example 44
6-(3,5-dimethylisoxazol-4-yl)-4-((5-fluoropyridin-2-yl)(hydroxy)(6(trifluoromethyl)pyridin-2-yI)methyl)-lH-benzo[d]imidazol-2(3H)-one
Step 1 :
[00220] To isopropylmagnesium chloride (0.63 mL, 1.26 mmol, 2 M in THF) in toluene (1.4 mL) was added 2-bromo-5-trifluoromethyl pyridine (300 mg, 1.6 mmol) in toluene (4 mL). After 3.5 hours, the Grignard solution (1.9 mL, 0.8 mmol) was added to tertbutyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-formyl-lH-indole-l-carboxylate (100 mg, 0.26 mmol) in toluene (9 mL) at 0°C and the mixture was allowed to warm to 20°C. After 16 hours, the reaction was quenched with saturated NH4Cl(aq) (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SÛ4, and concentrated in vacuo. The resulting unpurified 10 product, 100 mg, was treated to oxidation in lOmL DCM with Dess-Martin periodinane reagent (154.1 mg, 0.34 mmol). After 15 minutes, the reaction was quenched with saturated Na2S2O3(aq) (10 mL) and extracted with dichloromethane (3 x 10 mL). The combined organics were washed with water (30 mL) and brine (30 mL), and dried over Na2SO4. Purification by flash chromatography (0-50% ethyl acetate/hexane) afforded tert-butyl 6-(3,515 dimethylisoxazol-4-yl)-2-ethoxy-4-(6-(trifluoromethyl)picolinoyl)- lH-benzo[d]imidazole-1 carboxylate (30 mg, 23%) as an amber residue contaminated with unreacted aldéhyde.
[00221] CÆ5F3N4O5:531.0 (M+H).
Step 2:
[00222] To isopropylmagnesium chloride (1.32 mL, 2.64 mmol, 2 M in THF) in toluene (4mL) was added 2-bromo-5-fluoropyridine (388 mg, 2.05 mmol) in toluene (1 mL). After 3.5 hours the Grignard solution (1 mL, 0.65 mmol) was added to tert-butyl 6-(3,5dimethylisoxazol-4-yl)-2 ethoxypicolinoyl-lH-benzo[d]imidazole-l-carboxylate (30 mg, 0.13 mmol) in toluene (6 mL) at 0°C and the mixture was allowed to warm to 20°C. After 16 hours, the reaction was quenched with saturated NH4Cl(aq) (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SO4, and concentrated in vacuo. The resulting residue (100 mg) was dissolved in éthanol (3 mL) to which was added hydrochloric acid (0.2 mL, 0.8 mmol, 4 M in 1,4-dioxane). The mixture was heated to 70°C for 0.75 hours and then concentrated in vacuo. Purification by reverse-phase HPLC (25-50% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini C18 5μ) afforded the TFA sait of 6-(3,5dimethylisoxazol-4-yl)-4-((5-fluoropyridin-2-yl)(hydroxy)(6-(trifluoromethyl)pyridin-2yl)methyl)-lH-benzo[d]imidazol-2(3H)-one as a light yellow solid.
[00223] C24H17F4N5O3. 500.12 (M+H). IH NMR (400 MHz, Æ-acetonitrile) δ 8.82 (s,
IH), 8.76 (s, IH), 8.45 (d, J = 2.7 Hz, IH), 8.05 (m, IH), 7.86 (m, IH), 7.75 (m, 2H), 7.62 (m, IH), 6.93 (s, IH), 6.58 (s, IH), 6.93 (s, IH), 6.25 (s, IH), 2.31 (s, 3H), 2.16 (s, 3H). 19F NMR (377 MHz, 0/3-acetonitrile) δ -68, -76,-131.
Example 45 tert-Butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-(hydroxy(5-(trifluoromethyl)pyridin2-yl)m ethyl)- ΙΗ-benzo [d] imidazole-1 -carboxy la te
[00224] To 2-bromo-5-trifluoromethyl pyridine (200 mg, 0.89 mmol) in THF (4 mL) at -78°C was added «-butyllithium (0.36 mL, 0.9 mmol, 2.5M in hexanes). After 15 minutes, tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-formyl-lH-indole-l-carboxylate (60 mg, 0.16 mmol) in THF (1 mL) was added drop-wise to the reaction. After 60 minutes, the reaction was warmed, quenched with water (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SO4, and concentrated in vacuo. Purification of the resulting residue by flash column (0-50% ethyl acetate/hexanes) afforded 30 mg tert-butyl 6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-4-(hydroxy(5-(trifluoromethyl)pyridin-2-yl)methyl)-lHbenzo[d]imidazole-1 -carboxylate that was submitted to directly to final deprotection.
[00225] 30 mg (0.056 mmol) tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4(hydroxy(5-(trifluoromethyl)pyridin-2-yl)methyl)-lH-benzo[d]imidazole-l-carboxylate was dissolved in 3 mL éthanol, and hydrochloric acid (0.1 mL, 0.4 mmol, 4 M in 1,4-dioxane) was added. The mixture was heated to 70°C for 0.5 hours and then concentrated in vacuo. Purification by reverse-phase HPLC (25-50% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini Cl8 5μ) afforded the TFA sait of 6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(5(trifluoromethyl)pyridin-2-yl)methyl)-lH-benzo[d]imidazol-2(3H)-one as a light yellow solid.
[00226] C19H15F31N4O3. 405.1 (M+H). IH NMR (400 MHz, d3-acetonitrile) δ 8.91 (s, IH), 8.76 (s, IH), 8.3 (s, IH), 7.98 (d, J= 8.1, IH), 7.70 (d, J= 8.1, IH), 6.71 (m, 2H),
5.98 (s, IH), 2.24 (s, 3H), 2.08 (s, 3H). 19F NMR (376 MHz, ris-acetonitrile) δ -63.45, -74.7.
Example 46
6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(pyrrolidin-2-yl)methyl)-lH-benzo[d]imidazol2(3H)-one
[00227] N-Boc-pyrrolidine (150mg, 0.39 mmol) and TMEDA (0.2 mL, 158 mg, 1.36 mmol) was dissolved in dry MeTHF (2.6 mL) under Ar and cooled to -78 °C. Sec-BuLi (1.4M, 0.97 mL, 1.36 mmol) was added dropwise and the reaction was allowed to stir at -78 °C for 40 mins. tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-formyl-lHbenzo[d]imidazole-l-carboxylate (150 mg, 0.39 mmol) was dissolved in MeTHF (0.5 mL) and added dropwise via syringe to the reaction and allowed to stir at -78 °C for 10 minutes. The reaction was quenched with water and extracted three times with EtOAc, combined organic layers were washed once with brine, concentrated, and purified by reversephase HPLC to give tert-butyl 2-((6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lHbenzo[d]imidazol-4-yl)(hydroxy)methyl)pyrrolidine-l-carboxylate (53 mg, 30%) as a white powder. The solid (50 mg, 0.11 mmol) was dissolved in EtOH (5 mL) and HCl (1 mL) and heated for 12 hours at 65 °C. The reaction was cooled and concentrated to afford the desired product as a white powder.
[00228] Ci7H2oN403 329.3 (M+l). ’H NMR (400 MHz, DMSO-d6) δ 10.93 (s, 2H),
10.83 (d, J = 11.8 Hz, 2H), 9.07 (s, 2H), 8.47 (s, IH), 7.03 (d, J = 1.5 Hz, IH), 6.99 (s, IH),
6.86 (s, IH), 6.84 (d, J = 1.6 Hz, IH), 6.38 (d, J = 4.0 Hz, IH), 6.10 (d, J = 4.2 Hz, IH), 5.28 (s, IH), 4.98 (s, IH), 3.70 (d, J = 7.6 Hz, IH), 3.25 - 3.07 (m, 4H), 2.39 (s, 3H), 2.38 (s, 2H),
2.21 (s, 3H), 2.20 (s, 2H), 1.96 (q, J = 7.4 Hz, 3H), 1.86 (s, 2H), 1.77 (s, 2H), 1.67 (s, IH).
(1.1.4 mixture of diastereomers)
Example 47
4-(3-cycIopropyl-l-hydroxy-l-(pyridin-2-yl)propyl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo [d] imidazol-2(3H)-one
[00229] Magnésium métal (39.0 mg, 2.0 mmol) and iodine (one crystal) was taken up in dry diethyl ether (1.2 mL) and (2-bromoethyl)cyclopropane (200 mg, 1.3 mmol) was added dropwise until iodine color faded. The remainder was then added dropwise over 15 minutes to maintain a gentle reflux and then cooled to 0 °C. (2-cyclopropylethyl)magnesium bromide (1.1 M, 0.38 mL, 0.41 mmol) was added to a cooled (0 °C) solution of (6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin-2-yl)methanone (50 mg, 0.14 mmol) in dry THF (1.0 mL) under argon and allowed to stir for 10 minutes. The reaction was quenched with water, extracted three times with EtOAc, and combined organic layers were concentrated and purified by reverse-phase HPLC to give 3-cyclopropyl-l-(6(3,5-dimethylisoxazol-4-yl)-2-ethoxy- lH-benzo[d]imidazol-4-yl)- l-(pyridin-2-yl)propan-1 -ol intermediate. The intermediate was taken up in EtOH (1.5 mL) and 0.2mL concentrated HCl and heated to 65 °C for 2 hours and concentrated to afford the desired product as a white powder.
[00230] C23H24N4O3 405.2 (M+l). *H NMR (400 MHz, Methanol-d4) δ 8.73 (ddd, J =
5.8, 1.6, 0.7 Hz, IH), 8.43 (td, J= 8.0, 1.6 Hz, IH), 8.09 (dt, J = 8.2, 1.0 Hz, IH), 7.87 (ddd, J = 7.4, 5.7, 1.2 Hz, IH), 7.13 (d, J = 1.5 Hz, IH), 6.96 (d, J = 1.4 Hz, IH), 2.68 (ddd, J = 10.6, 8.6, 5.1 Hz, 2H), 2.40 (s, 3H), 2.23 (s, 3H), 1.37 (ddd, J = 11.8, 7.2, 4.7 Hz, IH), 1.26 - 1.13 (m, IH), 0.76 - 0.66 (m, IH), 0.43 (ddt, J = 8.7, 5.4, 2.4 Hz, 2H), 0.06 - -0.05 (m, 2H).
Example 48
6-(3,5-dimethylisoxazol-4-yl)-4-(2-ethyl-l-hydroxy-l-(pyridin-2-yl)butyl)-lHbenzo [d] imidazol-2(3H)-one
[00231] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)methanone (50 mg, 0.14 mmol) was dissolved in dry THF (1.4 mL) and cooled to 0 °C. Pentan-3-ylmagnesium bromide (2.0 M, 0.21 mL, 0.41 mmol) was added dropwise and the reaction was allowed to stir for 10 mins and then quenched with water. Reaction was extracted three times with EtOAc and combined organic layers were washed once with water, concentrated, and purified by reverse-phase HPLC to give 1-(6-(3,5-dimethylisoxazoI-4-yl)2-ethoxy-1 H-benzo[d]imidazol-4-yl)-2-ethyl-1 -(pyridin-2-yl)butan-1 -ol intermediate. The intermediate was taken up in EtOH (1.5 mL) and 0.2mL concentrated HCl and heated to 65 °C for 2 hours and concentrated to afford the desired product as a white powder.
[00232] C23H26N4O3 407.3 (M+l). ’H NMR (400 MHz, Methanol-d4) δ 8.78 (d, J =
5.6 Hz, IH), 8.54 (t, J = 7.6 Hz, IH), 8.23 (d, J = 7.8 Hz, IH), 7.98 (t, J = 6.4 Hz, IH), 7.21 (d, J = 1.2 Hz, IH), 6.97 (d, J = 1.1 Hz, IH), 2.71 (s, IH), 2.41 (s, 3H), 2.25 (s, 3H), 1.88 -
1.76 (m, IH), 1.59 - 1.29 (m, 3H), 1.09 (t, J = 7.4 Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H).
Example 49
4-((2,6-difluorophenyI)(hydroxy)(pyrazin-2-yl)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one
[00233] n-BuLi (0.58 mL, 0.93 mmol) was added dropwise to a solution of 1,3difluorobenzene (0.102 mL, 0.1 mmol) in THF (5 mL) cooled to -78 °C and allowed to stir for 1 hour. tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-formyl-lHbenzo[d]imidazole-l-carboxylate (200 mg, 0.52 mmol) in in THF was added and the reaction was allowed to stir for 5 mins at -78 °C, quenched with ammonium chloride, extracted with EtOAc and concentrated. The crude was then taken up in DCM (2 mL), Des-Martin periodinane (290 mg, 0.78 mmol) was added and the reaction was allowed to stir for 15 mins. The reaction was quenched with sat. Na2S2O3, extracted with EtOAc, concentrated and purified by silica gel chromatography to give tert-butyl 4-(2,6-difluorobenzoyl)-6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazole-l-carboxylate.
[00234] n-BuLi (0.21 mL, 0.33mmol) was added dropwise to a solution of 2,2,6,6tetramethylpiperidine (0.06 mL, 0.33mmol) in THF (0.7 mL) at 0°C and was allowed to stir for 5 minutes. Pyrazine (24 mg, 0.3 mmol) in THF (0.4 mL) was added and the reaction was stirred for an additional 5 minutes and then cooled to -78 °C. tert-butyl 4-(2,6difluorobenzoyl)-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-1 H-benzo[d]imidazole-1 carboxylate (50 mg, 0.10 mmol) in THF (0.4 mL) was added, the solution was allowed to stir for 5 minutes and then quenched with water. Solution was extracted three times with EtOAc, washed once with brine and concentrated. Crude was purified by reverse-phase HPLC and then taken up in EtOH (3 mL) and HCl (0.1 mL) and heated to 65 °C for 2 hours. Reaction was cooled and concentrated to afford desired product as a pale brown powder.
[00235] C25H2iF2N5O3 478.5 (M+l). JH NMR (400 MHz, Methanol-d4) 5 9.02 (s,
IH), 8.57 (d, J = 26.1 Hz, 2H), 7.44 (tt, J = 8.3, 5.9 Hz, IH), 7.02 - 6.89 (m, 4H), 2.33 (s, 3 H), 2.16 (s, 3 H).
Example 50
4-((2,6-difluorophenyl)(hydroxy)(pyridazin-3-yI)methyl)-6-(3,5-dimethylisoxazol-4-yl)lH-benzo[d]imidazoI-2(3H)-one
[00236] The following compound was made in a similar fashion as that of Example 49, but using pyridazine instead of pyrazine.
N-O
[00237] C25H2iF2N5O3 478.5 (M+l). *H NMR (400 MHz, Methanol-d4) δ 9.48 (s,
IH), 8.88 - 8.81 (m, IH), 8.42 (dd, J = 8.7, 5.0 Hz, IH), 7.54 (tt, J = 8.4, 6.1 Hz, IH), 7.05 (dd, J = 10.6, 8.6 Hz, 2H), 6.98 (d, J = 1.5 Hz, IH), 6.91 - 6.87 (m, IH), 2.32 (s, 3H), 2.15 (s, 3H).
Example 51,
Example 52, and
Example 53
6-(3,5-dimethylisoxazoI-4-yl)-4-((5-fluoropyridin-2-yl)(hydroxy)methyI)-lHbenzo [d] imidazol-2(3H)-one;
6-(3,5-dimethylisoxazol-4-yl)-4-((5-fluoropyridin-2-yl)(hydroxy)(2,4,6trifluorophenyl)methyl)-lH-benzo[d]imidazol-2(3H)-one;
and
6-(3,5-dimethylisoxazol-4-yI)-4-(fluorobis(5-fluoropyridin-2-yl)methyl)-lHbenzo [d] imidazol-2(3H)-one
[00238] To isopropylmagnesium chloride (0.63 mL, 1.26 mmol, 2 M in tetrahydroforan) in toluene (1.4 mL) was added 2-bromo-5-fluoropyridine (184.6 mg, 1.05 mmol) in toluene (0.48 mL). After 3.5 hours, the Grignard solution (1.9 mL, 0.65 mmol) was added to tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-formyl-lH-indole-l-carboxylate (62.2 mg, 0.16 mmol) in tetrahydrofuran (9 mL) at 0°C and the mixture was allowed to warm to 20°C. After 16 hours, the reaction was quenched with saturated NH4Cl(aq) (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SO4, and concentrated in vacuo. Purification by flash chromatography (0-50% ethyl acetate/hexane) afforded tert-butyl 6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-4-((5-fluoropyridin-2-yl)(hydroxy)methyl)-lHbenzo[d]imidazole-l-carboxylate as a yellow residue.
[00239] To tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-((5-fluoropyridin-2yl)(hydroxy)methyl)-lH-benzo[d]imidazole-l-carboxylate (41.2 mg, 0.09 mmol) in éthanol (5 mL) was added hydrochloric acid (0.66 mL, 2.64 mmol, 4 M in 1,4-dioxane). The mixture was heated to 60°C for 6 hours and then concentrated in vacuo. Purification by reverse-phase HPLC (25-50% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini Cl8 5μ) afforded 6-(3,5-dimethylisoxazol-4-yl)-4-((5-fluoropyridin-2-yl)(hydroxy)methyl)-lHbenzo[d]imidazol-2(3H)-one as a white solid.
[00240] C18H15FN4O3. 335.03 (M+l). *H NMR (400 MHz, DMSO-ίή?) δ 10.73 (s, IH),
10.70 (s, IH), 8.45 (d, J = 2.9 Hz, IH), 7.80 (dd, J = 8.7, 4.7 Hz, IH), 7.73 (td, J = 8.8, 2.9 Hz, IH), 6.81 (d, J = 1.6 Hz, IH), 6.74 (d, J = 1.5 Hz, IH), 6.03 (s, IH), 2.31 (s, 3H), 2.12 (s, 3H). 19F NMR (376 MHz, DMSO-d6) δ -76.42, -131.97.
[00241] To tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-((5-fluoropyridin-2yl)(hydroxy)methyl)-lH-benzo[d]imidazole-l-carboxylate (57 mg, 0.12 mmol) in dichloromethane (6 mL) was added Dess-Martin periodinane (154.1 mg, 0.34 mmol). After 15 minutes, the reaction was quenched with saturated Na2S2O3(aq) (10 mL) and extracted with dichloromethane (3 x 10 mL). The combined organics were washed with water (30 mL) and brine (30 mL), and dried over Na2SO4. To the crude solution was added Ν,Νdiisopropylethylamine (0.05 mL, 0.26 mmol), 4-(dimethylamino)pyridine (6.8 mg, 0.05 mmol), and di-tert-butyl dicarbonate (120.9 mg). After 90 minutes, the reaction mixture was washed with water (2 x 30 mL), dried over NaîSCL, and concentrated in vacuo. Purification by flash chromatography (0-50% ethyl acetate/hexane) afforded tert-butyl 6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-4-(5-fluoropicolinoyl)- lH-benzo[d]imidazole-1 -carboxylate as an amber residue.
[00242] To l-bromo-2,4,6-trifluorobenzene (0.02 ml, 0.16 mmol) in diethyl ether (0.52 mL) at -78°C was added w-butyllithium (0.12 mL, 0.18 mmol, 1.6 M in hexanes). After 30 minutes, tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-(5-fluoropicolinoyl)- 1Hbenzo[d]imidazole-l-carboxylate (50 mg, 0.10 mmol) in diethyl ether (1 mL) was added drop-wise to the reaction. After 60 minutes, the reaction was warmed, quenched with saturated NH4Cl(aq) (10 mL), extracted with ethyl acetate (3 x 10 mL), dried over Na2SÜ4, and concentrated in vacuo. To the crude residue in éthanol (3.5 mL) was added hydrochloric acid (0.35 mL, 1.4 mmol, 4 M in 1,4-dioxane) and the mixture was heated to 70°C in a microwave reactor for 45 minutes. Purification by reverse-phase HPLC (40-50% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini C18 5μ) afforded 6-(3,5dimethylisoxazol-4-yl)-4-((5-fluoropyridin-2-yl)(hydroxy)(2,4,6-trifluorophenyl)methyl)-lHbenzo[d]imidazol-2(3H)-one as a white solid.
[00243] C24Hi6F4N4O3. 485.12 (M+l). Ή NMR (400 MHz, chloroform-//) δ 9.40 (s,
IH), 9.18 (s, IH), 8.48 (d, J = 2.7 Hz, IH), 7.40 (td, J = 8.3, 2.8 Hz, IH), 7.15 (dd, J = 8.8,
4.2 Hz, IH), 6.99 (s, IH), 6.68 - 6.56 (m, 3H), 2.31 (s, 3H), 2.16 (s, 3H). 19F NMR (377 MHz, chloroform-d) δ -76.51, -102.54 - -103.06 (m), -106.62 (p, J = 7.9 Hz), -127.18 (dd, J = 7.3, 3.8 Hz).
[00244] To isopropylmagnesium chloride (0.34 ml, 0.57 mmol, 2 M in tetrahydrofuran) in toluene (0.26 mL) was added 2-bromo-5-fluoropyridine (100 mg, 0.57 mmol) in toluene (0.78 mL). After 4 hours, the Grignard solution (1.2 mL, 0.47 mmol) was added to tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-((5-fluoropyridin-2yl)(hydroxy)methyl)-lH-benzo[d]imidazole-l-carboxylate (57 mg, 0.12 mmol) in tetrahydrofuran (6 mL) at 0°C. After 60 minutes, the reaction was quenched with saturated NH4Cl(aq) (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SO4, and concentrated in vacuo. To the crude dissolved in éthanol (2.5 mL) was added hydrochloric acid (0.29 mL, 1.17 mmol, 4 M in 1,4-dioxane) and the mixture was heated to 70°C in a microwave reactor for 45 minutes. Purification by reverse-phase HPLC (30-45% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini C18 5μ) afforded 4-(bis(5fluoropyridin-2-yl)(hydroxy)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol2(3H)-one as a white solid.
[00245] C23Hi7F2N5O3. 450.11 (M+l). Ή NMR (400 MHz, DMSO-ûk) δ 10.72 (s,
IH), 9.75 (s, IH), 8.52 - 8.48 (m, 2H), 7.74 (td, J = 8.8, 2.9 Hz, 2H), 7.63 (dd, J = 8.9, 4.7 Hz, 2H), 6.84 (d, J = 1.2 Hz, IH), 6.45 (d, J = 1.3 Hz, IH), 2.27 (s, 3H), 2.08 (s, 3H). 19F NMR (376 MHz, DMSO-d6) δ -75.01, -130.07 (dd, J = 8.8, 4.4 Hz).
[00246] To 4-(bis(5-fluoropyridin-2-yl)(hydroxy)methyl)-6-(3,5-dimethylisoxazol-4yl)-lH-benzo[d]imidazol-2(3H)-one (10.4 mg, 0.02 mmol) in dichloromethane (2.3 mL) added (diethylamino)sulfur trifluoride (9.15 μΐ, 0.07 mmol) and stirred for 60 minutes before adding more (diethylamino)sulfur trifluoride (0.01 ml, 0.07 mmol). After 60 minutes from the second addition, the reaction was poured into saturated NaHCO3(aq) (5 mL), the layers were separated, and the aqueous was extracted with dichloromethane (2x5 mL). The combined organics were dried over Na2SO4 and concentrated in vacuo. Purification by reverse-phase HPLC (25-75% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini Cl8 5μ) afforded 6-(3,5-dimethylisoxazol-4-yl)-4-(fluorobis(5-fluoropyridin-2-yl)methyl)-lHbenzo[d]imidazol-2(3H)-one as an off-white solid.
[00247] C23Hi6F3N5O2. 452.05 (M+l). Ή NMR (400 MHz, DMSO-6&) δ 10.85 (s,
IH), 10.35 (s, IH), 8.55 (d, J = 2.9 Hz, 2H), 7.82 (td, J = 8.6, 2.9 Hz, 2H), 7.64 (dd, J = 8.8,
4.4 Hz, 2H), 6.92 (s, IH), 6.40 (s, IH), 2.27 (s, 3H), 2.07 (s, 3H). 19F NMR (376 MHz, DMSO-ifc) δ -74.14, -127.97 (dt, J= 8.3, 4.0 Hz), -136.81.
Example 54
4-((5-chloropyridin-2-yl)(hydroxy)(pyridm-2-yl)methyI)-6-(3,5-dimethyIisoxazol-4-yl)lH-benzo[d]imidazol-2(3H)-one
[00248] To 2-bromo-5-chloropyridine (55.42 mg, 0.29 mmol) in toluene (1 mL) at 78°C was added w-butyllithium (0.41 mL, 0.65 mmol, 1.6 M in tetrahydrofuran). After 60 minutes, tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-formyl-lH-indole-l-carboxylate (100 mg, 0.26 mmol) in toluene (0.3 mL) was added drop-wise to the reaction. After 60 minutes, the reaction was warmed, quenched with saturated NH4Cl(aq) (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SÛ4, and concentrated in vacuo. The crude material was dissolved in dichloromethane (6 mL) and Dess-Martin periodinane (143.06 mg, 0.34 mmol) was added. After 10 minutes, the reaction was quenched with saturated Na2S2O3(aq) (10 mL) and extracted with dichloromethane (3 x 10 mL). The combined organics were washed with water (30 mL) and brine (30 mL), dried over Na2SO4, and concentrated in vacuo. Purification by flash chromatography (0-50% ethyl acetate/hexanes) afforded tert-butyl 4-(5-chloropicolinoyl)-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy- 1Hbenzo[d]imidazole-l-carboxylate as an yellow residue.
[00249] To 2-bromopyridine (0.02 ml, 0.2 mmol) in tetrahydrofuran (4 mL) at -78°C was added /z-butyllithium (0.15 mL, 0.24 mmol, 1.6 M in hexanes). After 30 minutes, tertbutyl 4-(5-chloropicolinoyl)-6-(3,5-dimethyIisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazole-
1- carboxylate (33 mg, 0.07 mmol) in tetrahydrofuran (1 mL) was added drop-wise to the reaction. After 30 minutes, the reaction was warmed, quenched with saturated NHiClfaq) (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SÛ4, and concentrated in vacuo. To the crude residue in éthanol (3 mL) was added hydrochloric acid (0.17 mL, 0.66 mmol, 4 M in 1,4-dioxane) and the mixture was heated to 70°C in a microwave reactor for 45 minutes. Purification by reverse-phase HPLC (23-40% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini Cl8 5μ) afforded 4-((5-chloropyridin-2-yl)(hydroxy)(pyridin-2-yl)methyl)-6(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one as an off-white solid.
[00250] C23H18CIN5O3. 448.22 (M+l). !H NMR (400 MHz, DMSO-Je) δ 10.78 (s,
IH), 9.90 (s, IH), 8.62 - 8.53 (m, 2H), 8.04 - 7.96 (m, 2H), 7.66 (dd, 8.2, 5.2 Hz, 2H), 7.53 - 7.45 (m, IH), 6.87 (d, J= 1.1 Hz, IH), 6.44 (d, J = 1.6 Hz, IH), 2.27 (s, 3H), 2.07 (s, 3H).
Example 55
4-(bis(5-chloropyridin-2-yI)(hydroxy)methyl)-6-(3,5-dimethylisoxazol-4-yI)-lHbenzo[d]imidazol-2(3H)-one
[00251] The following analog was prepared in the same fashion as 4-((5-chloropyridin-
2- yl)(hydroxy)(pyridin-2-yl)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol2(3H)-one by substituting 2-bromo-5-chloropyridine for 2-bromopyridine.
4-(bis(5-chloropyridin-2-yl)(hydroxy)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one as an off-white solid.
[00252] C23H17CI2N5O3. 482.29 (Μ+1). *H NMR (400 MHz, DMSO-î/6) δ 10.81 (s,
IH), 9.85 (s, IH), 8.59 - 8.52 (m, 2H), 8.48 (d, J= 3.3 Hz, IH), 8.01 (dd, J= 8.3, 2.5 Hz,
IH), 7.77 (d, J= 8.6 Hz, IH), 7.18 (d, J= 5.0 Hz, IH), 7.06 (s, IH), 6.88 (d, J= 1.1 Hz, IH), 6.34 (d, J= 1.5 Hz, IH), 2.25 (s, 3H), 2.05 (s, 3H).
Example 56
6-(3,5-dimethylisoxazol-4-yI)-4-(hydroxy(pyrazin-2-yI)(2,4,6-trifluorophenyl)metliyl)lH-benzo[d]imidazol-2(3H)-one
[00253] To 2,2,6,6-tetramethylpiperidine (0.27 mL, 1.56 mmol) in tetrahydrofüran (Î6 mL) at -78 °C was added //-butyllithium (0.97 mL, 1.56 mmol, 1.6 M in hexanes). After 5 minutes, the reaction was warmed to 0°C. After stirring for 30 minutes, the reaction was cooled to -78°C, and pyrazine (137 mg, 1.69 mmol) in tetrahydrofüran (3.3 mL) and tertbutyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-formyl-lH-indole-l -carboxylate (498 mg, 1.3 mmol) in tetrahydrofüran (2.6 mL) were added simultaneously in a drop-wise manner. After stirring for 60 minutes, the reaction was quenched with saturated NHUCl^q) (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SO4, and concentrated in vacuo. Purification by flash chromatography (0-100% ethyl acetate/hexane) afforded tert-butyl 6(3,5 -dimethy li soxazol-4-yl)-2-ethoxy-4-(hydroxy(pyrazin-2-yl)methy 1)-1Hbenzo[d]imidazole-l-carboxylate. To tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4(hydroxy(pyrazin-2-yl)methyl)-lH-benzo[d]imidazole-l-carboxylate (50 mg, 0.11 mmol) in dichloromethane (2.5 mL) was added Dess-Martin periodinane (72.4 mg, 0.16 mmol). After 15 minutes, the reaction was quenched with saturated Na2S2Û3(aq) (10 mL) and extracted with dichloromethane (3x10 mL), dried over Na2SO4, and concentrated in vacuo. Purification by flash chromatography (0-100% ethyl acetate/hexanes) afforded tert-butyl 6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-4-(pyrazine-2-carbonyl)-lH-benzo[d]imidazole-lcarboxylate as a yellow oil.
[00254] To l-bromo-2,4,6-trifluorobenzene (0.01 ml, 0.12 mmol) in diethyl ether (0.5 mL) at -78°C was added w-butyUithium (0.13 mL, 0.14 mmol, 1.6 M in hexanes). After 30 tertbutyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-(pyrazine-2-carbonyl)-lHbenzo[d]imidazole-l-carboxylate (36.6 mg, 0.08 mmol) in diethyl ether (1 mL) was added drop-wise to the reaction. After 90 minutes, the reaction was warmed, quenched with saturated NH4Cl(aq) (10 mL), extracted with ethyl acetate (3x10 mL), dried over Na2SÛ4, and concentrated in vacuo. To the crude residue in éthanol (1.5 mL) was added hydrochloric acid (0.20 mL, 0.79 mmol, 4 M in 1,4-dioxane) and the mixture was heated to 70°C in a microwave reactor for 45 minutes. Purification by reverse-phase HPLC (35-50% acetonitrile/water with 0.01% trifluoroacetic acid, Gemini C18 5μ) afforded 6-(3,5dimethylisoxazol-4-yl)-4-(hydroxy(pyrazin-2-yl)(2,4,6-trifluorophenyl)methyl)-lHbenzo[d]imidazol-2(3H)-one as a pale yellow solid.
[00255] C23H16F3N5O3. 468.09 (M+l). ’H NMR (400 MHz, DMSO-i/e) δ 10.74 (s,
IH), 9.89 (s, IH), 9.12 (d, J= 1.2 Hz, IH), 8.60 - 8.49 (m, 2H), 7.39 (s, IH), 7.10 (t, J= 9.7 Hz, 2H), 6.83 - 6.77 (m, IH), 6.63 (d, J= 1.3 Hz, IH), 2.28 (s, 3H), 2.09 (s, 3H). 19F NMR (377 MHz, DMSO-rié) δ -74.73, -100.62 (t, J = 9.1 Hz), -108.90 (p, J= 8.8 Hz).
Example 57
6-(3,5-dimethyIisoxazoI-4-yI)-4-(l-methyl-4-phenyI-lH-pyrazol-5-yl)-lHbenzo [d] imidazol-2(3H)-one
Step 1 : l-Methyl-4-phenyl-5-(4,4,5,5-tetramethyl-L3,2-dioxaborolan-2-yl)-lH-pyrazole
Pd(dppf)Cl2, KOAc
1,4-dioxane, 100°C
[00256] 5-bromo-l-methyl-4-phenyl-lH-pyrazole (87 mg, 0.37 mmol) and 3,5Dimethylisoxazole-4-boronic acid pinacol ester (373 mg, 1.47 mmol) was added to a 1,4dioxane (2 ml). To the above mixture were added Pd(dppf)Cl2 (27 mg, 0.037 mmol) and potassium acetate (181 mg, 1.85 mmol). The reaction mixture was heated at 100°C for 2h. The reaction mixture was then diluted with EtOAc (100 ml), washed with bring (50mlX2). The organic solvent was evaporated and the residue was dissolved in DCM and purified with combi-flash column chromatography (product came out at 45% EtOAc/Hexane) to afford 141 mg product 1 -methyl-4-phenyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 1Hpyrazole.
[00257] C16H21BN2O2. 285.3 (M+l).
Step 2: Préparation of4-(2-ethoxv-4-(l-methyl-4-phenyl-lH-pyrazol-5-yl)-lHbenzo [d] imidazol-6-yl)-3,5-dimethylisoxazole
o DME/H2O, 130°C
[00258] 4-(2-ethoxy-4-iodo-1 H-benzo[d]imidazol-6-yl)-3,5 -dimethylisoxazole (100 mg , 0.26 mmol) and l-methyl-4-phenyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lHpyrazole (37 mg, 0.13 mmol) was added to a solvent mixture of 1,2-dimethoxyethane (2 ml) and water (1 ml). To the above mixture were added PEPPSI-Ipr (18 mg, 0.026 mmol) and CsCCh (127 mg, 0.39 mmol). The reaction mixture was heated at 130°C in microwave reactor for 30mins. The reaction mixture was then filtered and organic solvent was evaporated and the residue was purified with Prep HPLC (0-100% CH3CN/H2O) to afford 8 mg product 4-(2ethoxy-4-( 1 -methyl-4-phenyl-1 H-pyrazol-5-yl)-1 H-benzo[d]imidazol-6-yl)-3,5dimethylisoxazole.
[00259] C24H23N5O2. 414.5 (M+l).
Step 3:
HCI
Dioxane, 60°C
O-N
[00260] 4-(2-ethoxy-4-( 1 -methyl-4-phenyl- lH-pyrazol-5-yl)- lH-benzo[d]imidazol-65 yl)-3,5-dimethylisoxazole (8mg, 0.019 mmol) was dissolved in dioxane (0.5 ml), to the solution was added concentrated HCl (0.1 ml), heated at 60oC for 2h. Solvent was evaporated and the residue was purified with Prep HPLC (0-100% CH3CN/H2O) to afford 2 mg product 6-(3,5-dimethylisoxazol-4-yl)-4-(l-methyl-4-phenyl-lH-pyrazol-5-yl)-lH-benzo[d]imidazol2(3H)-one.
[00261] C22H19N5O2. 386.2 (M+l). IH NMR (400MHz, CD3OD) δ 8.20 (s, IH),
7.91 (s, IH), 7.64 (d, J = 7.6 Hz, 2H), 7.55 (d, J = 7.6 Hz, 2H), 6.94 (s, IH), 6.86 (s, IH), 3.87 (s, 3H), 2.39 (s, 3H), 2.22 (s, 3H).
Example 58
6-(3,5-dimethyIisoxazol-4-yl)-4-(4-methyl-l-phenyl-lH-pyrazol-5-yl)-lHbenzo [d] imidazol-2(3H)-one
[00262] 6-(3,5-dimethylisoxazoI-4-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yI)lH-benzo[d]imidazol-2(3H)-one (30 mg , 0.084 mmol) and 5-bromo-4-methyl-l-phenyl-1Hpyrazole (30 mg, 0.13 mmol) was added to a solvent mixture of 1,2-dimethoxyethane (2 ml) and water (1 ml). To the above mixture were added PEPPSI-Ipr (5.4 mg, 0.008 mmol) and Cs2CO3 (83 mg, 0.25 mmol). The reaction mixture was heated at 130oC in microwave reactor for 30mins. The reaction mixture was then filtered and organic solvent was evaporated and the residue was purified with Prep HPLC (0-100% CH3CN/H2O) to afford
3.9 mg product 6-(3,5-dimethylisoxazol-4-yl)-4-(4-methyl-l-phenyl-lH-pyrazol-5-yl)-lHbenzo[d]imidazol-2(3H)-one (yield = 12%).
[00263] C22H19N5O2. 386.3 (M+l). IH NMR (400MHz, CD3OD) δ 8.10 (s, IH),
7.77 (d, J = 8.0 Hz, 2H), 7.42 (t, J = 8.0 Hz, 2H), 7.23-7.22 (m, 2H), 6.94 (s, IH), 2.37 (s, 3H), 2.29 (s, 3H), 2.21 (s, 3H).
[00264] The following compounds were made in similar fashion as that of Example 58.
Example 59
6-(3,5-dimethy lisoxazol-4-yI)-4-(4-methyl-1 -pheny 1-1 H-py razol-3-yl)-1Hbenzo [d] imidazol-2(3H)-one
[00265] C22Hi9N5O2. 386.1 (M+l). 'HNMR (400MHz, CD3OD) δ 7.98 (s, IH), 7.73 (d, J= 8.4 Hz, 2H), 7.58 (d, J= 8.4 Hz, 2H), 7.48 (s, IH), 6.94 (s, IH), 6.90 (s, IH), 2.34 (s, 3H), 2.19 (s, 3H), 2.10 (s, 3H).
Example 60
4-(1,4-dicyclopropyl-lH-pyrazol-3-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzofd] imidazol-2(3H)-one
[00266] C21H21N5O2. 376.2 (M+l). Ή NMR (400MHz, CDsOD) δ 7.62 (s, IH), 7.48 (s, IH), 6.97 (s, IH), 3.71-3.31 (m, IH), 2.27 (s, 3H), 2.27 (s, 3H), 1.78-1.75 (m, 2H), 1.161.06 (m, 2H), 1.05-1.02 (m, 2H), 0.61-0.59 (m, 2H).
Example 61
4-(4-cyclopropyl-l-methyl-lH-pyrazoI-5-yl)~6-(3,5-dimethyIisoxazol-4-yl)-lHbenzo [d] imidazo!-2(3H)-one
[00267] Ci9Hi9N5O2. 350.2 (M+l). Ή NMR (400MHz, CD3OD) δ 7.19 (s, IH), 7.00 (s, IH), 6.86 (s, IH), 3.59 (s, 3H), 2.34 (s, 3H), 2.18 (s, 3H), 1.45-1.41 (m, IH), 0.65-0.63 (m, 15 2H), 0.45-0.38 (m, 2H).
Example 62
4-(4-cyclopropyl-1 -methyl- lH-pyrazol-3-yl)-6-(3,5-dimethylisoxazol-4-yl)-1Hbenzo [d] imidazol-2(3H)-one
[00268] C19H19N5O2. 350.2 (M+l). Ή NMR (400MHz, CD3OD) δ 7.53 (s, IH), 7.30 (s, IH), 6.87 (s, IH), 3.82 (s, 3H), 2.18 (s, 3H), 1.72 (s, 3H), 1.72-1.68 (m, IH), 0.83-0.75 (m, 2H), 0.50-0.42 (m, 2H).
Example 63
4-(l,3-dicyclopropyl-lH-pyrrol-2-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo [d] imidazol-2(3H)-one
[00269] C21H21N5O2. 376.2 (M+l). NMR (400MHz, CD3OD) δ 7.23 (s, IH), 7.09 (s, IH), 6.99 (s, IH), 3.48-3.42 (m, 3H), 2.27 (s, 3H), 2.00 (s, 3H), 1.51-1.23 (m, IH), 0.9115 0.85 (m, 2H), 0.80-0.71 (m, 4H), 0.56-0.46 (m, 2H).
Example 64
4-(2-cyclopropylphenyl)-6-(3,5-dimethylisoxazol-4-yi)-lH-benzo[d]imidazoI-2(3H)-one
[00270] C21H19N3O2. 346.1 (M+l). ’H NMR (400MHz, CD3OD) δ 7.35-7.3 l(m, IH),
7.25-7.24 (m, IH), 7.24-7.03 (m, IH), 6.99 (s, IH), 6.87 (s, IH), 2.42 (s, 3H), 2.26 (s, 3H),
1.77-1.73 (m, IH), 0.79-0.77 (m, 2H), 0.67 (bs, 2H).
Example 65
5-(3,5-dimethylisoxazol-4-yI)-l-methyl-7-(3-methylcinnolin-4-yl)-lH-benzo[d]imidazol-
2(3H)-one
N
I
N
[00271] C22H19N5O2. 386.2 (M+l). *H NMR (400MHz, CD3OD) δ 8.42 (d, J= 8.8
Hz, IH), 7.84 (t, J= 7.6 Hz, IH), 7.73 (t, J= Ί.6 Hz, IH), 7.44 (d, J= 8.8 Hz, IH), 7.14 (s, IH), 6.83 (s, IH), 2.68 (s, 3H), 2.55 (s, 3H), 2.33 (s, 3H), 2.17 (s, 3H).
Example 66
6-(3,5-dimethylisoxazol-4-yl)-4-(4-methyl-l-(tetrahydro-2H-pyran-2-yl)-lH-pyrazol-5- yl)-lH-benzo[d]imidazol-2(3H)-one
O-N
[00272] C21H23N5O3. 386.2 (M+l). ΉNMR (400MHz, CD3OD) δ 7.23 (s, IH), 7.00 (s, IH), 6.86 (s, IH), 3.83-3.57 (m, IH), 3.38-3.33 (m, 2H), 2.34 (s, 3H), 2.55 (s, 3H), 2.18 (s, 3H), 1.99 (s, 3H), 1.58-1.40 (m, 6H).
Example 67
4-(2-cyclobutylpyridin-3-yl)-6-(3,5-dimethylisoxazol-4-yI)-lH-benzo[d]imidazol-2(3H)one
O-N / Ύ
O
[00273] C21H20N4O2. 361.3 (M+l). ’H NMR (400MHz, CD3OD) δ 8.69 (d, J= 4.8
Hz, IH), 8.31 (d, 8.4 Hz, IH), 7.87-7.83 (m, IH), 7.04 (s, IH), 6.85 (s, IH), 3.90-3.86 (m,
IH), 2.33 (s, 3H), 2.30 (bs, IH), 2.14 (s, 3H), 2.11 (bs, IH), 1.92 (bs, 2H), 1.78-1.71(m, 2H).
100
Example 68
4-(4-amino-2-cyclopropylpyridm-3-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d] imidazol-2(3H)-one
[00274] C20H19N5O2. 362.3 (M+l). ’HNMR (400MHz, CD3OD) δ 10.63 (s, IH),
10.42 (s, IH), 7.82 (s, IH), 6.81 (s, IH), 6.61 (s, IH), 6.40 (s, IH), 5.21 (s, 2H), 2.28 (s, 3H),
2.17 (s, 3H), 1.45-1.43 (m, IH), 0.98-0.85 (m, 2H), 0.69-0.63 (m, 2H), 0.47-0.44 (m, 2H).
Example 69
4-(4-cyclopropylthiazol-5-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H) one
O-N
[00275] C18H16N4O2S. 353.3 (M+l). Ή NMR (400MHz, CD3OD) δ 8.81 (s, IH), 6.98 (s, IH), 6.88 (s, IH), 2.26 (s, 3H), 2.19 (s, 3H), 1.78 (bs, IH), 0.86 (bs, 2H), 0.82 (bs, 2H).
101
Example 70
4-([2,3'-bipyridin]-3-yl)-6-(3,5-dimethylisoxazoI-4-yl)-lH-benzo[d]imidazol-2(3H)-one
O-N
[00276] C22H17N5O2. 384.3 (M+l). ’H NMR (400MHz, CD3OD) δ 8.83 (dd, 1.2,
4.8 Hz, IH), 8.75 (s, IH), 8.63 (d, J= 5.2 Hz, IH), 8.23 (d, J= 7.2 Hz, IH), 8.08 (dd, J= 1.2,
8.0 Hz, IH), 7.72-7.67 (m, 2H), 6.99 (d, J= 1.2 Hz, IH), 6.86 (s, IH), 2.29 (s, 3H), 2.12 (s, 3H).
Example 71
4-(4-cyclopropylpyridin-3-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)one
O-N
[00277] C20H18N4O2. 347.3 (M+l). Ή NMR (400MHz, CD3OD) Ô 8.34 (d, J = 6.4
Hz, IH), 8.28 (s, IH), 6.98-6.97 (m, IH), 6.93 (d, J= 6.4 Hz, IH), 6.84 (d, 1.2 Hz, IH),
2.34 (s, 3H), 2.17 (s, 3H), 1.85-1.75 (m, IH), 0.95 (bs, 2H), 0.78 (bs, 2H).
102
Example 72
4-(3-cyclopropylpyridin-4-yl)-6-(3,5-dimethylisoxazol-4-yI)-lH-benzo[d]imidazol-2(3H)one
O-N
O
[00278] C20H18N4O2. 347.3 (M+l). JH NMR (400MHz, CD3OD) Ô 8.58 (d, J= 5.2
Hz, IH), 8.43 (s, IH), 7.82 (d, J= 6.4 Hz, IH), 7.05 (d, J= 1.2 Hz, IH), 6.94 (d, 1.6 Hz,
IH), 2.34 (s, 3H), 2.18 (s, 3H), 1.88-1.84 (m, IH), 1.00-0.95 (m, 2H), 0.85-0.81 (m, 2H).
Example 73
4-(2-cydopropylpyridin-3-yl)-6-(3,5-dimethyIisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)one
O-N
Z A
O
[00279] C20H18N4O2. 347.2 (M+l). Ή NMR (400MHz, CD3OD) δ 8.57 (d, 8.4
Hz, IH), 8.19 (d, 8.4 Hz, IH), 7.70-7.67 (m, IH), 7.10 (s, IH), 6.99 (s, IH), 2.43 (s, 3H),
2.27 (s, 3H), 2.14-2.08 (m, IH), 1.15 (bs, 4H).
Example 74
2-cyclopropyl-3-(6-(3,5-dimethylisoxazoI-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol4-yl)pyridine 1-oxide
103
O-N
Ο
[00280] 4-(2-cyclopropylpyridin-3-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one (35mg, 0.1 mmol) was dissolved in MeOH/DCM (1/1 mL). To the solution was added 3-Chloroperoxybenzoic acid (69.75 mg, 0.4 mol) and the mixture stirred at RT ovemight. The organic solvent was evaporated and the residue was purified with Prep HPLC (0-100% CHsCNÆhOjto afford 2-cyclopropyl-3-(6-(3,5-dimethylisoxazol-4-yl)2-oxo-2,3-dihydro- lH-benzo[d]imidazol-4-yl)pyridine 1 -oxide.
[00281] C20H18N4O3. 363.2 (M+l). ’H NMR (400MHz, CD3OD) δ 8.47 (dd, 1.2,
6.4 Hz, IH), 7.64 (dd, 1.2, 6.4 Hz, IH), 7.54 (t, J= 6.4 Hz, IH), 7.08 (d, J= 1.2 Hz, IH), 6.94 (d, J= 1.2 Hz, IH), 2.42 (s, 3H), 2.25 (s, 3H), 2.04-1.99 (m, IH), 0.96 (bs, IH), 0.75 (bs, IH), 0.61 (bs, IH), 0.54 (bs, IH).
Example 75
4-(5-amino-2-cyclopropylpyridin-3-yl)-6-(3,5-dimethylisoxazoL4-yl)-lHbenzo [d] imidazol-2(3H)-one
O-N
NH2
[00282] 6-(3,5-dimethylisoxazol-4-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)lH-benzo[d]imidazol-2(3H)-one (150 mg, 0.42 mmol) and 5-bromo-6-cyclopropylpyridin-3amine (180 mg, 0.84 mmol) were added to a solvent mixture of 1,2-dimethoxyethane (2 mL) and water (1 mL). To the mixture were added PEPPSI-Ipr (29 mg, 0.03 mmol) and CS2CO3 (413 mg, 1 mmol). The reaction mixture was heated at 130°C in microwave reactor for 30
104 mins. The reaction mixture was then filtered and organic solvent was evaporated and the residue was purified with Prep HPLC (0-100% CH3CN/H2O) to afford 129 mg of 4-(5amino-2-cyclopropylpyridin-3-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol2(3H)-one.
[00283] C20H19N5O2. 362.1 (M+l). IH NMR (400MHz, CD3OD) δ 10.98 (s, IH),
10.81 (s, IH), 7.79 (s, IH), 7.05 (s, IH), 6.99 (s, 2H), 2.26 (s, 3H), 2.18 (s, 3H), 1.62 (bs, IH), 0.82 (bs, 2H), 0.62 (bs, 2H).
Example 76
6-cyclopropyl-5-(6-(3,5-dimethy!isoxazol-4-yI)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol4-yl)nicotinonitriIe
[00284] 4-(5 -amino-2-cy clopropylpyridin-3 -y 1)-6-(3,5 -dimethylisoxazol-4-y 1)-1Hbenzo[d]imidazol-2(3H)-one (21 mg, 0.058 mmol) was suspended in a mixture of water (1 ml.) and con. HCl (1 mL), cooled suspension to 0°C, a solution of sodium nitrite (4 mg, 0.058 mmol) in water was added slowly. After 5 mins, the reaction mixture was neutralised by the addition of NaHCO3 solution. Then the résultant suspension was added in aliquots to a solution of copper (I) cyanide (5 mg, 0.058 mmol) and sodium cyanide (6 mg, 0.11 mmol) in water at room température. Heated to 70°C for 30 mins. Extracted with EtOAc, evaporated organic solvent, the residue was purified with Prep HPLC. (0-100% CH3CN/H2O) to afford
1.2 mg of 6-cyclopropyl-5-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lHbenzo[d]imidazol-4-yI)nicotinonitrile.
[00285] C21H17N5O2. 372.4 (M+l). IH NMR (400MHz, CD3OD) δ 8.63 (s, IH),
7.79 (s, IH), 7.06 (s, IH), 6.99 (s, IH), 2.25 (s, 3H), 2.18 (s, 3H), 1.88-1.80 (m, IH), 0.880.83 (m, 2H), 0.78-0.75 (m, 2H).
105
Example 77
4-(5-bromo-2-cyclopropylpyridin-3-yl)-6-(3,5-dimethylisoxazoI-4-yl)-lHbenzo [d] imidazol-2(3H)-one
O-N | O-N | |
AK | ||
/V y | ||
il 1 | *** fi | |
HN 7)| N | hnM | An |
^-NH IfJ O I | ^-NH O | |
nh2 | Br |
[00286] 4-(5-amino-2-cyclopropylpyridin-3-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one (75 mg, 0.21 mmol) was dissolved in acetonitrile (2 ml), at room température added tert-butyl nitrite (32 mg, 0.31 mmol) and CuBn (56 mg, 0.25 mmol), stirred at room température for Ih. The reaction mixture was diluted with EtOAc, washed with brine, evaporated organic solvent, purified with Prep HPLC. (0-100% CH3CN/H2O) to afford 6 mg of 4-(5-bromo-2-cyclopropylpyridin-3-yl)-6-(3,5dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one.
[00287] C20H17BrN4O2. 425.3 (M+l). IH NMR (400MHz, CD3OD) δ 8.42 (s, IH),
7.61 (s, IH), 6.99 (s, IH), 6.96 (s, IH), 2.33 (s, 3H), 2.18 (s, 3H), 1.78-1.70 (m, IH), 0.8815 0.81 (m, 2H), 0.71-0.64 (m, 2H).
106
Example 78
N-(6-cyclopropyl-5-(6-(3,5-dimethyIisoxazol-4-yl)-2-oxo-2,3-dihydro-lHbenzo[d]imidazol-4-yI)pyridin-3-yl)acetamide
O
[00288] 4-(5-Amino-2-cyclopropylpyridin-3-yl)-6-(3,5-dimethylisoxazol-4-yl)- 1Hbenzo[d]imidazol-2(3H)-one (75 mg, 0.21 mmol) was dissolved in acetonitrile (2 mL), at room température added tert-butyl nitrite (32 mg, 0.31 mmol) and CuBr2 (56 mg, 0.25 mmol), stirred at room température for Ih. The reaction mixture was diluted with EtOAc, washed with brine, evaporated organic solvent, purified with Prep HPLC. (0-100%
CH3CN/H2O) to afford 16 mg of N-(6-cyclopropyl-5-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo2,3-dihydro-lH-benzo[d]imidazol-4-yl)pyridin-3-yl)acetamide.
[00289] C22H21N5O3. 404.4 (M+l). *H NMR (400MHz, CD3OD) δ 8.89 (s, IH), 7.78 (s, IH), 7.06 (s, IH), 7.03 (s, IH), 2.33 (s, 3H), 2.17 (s, 3H), 2.12 (s, 3H), 1.82-1.78 (m, IH), 0.99-0.94 (m, 2H), 0.77-0.74 (m, 2H).
Example 79
4-(4-bromo-2-cyclopropyIpyridin-3-yI)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo [d] imidazol-2(3H)-one
107
[00290] 4-(4-bromo-2-cyclopropylpyridin-3-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one was made in similar fashion to 4-(5-bromo-2cyclopropylpyridin-3-yI)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one
[00291] C2oHi7BrN402. 425.3 (M+l). ’HNMR (400MHz, CD30D) δ 8.18 (d, J= 2.8
Hz, IH), 7.55 (d, J= 2.8 Hz, IH), 6.98 (s, IH), 6.78 (s, IH), 2.35 (s, 3H), 2.20 (s, 3H), 1.75-
1.65 (m, IH), 1.03-0.88 (m, 2H), 0.82-0.68 (m, 2H).
Example 80
4-(2,4-dicyclopropylpyridin-3-yI)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol2(3H)-one
[00292] 4-(4-bromo-2-cyclopropylpyridin-3-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one (17 mg , 0.04 mmol) and cyclopropyl boronic acid (100 mg, 1.2 mmol) were dissolved in dioxane (2 mL). To the reaction mixture were added K3PO4 (50 mg, 0.24 mol) and dichloro l,r-bis(diphenylphosphino)ferrocene palladium (II) dichloromethane (10 mg, 0.012 mmol). The reaction mixture was heated at 100°C for 3h. Solvent was evaporated, the residue was dissolved in EtOAc, washed with brine, evaporated organic solvent and the residue was purified with Prep HPLC (0-100% CH3CN/H2O) to afford 5.4 mg of 4-(2,4-dicyclopropylpyridin-3-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol2(3H)-one.
[00293] C23H22N4O2. 387.3 (M+l). IH NMR (400MHz, CD3OD) δ 8.30 (d, J = 6.4
Hz, IH), 7.19 (d, J = 6.4 Hz, IH), 7.05 (s, IH), 6.91 (s, IH), 2.38 (s, 3H), 2.21 (s, 3H), 1.95-
1.88 (m, IH), 1.72-1.67 (m, IH), 1.17-1.14 (m, 2H), 1.07-0.95 (m, 6H).
108
Example 81
6-(3,5-dimethylisoxazol-4-yl)-4-(6-(trifluoromethoxy)quinolin-5-yl)-lHbenzo [d] imidazol-2(3H)-one
Step 1:
N-O
O
N-O
[00294] Degassed dioxane (120 mL) was added to a round-bottom flask containing 6(3,5-dimethylisoxazol-4-yl)-4-iodo-lH-benzo[d]imidazol-2(3H)-one (6g, 16.9 mmol), dppfPdCh (630 mg, 5%), KOAc, (3.3g, 2 equiv) and bispinacolato diboron (8.6g, 2 equiv). The reaction mixture was sonicated to eliminate lumps, and was then heated to 120 °C ovemight. The reaction was complété via TLC and HPLC analysis. The reaction mixture was dry-loaded onto silica gel and purified by flash chromatography (rf 0.4 in ethyl acetate, eluting with ethyl acetate/methanol. 6-(3,5-dimethylisoxazol-4-yl)-4-(4,4,5,5-tetramethyll,3,2-dioxaborolan-2-yl)-lH-benzo[d]imidazol-2(3H)-one was isolated and subjected to highvacuum drying ovemight, and contained an équivalent of pinacol side-products by NMR.
Step 2:
+
dppfPdCI2 DBU H2O DMSO
N-O
[00295] A solution of 5-bromo-6-(trifluoromethoxy)quinoline (obtained by bromination of 6-trifluoromethoxyquinoline) (50 mg, 0.17 mmol), 6-(3,5-dimethylisoxazol4-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-benzo[d]imidazol-2(3H)-one (91 mg, 0.26 mmol), dichloro l,l-bis(diphenylphosphino)ferrocene palladium(II)
109 dichloromethane (12.7 mg, 0.02 mmol), l,8-diazabicyclo[5.4.0]undec-7-ene (0.2 mL, 1.37 mmol), DMSO (0.2 mL) and water (0.2 mL) under nitrogen was heated at 120 °C for lh. The reaction mixture was filtered and purified by reverse-phase HPLC to give 6-(3,5dimethylisoxazol-4-yl)-4-(6-(trifluoromethoxy)quinolin-5-yl)-lH-benzo[d]imidazol-2(3H)one.
[00296] C22H15F3N4O3· 441.1 (M+1)?H NMR (400 MHz, DMSO-^6) δ 10.88 (s, IH),
10.53 (d, J= 2.0 Hz, IH), 9.00 (dd, J= 4.2, 1.7 Hz, IH), 8.25 (d, J= 9.3 Hz, IH), 7.94 - 7.82 (m, 2H), 7.58 (dd, J= 8.6, 4.2 Hz, IH), 7.08 - 6.97 (m, IH), 6.88 (d, J= 1.5 Hz, IH), 2.39 (s, 3H), 2.21 (s, 3H).
Example 82
4-(5,7-difluoroquinolin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)one
O-N
[00297] A mixture of 6-(3,5-dimethylisoxazol-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)-lH-benzo[d]imidazol-2(3H)-one_(0.05g), commercially available 4bromo-5,7-difluoroquinoline (0.137g), Peppsi catalyst (0.009g), and CS2CO3 (0.183g) were stirred under N2 in water/dioxane (1 mL each) at 140 °C for 30 min. After cooling to room température, brine (1 mL) was added, the organic layer separated and volatiles removed under vacuum. The residue was purified by préparative HPLC (5-95% MeCN in HzO) to afford the title compound.
[00298] C21H14F2N4O2; 393.20 (M+l). *HNMR (400 MHz, DMSO-d6) δ 10.85 (s,
Ή), 10.59 (d, J = 1.7 Hz, IH), 9.01 (d, J = 4.5 Hz, IH), 7.78 (dt, J = 9.6, 1.7 Hz, IH), 7.66 7.37 (m, 2H), 6.95 (dt, J = 18.3, 1.2 Hz, 2H), 2.38 (s, 3H), 2.32 (s, 3H).
110
Example §3
4-(5,8-difluoroquinolin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)one
O-N
O
[00299] 4-(5,8-difluoroquinolin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one was made in a similar fashion as that of Example 82.
[00300] C21H14F2N4O2; 393.18 (M+l). IH NMR (400 MHz, DMSO-d6) δ 10.85 (d,
J = 1.5 Hz, IH), 10.57 (d, J = 1.8 Hz, IH), 9.03 (d, J = 4.4 Hz, IH), 7.76-7.60 (m, IH), 7.35 (ddd, J = 12.3, 8.7, 3.9 Hz, IH), 6.94 (dd, J = 13.6, 1.6 Hz, 2H), 2.39 (s, 3H), 2.21 (s, 3H).
Example 84
4-(5-chloroquinolin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one
O-N
O
[00301] The boronic acid (0.05g), bromide (0.137g), Peppsi catalyst (0.009g), Cs2CO3 15 (0.183g) was stirred under N2 in water/dioxane (1 ml each) at 140 C for 30 min. After cooling to RT, brine (1 mL) was added, the organic layer separated and volatiles removed under vacuum. The residue was purified by préparative HPLC (5-95% MeCN in H2O) to afford the title compound.
111
[00302] C21H15C1N4O2; 391.15 (M+l). IH NMR (400 MHz, DMSO-d6) δ 10.78 (d,
J = 1.9 Hz, IH), 10.52 (d, J = 1.9 Hz, IH), 8.63 (d, J = 5.6 Hz, IH), 8.11 (dd, J = 6.8, 2.6 Hz, IH), 8.04 (d, J = 5.7 Hz, OH), 7.83 - 7.72 (m, IH), 2.36 (s, 3H), 2.18 (s, 3H).
[00303] The following comounds were prepared in a similar fashion to that of Example
82, using the appropriate bromo or chloro dérivative:
Example 85
6-(3,5-dimethylisoxazoI-4-yl)-4-(6-(2,2,2-trifluoroethoxy)quinolin-5-yl)-lHbenzo [d] imidazol-2(3H)-one
N-O | ||
F _ | ||
F\ | F | |
A | ||
NH) | A- | |
y-NH | A | |
0 ί |
[00304] C23H17F3N4O3. 455.1 (M+l). ’H NMR (400 MHz, DMSO-fifc) δ 10.77 (d, J =
2.0 Hz, IH), 10.38 (d, J= 2.0 Hz, IH), 8.87 (dd, J=4.5, 1.6 Hz, IH), 8.17 (d, J= 9.3 Hz, IH), 7.89 (dd, J= 9.0, 5.4 Hz, 2H), 7.52 (dd, J= 8.6, 4.2 Hz, IH), 6.97 (d, J= 1.5 Hz, IH),
6.81 (d, J= 1.6 Hz, IH), 4.86 (ddq, J= 56.9, 12.0, 8.9 Hz, 2H), 2.39 (s, 3H), 2.21 (s, 3H).
112
Example 86
6-(3,5-dimethyIisoxazol-4-yl)-4-(6-methyl-2-(trifluoromethyI)quinolin-5-yl)-lHbenzo[d]imidazol-2(3H)-one
[00305] C23H17F3N4O2. 439.2 (M+l). NMR (400 MHz, DMSO-fifc) δ 10.89 (s, IH),
10.39 (d, J = 2.1 Hz, IH), 8.16 (d, J= 8.7 Hz, IH), 7.98 (d, J=8.8Hz, IH), 7.93 (d, J =8.8 Hz, IH), 7.86 (d, J= 8.8 Hz, IH), 7.02 (d,J= 1.4 Hz, IH), 6.84 (d,J= 1.5 Hz, IH), 2.41 (s, 3H), 2.32 (s, 3H), 2.24 (s, 3H).
Example 87
6-(3,5-dimethylisoxazol-4-yl)-4-(3-(trifluoromethyl)quinolin-4-yl)-lH-benzo[d]imidazol2(3H)-one
[00306] C22H15F3N4O2. 425.2 (M+l). *H NMR (400 MHz, DMSO-J6) δ 10.95 (s, IH),
10.54 (d, J= 1.9 Hz, IH), 9.29 (s, IH), 8.24 (d, J = 8.4 Hz, IH), 7.96 (t, J = 7.7 Hz, IH), 7.67
113 (t, J= 7.6 Hz, IH), 7.47 - 7.37 (m, IH), 7.06 (d, 1.5 Hz, IH), 6.92 (d, J= 1.6 Hz, IH),
2.40 (s, 3 H), 2.22 (s, 3H).
Example 88
4-(6-cyclopropylquinolin-5-yl)-6-(3,5-dimethylisoxazol-4-yI)-lH-benzo[d]imidazol2(3H)-one
[00307] C24H20N4O2. 397.1 (M+l). ’H NMR (400 MHz, DMSO-rfe) δ 10.83 (d, J = 1.9
Hz, IH), 10.39 (d, J= 2.1 Hz, IH), 8.83 - 8.78 (m, IH), 7.99 (d, 8.9 Hz, IH), 7.64 (d, J =
8.5 Hz, IH), 7.41 (dd, J= 8.6, 4.2 Hz, IH), 7.34 (d, J= 9.0 Hz, IH), 6.99 (d, J= 1.5 Hz, IH),
6.82 (d, J= 1.5 Hz, IH), 2.41 (s, 3H), 2.23 (s, 3H), 1.80 - 1.73 (m, IH), 0.86 (t, J= 6.8 Hz, 4H).
114
Example 89
6-(3,5-dimethylisoxazol-4-yl)-4-(3-methylquinolin-4-yl)-lH-benzo[d]imidazol-2(3H)-one
N-O
[00308] C22Hi8N4O2. 371.1 (M+l).’HNMR (400 MHz, DMSO-Je) δ 10.95 (d, J= 1.9
Hz, IH), 10.49 (d, J= 2.0 Hz, IH), 9.09 (s, IH), 8.15 (d, J= 8.4 Hz, IH), 7.84 (t, 7.8 Hz,
IH), 7.62 (t, J= 7.5 Hz, IH), 7.49 (d, J= 8.4 Hz, IH), 7.05 (d, 1.5 Hz, IH), 6.87 (d, J =
1.5 Hz, IH), 2.41 (s, 3H), 2.29 (s, 3H), 2.24 (s, 3H).
Example 90
6-(3,5-dimethylisoxazol-4-yl)-4-(3-methylcinnolin-4-yl)-lH-benzo[d]imidazoI-2(3H)-one
N-O
[00309] C2iHnN5O2. 372.1 (M+l). ’H NMR (400 MHz, DMSO-de) δ 10.97 (s, IH),
10.55 (d, J= 2.0 Hz, IH), 8.62 - 8.41 (m, IH), 7.97 - 7.85 (m, IH), 7.78 (ddd, J= 8.4, 6.9,
1.4 Hz, IH), 7.47 (d, J= 8.5 Hz, IH), 7.15 - 7.02 (m, IH), 6.95 (d, J= 1.5 Hz, IH), 2.69 (s, 15 3H), 2.42 (s, 3H), 2.25 (s, 3H).
115
Example 91
6-(3,5-dimethylisoxazol-4-yl)-4-(3-fluoro-6-methoxyquinoIin-5-yl)-lH-benzo[d]imidazol2(3H)-one
N-O
[00310] C22H17FN4O3. 405.1 (M+l). Ή NMR (400 MHz, DMSO-î76) δ 10.80 (d, J =
2.0 Hz, IH), 10.41 (s, IH), 8.79 (d, J = 2.7 Hz, IH), 8.17 (d, J = 9.4 Hz, IH), 7.77 (d, J=9.4 Hz, IH), 7.50 - 7.41 (m,lH), 7.00 - 6.90 (m, IH), 6.88 - 6.76 (m, IH), 3.89 (s, 3H), 2.41 (s, 3H), 2.24 (s, 3H). 19F NMR (376 MHz, DMSOé) δ -128.19 (d, J= 10.8 Hz).
Example 92
6-(3,5-dimethylisoxazol-4-yI)-4-(2,6-dimethylquinolin-5-yl)-lH-benzo[d]imidazol-2(3H)one
N-O
[00311] C23H20N4O2. 385.1 (M+l). Ή NMR (400 MHz, DMSOé) δ 10.94 (s, IH),
10.40 (d, J= 1.9 Hz, IH), 8.11 (d, J= 8.5 Hz, 2H), 7.99 (d, J= 8.8 Hz, IH), 7.68 (d, J= 8.7
Hz, IH), 7.03 (d, J= 1.6 Hz, IH), 6.82 (d, J= 1.5 Hz, IH), 2.85 (s, 3H), 2.41 (s, 3H), 2.31 (s, 3H), 2.24 (s, 3H).
116
Example 93
4-(3-chloroquinolin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one
[00312] C2iHi5C1N4O2. 391.1 (M+l). *H NMR (400 MHz, DMSO-Je) δ 10.95 (d, J =
1.9 Hz, IH), 10.61 (s, IH), 9.03 (s, IH), 8.22 - 8.02 (m, IH), 7.91 - 7.77 (m, IH), 7.69 - 7.58 (m, IH), 7.47 (d, J= 8.4 Hz, IH), 7.06 (d, J= 1.5 Hz, IH), 6.92 (d, J= 1.6 Hz, IH), 2.42 (s, 3H), 2.24 (s, 3H).
Example 94
4-(6-(difluoromethoxy)quinolin-5-yl)-6-(3,5-dimethylisoxazol-4-yI)-lHbenzo [d] imidazol-2(3H)-one
[00313] C22H16F2N4O3. 423.1 (M+l). *H NMR (400MHz, DMSO-4s) δ 10.86 (s, IH),
10.50 (s, IH), 8.98 - 8.92 (m, IH), 8.22 (d, J= 9.3 Hz, IH), 7.86 (d, J= 8.6 Hz, IH), 7.80 (d, 15 J= 9.2 Hz, IH), 7.58 - 7.51 (m, IH), 7.23 (dd, J= 74.5, 72.9 Hz, IH), 7.04 - 6.98 (m, IH),
6.87 (d, J= 1.6 Hz, IH), 2.41 (s, 3H), 2.24 (s, 3H).
117
Example 95
4-(3-chloro-8-fluoroquinoIin-4-yl)-6-(3,5-dimethyIisoxazol-4-yl)-lH-benzo[d]imidazol2(3H)-one
[00314] C21H14CIFN4O2. 409.1 (M+l). ’H NMR (400 MHz, DMSO-rie) δ 10.95 (d, J =
2.0 Hz, IH), 10.58 (d, J= 2.0 Hz, IH), 9.08 (s, IH), 7.73 - 7.47 (m, 2H), 7.34 - 7.21 (m,
IH), 7.15 - 7.00 (m, IH), 6.94 (t, J = 1.3 Hz, IH), 2.42 (s, 3H), 2.24 (s, 3H).
Example 96
6-(3,5-dimethylisoxazol-4-yI)-4-(2-methylbenzo[d]thiazoI-7-yl)-lH-benzo[d]imidazol2(3H)-one
[00315] C20H16N4O2S. 377.1 (M+l). ’H NMR (400 MHz, DMSO-ofc) δ 10.91 (d, J=
2.2 Hz, IH), 10.68 (d, 2.0 Hz, IH), 7.95 (dd, J= 8.0, 1.1 Hz, IH), 7.59 (t, J= 7.8 Hz,
IH), 7.50 (dd, J =7.4, 1.1 Hz, IH), 7.09-7.01 (m, IH), 7.00 - 6.92 (m, IH), 2.80 (s, 3H),
2.43 (s, 3H), 2.26 (s, 3H).
118
Example 97
6-(3,5-dimethylisoxazol-4-yl)-4-(2-methyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-lHbenzo [d] imidazol-2(3H)-one
[00316] C20H17N5O2. 360.2 (M+l). rH NMR (400 MHz, DMSO-c/e) δ 11.73 (s, IH),
10.75 (d, J= 1.8 Hz, IH), 10.40 (d, 1.8 Hz, IH), 8.14 (dd, J= 4.7, 1.6 Hz, IH), 7.64 (d, J = 7.8 Hz, IH), 7.02 (dd, J= 7.8, 4.7 Hz, IH), 6.86 (m, , 2H), 2.42 (s, 3H), 2.37 (s, 3H), 2.25 (s, 3H).
Example 98
6-(3,5-dimethylisoxazoI-4-yl)-4-(6-methyI-1,7-naphthyridin-5-yI)- ΙΗ-benzo [d] imidazol2(3H)-one
[00317] C21H17N5O2. 372.1 (M+l). NMR (400 MHz, DMSO^fc) δ 10.93 (d, J =
1.9 Hz, IH), 10.48 (d,J= 1.9 Hz, IH), 9.52 (s, IH), 9.06 (dd, .7= 4.0, 1.7 Hz, IH), 7.867.67 (m, 2H), 7.03 (d,.7 = 1.6 Hz, IH), 6.89 (d, J= 1.6 Hz, IH), 2.48 (s, 3H), 2.41 (s, 3H), 2.24 (s, 3H).
119
Example 99
6-(3,5-dimethylisoxazol-4-yl)-4-(8-methoxy-3-methyIquinolin-4-yl)-lHbenzo[d]imidazol-2(3H)-one
N-O
[00318] C23H20N4O3. 401.1 (M+l). JH NMR (400 MHz, DMSO-î/6) δ 10.87 (s, IH),
10.69 - 10.18 (m, IH), 8.81 (s, IH), 7.38 (s, IH), 7.13 (s, IH), 7.01 (d, 5.0 Hz, IH), 6.90 (d, J= 7.4 Hz, IH), 6.79 (d, J= 4.9 Hz, IH), 3.97 (s, 3H), 2.41 (s, 3H), 2.23 (d, J= 4.8 Hz, 6H).
Example 100
4-(3-chloro-2-methylqumolin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol2(3H)-one
N-O
[00319] C22H17CIN4O2. 405.1 (M+l). *H NMR (400 MHz, DMSO-4) δ 10.90 (s, IH),
10.55 (s, IH), 8.04 (s, IH), 7.76 (s, IH), 7.52 (s, IH), 7.37 (s, IH), 7.05 (s, IH), 6.89 (s, IH),
2.81 (s, 3H), 2.42 (s, 3H), 2.25 (d, J = 4.1 Hz, 3H).
120
Example 101
6-(3,5-dimethylisoxazol-4-yl)-4-(3-ethyl-2-methyIquinolin-4-yI)-lH-benzo[d]imidazol2(3H)-one
N-O
[00320] C24H22N4O2. 399.2 (M+l). *H NMR (400 MHz, DMSO-4,) δ 10.86 (s, IH),
10.43 (s, IH), 7.95 (s, IH), 7.63 (s, IH), 7.40 (d, J= 8.8 Hz, IH), 7.17 (d, J= 8.2 Hz, IH),
7.01 (s, IH), 6.81 (s, IH), 2.76 (s, 5H), 2.41 (s, 3H), 2.23 (s, 3H), 1.00 (d, J= 7.8 Hz, 3H).
Example 102
4-(6-(3,5-dimethylisoxazoI-4-yI)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)-3methylquinoline-8-carbonitrile
N-O
[00321] C23H17N5O2. 396.1 (M+l). *H NMR (400 MHz, DMSO-Je) δ 10.93 (d, J =
1.8 Hz, IH), 10.45 (d, J= 1.9 Hz, IH), 9.10 (s, IH), 8.31 (dd, J =6.9, 1.6 Hz, IH), 7.88-
7.51 (m,2H), 7.16-6.92 (m, IH), 6.88 (d, J= 1.6 Hz, IH), 2.41 (s, 3H), 2.30 (s, 3H), 2.24 (s, 3H).
121
Example 103
4-(3-(difluoromethyl)quinolin-4-yl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol2(3H)-one
[00322] C22H16F2N4O2. 407.1 (M+l). ’H NMR (400 MHz, DMSO-^e) δ 10.96 (d, J =
1.8 Hz, IH), 10.54 (d, J= 1.9 Hz, IH), 9.22 (s, IH), 8.19 (dd, J= 8.5, 1.2 Hz, IH), 8.06-
7.78 (m, IH), 7.64 (ddd, J = 8.3, 6.8, 1.3 Hz, IH), 7.54-7.35 (m, IH), 7.08 (d,J= 1.6 Hz, IH), 7.05 - 6.67 (m, 2H).
Example 104
4-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lB[-benzo[d]imidazol-4-yl)cinnoline-
3-carboxylic acid
N-0
PdCI2-dppf DBU | N-O | O..OH |
DMSO, H2O | A A | |
110°C | HN | yS |
^r-NH | ||
u [I |
[00323] A mixture of 6-(3,5-dimethylisoxazol-4-yl)-4-(4,4,5,5-tetramethyl-l,3,215 dioxaborolan-2-yl)-lH-benzo[d]imidazol-2(3H)-one (100.0 mg, 0.282 mmol) and methyl 4chlorocinnoline-3-carboxylate (94.0 mg, 0.422 mmol) was treated with PdCl2dppf-CH2Cl2 (20.6 mg, 0.028 mmol) in the presence of l,8-Diazabicycloundec-7-ene (DBU, 300.0 mg, 1.971 mmol, 7.0 equiv) in DMSO (1 mL) and water (1 mL). The reaction mixture was heated at 110 °C for 12 min in oil bath. The reaction mixture was purified by HPLC to give 4-(6
122 (3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)cinnoline-3carboxylic acid.
[00324] C21H15N5O4. MS. m/z 402.0 (M+l). !H NMR (400 MHz, Methanol-^) δ 8.67 (d, J= 8.8 Hz, IH), 8.09 (t, J= 8.8 Hz, IH), 7.92 (d, J= 8.8 Hz, IH), 7.70 (d, J= 8.8 Hz,
IH), 7.17 (s, IH), 6.96 (s, IH), 2.44 (s, 3H), 2.29 (s, 3H).
Example 105
6-(3,5-dimethylisoxazol-4-yl)-4-(3-methylisoquinoIin-4-yl)-lH-benzo[d]iniidazoI-2(3H)one
DMSO, H2O
110°C
PdCI2dppf DBU
[00325] 6-(3,5-Dimethylisoxazol-4-yI)-4-(3-methylisoquinolin-4-yl)-lHbenzo[d]imidazol-2(3H)-one was prepared from 4-iodo-3-methylisoquinoline in a similar fashion as Example 104.
[00326] C22H18N4O2. MS. m/z 371.1 (M+l). Ή NMR (400 MHz, Methanol-iA) 9.26 (s, IH), 8.16 (d, J= 7.7 Hz, IH), 7.67 (m, 2H), 7.42 (d, J= 8.2 Hz, IH), 7.15 (s, IH), 6.91 (s, IH), 2.50 (s, 3H), 2.45 (s, 3H), 2.29 (s, 3H).
123
Example 106
6-(3,5-dimethyIisoxazol-4-yI)-4-(2-methylnaphthalen-l-yl)-lH-benzo[d]imidazol-2(3H)one
N-O
PEPPSI-iPr
CS2CO3 dioxane, H2O
MW, 150°C
[00327] In a 2-5 mL Smith Process Vial, 6-(3,5-dimethylisoxazol-4-yl)-4-iodo-lHbenzo[d]imidazol-2(3H)-one (100.0 mg 0.282 mmol), (2-methylnaphthalen-l-yl)boronic acid (176.0 mg, 0.946 mmol, 3.36 equiv), PEPPSI-iPr (19.2 mg, 0.028 mmol, 0.1 equiv) and CS2CO3 (337.0 mg, 1.126 mmol, 4 equiv) were placed. The mixture was suspended in 1,4dioxane (1.5 mL) and water (0.5 mL) under N2. The mixture was heated at 150°C for 75 min using microwave reactor (Biotage Optimizer). After an aqueous work up, the crude product was purified by a silica-gel column chromatography (hexane / EtOAc 20:80) to give 6-(3,5dimethylisoxazol-4-yl)-4-(2-methylnaphthalen-l-yl)-lH-benzo[d]imidazol-2(3H)-one.
[00328] C23H19N3O2. MS. m/z 370.1 (M+l). IH NMR (400 MHz, Methanol-d4) δ
7.88 (d, J = 8.6 Hz, 2H), 7.50 (d, J = 8.6 Hz, IH), 7.45 - 7.38 (m, IH), 7.38 - 7.33 (m, 2H),
7.10 (s, IH), 6.82 (s, IH), 2.43 (s, 3H), 2.28 (s, 6H).
124
Example 107
4-(2-(difluoromethyl)-3-methylquinolin-4-yI)-6-(3,5-dimethyIisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one
[00329] 4-(2-(Difluoromethy l)-3 -methylquinolin-4-yl)-6-(3,5 -dimethylisoxazol-4-y 1)lH-benzo[d]imidazol-2(3H)-one was prepared from 2-(difluoromethyl)-4-iodo-3methylquinoline in a similar fashion as Example 104.
[00330] C23H18F2N4O2. MS. m/z 421.1 (M+l). *H NMR (400 MHz, Methanol-J4) δ
8.18 (d, J= 9.0 Hz, IH), 7.83 - 7.74 (m, IH), 7.63 - 7.57 (m, IH), 7.45 (d, J= 9.4 Hz, IH), 10 7.23 - 6.87 (m, 2H), 2.44(s, 6H), 2.30 (s, 3H).
Example 108
4-chloro-5-(3,5-dimethylisoxazol-4-yl)-7-(6-methylquinolin-5-yl)-lH-benzo[d]imidazol2(3H)-one
[00331] In 0.5 -2 mL Smith Process Vial, the substrate (25.0 mg, 0.067 mmol) and
NCS (36.3 mg, 0.135 mmol) were dissolved into THF (2 mL). The mixture was heated at 80°C for 2 h in an oil bath. The reaction mixture was purified by HPLC (5-95% acetonitrile: water with 0.05% trifluoroacetic acid, on a Phenomenex Luna C18 column) to give the desired product.
125
NOS
THF °C
[00332] C22H17CIN4O2. MS. m/z 405.1 (M+l), 407.1 (M+2+1). *H NMR (400 MHz,
Methanol-^) δ 9.25 - 9.05 (d, J= 5.8 Hz, IH), 8.47 - 8.40 (m, IH), 8.30 (d, J= 9.0 Hz, IH),
8.20 (d, J= 9.0 Hz, IH), 7.96 - 7.90 (m, IH), 7.19 (s, IH), 2.40 (s, 3/2H), 2.39 (s, 3/2H), 2.38 (s, 3/2H), 2.34 (s, 3/2H) 2.21 (s, 3/2H), 2.19 (s, 3/2H).
Example 109
6-(3,5-dimethylisoxazol-4-yl)-4-(8-fluoro-6-methylquinolin-5-yl)-lH-benzo[d]imidazol2(3H)-one
Step 1 :
[00333] 3,5-Dicyclopropylisoxazole (70.0 mg, 0.469 mmol) was treated with NBS (167.0 mg, 0.938 mmol, 2 equiv) in CH2C12 at room température for 12 h. The solvent was removed under a reduced pressure and the residue was directly loaded onto a silica gel column chromatography (hexane EtOAc 87:13) to give 5-bromo-8-fluoro-6methylquinoline.
[00334] C9H10BrON. MS. m/z 239.9 (M-l+1), 241.9 (M+l+1).
Step 2:
126
PEPPSI-iPr
CS2CO3 dioxane, H2O
MW, 150°C
[00335] C22H17FN4O2. MS. m/z 398.1 (M+l). NMR (400 MHz, Methanol-^) δ
8.93 (d, IH, J = 4.0 Hz), 8.08 (d, IH, J = 8.0 Hz), 7.70 (d, IH, J = 11.2 Hz), 7.67 (dd, IH, J = 8.0, 4.0 Hz), 7.15 (d, IH, J = 1.0 Hz), 6.88 (d, IH, J = 1.0 Hz), 2.43 (s, 3H), 2.38 (s, 3H),
2.28(s,3H).
Example 110,
Example 111, and
Example 112
7-(3,5-dimethyl-lH-pyrazol-4-yl)-5-(3,5-dimethylisoxazol-4-yl)-l-methyl-lHbenzo [d] imidazol-2(3H)-one
PEPPSI
CSjjOOg dme/h2o
[00336] 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-l-methyl-lH-benzo[d]imidazol-2(3H)one (60 mg, 0.16 mmol) was placed in a microwave vial followed by the addition of PEPPSI (11 mg, 0.016 mmol) and césium carbonate (158.9 mg, 4.9 mmol). The material was then dissolved in 1.5 mL of DME and 1.5 mL of water. The vial was then placed in the microwave where it was heated to 165°C for one hour. The crude solution was then diluted with water and extracted 3 times with ethyl acetate. Combined organic layers were washed with brine, dried over sodium sulphate, filtered, concentrated in vacuo, and purified via HPLC to afford
127
7-(3, 5-dimethy l-1 H-pyrazol-4-yl)-5 -(3,5 -dimethy li soxazol-4-yl)-1 -methyl-1Hbenzo[d]imidazol-2(3H)-one.
[00337] C18H19N5O2; 338.2 (m/z +1). *H NMR (400 MHz, cd3od) δ 7.03 (d, 1.6
Hz, IH), 6.75 (d, J= 1.6 Hz, IH), 3.01 (s, 3H), 2.41 (s, 3H), 2.26 (s, 3H), 2.12 (s, 6H).
Example 113
6-(3,5-dimethylisoxazol-4-yl)-4-(l-(4-fluorophenyI)vinyI)-lH-benzo[d]imidazol-2(3H)one
N-O
[00338] 6-(3,5-Dimethylisoxazol-4-yl)-4-iodo-1 H-benzo[d]imidazol-2(3H)-one (100 mg, 0.28 mmol), l-(4-Fluorophenyl)vinylboronic acid, pinacol ester (209.59 mg, 0.84 mmol), PEPPSI-IPr catalyst (19.19 mg, 0.03 mmol), l,8-Diazabicyclo[5.4.0]undec-7-ene solution (0.25 ml, 1.69 mmol) were mixed in l-Methyl-2-pyrrolidinone (6 ml) and Water (3 ml) in sealed in a microwave vial and heated to 110°C for 30 minutes in a microwave reactor. The reaction mixture was then cooled and partitioned between water and ethyl acetate. The organic layer was washed with water then brine and dried over sodium sulfate. Purification on silica gel (Hexane/EtOAc) followed by préparative HPLC afforded 6-(3,5dimethylisoxazol-4-yl)-4-( 1 -(4-fluorophenyl)vinyl)- lH-benzo[d]imidazol-2(3H)-one.
[00339] C20H16FN3O2; 350.2 (M+l). IH NMR (400 MHz, DMSO-d6) δ 7.35 (dd, J = 8.7, 5.6 Hz, 2H), 7.16 (t, J = 8.8 Hz, 2H), 6.86 (d, J = 1.6 Hz, IH), 6.59 (d, J = 1.6 Hz, IH),
5.81 (s, IH), 5.44 (s, IH), 2.32 (s, 3H), 2.14 (s, 3H). 19F NMR (376 MHz, DMSO-d6) δ -
114.96 (ddd, J = 14.4, 9.1, 5.5 Hz).
[00340] The following compound(s) were made in a similar fashion using appropriately substituted boronic acids or esters.
128
Example 114
6-(3,5-dimethyIisoxazol-4-yl)-4-(2-(morpholinomethyI)phenyl)-lH-benzo[d]imidazol2(3H)-one
[00341] C23H24N4O3; 405.2 (M+l). IH NMR (400 MHz, DMSO-d6) δ 7.52 (dd, J =
7.4, 1.7 Hz, IH), 7.40 (dtd, J = 14.7, 7.3, 1.7 Hz, 2H), 7.30 (dd, J = 7.2, 1.8 Hz, IH), 6.90 (d, J = 1.6 Hz, IH), 6.78 (d, J = 1.6 Hz, IH), 3.47 (t, J = 4.4 Hz, 3H), 2.41 (s, 3H), 2.24 (s, 5H),
1.66 (d, J = 5.6 Hz, IH), 1.54 (dq, J = 13.7, 6.9, 6.3 Hz, 2H).
Example 115
6-(3,5-dimethylisoxazol-4-yl)-4-(l-(4-fluorophenyl)ethyl)-lH-benzo[d]imidazol-2(3H)one
GS-646621
[00342] A su spension of 6-(3,5 -dimethy lisoxazol-4-y 1)-4-( 1 -(4-fluorophenyl)viny 1)lH-benzo[d]imidazol-2(3H)-one (60 mg, 0.172 mmol) and 10% palladium on carbon (20 mg) in 5 mL éthanol was purged with hydrogen gas and allowed to stir for 2 hours. The reaction
129 mixture was then filtered and the solvents evaporated. Residue was purified by préparative HPLC which afforded 6-(3,5-dimethylisoxazol-4-yl)-4-(l-(4-fluorophenyl)ethyl)-lHbenzo[d]imidazol-2(3H)-one.
[00343] C20H18FN3O2; 352.2 (M+l). !H NMR (400 MHz, DMSO-d6) δ 10.92 (s, IH),
10.71 (s, IH), 7.45 (dd, J = 8.6, 5.7 Hz, 2H), 7.12 (t, J = 8.9 Hz, 2H), 6.84 (d, J = 1.5 Hz, IH), 6.73 (d, J = 1.5 Hz, IH), 4.43 (q, J = 7.2 Hz, IH), 2.35 (s, 3H), 2.17 (s, 3H), 1.61 (d, J = 7.2 Hz, 3H). 19F NMR (376 MHz, DMSO-d6) δ -117.55 (tt, J = 9.1, 5.6 Hz).
Example 116
5-(3,5-dimethylisoxazol-4-yl)-l-ethyl-7-(6-methylquinolin-5-yl)-lH-benzo[d]imidazol-
2(3H)-one
Cs2CO3, THF
ICH2CH3
1. NaOMe/ MeOH ----------».
2. SnCI2/EtOH
Step 1:
[00344] 4-(3,5-Dimethylisoxazol-4-yl)-2-iodo-6-nitroaniline (4g, 11.1 mmol) was dissolved in 100 mL DCM and to the solution was added pyridine (2.7 mL, 33.3 mmol) before cooling to 0°C under argon. To the solution was then added dropwise triflic anhydride (3g, 14.5 mmol) before allowing the reaction to slowly warm to room température ovemight.
The reaction mixture was suspended slowly into stirring DCM / water before extracting 3 times with DCM. Organics were then washed with water, brine then dried over sodium
130 sulfate. Solvent was removed under reduced pressure to yield crude N-(4-(3,5dimethylisoxazol-4-yl)-2-iodo-6-nitrophenyl)-2,2,2-trifluoroacetamide as a brown oil.
Step 2:
[00345] A mixture of N-(4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6-nitrophenyl)-2,2,2trifluoroacetamide (2.2 g, 4.83 mmol), césium carbonate (3.94 g, 12.08 mmol) and N,NDimethylformamide (100 ml) was stirred at room température under argon. To the mixture was added iodoethane (3.77 g, 24.17 mmol) and reaction was heated to 45°C ovemight. Crude mixture was diluted in EtOAc and water and extracted 3 times with EtOAc. Organics were washed with water, aq LiCl, then brine, dried over sodium sulfate and evaporated to dryness under reduced pressure to afford crude N-(4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6nitrophenyl)-N-ethyl-2,2,2-trifluoroacetamide as a dark oil.
Step 3 :
[00346] Crude N-(4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6-nitrophenyl)-N-ethyl-2,2,2trifluoroacetamide (1.5g, 3.1 mmol) was dissolved in 100 mL of methanol. To the mixture was added IM sodium methoxide in methanol (15.5 mL, 15.5 mmol) and reaction stirred at room température until complété. Reaction was then quenched with 15 mL of IM HCl or until pH is approximately neutral then diluted with aqueous ammonium chloride. Methanol was removed under reduced pressure and then remaining suspension was extracted with EtOAc. The solution was washed with water, brine then dried over sodium sulfate. Solvents were removed under reduced pressurethe residue was then dissolved in 20 mL of éthanol and placed in a sealed pressure tube with stannous chloride (2.2 g, 11.62 mmol).The mixture was heated at 120°C for 1 hour. Reaction mixture was cooled to room température. To the mixture was added IM NaOH (10 mL) and the mixture was stirred at room termperature for 30 minutes. At this point the reaction mixture was diluted with water and extracted with EtOAc (3 times). The solution was washed with water, brine and dried over sodium sulfate. Solvents were removed under reduced pressure and crude product was purified by silica gel chromatography (Hexanes / EtOAc as the eluent) to provide 4-(3,5-dimethylisoxazol-4-yl)~ Nl-ethyl-6-iodobenzene-l,2-diamine(310 mg, 22%).
Step 4:
131
[00347] 4-(3,5-Dimethylisoxazol-4-yl)-N 1 -ethyl-6-iodobenzene-1,2-diamine (105 mg,
0.29 mmol), 6-methylquinolin-5-ylboronic acid (274.86 mg, 1.47 mmol), 1,8Diazabicyclo[5.4.0]undec-7-ene (0.26 mL, 1.76 mmol), l-Methyl-2-pyrrolidinone (5 mL), and water (2 mL) were placed in microwave vial, pre-stirred for 2 minutes, then heated to 110°C for 15 minutes. Reaction mixture was diluted with EtOAc and aqueous ammonium chloride and extracted with EtOAc (3 times). Organics were washed with ammonium chloride, water and brine and dried over sodium sulfate. Solvent was evaporated to dryness. Crude material was purified by silica gel chromatography (DCM / MeOH as eluent) to afford 4-(3,5-dimethylisoxazol-4-yl)-Nl-ethyl-6-(6-methylquinolin-5-yl)benzene-l,2-diamine.
Step 5 :
[00348] 4-(3,5-Dimethylisoxazol-4-yl)-Nl-ethyl-6-(6-methylquinolin-5-yl)benzene1,2-diamine (90 mg, 0.24 mmol) and Ι,Γ-carbonyldiimidazole (86.2 mg, 0.53 mmol) were added to tetrahydrofuran (10 ml) in a sealed vessel and heated to 105°C ovemight. The reaction mixture was the diluted in EtOAc and aqueous ammonium chloride and extracted with EtOAc (3 times). Organics were washed with ammonium chloride, water and brine and dried over sodium sulfate. Solvent was evaporated to drynessCrude material was purified by silica gel chromatography (DCM / MeOH as eluent) then by préparative HPLC to afford 5(3,5 -dimethylisoxazol-4-yl)-1 -ethyl-7-(6-methylquinolin-5 -yl)-1 H-benzo[d]imidazol-2(3 H)one.
[00349] C24H22N4O2. 399.2 (M+l). IH NMR (400 MHz, Methanol-d4) δ 8.86 (d, J =
4.2 Hz, IH), 8.12 (d, J = 8.7 Hz, IH), 7.97 - 7.89 (m, IH), 7.85 (d, J = 8.7 Hz, IH), 7.51 (dd, J = 8.6, 4.3 Hz, IH), 7.19 (d, J = 1.6 Hz, IH), 6.82 (d, J = 1.6 Hz, IH), 3.19 - 3.00 (m, J = 7.1 Hz, 2H), 2.43 (s, 3H), 2.36 (s, 3H), 2.27 (s, 3H), 0.52 (t, J = 7.1 Hz, 3H).
132
Example 117
5-(3,5-dimethylisoxazol-4-yl)-7-(6-methylquinolin-5-yI)-l-(2,2,2-trifluoroethyl)-lH- benzo [d] imidazol-2(3H)-one
Step 1:
[00350] 4-Bromo-2-chloroaniline (5000 mg, 24.22 mmol) was dissolved in trifluoroacetic acid (40 ml) and 1,2-dimethoxyethane (50 ml) then cooled under argon to 0°C. To the mixture was added 2-picoline borane complex (12951.34 mg, 121.08 mmol) and then the reaction mixture was heated 110°C for 90 minutes. Solvents were removed under reduced pressure and crude material was taken up in IN HCl and stirred at 110°C 30 minutes. Crude mixture was then diluted with EtOAc and water and extracted EtOAc (3 times). Organics were washed with water then brine, dried over sodium sulfate and evaporated to dryness under reduced pressure. Crude material was purified by silica gel chromatography using EtOAc/Hexanes as the eluent to afford 4-bromo-2-chloro-N-(2,2,2trifluoroethyl)aniline.
Step 2:
[00351] A mixture of 4-Bromo-2-chloro-N-(2,2,2-trifluoroethyl)aniline (5280 mg, 18.3 mmol), 3,5-dimethylisoxazole-4-boronic acid, pinacol ester (4082.76 mg, 18.3 mmol), PEPPST'-IPr catalyst (1247.24 mg, 1.83 mmol), Césium carbonate (17889.52 mg,
54.91 mmol) in 120 mL DMEH2O (2:1) was heated to 90°C under argon. The reaction mixture was then cooled and partitioned between water and ethyl acetate. The organic layer was washed with water then brine and dried over sodium sulfate. Purification on silica gel (Hexanes/EtOAc) afforded 2-chloro-4-(3,5-dimethylisoxazol-4-yl)-N-(2,2,2trifluoroethyl)aniline.
Step 3 :
133
[00352] 2-Chloro-4-(3,5-dimethylisoxazol-4-yl)-N-(2,2,2-trifluoroethyl)aniline (200 mg, 0.66 mmol) was dissolved in dichloromethane (10 mL) and acetonitrile (10 mL) and cooled to 0°C under argon. To reaction mixture was added 0.5M nitronium tetrafluoroborate (1.84 ml) slowly over 20 minutes. Reaction mixure was stiired at 0°C, for 1 hour and allowed to warm to room température.After 3 hours, the reaction mixture was cooled to 0°C again and 0.5M nitronium tetrafluoroborate in sulfolane (1.84 ml) was added and the reaction solution was stirred at room température ovemight. Reaction solvents were removed under reduced pressure and the residue taken up in EtOAc and the solution was washed with aq. NaHCO3, then water, brine and dried over sodium sulfate. sSolvents were removed under reduced pressure to yield a dark red oil/liquid. This material was dissolved in 2 mL of éthanol and 2 mL of acetic acid. To the solution was added Zinc dust and suspension was stirred. After 30 minutes of stirring the zinc dust was filtered off and the solvents were removed under reduced pressure. The residue was dissolved in EtOAc and the solution was washed with aq. NaHCO3, then water, brine and dried over sodium sulfate. Solvent was removed and the crude residue was purified by silica gel chromatography (Hexanes/EtOAc as the eluent) to afford 6-chloro-4-(3,5-dimethylisoxazol-4-yl)-Nl-(2,2,2trifluoroethyl)benzene-l,2-diamine as a light colored oil.
Example 118
The following compound was synthesized in a similar fashion as that of Example 117.
[00353] C24Hi9F3N4O2; 453.3 (M+l). IH NMR (400 MHz, DMSO-d6) δ 11.51 (s,
IH), 8.86 (dd, J = 4.2, 1.6 Hz, IH), 8.16 - 7.97 (m, IH), 7.78 (d, J = 8.7 Hz, IH), 7.73 - 7.61 (m, IH), 7.44 (dd, J = 8.6, 4.2 Hz, IH), 7.14 (d, J= 1.7 Hz, IH), 6.81 (d, J = 1.7 Hz, IH),
134
3.89 - 3.58 (m, 2H), 2.39 (s, 3H), 2.22 (d, J = 4.6 Hz, 6H). 19F NMR (376 MHz, DMSO-d6) δ -69.65 (t, J = 8.9 Hz).
Example 119
5-(3,5-dimethyIisoxazol-4-yl)-l-methyl-7-(6-methylquinoIiii-5-yl)-lH-benzo[d]imidazol2(3H)-one
Step 1: 4-(3,5-dimethylisoxazol-4-yl)-2-iodo-N-methyl-6-nitroaniline
N-O | Mel, Cs2CO3 |
iil | DMF |
o2n γ i | |
nh2 |
[00354] To a flask containing 4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6-nitroaniline (1000 mg, 2.78 mmol, 1 equiv) was added DMF (15 mL, 0.2 M), césium carbonate (1.4 gm, 4.17 mmol, 1.5 equiv.) and idomethane (260 pL, 4.17 mmol, 1.5 equiv). After an hour, the reaction was quenched with water and partitioned between water and ethyl acetate. The organic layer was washed with brine and dried over sodium sulfate. Purification was carried out by flash column chromatography to furnish 4-(3,5-dimethylisoxazol-4-yl)-2-iodo-Nmethyl-6-nitroaniline (615 mg, 60 %). *H NMR (400 MHz, cdch) δ 7.81 (t, J= 3.0 Hz, IH), 7.70 (d, J= 2.1 Hz, IH), 2.97 (s, 3H), 2.40 (d, J= 16.8 Hz, 3 H), 2.26 (d, J = 14.2 Hz, 3H).
[00355] LCMS (m/z +1) 373.
Step 2: 5-(3,5-dimethylisoxazol-4-yl)-l-methyl-7-(6-methylquinolin-5-yl)-lHbenzo[d]imidazol-2(3H)-one
135
[00356] To a microwave vial containing 4-(3,5-dimethylisoxazol-4-yl)-2-iodo-Nmethyl-6-nitroaniline (610 mg, 1.64 mmol, 1 equiv) was added EtOH (12 mL, 0.25M) and tin (II) chloride (622 mg, 3.28 mmol, 2 equiv). The reaction mixture was heated for 30 min at
110 °C. The reaction was then stirred in 2N NaOH solution for 20 minutes and partitioned between water and ethyl acetate. The organic layer was washed with brine and dried over sodium sulfate. Purification was carried out by flash column chromatography to furnish 4(3, 5-dimethylisoxazol-4-yl)-6-iodo-N 1 -methylbenzene-1,2-diamine.
[00357] LCMS (m/z +1) 344.02
Step 3: 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-l-methyl-lH-benzo[d]imidazol-2(3H)-one
To a flask containing 4-(3,5-dimethylisoxazol-4-yl)-6-iodo-Nl-methylbenzene- 1,2-diamine (299 mg, 0.87mmol, 1 equiv) was added THF (8 mL) and CDI (282 mg, 1.74 mmol, 2 equiv).
The reaction mixture was heated for 2 hr at 120 °C. The reaction mixture was then concentrated in vacuo and the solid triturated with diethyl ether to furnish 5-(3,515 dimethylisoxazol-4-yl)-7-iodo-1 -methyl-lH-benzo[d]imidazol-2(3H)-one as a light yellow solid.
LCMS (m/z +1) 370.00.
Step 4:
136
[00358] To a microwave vial containing 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-lmethyl-lH-benzo[d]imidazol-2(3H)-one (40 mg, 0.11 mmol, 1 equiv.) were added 3,5- 6methylquinolin-5-ylboronic acid (51 mg, 0.27 mmol, 2.5 equiv.), CS2CO3 (141 mg, 0.43 mmol, 4 equiv.) and PEPPSI™-IPr catalyst (8 mg, 0.02 mmol, 0.1 equiv.) in DME-H2O (20 mL, 0.2 M, 2/1, v/v). The mixture was heated to 140 °C. After 2 hr, the reaction was complété. Following cooling, the reaction mixture was extracted with EtOAc and washed with water, saturated NH4CI. After drying with MgSÛ4, it was filtered and concentrated to dryness under reduced pressure. Purification was carried out by reverse phase HPLC to fumish the title compound.
[00359] ’H NMR (400 MHz, cd3od) δ 8.82 (d, J = 4.3 Hz, IH), 8.09 (d, J = 8.7 Hz, IH), 7.82 (t, 7.1 Hz, 2H), 7.47 (dd, J = 8.5, 4.3 Hz, IH), 7.17 (d, J= 1.6 Hz, IH), 6.82 (d,
J= 1.6 Hz, IH), 2.53 (s, 3H), 2.42 (s, 3H), 2.33 (s, 3H), 2.27 (s, 3H). LCMS (m/z +1) 385.23.
Example 120
7-(l,4-dimethyl-lH-pyrazol-5-yl)-5-(3,5-dimethylisoxazol-4-yl)-l-methyI-lH- benzo [d] imidazol-2(3H)-one
[00360] To a microwave vial containing 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-lmethyl-lH-benzo[d]imidazol-2(3H)-one (40 mg, 0.11 mmol, 1 equiv.) were added 1,4dimethyl-lH-pyrazol-5-ylboronic acid (72 mg, 0.32 mmol, 3 equiv.), CS2CO3 (141 mg, 0.43 mmol, 4 equiv.) and PEPPSI™-IPr catalyst (8 mg, 0.02 mmol, 0.1 equiv.) and DME-H2O (20 mL, 0.2 M, 2/1, v/v). The mixture was heated to 140°C. After 1 hr, the reaction was complété. Following cooling, the reaction was extracted with EtOAc and the organic solution was washed with water, saturated NH4CI. After drying with MgSÜ4, it was filtered and concentrated to dryness under reduced pressure. Purification of the residue was carried out by reverse phase HPLC to fumish the desired product.
137
[00361] IH NMR (400 MHz, cd3od) δ 7.44 (s, IH), 7.15 (d, J = 1.6 Hz, IH), 6.88 (d, J = 1.6 Hz, IH), 3.65 (s, 3H),.9O (s, 3H), 2.42 (s, 3H), 2.27 (s, 7H), 1.95 (s, 3H). LCMS (m/z +1)338.19.
Example 121
5,7-bis(3,5-dimethylisoxazol-4-yl)-l-methyl-lH-benzo[d]imidazol-2(3H)-one
[00362] To a microwave vial containing 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-lmethyl-lH-benzo[d]imidazo 1-2(3H)-one (40 mg, 0.11 mmol, 1 equiv.) were added 3,5dimethylisoxazole-4-boronic acid pinacol ester (72 mg, 0.32 mmol, 3 equiv.), CS2CO3 (141 mg, 0.43 mmol, 4 equiv.), PEPPSI™-IPr catalyst (8 mg, 0.02 mmol, 0.1 equiv.) and DMEH2O (20 mL, 0.2 M, 2/1, v/v). The mixture was heated to 140°C. After 1 hr, the reaction was complété. Following cooling, the reaction mixture was extracted with EtOAc and the organic solution was washed with water, saturated NH4CI. After drying with MgSÛ4, it was filtered and concentrated to dryness. The resulting solid was washed with EtOAc. Purification of the residue was carried out by reverse phase HPLC to furnish the title compound.
[00363] *H NMR (400 MHz, cd3od) Ô 7.09 (d, J = 1.6 Hz, IH), 6.81 (d, J = 1.6 Hz, IH) 3.11 (d, J= 14.5 Hz, 3H), 2.41 (s, 3H), 2.35-2.23 (m, 6H), 2.15 (s, 3H). LCMS (m/z+1) 339.15.
138
Example 122
6-(3,5-dimethylisoxazol-4-yl)-4-(l-ethyI-4-methyl-lH-pyrazoI-5-yl)-lH- benzo [d] imidazoI-2(3H)-one
[00364] To a microwave vial containing 6-(3,5-dimethylisoxazol-4-yl)-4-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-benzo[d]imidazol-2(3H)-one (40 mg, 0.11 mmol, 1 equiv.) were added 5-bromo-l-ethyl-4-methyl-lH-pyrazole 11 (64 mg, 0.34 mmol, 3 equiv.), Pd(dppf)Cl2. CH2O2 (9 mg, 0.011 mmol, 0.1 equiv.), DBU (101 pL, 6 equiv.) andDMSOH2O (4 mL, 0.2 M, 2/1, v/v). The mixture was heated to 120°C for 30 min in micro wave. The 10 reaction was concentrated under reduced pressure and purification was carried out by reverse phase HPLC.
[00365] IH NMR (400 MHz, Methanol-d4) δ 7.45 (d, J = 0.8 Hz, IH), 7.09 (d, J = 1.6 Hz, IH), 6.88 (d, J = 1.6 Hz, IH), 4.02 (dd, J = 28.3, 7.2 Hz, IH), 2.43 (s, 4H), 2.27 (s, 4H), 1.96 (d, J = 0.7 Hz, 3H), 1.25 (t, J= 7.2 Hz, 4H). LCMS (m/z +1) 338.22.
Example 123
5-(6-(3,5-dimethylisoxazol-4-yI)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)-l-methyllH-pyrazole-4-carboxamide
139
[00366] To a microwave vial containing 6-(3,5-dimethylisoxazol-4-yl)-4-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-benzo[d]imidazol-2(3H)-one (100 mg, 0.28 mmol, 1 equiv.) was added 5-bromo-l-methyl-lH-pyrazole-4-carbonitrile (130 mg, 0.30 mmol, 2.5 equiv.), Pd(dppf)C12.CH2C12 (23 mg, 0.03 mmol, 0.1 equiv.) and DBU (253 pL, 1.69 mmol, 6 equiv.) and dissolved in DMSO-H2O (4 mL, 0.2 M, 2/1, v/v). The mixture was heated to 120°C for 30 min in micro wave. The reaction was concentrated in vacuo and purification was then carried out by reverse phase HPLC.
[00367] LCMS (m/z +1) 352.99. IH NMR (400 MHz, Methanol-d4) δ 8.04 (s, IH),
7.10 (d, J = 1.6 Hz, IH), 6.95 (d, J = 1.6 Hz, IH), 3.72 (s, 4H), 2.40 (d, J = 15.8 Hz, 4H), 2.25 (d, J = 16.4 Hz, 4H).
Example 124 l-cyclopropyl-5-(3,5-dimethylisoxazol-4-yl)-7-(6-methylquinolin-5-yl)-lHbenzo [d] imidazoI-2(3H)-one
Step 1: 5-(3,5-dimethylisoxazol-4-yl)-7-iodo-l-methyl-lH-benzo[d]imidazol-2(3H)-one
N-O
O-N
[00368] To a mixture of 4-(3,5-dimethylisoxazol-4-yl)-6-iodo-Nl-methylbenzene-l,2diamine (1.89 g, 5.5 mmol, 1 equiv.) in a pressure tube was added THF (5 mL) and CDI (2.67 g, 18.5 mmol, 3 equiv.). The mixture was heated to 120°C for 30 minutes in a microwave reactor. The reaction was concentrated in vacuo and purified by HPLC to provide 5-(3,5dimethylisoxazol-4-yl)-7-iodo-l-methyl-lH-benzo[d]imidazol-2(3H)-one.
[00369] LCMS (m/z +1) 370.16.
Step 2 : N-cyclopropyl-4-(3,5-dimethyiisoxazol-4-yl)-2-iodo-6-nitroaniline
140
O-N
O-N
[00370] To a mixture of 4-(4-bromo-3-iodo-5-nitrophenyl)-3,5-dimethylisoxazole (1 g, 2.36 mmol, 1 equiv.) in a pressure tube was added NMP (10 mL) and cyclopropylamine (982 gL, 14.2 mmol, 6 equiv.). The mixture was heated to 130°C for 60 minutes in a microwave reactor. The reaction was concentrated under reduced pressure and purifîed by flash column chromatography to provide N-cyclopropyl-4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6nitroaniline.
[00371] LCMS (m/z +1) 400.02
Step 3: l-cyclopropyl-5-(3,5-dimethylisoxazol-4-yl)-7-iodo-lH-benzord]imidazol-2(3H)-one
[00372] To a mixture of Nl-cyclopropyl-4-(3,5-dimethylisoxazol-4-yl)-6iodobenzene-l,2-diamine (170 mg, 0.46 mmol, 1 equiv.) in a pressure tube was added THF (5 mL) and CDI (223 mg, 1.38 mmol, 3 equiv..). The mixture was heated to 120°C for 30 minutes in a microwave reactor. The reaction was concentrated in vacuo and purified by
HPLC to provide l-cyclopropyl-5-(3,5-dimethylisoxazol-4-yI)-7-iodo-lH-benzo[d]imidazol2(3H)-oneLCMS (m/z +1) 396.3.
Step 4:
141
O-N
O-N
[00373] To a micro wave vial containing l-cyclopropyl-5-(3,5-dimethylisoxazol-4-yl)-
7-iodo-lH-benzo[d]imidazol-2(3H)-one (25 mg, 0.063 mmol, 1 equiv.) was added 3,5- 6methylquinolin-5-ylboronic acid (71 mg, 0.38 mmol, 6 equiv.), Pd(dppf)C12.CH2Ch (11 mg,
0.013 mmol, 0.1 equiv.) and DBU (76 pL, 0.51 mmol, 8 equiv.) and dissolved in DMSOH2O (4 mL, 0.2 M, 2/1, v/v). The mixture was heated to 140“C for 30 minutes in the microwave reactor.. Purification was carried out by reverse phase HPLC.
[00374] IH NMR (400 MHz, Methanol-d4) δ 8.80 (dd, J = 4.4, 1.6 Hz, IH), 8.10 7.98 (m, IH), 7.93 (dd, J = 8.6, 1.3 Hz, IH), 7.79 (d, J = 8.7 Hz, IH), 7.47 (dd, J= 8.6, 4.3
Hz, IH), 7.13 (d, J= 1.7 Hz, IH), 6.85 (d, J= 1.7 Hz, 1 H), 4.57 (s, 0H), 2.42 (s, 3H), 2.39 (s,
3H), 2.27 (s, 3H), 1.93 (dt, J= 7.0, 3.4 Hz, IH). LCMS (m/z +1) 411.24.
Example 125, and
Example 126
6-(3,5-dimethylisoxazol-4-yl)-4-(6-(trifluoromethyl)quinolin-5-yl)-lH-benzo[d]imidazol2(3H)-one and
6-(3,5-dimethylisoxazol-4-yI)-4-(6-(trifluoromethyl)quinoIin-7-yl)-lH-benzo[d]imidazol-
2(3H)-one
142
O-N
[00375] To a microwave vial containing 6-(3,5-dimethylisoxazol-4-yl)-4-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-benzo[d]imidazol-2(3H)-one (100 mg, 0.28 mmol, equiv.) was added 5-chloro-6-(trifluoromethyl)quinolone (140 mg, 0.56 mmol, 2 equiv.), Cs2CO3 (450 mg, 1.41 mmol, 5 equiv.) and PEPPSI™-IPr catalyst (45 mg, 0.056 mmol, 0.2 equiv.) and dissolved in DME-H2O (4 mL, 0.2 M, 2/1, v/v). The mixture was heated tol20°C for 30 min in microwave. The reaction was concentrated in vacuo and purification was carried out by reverse phase HPLC.
]00376] IH NMR (400 MHz, Methanol-d4) δ 9.00 (dd, J = 4.2, 1.6 Hz, IH), 8.32 (d, J = 9.1 Hz, IH), 8.19 (d, J = 9.0 Hz, IH), 7.97 - 7.76 (m, IH), 7.56 (dd, J = 8.6, 4.3 Hz, IH),
7.16 (d, J = 1.5 Hz, IH), 6.91 (d, J = 1.4 Hz, IH), 2.42 (s, 3H), 2.27 (s, 3H). LCMS (m/z +1) 425.38
[00377] IH NMR (400 MHz, Methanol-d4) δ 9.03 (ddd, J = 20.6, 4.3, 1.6 Hz, IH),
8.69 - 8.48 (m, IH), 8.32 (d, J = 9.0 Hz, 0H), 8.19 (d, J = 9.0 Hz, 0H), 8.09 (s, IH), 7.86 (d, J = 8.7 Hz, 0H), 7.72 (dd, J = 8.4, 4.4 Hz, IH), 7.56 (dd, 8.6, 4.3 Hz, 0H), 7.12 (dd, J= 32.1, 1.5 Hz, IH), 6.93 (d, J= 10.3 Hz, IH), 2.42 (s, 3H), 2.27 (s, 3H). LCMS (m/z +1) 425.38.
Example 127 and
Example 128 (S)-6-(3,5-dimethyIisoxazol-4-yI)-4-(6-(trifluoromethyI)quinolin-5-yl)-lHbenzo [d] imidazol-2(3H)-one and
143 (R)-6-(3,5-dimethylisoxazol-4-yl)-4-(6-(trifluoromethyl)quinoIin-5-yl)-lHbenzo [d] imidazol-2(3H)-one
[00378] The crude was separated to provide the two atropisomers using HPLC chiral 5 séparation.
[00379] IH NMR (400 MHz, Methanol-d4) δ 9.00 (dd, J = 4.2, 1.6 Hz, IH), 8.32 (d, J = 9.1 Hz, IH), 8.19 (d, J = 9.0 Hz, IH), 7.97 - 7.76 (m, IH), 7.56 (dd, J= 8.6, 4.3 Hz, IH),
7.16 (d, J= 1.5 Hz, IH), 6.91 (d, J= 1.4 Hz, IH), 2.42 (s, 3H), 2.27 (s, 3H). LCMS (m/z +1) 425.38.
Example 129
5-(3,5-dimethylisoxazol-4-yI)-l-methyl-7-(6-(trifluoromethyl)quinolin-5-yI)-lHbenzo [d] imidazol-2(3H)-one
O—N
GS-645S18
[00380] To a micro wave vial containing 5-(3,5-dimethylisoxazol-4-yl)-l-methyl-7(4,4,5,5-tetramethyl-l,3,2-dioxaboroIan-2-yl)-lH-benzo[d]imidazol-2(3H)-one (30 mg, 0.08 mmol, 1 equiv.) was added 5-bromo-6-(trifluoromethyl)quinoline (68 mg, 0.24 mmol, 3 equiv.), CS2CO3 (105 mg, 0.33 mmol, 4 equiv.) and PEPPSI™-IPr catalyst (11 mg, 0.016 mmol, 0.2 equiv.) and dissolved in DME-H2O (4 mL, 0.2 M, 2/1, v/v). The mixture was
144 heated tol20°C for 30 min in micro wave. The reaction was concentrated in vacuo and purification was then carried out by reverse phase HPLC .
[00381] IH NMR (400 MHz, Methanol-d4) δ 9.28 (s, IH), 8.30 -8.19 (m, IH), 7.98 (ddd, J = 8.5, 6.9, 1.4 Hz, IH), 7.70 (ddd, J = 8.3, 6.9, 1.2 Hz, IH), 7.59 - 7.44 (m, IH), 7.23 (d, J= 1.6 Hz, IH), 6.92 (d, J= 1.5 Hz, IH), 2.54 (s, 4H), 2.41 (s, 3H), 2.25 (s, 4H). LCMS (m/z+1) 385.22
Example 130
5-(3,5-dimethylisoxazol-4-yl)-l-methyl-7-(6-(trifliioromethoxy)quinolin-5-yl)-lHbenzo [d] imidazol-2(3H)-one
[00382] To a microwave vial containing 5-(3,5-dimethylisoxazol-4-yl)-l-methyl-7(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-benzo[d]imidazol-2(3H)-one (52 mg, 0.14 mmol, 1 equiv.) was added 5-bromo-6-(trifluoromethoxy)quinoline (124 mg, 0.42 mmol, 3 equiv.), Cs2CO3 (230 mg, 0.70 mmol, 5 equiv.) and PEPPSI™-IPr catalyst (9.5 mg, 0.014 mmol, 0.1 equiv.) and dissolved in DME-H2O (4 mL, 0.2 M, 2/1, v/v). The mixture was heated tol20°C for 30 min in micro wave. The reaction was concentrated in vacuo and purification was then carried out by reverse phase HPLC.
[00383] IH NMR (400 MHz, Methanol-d4) δ 8.97 (dd, J = 4.3, 1.6 Hz, IH), 8.31 (d, J = 9.4 Hz, IH), 8.11 - 7.83 (m, 2H), 7.59 (dd, J = 8.6, 4.3 Hz, IH), 7.20 (d, J = 1.6 Hz, IH),
6.89 (s, IH), 2.61 (s, 3H), 2.41 (s, 3H), 2.26 (s, 3H). 19F NMR (376 MHz, Methanol-J4) δ 58.53. LCMS (m/z +1) 455.29
145
Example 131
4-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)-3methylquinoline 1-oxide
mCPBA
-
[00384] A solution of 6-(3,5-dimethylisoxazol-4-yl)-4-(3-methylquinolin-4-yl)-lHbenzo[d]imidazol-2(3H)-one (30 mg, 0.08 mmol) and mCPBA (100 mg, 0.58 mmol) in dichloromethane (0.5 mL) and methanol (0.5 mL) was stirred for 1 hour at room température. The reaction was quenched with sodium sulfite solution, extracted with ethyl acetate and purified by reverse-phase HPLC.
[00385] C22H18N4O3. 387.1 (M+l). ’H NMR (400 MHz, DMSO-î/6) δ 10.90 (d, J =
1.9 Hz, IH), 10.48 (d, J= 2.0 Hz, IH), 8.73 (s, IH), 8.62 - 8.56 (m, IH), 7.81 - 7.75 (m, IH), 7.63 (ddd, J = 8.3, 6.9, 1.3 Hz, IH), 7.41 (dd,J=8.6, 1.3 Hz, IH), 7.10-7.02 (m, IH), 6.88 (d, J= 1.6 Hz, IH), 2.43 (s, 3H), 2.25 (s, 3H), 2.17 (s, 3H).
Example 132 (R)-5-(6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yI)-6methylqumoline 1-oxide
146
[00386] C22H18N4O3. 387.1 (Μ+1). *H NMR (400 MHz, DMSO-J6) δ 10.86 (d, 2.2
Hz, IH), 10.40 (s, IH), 8.63 - 8.48 (m, 2H), 7.80 (d, J= 9.0 Hz, IH), 7.34 (dd, J= 8.8, 6.0
Hz, IH), 7.26 - 7.15 (m, IH), 7.05 - 6.96 (m, IH), 6.81 (t, J= 1.2 Hz, IH), 2.40 (s, 3H), 2.24 (d,J = 7.9Hz, 6H).
Example 133
6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxydi(pyridin-2-yl)methyI)-lH-benzo[d]imidazol2(3H)-one
[00387] Butyllithium (1,6M solution in hexanes, 24 mL, 38 mmol) was added dropwise over 20 minutes to a solution of 2-bromopyridine (3.7 mL, 38 mmol in methylTHF (100 mL) at -78 °C. The reaction mixture was stirred for 1 hour and a solution of methyl 2,3-diamino-5-(3,5-dimethylisoxazol-4-yl)benzoate (2.0 g, 7.7 mmol) in 20 mL of methyl-THF was added. The reaction mixture was warmed to room température, stirred for 30 minutes and quenched with water. The reaction mixture was extracted with ethyl acetate and purified by silica gel chromatography (90:9:1 ethyl acetate/methanol/ammonium hydroxide) to give (2,3-diamino-5-(3,5-dimethylisoxazol-4-yl)phenyl)di(pyridin-2yl)methanol as an orange powder..
[00388] CDI (1. Ig, 6 mmol) was added to a solution of (2,3-diamino-5-(3,5dimethylisoxazol-4-yl)phenyl)di(pyridin-2-yl)methanol (1.43 g, 3.7 mmol) in THF (10 mL) and the reaction mixture was stirred for 3 days. The reaction mixture was diluted with 100 mL water and 100 mL ethyl acetate and sonicated and filtered to yield the desired product.
[00389] C23H19N5O3. 414.1 (M+l). IH NMR (400 MHz, DMSO-d6) δ 10.69 (d, J = 1.6 Hz, IH), 9.79 (s, IH), 8.49 (ddd, J = 4.9, 1.8, 0.9 Hz, 2H), 7.80 (td, J = 7.7, 1.8 Hz, 2H),
7.58 (dt, J = 8.0, 1.1 Hz, 2H), 7.30 (ddd, J = 7.5, 4.8, 1.1 Hz, 2H), 6.86 (s, IH), 6.81 (d, J =
1.5 Hz, IH), 6.56 (d, J = 1.6 Hz, IH), 2.26 (s, 3H), 2.06 (s, 3H).
147
[00390] The following compound was made similarly to 6-(3,5-dimethylisoxazol-4yl)-4-(hydroxydi(pyridin-2-yl)methyl)-lH-benzo[d]imidazol-2(3H)-one using 2-pyridyl-6magnesiumbromide:
Example 134
6-(3,5-dimethylisoxazol-4-yI)-4-(hydroxybis(6-methyIpyridin-2-yl)methyl)-lH- benzo[d]imidazol-2(3H)-one
[00391] GS-694472 CisIfaNsOs. 442.1 (M+l). ’H NMR (400 MHz, DMSO-J6) Ô
10.77 (s, IH), 10.07 (s, IH), 7.89 (d, J= 17.5 Hz, 2H), 7.51 (t, J= 8.0 Hz, 2H), 7.39 (d, J =
37.6 Hz, 2H), 6.86 (d, J= 1.3 Hz, IH), 2.50 (s, 6H), 2.27 (s, 3H), 2.08 (s, 3H).
Example 135
6-(3,5-dimethylisoxazol-4-yI)-4-(l-hydroxy-2-methyl-l-(pyridin-2-yl)butyl)-lH- benzo[d]imidazol-2(3H)-one
Step 1:
148
[00392] Methyl ester (25 g, 0.096 mol) was dissolved in a mixture of MeOH (400 mL) and 1 M NaOH (200 mL), an air condenser was attached and the reaction was heated to 60 °C for 1.5 hours. Reaction was allowed to cool to room température and concentrated in vacuo. The residue was then diluted in a minimal amount of water and neutralized with 1 M HCl until pH 6-7. The precipitate was collected by vacuum filtration, taken up in MeOH, and concentrated in vacuo to give 2,3-diamino-5-(3,5-dimethylisoxazol-4-yl)benzoic acid as a brown powder .Material was used without further purification.
[00393] C12H13N3O3 248.1 (M+l)
N-O | HATU, DIPEA — H^HCI | N-O |
Il i | DMF | lil |
AA .oh | UL | |
H2N J]’ | A | |
NH2 0 | NH2 |
[00394] 2,3-diamino-5-(3,5-dimethylisoxazol-4-yl)benzoic acid (22 g, 0.089 mol) was dissolved in DMF (C=3.0 M) and HATU (1.3 eq), DIPEA (7 eq), and N,Odimethylhydroxylamine hydrochloride (2.5 eq) were added in one portion and the reaction was allowed to stir under air at room température for 1 hr. The reaction was concentrated in vacuo and the residue was dissolved in ethyl acetate. The solution was washed once with NaHCOs and three times with brine. The crude was concentrated in vacuo and purified via silica gel chromatography to give 2,3-diamino-5-(3,5-dimethylisoxazol-4-yl)-N-methoxy-Nmethylbenzamide as a light brown powder.
[00395] 2,3-diamino-5-(3,5-dimethylisoxazol-4-yl)-N-methoxy-N-methylbenzamide (25 g, 0.086 mol) was dissolved in a 1:1 mixture (32 mL total) of tetraethylorthocarbonate and AcOH and allowed to stir under air at room température for 1.5 hr. The reaction mixture was concentrated in vacuo at room température and the crude residue was dissolved in EtOAc. The solution was washed three times with bicarb, once with water, and organic layer was concentrated in vacuo to give 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-N-methoxy-Nmethyl-lH-benzo[d]imidazole-4-carboxamide as a dark oil. Crude material was used without further purification.
149
N-O N-O
[00396] 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-N-methoxy-N-methyl-lHbenzo[d]imidazole-4-carboxamide (23 g, 0.067 mol) was dissolved in THF (80 mL, 1.0 M) and Boc2Û (2 eq), DMAP (0.4 eq), and triethylamine (3.5 eq) were added to the reaction mixture and allowed to stir under air at room température for 1 hr. Reaction mixture was then concentrated in vacuo and purified by silica gel chromatography (80-100 % EtOAc/hex) to give tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-(methoxy(methyl)carbamoyl)lH-benzo[d]imidazole-l-carboxylate %) as a white powder.
[00397] 2-bromopyridine (4.5 mmol, 2 eq) was dissolved in 2-MeTHF (C=0.15 M) and cooled to -78 °C under Ar. n-BuLi (1.6 M, 2 eq) was added dropwise to the solution over 15 minutes and the reaction was allowed to stir at -78 °C for 1 hour. tert-butyl 6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-4-(methoxy(methyl)carbamoyl)-lH-benzo[d]imidazole-lcarboxylate (1 g, 2.25 mmol) was dissolved in a minimal amount of 2-MeTHF and added to the reaction via syringe in one portion and the reaction was then allowed to slowly warm to room température. The reaction was quenched with water, diluted with EtOAc, washed twice with brine, and concentrated in vacuo. The crude material was purified by silica gel chromatography to give tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-picolinoyl-lHbenzo[d]imidazole-l -carboxylate (300 mg, 29%) as a yellow powder and (6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-1 H-benzo[d]imidazol-4-yl)(pyridin-2-yl)methanone (460 mg, 56%) as a pale yellow powder.
150
[00398] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)methanone (20 mg, 0.055mmol) was dissolved in dry THF (0.55 mL) under argon. Secbutylmagnesium bromide (1.0 M in THF, 0.27 mL, 0.28 mmol) was added dropwise and the reaction was allowed to stir for 10 minutes. The reaction was quenched with water, concentrated and purified by reverse-phase HPLC to give 1-(6-(3,5-dimethylisoxazol-4-yl)-2ethoxy-1 H-benzo[d]imidazol-4-yl)-2-methyl-1 -(pyridin-2-yl)butan-1 -ol intermediate. Intermediate was taken up in 0.5 mL EtOH and 0.3 mL 4.0M HCl/dioxane and heated to 65°C for 1 hr. Reaction was concentrated and purified by reverse phase HPLC to afford the desired product
[00399] C22H24N4O3 393.5 (M + 1). ’H NMR (400 MHz, DMSO-û?6) δ 10.64 (s, IH),
9.99 (s, IH), 8.54 (s, IH), 7.84 (s, 2H), 7.27 (s, IH), 7.11 (t, J= 1.8 Hz, IH), 6.71 (d, J= 3.1 Hz, IH), 2.36 (d, 5.7 Hz, 3H), 2.18 (d, J= 5.8 Hz, 3H), 0.87 (t, J- 7.3 Hz, 5H), 0.80 (d, J = 7.2 Hz, 3H), 0.62 (d, J = 6.5 Hz, 2H).
Example 136
4-(cyclopropyl(hydroxy)(pyridin-2-yl)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo [d] imidazol-2(3H)-one
151
[00400] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)methanone (40 mg, 0.1 Immol) was dissolved in dry THF (1.1 mL) and cyclopropylmagnesium bromide (0.5 M in diethylether, 1.1 mL, 0.55 mmol) was added dropwise at rt and the reaction was allowed to stir for 10 minutes. The reaction was quenched with water, concentrated, and purified by reverse-phase HPLC to give cyclopropy 1(6-(3,5 -dimethy li soxazol-4-yl)-2-ethoxy-1 H-benzo[d]imidazol-4-yl)(pyridin-2yl)methanol intermediate which was taken up in 1.0 mL EtOH and 0.7 mL 4.0M HCl/dioxane and heated for 2 hours at 65°C. Reaction was then concentrated down and purified by reverse-phase HPLC to afford the desired product as a white powder.
[00401] C21H20N4O3 377.3 (M+l)
[00402] IH NMR (400 MHz, DMSO-d6) δ 10.66 (s, IH), 9.73 (s, IH), 8.54 (s, IH), 7.92 (s, IH), 7.71 (d, J = 8.0 Hz, IH), 7.40 (s, IH), 7.27 (s, IH), 6.81 (s, IH), 2.39 (s, 3H), 2.21 (s, 3H), 2.01 (s, IH), 0.54 (d, J= 5.6 Hz, 3H), 0.29 (d, J= 10.3 Hz, IH).
Example 137
6-(3,5-dimethylisoxazol-4-yl)-4-(l-hydroxy-l-(pyridin-2-yl)propyl)-lH- benzo [d] imidazol-2(3H)-one
[00403] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)methanone (20 mg, 0.055 mmol) was dissolved in dry THF (0.5 mL) and ethylmagnesium bromide (1.0 M, 0.27 mL, 0.27 mmol) was added dropwise. The reaction was allowed to stir at r.t. for 10 minutes and then a mixture of EtOH (1 mL) and 4.0M
HCl/dioxane (0.5 mL) was added and the reaction was heated to 65 °C for 3 hours. The reaction was concentrated and purified by reverse-phase HPLC to afford the desired product as a white powder.
152
[00404] C20H20N403 365.1 (M+l). IHNMR (400 MHz, DMSO-d6) δ 10.67 (s,
IH), 9.89 (s, IH), 8.57 (s, IH), 7.88 (s, 2H), 7.35 (s, IH), 6.97 (s, IH), 6.75 (s, IH), 2.42 (d, J = 9.1 Hz, 2H), 2.35 (s, 3H), 2.17 (s, 3H), 0.79 (t, J= 7.2 Hz, 3H).
Example 138
4-(cyclopentyl(hydroxy)(pyridin-2-yl)methyl)-6-(3,5-dimethylisoxazol-4-yI)-lHbenzo [d] imidazol-2(3H)-one
[00405] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)methanone (50 mg, 0.14 mmol) was dissolved in dry THF (1.4 mL) under argon and cooled to 0 °C. Cyclopentylmagnesium chloride (2.0 M, 0.14 mL, 0.28 mmol) was added dropwise and reaction was allowed to stir for 10 minutes then quenched with water. Reaction mixture was extracted three times with EtOAc and combined organic layers were washed once with water and concentrated. Residue was taken up in EtOH (1.5 mL) and 4.0M HCl/dioxane (0.75 mL) and heated to 65 °C for 2 hours. Reaction was concentrated and purified by reverse-phase HPLC to afford the desired product as a white powder.
[00406] C23H24N4O3.405.2 (M+l). IH NMR (400 MHz, DMSO-d6) δ 10.77 (d, J = 5.3 Hz, IH), 10.03 (s, IH), 8.67 (s, IH), 8.14 (s, IH), 7.94 (s, IH), 7.61 (s, IH), 7.19 (s, IH), 6.80 (s, IH), 3.55-3.45 (m, IH), 2.39 (s, 3H), 2.22 (s, 3H), 1.69- 1.60 (m, 2H), 1.55 (dd, J =11.5, 5.4 Hz, 3H), 1.46 (d, J = 7.7 Hz, IH), 1.31 (d, J =11.1 Hz, IH), 1.12 (s, IH).
Example 139
6-(3,5-dimethylisoxazol-4-yl)-4-(l-hydroxy-l-(pyridin-2-yl)pent-4-en-l-yl)-lHbenzo [d] imidazol-2(3H)-one
153
N-O
[00407] Magnésium métal (20 mg, 0.82 mmol) was taken up in THF (1.5 mL) and (bromomethyl) cyclopropane (100 mg, 0.71 mmol) was added dropwise and the reaction was heated to 65 °C for 1 hr. (Cyclopropylmethyl)magnesium bromide (0.5 M, 0.83 mL, 0.41 mmol) was then added dropwise to a solution of (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lHbenzo[d]imidazol-4-yl)(pyridin-2-yl)methanone (50 mg, 0.14 mmol) in dry THF (1.4 mL) which was cooled to 0 °C. Reaction mixture was allowed to stir for 10 mins, quenched with water and extracted three times with EtOAc. Combined organic layers were washed once with water and concentrated. Residue was dissolved in a mixture of EtOH (1.5 mL) and 4.0M HCl/dioxane (0.75 mL) and heated for 2 hours at 65 °C. Reaction was then concentrated and purified by reverse-phase HPLC to to afford the desired product as a white powder.
[00408] C22H22N4O3. 391.5 (M+l). IH NMR (400 MHz, DMSO-d6) δ 10.68 (s,
IH), 9.93 (s, IH), 8.55 (s, IH), 7.88 (s, 2H), 7.32 (s, IH), 6.95 (s, IH), 6.75 (s, IH), 5.82 (dd, J = 9.8, 7.0 Hz, IH), 5.00-4.85 (m, 3H), 2.35 (s, 3H), 2.16 (s, 3H), 2.10-1.90 (m, 4H).
Example 140
6-(3,5-dimethylisoxazoI-4-yl)-4-(4,4,4-trifluoro-l-hydroxy-l-(pyridin-2-yl)butyl)-lHbenzo[d]imidazol-2(3H)-one
N-O
154
[00409] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)methanone (50 mg, 0.14 mmol) was dissolved in dry THF (1.4 mL) and cooled to 0 °C. (3,3,3-trifluoropropyl)magnesium bromide (0.5 M, 0.55 mL, 0.28 mmol) was added dropwise and the reaction was allowed to stir for 10 mins and then quenched with water. Reaction was extracted three times with EtOAc and combined organic layers were washed once with water and concentrated. Residue was taken up in EtOH (1.5 mL) and 4.0M HCl/dioxane (0.75 mL), heated to 65 °C for two hours, concentrated, then purified by reverse-phase HPLC to afford the desired product as a white powder.
[00410] C21H19F3N4O3 433.4 (M+l). ’H NMR (400 MHz, DMSO-d6) δ 10.72 (s,
IH), 10.05 (s, IH), 8.56 (d, J = 4.6 Hz, IH), 7.88 (s, 2H), 7.31 (s, IH), 6.82 (s, IH), 6.76 (s, IH), 2.67 (s, IH), 2.60 (d, J = 4.0 Hz, IH), 2.32 (s, 4H), 2.16 (s, 2H), 2.13 (s, 3H).
Example 141
6-(3,5-dimethylisoxazoI-4-yl)-4-(l-hydroxy-2-methyl-l-(pyridin-2-yl)propyl)-lHbenzo [d] imidazol-2(3H)-one
N-O
HN
[00411] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)methanone (50 mg, 0.14 mmol) was dissolved in dry THF (1.4 mL) and cooled to 0 °C.
Isopropylmagnesium bromide (2.0 M, 0.14 mL, 0.28 mmol) was added dropwise and the reaction was allowed to stir for 10 mins and then quenched with water. Reaction was extracted three times with EtOAc and combined organic layers were washed once with water and concentrated. Residue was taken up in EtOH (1.5 mL) and 4.0M HCl/dioxane (0.75 mL), heated to 65 °C for two hours, concentrated, then purified by reverse-phase HPLC to afford the desired product as a white powder.
155
[00412] C21H22N4O3 379.3 (M+l). 1HNMR (400 MHz, DMSO-d6) δ 10.70 (s,
IH), 10.01 (d, J = 2.1 Hz, IH), 8.60 (s, IH), 7.91 (s, 2H), 7.41 (s, IH), 7.15 (s, IH), 6.74 (s, IH), 3.17 (s, IH), 2.37 (s, 3H), 2.33 (d, J = 1.7 Hz, OH), 2.20 (s, 3H), 2.15 (s, OH), 1.23 (d, J = 6.7 Hz, IH), 0.93 (d, J = 6.0 Hz, 3H), 0.65 (d, J = 6.9 Hz, 3H).
Example 142
4-(cyclobutyI(hydroxy)(pyridm-2-yl)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one
[00413] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)methanone (50 mg, 0.14 mmol) was dissolved in dry THF (1.4 mL) and cooled to 0 °C. Cylobutylmagnesium chloride (0.5 M, 1.1 mL, 0.55 mmol) was added dropwise and the reaction was allowed to stir for 10 mins and then quenched with water. Reaction was extracted three times with EtOAc and combined organic layers were washed once with water, concentrated, and purified by reverse-phase HPLC to give cyclobutyl(6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin-2-yl)methanol intermediate. The intermediate was taken up in EtOH (1.5 mL) and 4.0 M HCl/dioxane and heated to 65 °C for 2 hours, concentrated and purified by reverse-phase HPLC to afford the desired product as a white powder.
[00414] C22H22N4O3 391.5 (M+l). IH NMR (400 MHz, DMSO-d6) δ 10.70 (s,
IH), 9.93 (d, J = 2.6 Hz, IH), 8.58 (s, IH), 7.96 (s, IH), 7.72 (d, J = 8.0 Hz, IH), 7.43 (s, IH), 7.00 (s, IH), 6.79 (d, J = 2.1 Hz, IH), 3.82 - 3.71 (m, IH), 2.39 (s, 3H), 2.21 (s, 3H), 2.19-2.10(m, IH), 2.02-1.94(m> IH), 1.91 (s, IH), 1.80 (q, J = 9.1 Hz, IH), 1.67 (t,J = 9.7 Hz, IH), 1.44 (q, J = 6.2, 3.9 Hz, IH).
156
Example 143
6-(3,5-dimethylisoxazol-4-yl)-4-(l-hydroxy-3,3-dimethyl-l-(pyridin-2-yl)butyl)-lHbenzo [d] imidazoI-2(3H)-one
[00415] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)methanone (50 mg, 0.14 mmol) was dissolved in dry THF (1.4 mL) and cooled to 0 °C. Neopentylmagnesium chloride (1.0 M, 0.55 mL, 0.55 mmol) was added dropwise and the reaction was allowed to stir for 10 mins and then quenched with water. Reaction was extracted three times with EtOAc and combined organic layers were washed once with water, concentrated, and purified by reverse-phase HP LC to give 1-(6-(3,5-dimethylisoxazol-4-yl)2-ethoxy-lH-benzo[d]imidazol-4-yl)-3,3-dimethyl-1 -(pyridin-2-yl)butan-1 -ol intermediate. The intermediate was taken up in EtOH (1.5 mL) and 4.0 M HCl/dioxane and heated to 65 °C for 2 hours, concentrated and purified by reverse-phase HPLC to afford the desired product as a white powder.
[00416] C23H26N4O3 407.3 (M+l). IH NMR (400 MHz, DMSO-d6) δ 10.70 (d, J =
4.6 Hz, IH), 9.94 (d, J = 2.5 Hz, IH), 8.58 (s, IH), 7.98 (s, 2H), 7.38 (s, IH), 7.09 (d, J = 2.5 Hz, IH), 6.73 (d, J = 2.9 Hz, IH), 2.51 (s, 2H), 2.35 (s, 3H), 2.17 (d, J = 1.0 Hz, 3H), 0.79 (s, 9H).
157
Example 144
4-(cyclohexyl(hydroxy)(pyridin-2-yl)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo [d] imidazol-2(3H)-one
[00417] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)methanone (50 mg, 0.14 mmol) was dissolved in dry THF (1.4 mL) and cooled to 0 °C. Cyclohexylmagnesium chloride (2.0 M, 0.21 mL, 0.41 mmol) was added dropwise and the reaction was allowed to stir for 10 mins and then quenched with water. Reaction was extracted three times with EtOAc and combined organic layers were washed once with water, concentrated, and purified by reverse-phase HPLC to give cyclohexyl(6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin-2-yl)methanol intermediate. The intermediate was taken up in EtOH (1.5 mL) and 0.2mL concentrated HCl and heated to 65 °C for 2 hours and concentrated afford the desired product as a white powder.
[00418] C24H26N4O3 419.8 (M+l). IH NMR (400 MHz, Methanol-d4) δ 8.77 (d, J = 5.7 Hz, IH), 8.54 (t, J = 7.5 Hz, IH), 8.15 (d, J= 7.9 Hz, IH), 7.97 (dd, J= 7.3, 5.7 Hz, IH), 7.24 (d, 1.4 Hz, IH), 6.99 (d, J= 1.2 Hz, IH), 2.84 (d, 10.6 Hz, IH), 2.42 (s,
3H), 2.27 (s, 3H), 2.00 - 1.72 (m, 5H), 1.55 - 1.33 (m, 5H).
158
Example 145
4-((6-chIoropyridin-2-yl)(hydroxy)(pyridin-2-yI)methyl)-6-(3,5-dimethylisoxazol-4-yl)ΙΗ-benzo [d] imidazol-2(3H)-one
N-O
[00419] To a solution of 2-bromo-6-chloropyridine (83 mg, 0.43 mmol) in 2-MeTHF (1.5 mL) cooled to -78 °C was added n-BuLi (1.6 M, 0.27 mL, 0.43 mmol) dropwise and the reaction was allowed to stir for 40 mins. A solution of (6-(3,5-dimethylisoxazol-4-yl)-2ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin-2-yl)methanone (100 mg, 0.22 mmol) in 2MeTHF (0.5 mL) was added to the reaction and the reaction was allowed to stir for an additional 10 mins at -78 °C and then quenched with water. The reaction mixture was extracted three times with EtOAc and combined organic layers were washed once with water, concentrated, and purified by silica gel chromatography to yield (6-chloropyridin-2-yl)(6(3,5 -dimethyli soxazol-4-yl)-2-ethoxy-1 H-benzo [d]imidazol-4-yl)(pyridin-2-yl)methanol (51 mg, 41%) as a white solid. The solid (26.5 mg, 0.055 mmol) was taken up in EtOH (1 mL) and 4M HCl/dioxane (0.5 mL) and heated for two hours at 65 °C and then concentrated to afford the desired product as a pale yellow powder.
[00420] C23H18C1N5O3 448.9 (M+l). IH NMR (400 MHz, DMSO-d6) δ 10.80 -
10.72 (m, IH), 9.87 (s, IH), 8.54 (d, J = 4.8 Hz, IH), 7.89 (t, J - 7.9 Hz, 2H), 7.63 (d, J = 8.1 Hz, IH), 7.56 (d, J = 7.7 Hz, IH), 7.45 (d, J = 7.9 Hz, IH), 7.39 (s, IH), 6.86 (s, IH), 6.51 (s, IH), 2.30 (s, 3H), 2.10 (s, 3H).
159
Example 146
6-(3,5-dimethyIisoxazol-4-yI)-4-(hydroxy(6-(2-methoxyethoxy)pyridin-2-yI)(pyridin-2yl)methyl)-lH-benzo[d]imidazol-2(3H)-one
[00421] 2-methoxyethanol (25 mg, 0.33 mmol) was dissolved in THF (0.5 mL) and cooled to 0 °C. Sodium hydride (8 mg, 0.33 mmol) was added in one portion and the reaction was allowed to corne to rt and stir for 10 minutes. The reaction was then cooled back to 0 °C and tert-butyl 4-((6-chloropyridin-2-yl)(hydroxy)(pyridin-2-yl)methyl)-6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazole-l-carboxylate (24 mg, 0.04 mmol) was added and the reaction was sealed and heated to 80 °C ovemight. Reaction was concentrated and the residue was taken up in EtOH (1.5 mL) and 4M HCl/dioxane (0.5 mL) and heated for 2 hours at 60 °C. The reaction was cooled to rt and filtered to remove the sodium sait. Filterate was concentrated to afford the desired product as a brown film.
[00422] C26H25N5O5 488.5 (M+l). IHNMR (400 MHz, DMSO-d6) δ 10.81 (s,
IH), 9.97 (s, IH), 8.63 (s, IH), 7.77 (d, J = 7.9 Hz, IH), 7.69 (s, IH), 7.28 (s, IH), 6.89 (s, IH), 6.81 - 6.72 (m, IH), 6.41 (s, IH), 4.10 (d, J - 4.5 Hz, 2H), 3.75 - 3.61 (m, 2H), 3.15 (s, 3H), 2.26 (s, 3H), 2.06 (s, 3H).
160
Example 147
6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(6-methylpyridin-2-yl)(pyridin-2-yl)methyl)ΙΗ-benzo [d] imidazol-2(3H)-one
4M HCl in dioxane
Ethanol, 70C
N~O
[00423] In a 2-neck, 50-mL round-bottom flask, a solution of 6-bromo-2-picoline (28.6 mg, 0.177 mmol) in 2 mL of 2-methyltetrahydrofuran was cooled to -78°C in a dry ice/acetone bath while stirring under nitrogen. To this stirring solution, a 1.42 M nbutyllithium solution in hexanes (0.12 mL, 0.17 mmol) was added dropwise and the reaction mixture was stirred at -78°C for 30 minutes. 7ert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2ethoxy-4-picolinoyl-lÆ-benzo[t7]imidazole-l-carboxylate (34.8 mg, 0.0752 mmol) was added dropwise in a solution of 1 mL of 2-methyltetrahydrofùran. The reaction mixture was warmed to room température for 30 minutes before the reaction was quenched with brine and diluted with ethyl acetate. The organic layer was separated and saved and the aqueous layer was extracted three times with ethyl acetate. The organic layers were dried over sodium sulfate, decanted and concentrated. C31H33N5O5. 556.1 (M+l).
[00424] The crude intermediate was taken up in 2 mL of éthanol and transferred to a microwave vial. 4M hydrochloric acid in dioxane (0.10 mL, 0.40 mmol) was added to the reaction mixture and the vial was sealed and heated at 70°C for 1 hour or until reaction completion. The reaction mixture was concentrated and the product was isolated by preparatory HPLC as a yellow oil.
[00425] C24H21N5O3. 428.0 (M+l). 1HNMR (400 MHz, Methanol-d4) δ 8.68 (ddd, J = 5.3, 1.8, 0.9 Hz, IH), 8.25 - 8.16 (m, 2H), 7.92 (dt, J = 8.1, 1.0 Hz, IH), 7.73-7.61 (m, 3H), 7.09 (d, J = 1.5 Hz, IH), 6.42 (d, J= 1.5 Hz, IH), 2.75 (s, 3H), 2.31 (s, 3H), 2.14 (s,
3H).
161
Example 148
6-(3,5-dimethylisoxazol-4-yl)-4-((6-ethylpyridin-2-yl)(hydroxy)(pyridin-2-yl)methyl)lH-benzo]d]imidazol-2(3H)-one
[00426] A procedure similar to that used for Example 162 was used to produce the intermediate (C32H35N5O5. 570.1(M+1)), which was taken directly to the deprotection step to yield a yellow oil. .
N-O
O
[00427] C25H23N5O3. 442.0 (M+l). ’H NMR (400 MHz, Methanol^) δ 8.75 - 8.68 (m, IH), 8.29 (td, J= 7.9, 1.7 Hz, IH), 8.18 (t, J= 7.9 Hz, IH), 7.94 (dt, J= 8.1, 1.0 Hz, IH),
7.76 (ddd, J= 7.7, 5.4, 1.1 Hz, IH), 7.70 - 7.62 (m, 2H), 7.09 (d, J= 1.5 Hz, IH), 6.43 (d, J = 1.5 Hz, IH), 3.00 (q, J= 7.6 Hz, 2H), 2.31 (s, 3H), 2.13 (s, 3H), 1.32 (t, J= 7.6 Hz, 3H).
Example 149
6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(phenyl)(pyridin-2-yl)methyl)-lHbenzo [d] imidazol-2(3H)-one
[00428] In a 2-neck, 50-mL round bottom flask, a solution of (6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-lÆ-benzo[6/]imidazole-4-yl)(pyridin-2-yl)methanone (31.5 mg, 0.0870 mmol) in 2 mL of tetrahydrofuran was cooled to 0°C while stirring under nitrogen. A 2M solution of phenylmagnesium chloride in tetrahydrofuran (0.13 mL, 0.26
162 mmol) was added dropwise to the reaction mixture and allowed to warm to room température for 30 minutes. The reaction mixture was quenched with 2 M aqueous hydrochloric acid and neutralized with aqueous sodium bicarbonate. The aqueous layer was extracted with ethyl acetate three times, and the combined organic layers were concentrated and taken directly to the deprotection step. C26H24N4O3, 441.1 (M+l).
[00429] The crude intermediate was dissolved in 3 mL of éthanol and transferred to a microwave vial. Hydrochloric acid in dioxane (0.10 mL, 0.40 mmol) was added and the reaction vial was sealed and heated at 70°C for 1 hour. The reaction mixture was concentrated down and the product was isolated by preparatory HPLC as a white solid.
[00430] C26H24N4O3. 413.1 (M+l). IH NMR (400 MHz, Methanol-^) δ 8.80 (ddd,
J= 5.6, 1.7, 0.8 Hz, IH), 8.38 (td, J= 7.9, 1.7 Hz, IH), 7.89 (ddd, J= 7.8, 5.6, 1.2 Hz, IH),
7.77 (dt, .7=8.1, 1.0 Hz, IH), 7.51-7.41 (m, 3H), 7.37 (dd, J= 7.9, 1.8Hz,2H), 7.08 (d,J =
1.5 Hz, IH), 6.48 (d, J= 1.5 Hz, IH), 2.30 (s, 3H), 2.13 (s, 3H).
Example 150
6-(3,5-dimethylisoxazol-4-yl)-4-((3-ethylphenyl)(hydroxy)(pyridin-2-yl)methyl)-lHbenzo [d] imidazol-2(3H)-one
4M HCl in dioxane
Ethanol, 70C
N-O
[00431] In a 2-neck, 50-mL round bottom flask, l-bromo-3-ethylbenzene (43.2 mg,
0.233 mmol) was cooled to -78°C in 2 mL of tetrahydrofuran while stirring under nitrogen.
A 1.47 M solution of tert-butyllithium in pentane (310 pL, 0.456 mmol) was added dropwise and the reaction was allowed to stir for 15 minutes. In a solution of 1 mL of tetrahydrofuran, tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-picolinoyl- 17/-benzo[i7|imidazole-1 carboxylate (35.0 mg, 0.0757 mmol) was added dropwise. The reaction mixture was warmed to room température while stirring under nitrogen for 15 minutes or until reaction completion.
163
The reaction mixture was slowly quenched with brine and diluted with ethyl acetate. The organic layer was separated and saved and the aqueous layer was extracted with ethyl acetate three times. The organic layers were combined, dried over sodium sulfate, decanted and concentrated.
[00432] The crude intermediate was dissolved in 1 mL of éthanol and transferred to a microwave vial before 4M hydrochloric acid in dioxane (0.100 mL, 0.400 mmol) was added. The vial was sealed and heated at 70°C for one hour or until reaction completion. The reaction mixture was concentrated and isolated by preparatory HPLC to yield the title compound.
[00433] C26H24N4O3. 441.1 (M+l). 1HNMR(400 MHz, Methanol-d4) δ 8.89 -
8.81 (m, IH), 8.58 (td, J = 8.0, 1.6 Hz, IH), 8.08 (ddd, J= 7.4, 5.8, 1.2 Hz, IH), 7.92-7.83 (m, IH), 7.40 (t, J= 7.7 Hz, IH), 7.36 - 7.29 (m, 2H), 7.14 (d, J= 1.7 Hz, IH), 7.11 (d, J=
1.5 Hz, IH), 6.47 (d, J= 1.5 Hz, IH), 2.69 (q, J= 7.6 Hz, 2H), 2.31 (s, 3H), 2.13 (s, 3H), 1.23 (t, J=7.6Hz, 3H).
Example 151
6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(pyridin-2-yl)(m-toIyl)methyl)-lHbenzo[d]imidazol-2(3H)-one
[00434] A procedure similar to that used for Example 165 was used to produce the intermediate (C27H26N4O3, 455.1 (M+l)) which was immediately taken forward to the deprotection step to yield a yellow solid (7.7 mg, 23%).
[00435] C25H22N4O3. 427.1 (M+l). Ή NMR (400 MHz, Methanol-^) δ 8.87 (dd, J =
6.0, 1.4 Hz, IH), 8.61 (td, J= 7.9, 1.5 Hz, IH), 8.16 - 8.06 (m, IH), 7.90 (d, J= 8.1 Hz, IH),
164
7.39 (t, J = 7.7 Hz, IH), 7.34-7.25 (m, 2H), 7.14 (d, J= 7.8 Hz, IH), 7.12 (d,J= 1.5 Hz,
IH), 6.48 (d, J = 1.5 Hz, IH), 2.38 (s, 3H), 2.32 (s, 3H), 2.14 (s, 3H).
Example 152
6-(3,5-dimethylisoxazol-4-yI)-4-(hydroxy(3-methoxyphenyl)(pyridin-2-yl)methyl)-lHbenzo [d] imidazol-2(3H)-one
[00436] A procedure similar to that used to synthesize the compound of Example 166 was used to produce the product as a white solid.
[00437] C25H22N4O4. 443.0 (M+l). ’H NMR (400 MHz, Chloroform-J) δ 8.67 (m,
IH), 8.56 (bs, IH), 8.43 (bs, IH), 7.72 (t, 2H), 7.34 (m, IH), 7.10 (d, J= 7.8 Hz, IH), 6.86 (m, 3H), 6.78 (d, J= 7.8 Hz, IH), 6.25 (s, IH), 3.75 (s, 3H), 2.25 (s, 3H), 2.10 (s, 3H).
Example 153
Préparation of 6-(3,5-dimethyIisoxazol-4-yl)-4-((7-fluoroquinolin-2yl)(hydroxy)(phenyl)methyl)-lH-benzo[d]imidazol-2(3H)-one
165
[00438] Tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4(methoxy(methyl)carbamoyI)-lH-benzo[d]imidazole-l-carboxylate was dissolved in THF (3 mL). To the solution was added a solution of phenyl magnésium chloride (2M in THF, 0.508 mmol, 0.254 mmol) at -78°C. after the addition, the reaction was allowed to warm up to room température. The reaction was stirred for 17 hat the same température. The reaction mixture was quenched with water (30 mL). The whole was extracted with AcOEt (30 mL x 3). Organic layer was washed with brine (30 mL) and dried over Na2SO4- The solvent was removed under a reduced pressure to give the crude product. The crude product was purified by a silica gel column chromatography (hexane: EtOAc, 7:1 to 3:1) to give tert-butyl 4benzoyl-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-1 H-benzo[d]imidazole-1 -carboxylate.
[00440] To a solution of 7-fluoro-2-bromoquinoline (54.1 mg) in THF (2 mL) was added BuLi (1.6 M, 0.25 mL) at -78°C. After 5 min, a solution of phenyl ketone (60.0 mg) in THF (1 mL) was added at-78°C. The reaction was immediately allowed to warm up to room température and stirred for 30 min. The reaction mixture was quenched with water (30 mL). The whole was extracted with AcOEt (30 mL x 3). Organic layer was washed with brine (30 mL) and dried over Na2SO4. The solvent was removed under a reduced pressure to give the crude product. The crude product was treated with TFA to cleave the Boc group. The crude product was purified by a silica gel column chromatography (hexane: EtOAc, 7:1 to 3:1) to give tert-butyl 4-benzoyl-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazole-lcarboxylate (18.0 mg). tert-butyl 4-benzoyl-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lHbenzo[d]imidazole-l-carboxylate. C26H27N3O5. MS. m/z 509.2 (M+l).
166
[00441] Tert-butyl 4-benzoyl-6-(3,5-dimethyli soxazol-4-yl)-2-ethoxy-1Hbenzo[d]imidazole-l-carboxylate (18.0 mg) was dissolved into EtOH (2 mL) and 4M HCl/dioxane (2 mL). The solution was heated at 70°C for 30 min. The reaction mixture was quenched with water (30 mL). The whole was extracted with EtOAc (30 mL x3). Combined organic layers were washed with brine (50 mL). The solvent was removed under a reduced pressure to give a crude product. The crude product was purified by a a silica gel column chromatography (hexane: EtOAc, 7:1 to 3:1) to give tert-butyl 4-benzoyl-6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-1 H-benzo[d]imidazole-1 -carboxylate.
[00442] C28H21FN4O3. MS. m/z 481.1 (M+l). 1H NMR (400 MHz, Methanol-d4) δ
8.31 (1, J = 8.7 Hz, IH), 8.13 (dd, J= 9.2, 5.3 Hz, IH), 7.67 - 7.56 (m, 3H), 7.40 - 7.25 (m, 5H), 6.98 (d, J= 1.6 Hz, IH), 6.61 (d, J= 1.6 Hz, IH), 2.28 (s, 3H), 2.11 (s, 3H).
Example 154
6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(phenyl)(quinolin-2-yl)methyl)-lHbenzo [d] imidazoI-2(3H)-one
167
[00443] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazoI-4yl)(phenyl)(quinolin-2-yl)methanol was synthesized in the similar fashion with tert-butyl 4benzoyl-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-1 H-benzo[d]imidazole-1 -carboxylate.
[00444] C30H26N4O3. MS. m/z 491.2 (M+l).
[00445] C28H22N4O3. MS. m/z 463. 1 (M+1 ). ). 'H NMR (400 MHz, Methanol-tA) δ
8.30 (d, J= 8.6 Hz, IH), 8.09 (d, J= 8.6 Hz, IH), 7.93 (d, J= 8.6 Hz, IH), 7.77 (ddd, 8.6, 7.0, 1.2 Hz, IH), 7.61 (ddd, J= 8.6, 7.0, 1.2 Hz, IH), 7.54 (d, J = 8.6 Hz, IH), 7.40-7.26 (m, 5H), 6.98 (d, J = 1.5 Hz, IH), 6.61 (d, 1.5 Hz, IH), 2.27 (s, 3H), 2.10 (s, 3H).
Example 155
6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(pyridin-2-yl)(quinolin-2-yl)methyl)-lHbenzo [d] imidazol-2(3H)-one
[00446] (6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)(pyridin2-yl)(quinolin-2-yl)methanol was synthesized in the similar fashion with tert-butyl 4benzoyl-6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-1 H-benzo[d]imidazole-1 -carboxylate. C29H25N5O3. MS. m/z 492.2 (M+l).
168
[00447] C28H22N4O3. MS. m/z 463.1 (M+l). ). Ή NMR (400 MHz, Methanol-^) δ
8.78 (dd, J= 6.6, 1.0 Hz, IH), 8.66 (d, J= 8.8 Hz, IH), 8.47 (td, J= 8.8, 1.0 Hz, IH), 8.158.03 (m, 3H), 8.00 - 7.83 (m, 3H), 7.76 (t, J= 8.0 Hz, IH), 7.07 (d, J= 1.0 Hz, IH), 6.46 (d, ./ = 1.0 Hz, IH), 2.22 (s, 3H), 2.04 (s, 3H).
Example 156
1-tert-butyl 4-methyl 6-(3,5-dimethylisoxazoI-4-yl)-3-methyl-2-oxo-2,3-dihydro-lH· benzo [d] imidazole-1,4-dicarboxylate
N-O
[00448] Methyl 2-fluoro-3-nitrobenzoate (25g, 0.126 mol) was dissolved in DCM (400 ml) and to this was added Potassium carbonate (34.7 g, 0.25 mol) followed by Methylamine (20.63 ml, 0.5 mol). Reaction was stirred at room température under argon. Upon completion reaction was diluted with water and extracted with DCM (3x) then dried over magnésium sulfate. Solvents were removed under reduced pressure to afford methyl 2(methylamino)-3-nitrobenzoate as a yellow solid.
169
[00449] Methyl 2-(methylamino)-3-nitrobenzoate (25.5 g, 0.121 mol) was dissolved in acetic acid (100 ml) and DCM (40 ml). In a separate flask bromine (7.46 ml, 0.15 mol) was dissolved in acetic acid (15ml). The first solution was then slowly added to the bromine solution via an addition tunnel and the reaction was stirred for 90 minutes. At this point the reaction was poured onto ice (200 g). After the ice had melted DCM was added and the reaction was extracted with DCM (3x), dried over magnésium sulfate then solvents removed under reduced pressure to methyl 5-bromo-2-(methylamino)-3-nitrobenzoate as a bright orange solid.
[00450] Methyl 5-bromo-2-(methylamino)-3-nitrobenzoate (20.1 g, 96.5 mmol), 3,5dimethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)isoxazole (24.82 g, 111.25 mmol), PEPPSI-IPr catalyst (2.63 g, 3.86 mmol), Césium carbonate (67.96 g, 208.59 mmol), 1,2Dimethoxyethane (100 ml) and Water (30 ml) were mixed together and the solution degassed for 5 minutes before heating to 110°C for 1 hour. Reaction mixture was then cooled, diluted with EtAc and water and extracted EtAc (3x). Organics were washed with water then brine, dried over sodium sulfate and evaporated to diyness under reduced pressure. Crude material purified by silica gel chromatography using EtAc/Hex as the eluent to methyl 5-(3,5dimethylisoxazol-4-yl)-2-(methylamino)-3-nitrobenzoate (20.5 g, 96%).
[00451] To methyl 5-(3,5-dimethylisoxazol-4-yl)-2-(methylamino)-3-nitrobenzoate (2000 mg, 6.55 mmol) was added stannous chloride (3726.66 mg, 19.65 mmol) and Ethanol (100 ml) in a pressure tube. The suspension was then heated in sealed vessel to 120°C for 90 minutes at which point the reaction was cooled then stirred in a mixture of EtAc / IN NaOH for 1 hour or until précipitâtes form. Précipitâtes were filtered and crude mixture was diluted in EtAc and water and extracted 3x with EtAc. Organics were washed with water then brine, dried over sodium sulfate and evaporated to dryness under reduced pressure. Residue was purified by silica gel chromatography using MeOH/DCM as the eluent to afford methyl 3-amino-5-(3,5-dimethylisoxazol-4-yl)-2-(methylamino)benzoate as a dark foarm (1.1g, 61%)
Methyl 3-amino-5-(3,5-dimethylisoxazol-4-yl)-2-(methylamino)benzoate (1.1 g, 4 mmol) and l,l'-carbonyldiimidazole (1.3 g, 7.99 mmol) were stirred in Tetrahydrofuran (100 ml) in a sealed pressure vessel. Reaction was heated to 100°C and allowed to react overnight.Next day solvents were removed under reduced pressure. Material was slurried in minimal DCM, sonicated and filtered. Solids were air dried to afford methyl 6-(3,5-dimethylisoxazol-4-yl)170
3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazole-4-carboxylate as an off-white powder (417 mg, 35%).
[00452] Methyl 6-(3,5-dimethylisoxazol-4-yl)-3-methyl-2-oxo-2,3-dihydro- 1Hbenzo[d]imidazole-4-carboxylate (410 mg, 1.36 mmol) was dissolved in THF (10 ml) and to this was added Di-tert-butyl dicarbonate 97% (593.97 mg, 2.72 mmol) followed by 4(Dimethylamino)pyridine (33.25 mg, 0.27 mmol) and fmally Triethylamine (0.57 ml, 4.08 mmol). Reaction was allowed to stir at room température under argon for 3 hours, or until complété. Reaction was then diluted in EtAc and aqueous ammonium chloride and extracted with EtAc (3x). Organics were washed with ammonium chloride, water and brine and dried over sodium sulfate before evaporating to dryness. Crude material was purified by silica gel chromatography (EtAc / Hexanes as the eluent) to provide 1-tert-butyl 4-methyl 6-(3,5dimethylisoxazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazole-l,4-dicarboxylate as an opaque oil.
Example 157
5-(3,5-dimethylisoxazol-4-yl)-7-(hydroxydi(pyridin-2-yl)methyl)-l-methyl-lHbenzo [d] imidazol-2(3H)-one
[00453] To a dry, argon purged flask was added 5mL THF and 2-bromopyridine (0.06 ml, 0.62 mmol). Reaction was cooled to -78°C under argon and then slowly was added 1.6M
N-butyllithium in hexanes (0.43 ml) over 10 minutes. Lithio species was allowed to form for minutes at which point 1-tert-butyl 4-methyl 6-(3,5-dimethylisoxazol-4-yl)-3-methyl-2oxo-2,3-dihydro-lH-benzo[d]imidazole-l,4-dicarboxylate (50 mg, 0.12 mmol) in 0.5 mL
THF was added slowly. Reaction stirred at -78°C for 5 minutes then allowed to warm. When reaction vessel neared 0°C was quenched with IN HCl. Reaction was diluted with
171
EtAc/EbO and basified with IN NaOH until neutral. Mixture was extracted with EtAc (3x) then organics were washed with water then brine and dried over sodium sulfate. Solvents were removed under reduced pressure and crude mixture was purified by préparative HPLC to afford GS-650721 (1 lOmg, 21%).
[00454] C24H21N5O3; 428.1 (M+l). IH NMR (400 MHz, DMSO-d6) δ 11.09 (s, IH),
8.57 - 8.50 (m, 2H), 7.89 (t, J = 7.7 Hz, 2H), 7.55 (d, J = 8.0 Hz, 2H), 7.39 (t, J = 6.1 Hz, 2H), 6.97 (d, J = 1.7 Hz, IH), 5.86 (d, J = 1.7 Hz, IH), 2.76 (s, 3H), 2.18 (s, 3H), 1.97 (s, 3H).
Example 158,
Example 159, and
Example 160 f 4-(cyclopentyI(hydroxy)methyl)-6-(3,5-dimethyIisoxazol-4-yl)-lH-benzo[d]imidazoI2(3H)-one;
4-(dicyclopentyl(hydroxy)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol2(3H)-one;
and
4-(cyclopentanecarbonyl)-6-(3,5-dimethyIisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one
[00455] To a mixture containing methyl 6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3dihydro-lH-benzo[d]imidazole-4-carboxylate (60 mg, 0.21 mmol, 1 equiv.) and THF (3 mL) is added cylopentyl magnésium chloride (0.88 mL, 1.46 mmol, 7 equiv.) at 0°C for 5 min.
After completion, the reaction was quenched and extracted with EtOAc and washed with
172 water, saturated NH4CI. After drying with MgSO4, it was filtered and concentrated to dryness. Purification was carried out by reverse phase HPLC.
[00456] IH NMR (400 MHz, Methanol-d4) δ 6.96 (d, J = 1.5 Hz, IH), 6.88 (d, J = 1.6 Hz, IH), 4.66 (d, J = 8.3 Hz, IH), 2.39 (s, 3H), 2.24 (s, 3H), 1.93 - 1.80 (m, IH), 1.76 - 1.43 (m, 3H), 1.40 (s, OH), 1.28 (d, J = 8.3 Hz, IH). LCMS (m/z +1) 328.38
[00457] IH NMR (400 MHz, Methanol-d4) δ 6.94 - 6.68 (m, IH), 2.53 (s, 0H), 2.53 (d, J = 17.1 Hz, IH), 2.38 (s, 2H), 2.23 (s, 2H), 1.84 (dd, J = 12.4, 6.4 Hz, IH), 1.59 - 1.43 (m, 6H), 1.43-1.31 (m, 2H). LCMS (m/z +1) 396.49
[00458] IH NMR (400 MHz, Methanol-^) δ 7.59 (d, J = 1.5 Hz, IH), 7.19 (d, J = 1.5 Hz, IH), 3.86 (t, 7.8 Hz, IH), 2.43 (s, 3H), 2.27 (s, 3H), 2.02 - 1.89 (m, 4H), 1.71 (td, ./ =
5.4, 3.3 Hz, 4H).LCMS (m/z +1) 326.36
Example 161 and
Example 162 (6-(3,5-dimethylisoxazol-4-yl)-4-(3-hydroxypentan-3-yl)-lH-benzo[d]imidazol-2(3H)-one and methyl 6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3-dihydro-lH-benzo[d]imidazole-4carboxylate
[00459] Into a flask containing methyl 6-(3,5-dimethylisoxazol-4-yl)-2-oxo-2,3dihydro-lH-benzo[d]imidazole-4-carboxylate (60 mg, 0.21 mmol, 1 equiv.) is added cylopentylmagnesium chloride (0.88 mL, 1.46 mmol, 7 equiv., IM Hexanes) at 0°C for 5
173 min. After completion, the reaction was quenched and extracted with EtOAc and washed with water, saturated NELCl. After drying with MgSO4, it was filtered and concentrated to dryness. Purification was carried out by reverse phase HPLC to GS-646013 and GS-646012. IH NMR (400 MHz, Methanol-d4) Ô 7.07 - 6.91 (m, IH), 6.88 (d, J = 1.6 Hz, IH), 2.39 (s, 3H), 2.23 (s, 3H), 1.81 (td, J = 7.0, 3.6 Hz, 2H), 0.95 (t, J = 7.4 Hz, 3H). LCMS (m/z +1) 288.15
[00460] IH NMR (400 MHz, Methanol-d4) δ 7.55 (d, J = 1.6 Hz, IH), 7.18 (d, J = 1.6 Hz, IH), 3.97 (s, 3H), 2.40 (s, 3H), 2.24 (s, 3H). LCMS (m/z +1) 288.29
[00461] IH NMR (400 MHz, Methanol-d4) δ 6.86 (d, J = 1.5 Hz, IH), 6.74 (d, J = 1.5
Hz, IH), 2.39 (s, 3H), 2.23 (s, 3H), 1.94 (dd, J = 14.3, 7.3 Hz, 2H), 1.90 - 1.74 (m, 2H), 0.82 (t, J = 7.4 Hz, 7H). LCMS (m/z +1) 316.38
Example 163 and
Example 164
5-(3,5-dimethylisoxazol-4-yl)-l-methyl-7-(6-(trifluoromethyI)quinolin-7-yl)-lH- benzo[d]imidazol-2(3H)-one and
7-(6-(3,5-dimethylisoxazol-4-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-4-yl)-
6-(trifluoromethyl)quinoline 1-oxide
N-O
[00462] To a microwave vial containing 7-chloro-5-(3,5-dimethylisoxazol-4-yl)-lmethyl-lH-benzo[d]imidazol-2(3H)-one (100 mg, 0.36 mmol, 1 equiv.) was added 5(434,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-6-(trifluoromethyl)quinolone (350 mg, 1.08
174 mmol, 3 equiv.), CS2CO3 (704 mg, 2.16 mmol, 6 equiv.) and PEPPSI™-IPr catalyst (98 mg, 0.14 mmol, 0.4 equiv.) and dissolved in DME-H2O (4 mL, 0.2 M, 2/1, v/v). The mixture was heated tol20°C for 30 min in microwave. The reaction was concentrated in vacuo and purification was carried out by reverse phase EIPLC.
[00463] IH NMR (400 MHz, Methanol-d4) δ 9.03 (dd, J = 4.2, 1.6 Hz, IH), 8.32 (d, J = 9.1 Hz, IH), 8.19 (d, J = 9.0 Hz, IH), 7.97 - 7.76 (m, IH), 7.56 (dd, J = 8.6, 4.3 Hz, IH),
7.16 (d, J = 1.5 Hz, IH), 6.91 (d, J = 1.4 Hz, IH), 2.74 (s, 3H), 2.42 (s, 3H), 2.27 (s, 3H). LCMS (m/z +1)439.4
[00464] IH NMR (400 MHz, Methanol-d4) δ 9.19 (s, IH), 8.30 - 8.17 (m, IH), 8.07 7.85 (m, 3H), 7.67 (ddd, J = 8.3, 7.0, 1.2 Hz, IH), 6.79 (d, J= 1.3 Hz, IH), 5.88 (d, J= 1.3 Hz, IH), 3.81 (s, 3H), 2.05 (s, 3H), 1.86 (s, 3H). LCMS (m/z +1) 455.26
Example 165
4-(l-cyclopentyl-l-hydroxypropyl)-6-(3,5-dimethyIisoxazoI-4-yl)-lH-benzo[d]imidazol2(3H)-one
N-O
ο
N-O
O
[00465] Into a flask containing the ketone (25 mg, 0.077 mmol, 1 equiv.) is added ethyl magnésium bromide (0.28 mL, 0.28 mmol, 4 equiv., IM) at 0°C for 5 min. After completion, the reaction was quenched and extracted with EtOAc and washed with water, saturated NEUCl. After drying with MgSÛ4, it was filtered and concentrated to dryness. Purification was carried out by reverse phase HPLC.
[00466] 3H NMR (400 MHz, Methanol-i/4) δ 6.85 (d, J= 1.5 Hz, IH), 6.78 (s, IH), 2.41 (d, 16.9 Hz, 4H), 2.25 (d, J= 17.0 Hz, 4H), 2.03 - 1.68 (m, 4H), 1.50 (dtd, J= 29.4,
175
15.0, 13.9, 7.8 Hz, 5H), 0.76 (t, 7.4 Hz, 4H). 19F NMR (376 MHz, DMSO-i/e) δ -136.97 (d, J= 6.5 Hz). LCMS (M+l) 355.96
Example 166
5-(3,5-dimethylisoxazol-4-yl)-4-fluoro-7-(6-methylquinolin-5-yl)-lH-benzo[d]imidazol2(3H)-one
[00467] To a microwave vial containing 7-chloro-5-(3,5-dimethylisoxazol-4-yl)-4fluoro-lH-benzo[d]imidazol-2(3H)-one (16 mg, 0.057 mmol, 1 equiv.) was added 3,5- 6methylquinolin-5-ylboronic acid (53 mg, 0.28 mmol, 5 equiv.), CS2CO3 (11 lmg, 0.34 mmol, 6 equiv.) and PEPPSI™-IPr catalyst (7 mg, 0.0011 mmol, 0.2 equiv.) and dissolved in DMEH2O (20 mL, 0.2 M, 2/1, v/v). The mixture was heated to 140 °C. After 2 h, the reaction was complété. After cooling, the reaction was extracted with EtOAc and washed with water, saturated NH4CI. After drying with MgSO4, it was filtered and concentrated to dryness. The resulting solid was washed with EtOAc. Purification was carried out by reverse phase HPLC to fùrnish 5-(3,5-dimethylisoxazol-4-yl)-4-fluoro-7-(6-methylquinolin-5-yl)-lHbenzo [d] imidazol-2(3 H)-one.
[00468] IH NMR (400 MHz, DMSO-d6) δ 11.42 (d, J = 1.8 Hz, IH), 10.63 (s, IH),
8.82 (dd, J = 4.2, 1.6 Hz, IH), 7.99 (d, J = 8.6 Hz, IH), 7.79 - 7.56 (m, 2H), 7.40 (dd, J = 8.5,
4.2 Hz, IH), 6.77 (d, J = 6.6 Hz, IH), 2.34 (d, J = 0.9 Hz, 3H), 2.24 (s, 3H), 2.17 (d, J = 0.9 Hz, 3H).
[00469] 19F NMR (376 MHz, DMSO-d6) δ -136.97 (d, J = 6.5 Hz). LCMS (m/z +1)
389.28
176
Example 167 and
Example 168 (7R and 7S)-5-(3,5-dimethylisoxazol-4-yl)-4-fluoro-7-(6-methylquinolin-5-yl)-lHbenzo[d]imidazol-2(3H)-one
[00470] The racemate of Example 166 was separated with super critical column chromatography (JASCO SFC) using DAICEL AD-H (10 mm x 250 mm, 20% MeOH, 15 mL/min, 40°C, 15 atm). RT 2.733 min, 1.9 mg (GS-649951). RT 3.742 min, 2.6 mg.
Example 169
5-(3,5-dimethyIisoxazoI-4-yl)-4-fluoro-7-(hydroxydi(pyridin-2-yl)methyI)-lH- benzo [d] imidazol-2(3H)-one
Step 1: Methyl 2-amino-5-(3,5-dimethylisoxazol-4-yl)-4-fluorobenzoate
[00471] To methyl 2-amino-5-bromo-4-fluorobenzoate (20g, 80.6 mol.) and 3,5Dimethylisoxazole-4-boronic acid pinacol ester (24.2g, 108.9 mol., 1.35 mmol) was added to a solvent mixture of 1,2-dimethoxymethane (120ml) and water (60 ml). To the above mixture were added PEPPSI-Ipr (3120 mg, 4.2 mmol, 0.05 equiv.) and CS2CO3 (78.8 g, 241 mol., 3 equiv.). The reaction mixture was heated at 120°C for 2 h in a pressure tube. The reaction
177 mixture was then diluted with EtOAc (100 ml), washed with bring (50mlX2). The organic solvent was evaporated and the residue was dissolved in DCM and purified with combi-flash column chromatography (product came out at 50% EtOAc/Hexane) to afford methyl 2amino-5-(3,5-dimethylisoxazol-4-yl)-4-fluorobenzoate.
[00472] 1HNMR (400 MHz, Chloroform-d) δ 7.79 (dd, J = 8.1, 1.2 Hz, IH), 6.80 6.60 (m, IH), 3.90 (s, 4H), 2.34 (d, J = 8.3 Hz, 4H), 2.20 (d, J = 5.5 Hz, 4H). 19F NMR (377 MHz, Chloroform-d) δ -96.83 - -101.99 (m), -105.54 (d, J = 13.8 Hz). LCMS (m/z +1) 265.32.
Step 2: Methyl 2-amino-5-(3,5-dimethylisoxazol-4-yl)-4-fluoro-3-nitrobenzoate
[00473] To a mixture of methyl 2-amino-5-(3,5-dimethylisoxazol-4-yl)-4fluorobenzoate (14g, 53 mmol, 1 equiv.) and TFA (100 mL) is slowly added nitronium tetrafluoroborate (9.1 g, 68.9 mmol, 1.3 equiv.). After completion, the mixture was concentrated under reduced pressure. The residue was dissolved and then the residue was dissolved in EtOAc (200 ml) and washed with brine (30mlX2). The organic solvent was evaporated. Methyl 2-amino-5-(3,5-dimethylisoxazol-4-yl)-4-fluoro-3-nitrobenzoate was used without further purification. 'H NMR (400 MHz, Chloroform-d) δ 6.92 (d, J = 5.8 Hz, IH), 4.24 (s, 4H), 4.07 - 3.85 (m, 5H), 2.46 - 2.34 (m, 4H), 2.31 - 2.22 (m, 5H).
[00474] 19F NMR (377 MHz, Chloroform-d) δ -76.44, -121.12 (d, J = 5.7 Hz). LCMS (m/z+1) 310.2
Step 3: Methyl 2,3-diamino-5-(3,5-dimethylisoxazol-4-yl)-4-fluorobenzoate
178
[00475] Into a pressure tube containing N-methyl 2-amino-5-(3,5-dimethylisoxazol-4yl)-4-fluoro-3-nitrobenzoate (16.5 g, 53.2 mol., 1 equiv.) is added EtOH (200 mL) and tin (II) chloride (20.2 g, 107 mol., 2 equiv.). The reaction was heated for 3 h at 130 °C. The reaction was then stirred in 2N NaOH solution for 20 minutes before being partitioned between water and ethyl acetate. The organic layer was washed with brine and dried over sodium sulfate. Purification was carried out by flash column chromatography to furnish methyl 2,3-diamino-
5-(3,5-dimethylisoxazol-4-yl)-4-fluorobenzoate (5700 mg, 39 %). LCMS (m/z +1) 270.2.
Step 4:
N-O
N-O
[00476] A flask containing 2-bromopridine (135 pL, 1.37 mmol, 7 equiv.) and THF (3 mL) is cooled to -78 °C before BuLi (0.86 mL, 1.37 mmol, 7 equiv.) is added. After 30 min, methyl 6-(3,5-dimethylisoxazol-4-yl)-7-fluoro-2-oxo-2,3-dihydro-lH-benzo[d]imidazole-4carboxylate (60 mg, 0.197 mmol, 1 equiv.) dissolved in THF (2 mL) is added to the reaction mixture. After completion, the reaction was quenched and extracted with EtOAc and washed with water, saturated NH4CI. After drying with MgSÛ4, it was filtered and concentrated to dryness. Purification was carried out by reverse phase HPLC.
[00477] IH NMR (400 MHz, Methanol-d4) δ 8.62 (dd, J = 5.3, 1.6 Hz, 2H), 8.13 (t, J = 8.0 Hz, 2H), 7.84 (d, J = 8.1 Hz, 2H), 7.60 (dd, J = 7.6, 5.3 Hz, 2H), 6.43 (d, J = 6.4 Hz, IH), 2.24 (s, 3H), 2.07 (s, 3H). 19F NMR (377 MHz, Methanol-d4) δ -77.88, -137.06. LCMS (m/z+1) 431.92
179
Example 170,
Example 171, and
Example 172
5-(3,5-dimethylisoxazol-4-yl)-4-fluoro-7-(hydroxydi(pyridin-2-yl)methyl)-lH- benzo[d]imidazol-2(3H)-one;
7-((lH-imidazol-l-yl)di(pyridin-2-yl)methyl)-5-(3,5-dimethylisoxazol-4-yl)-4-fluoro-lH- benzo [d] imidazoI-2(3H)-one;
and
7-(di(pyridin-2-yl)methyl)-5-(3,5-dimethylisoxazol-4-yl)-4-fluoro-lH-benzo[d]imidazol-
2(3H)-one
[00478] Alternatively, the tiltle compound was made from (2,3-diamino-5-(3,5dimethylisoxazol-4-yl)-4-fluorophenyl)di(pyridin-2-yl)methanol. Into a microwave vial containing (2,3-diamino-5-(3,5-dimethylisoxazol-4-yl)-4-fluorophenyl)di(pyridin-2yl)methanol (50 mg, 0.12 mmol, 1 equiv.) is added THF (5 m) and CDI (30 mg, 0185 mmol,
1.5 equiv.). The mixture was heated to 120°C for 30 minutes in a microwave reactor. The reaction was concentrated in vacuo and purified by HPLC.
[00479] IH NMR (400 MHz, Methanol-d4) δ 8.65 (ddt, J = 5.4, 1.6, 0.7 Hz, 2H),
8.33 - 8.14 (m, 2H), 7.92 (dt, J = 8.1, 0.9 Hz, 2H), 7.68 (ddt, J = 7.3, 5.4, 0.9 Hz, 2H), 6.39 (d, J = 6.4 Hz, IH), 2.24 (s, 4H), 2.06 (s, 4H). 19F NMR (377 MHz, Methanol-d4) δ -77.95 , 136.55 (d, J = 6.2 Hz).
[00480] LCMS (m/z+1) 431.92
[00481] IH NMR (400 MHz, Methanol-d4) δ 9.50 (t, J = 1.5 Hz, 0H), 8.67 (ddd, J =
4.8, 1.8, 0.9 Hz, IH), 7.96 - 7.79 (m, IH), 7.54 (t, J = 1.8 Hz, 0H), 7.47 (ddd, J = 7.7, 4.7, 0.9
180
Hz, IH), 7.03 (dd, J = 8.1, 1.0 Hz, IH), 5.92 (d, J = 6.3 Hz, OH), 2.23 (d, J = 0.9 Hz, IH), 2.05 (d, J = 0.9 Hz, IH).
[00482] 19F NMR (377 MHz, Methanol-d4) δ -77.74, -134.19 (d, J = 6.2 Hz). LCMS (m/z+1) 482.17
[00483] IH NMR (400 MHz, DMS0-d6) δ 7.70 (dt, J = 4.8, 1.3 Hz, IH), 6.98 (td, J =
7.8, 1.9 Hz, IH), 6.50 (ddd, J = 7.6, 4.9, 1.1 Hz, IH), 6.45 (d, J = 7.9 Hz, IH), 5.83 (d, J = 6.5 Hz, IH), 5.16 (s, IH), 1.44 (d, J = 0.9 Hz, 2H), 1.27 (d, J = 0.8 Hz, 2H). 19F NMR (377 MHz, DMS0-d6) δ -78.29, -128.15, -140.19 (d, J = 6.3 Hz). LCMS (m/z+1) 416.19.
Example 173 and
Example 174
6-(3,5-dimethylisoxazol-4-yl)-4-(3-hydroxy-2,4-dimethylpentan-3-yl)-lH- benzo [d] imidazol-2(3H)-one and
6-(3,5-dimethylisoxazol-4-yl)-4-isobutyryl-lH-benzo[d]imidazol-2(3H)-one
THF
[00484] Methyl 6-(3,5-dimethylisoxazol-4-yi)-2-oxo-2,3-dihydro-lHbenzo[d]imidazole-4-carboxylate (100 mg, 0.35 mmol) was dissolved in 5 mL of THF and stirred at room température followed by the addition of isopropylmagnesium bromide (0.87 mL, 2.0 mmol). Addition Grignard was added in 1 hour intervals until the starting material was consumed. Once complété, the crude reaction mixture was quenched with DI water and extracted 3x with ethyl acetate. Combined organic layers were washed with brine, dried over sodium sulphate, filtered, concentrated in vacuo, and purified via HPLC.
181
[00485] C19H25N3O3; 344.2 (m/z +1). IH NMR (400 MHz, cd3od) 5 6.88 (d, J = 1.4
Hz, IH), 6.70 (s, IH), 2.39 (s, 3H), 2.34 (dd, J = 13.4, 6.7 Hz, 2H), 2.23 (s, 3H), 0.91 (d, J = 6.7 Hz, 6H), 0.85 (d, J = 6.8 Hz, 6H).
[00486] C16H17N3O3; 300.1 (m/z +1). ’H NMR (400 MHz, cd3od) δ 7.59 (s, IH),
7.20 (d, J= 1.3 Hz, IH), 3.68 (dt, J= 13.6, 6.8 Hz, IH), 2.43 (s, 3H), 2.27 (s, 3H), 1.23 (d, J = 6.8 Hz, 6H).
Example 175
6-(3,5-dimethylisoxazoI-4-yl)-4-(l-hydroxy-l-(pyridin-2-yl)pentyl)-lH- benzo [d] imidazol-2(3H)-one
[00487] A solution of tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-picolinoyllH-benzo[d]imidazole-l-carboxylate was treated with n-BuLi (1.5 equiv) at -78°C. The reaction was stirred for 15 minutes and quenched with IM HCl, concentrated, dissolved in éthanol (1 mL) and 4M HCl in dioxane (0.5 mL) and heated to 80°C for lh. The reaction mixture was concentrated and purified by reverse-phase HPLC to give the desired product.
[00488] C22H24N4O3. 393.1 (M+l). IHNMR (400 MHz, DMSO-d6) δ 10.68 (s,
IH), 9.89 (d, J= 1.9 Hz, IH), 8.56 (d, ./ = 4.9 Hz, IH), 7.88 (d, J= 7.7 Hz, 2H), 7.37 (s, IH), 6.96 (d, J= 1.6 Hz, IH), 6.74 (d, J= 1.5 Hz, IH), 2.34 (m, 4H), 2.15 (s, 3H), 1.37- 1.22 (m, 4H), 1.22 - 1.01 (m, IH), 0.80 (t, J= 7.0 Hz, 4H).
182
Example 176
[00489] A solution of tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-picolinoyllH-benzo[d]imidazole-l-carboxylate (360 mg, 0.79 mmol) and p-Toluenesulfonylmethyl isocyanide (183.95 mg, 0.94 mmol) in methanol (5 mL) was stirred at room température ovemight. The reaction mixture was concentrated and IM aqueous HCl (3 mL) and concentrated HCl (3 mL) was added. The reaction mixture was stirred for 30 minutes, concentrated and purified by reverse-phase HPLC to give 2-(6-(3,5-dimethylisoxazol-4-yl)-2ethoxy-lH-benzo[d]imidazol-4-yl)-2-hydroxy-2-(pyridin-2-yl)acetaldehyde.
[00490] Ethyl magnesiumbromide (3M, 0.61 mL, 1.84 mmol) was added to a solution of 2-(6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-lH-benzo[d]imidazol-4-yl)-2-hydroxy-2(pyridin-2-yl)acetaldehyde (120 mg, 0.31 mmol) in methyl-THF at 0°C. After 15 min, the reaction mixture was quenched with IM HCl, concentrated and a portion of this material was purified by reverse-phase HPLC to give the major diastereomer 4-(l,2-dihydroxy-l-(pyridin2-yl)butyl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one.
[00491] 4-( 1,2-dihydroxy-1 -(pyridin-2-yl)butyl)-6-(3,5-dimethylisoxazol-4-yl)-1Hbenzo[d]imidazol-2(3H)-one.
[00492] C21H22N4O4. 395.1 (M+l). IH NMR (400 MHz, DMSO-t/e) δ 10.73 10.59 (m, IH), 9.81 (s, IH), 8.63 (d, J= 4.7 Hz, IH), 8.04 (s, IH), 7.79 (d, J= 7.9 Hz, IH),
7.50 (s, IH), 7.11 (d,J= 1.7 Hz, IH), 6.77 (s, IH), 4.39 (d, J= 9.6 Hz, IH), 2.34 (s, 3H),
2.15 (s, 3H), 1.40- 1.14 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H).
183
[00493] Dess-Martin Periodinane (90 mg, 0.24 mmol) was added to a solution of 4( 1,2-dihydroxy-1 -(pyridin-2-yl)butyl)-6-(3,5-dimethylisoxazol-4-yl)- lH-benzo[d]imidazol2(3H)-one (50 mg, 0.12 mmol) in a mixture of dichlormethane and THF. The reaction was stirred for 72 h at room température, concentrated and purified by reverse-phase HPLC. A portion of this product was dissolved in concentrated HCl (0.1 mL) and éthanol (1 mL), heated at 80°C for 3 h and concentrated to give 6-(3,5-dimethylisoxazol-4-yl)-4-(l-hydroxy2-oxo-1 -(pyridin-2-yl)butyl)- lH-benzo[d]imidazol-2(3H)-one.
[00494] C21H20N4O4. 393.1 (M+l). IH NMR (400 MHz, DMSO-d6) δ 10.73 (s,
IH), 9.87 (s, IH), 8.62 - 8.39 (m, IH), 7.89 (t, J= 7.9 Hz, IH), 7.61 (d, J= 7.9 Hz, IH), 7.50 - 7.27 (m, IH), 6.83 (s, IH), 6.40 (s, IH), 2.83 (dd, J= 18.2, 8.0 Hz, 2H), 2.27 (s, 3H), 2.07 (s, 3H), 0.91 (t, J= 7.2 Hz, 3H).
Example 177
6-(3,5-dimethylisoxazol-4-yl)-4-(5,5,5-trifluoro-l,2-dihydroxy-l-(pyridin-2-yl)pentyl)-
H-benzo [d] imidazol-2(3H)-one
N-O
[00495] The following two diastereomers were likewise prepared using trifluoromethylethylmagnesium bromide in place of ethylmagnesium bromide.
[00496] Major diastereomer: C22H21F3N4O4. 463.1 (M+l). *H NMR (400 MHz, DMSO-riô) δ 10.67 (s, IH), 9.80 (d, J= 6.8 Hz, IH), 8.59 (s, IH), 7.91 (s, IH), 7.76 (s, IH), 7.39 (s, IH), 7.06 (s, IH), 6.76 (s, IH), 4.58 (d, J= 9.9 Hz, IH), 2.40-2.50 (m, 2H), 2.42 2.30 (m, 3H), 2.13 (s, 3H), 1.48 (m, 2H).
[00497] Minor diastereomer: C22H21F3N4O4. 463.1 (M+l). *H NMR (400 MHz, DMSO-i/e) δ 10.59 (s, IH), 10.03 (s, IH), 8.56 (dd, J= 5.4, 1.7 Hz, IH), 7.52 (s, IH), 6.64 (d,
184
J= 1.6 Hz, IH), 6.41 (s, IH), 5.07 (s, IH), 2.40 (m, 2H) 2.17 (s, 3H), 1.99 (s, 3H), 1.65 (d, J = 15.9 Hz, 2H).
Example 178
6-(3,5-dimethylisoxazol-4-yl)-4-(2,2,3,3,3-pentafluoro-l-hydroxypropyl)-lHbenzo [d] imidazol-2(3H)-one
[00498] A solution of tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy-4-formyl-lHbenzo[d]imidazole-l-carboxylate (100 mg, 0.26 mmol), pentafluoroiodoethane (350 mg, 1.42 mmol) and DM F was cooled to -15°C under nitrogen. Tetra(dimethlamino)ethylene was added (0.33 mL, 1.42 mmol) and the reaction mixture was irradiated with a sun lamp. A thick precipitate formed, and after 30 minutes, the reaction mixture was diluted with ethyl acetate fdtered. The filtrate was washed with water and the organic layer was concentrated and dissolved in éthanol (3 mL) and 4M HCl in dioxane (1 mL) and heated to 70°C for lh. The reaction mixture was concentrated and purified by reverse-phase HPLC to give the desired product as a white powder.
[00499] C15H12F5N3O3. 378.1 (M+l). 1HNMR (400 MHz, DMSO-d6) δ 11.02 (d,
J = 2.0 Hz, IH), 10.82 (s, IH), 7.14 - 6.64 (m, 3H), 5.64 - 5.45 (m, IH), 2.36 (s, 3H), 2.18 (s, 3H).
185
Example 179
6-(3,5-dimethylisoxazol-4-yl)-4-(2,2,2-trifluoro-l-hydroxyethyl)-lH-benzo[d]imidazol2(3H)-one
[00500] The following compound was likewise prepared from trifluoroiodomethane to give 6-(3, 5-dimethylisoxazol-4-yl)-4-(2,2,2-trifluoro-1 -hydroxyethyl)- lH-benzo[d]imidazol2(3H)-one as a white powder.
[00501] C14H12F3N3O3. 328.1 (M+l). IHNMR (400 MHz, DMSO-d6) δ 10.95 10.85 (m, IH), 10.82 (d, J = 1.9 Hz, IH), 7.11 - 7.00 (m, IH), 6.90 (dd, J = 13.1, 3.6 Hz,
2H), 5.43 (d, J =8.0 Hz, IH), 2.35 (s, 3H), 2.17 (s, 3H).
Example 180
4-(l,6-dihydroxy-2-oxo-l-(pyridin-2-yl)hexyi)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo [d] imidazol-2(3H)-one
[00502] The following compound was isolated as a side product from the previous sériés of reactions:
[00503] C23H24N4O5. 437.1 (M+l). ’HNMR (400 MHz, DMSO-î/6) δ 10.74 (d, J =
1.9 Hz, IH), 9.89 (d, J= 1.9 Hz, IH), 8.53 (dd, J= 5.0, 1.5 Hz, IH), 7.87 (td, J= 7.7, 1.7 Hz,
186
IH), 7.60 (d, J= 8.0 Hz, IH), 7.37 (dd, J= 7.5, 4.8 Hz, IH), 6.96 (s, IH), 6.85 - 6.77 (m,
IH), 6.41 (d, J= 1.5 Hz, IH), 3.27 (t, J= 6.5 Hz, 2H), 2.82 (ddd, J= 17.9, 8.6, 6.2 Hz, IH),
2.45 - 2.36 (m, IH), 2.26 (s, 3H), 2.07 (s, 3H), 1.55 - 1.34 (m, 2H), 1.29 (td, J= 8.8, 4.6 Hz, 2H).
Example 1S1
6-(3,5-dimethylisoxazol-4-yl)-4-(2-ethoxy-l-hydroxy-l-(pyridin-2-yl)propyl)-lHbenzo [d] imidazol-2(3H)-one
[00504] Prepared analagously to give 6-(3,5-dimethylisoxazol-4-yl)-4(hydroxy(pyridin-2-yl)(tetrahydro-2H-pyran-2-yl)methyl)-lH-benzo[d]imidazol-2(3H)-one using ethyl vinyl ether in place of 2,3-dihydro-2H-pyran.
[00505] C22H24N4O4. 409.1 (M+l). IH NMR (400 MHz, DMSO-d6) δ 10.67 (d, J =
2.1 Hz, IH), 9.72 (s, IH), 8.69 - 8.55 (m, IH), 7.87 (t, J = 7.6 Hz, IH), 7.73 (d, J = 8.1 Hz,
IH), 7.36 (d, J = 7.2 Hz, IH), 7.15 (d, J= 1.5 Hz, IH), 6.77 (d, J= 1.5 Hz, IH), 4.50 (q, J =
6.1Hz, IH), 3.62-3.44 (m, IH), 3.26 - 3.09 (m, IH), 2.36 (s, 3H), 2.18 (s, 3H), 1.02-0.85 (m, 6H).
187
Example 182 l-(6-(2-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][l,2,4]triazoIo[4,3a][l,4]diazepiii-6-yl)acetyl)hydrazinyl)-6-oxohexyl)-3,3-dimethyl-2-((lE,3E,5E)-5-(l,3,3trimethylindolin-2-ylidene)penta-l,3-dieii-l-yl)-3H-indol-l-ium
Cl
[00506] 2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2f][l,2,4]triazolo[4,3-a][l,4]diazepin-6-yl)acetic acid (7 mg, 0.018 mmol) was dissolved in lml DMF, to the solution was added HATU (lOmg, 0.027 mmol) and the reaction mixture was stirred at RT for 30mins, then to the reaction mixture was added l-(6-hydrazinyl-6oxohexyl)-3,3 -dimethyl-2-(( lE,3E,5E)-5-(l,3,3 -trimethylindolin-2-ylidene)penta-1,3 -dien-1 yl)-3H-indol-l-ium (5mg, 0.009 mmol) at RT. The reaction was stirred at RT ovemight. The solvent was then evaporated, the residue was purified with Prep HPLC to afford 3.6 mg product l-(6-(2-(2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2f][4 ,2,4]triazolo[4,3-a][l,4]diazepin-6-yl)acetyl)hydrazinyl)-6-oxohexyl)-3,3-dimethyl-2((lE,3E,5E)-5-(l,3,3-trimethylindolin-2-ylidene)penta-l,3~dien-l-yl)-3H-indol-l-ium.
[00507] CsiHseClNsOaS. 879.4 (M-l). ’HNMR (400MHz, CD3OD) δ 7.18-7.10 (m,
2H), 6.44-6.38 (m, 4H), 6.35-6.28 (m, 4H), 6.22-6.17 (m, 5H), 5.58-5.45 (m, IH), 5.23-5.17 (m, 2H), 3.62-3.58 (m, IH), 3.08-2.97 (m, 2H), 2.58-2.52 (m, IH), 2.48 (s, 3H), 2.22 (s, 3H),
1.60 (s, 3H), 1.38 (s, 3H), 1.23-1.20 (m, 2H), 0.82-0.65 (m, 4H), 0.62-0.60 (m, 12H), 0.54-0.48 (m, 2H).
188
Example 183
4-((6-(dimethylamino)pyridin-2-yl)(hydroxy)(pyrîdin-2-yl)methyl)-6-(3,5dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one
[00508] A procedure similar to that used for 6-(3,5-dimethylisoxazol-4-yl)-4(hydroxy(6-methylpyridin-2-yl)(pyridin-2-yl)methyl)-lH-benzo[d]imidazol-2(3H)-one, using 6-bromo-2-N,N-dimethylaminopyridine as the starting material was used to produce the intermediate (C32H36N6O5, 585.2 (M+l)), which was taken directly to the deprotection step to yield the title compound as a yellow oil.
[00509] C25H24N6O3. 457.1 (M+l). !H NMR (400 MHz, Chloroform-ri) δ 8.78 (ddd, J = 5.4, 1.7, 0.9 Hz, IH), 8.30 (td, J= 7.9, 1.7 Hz, IH), 8.03 (dt, J= 8.2, 1.0 Hz, IH), 7.87 (dd, J=8.9, 7.4 Hz, IH), 7.78 (ddd, J= 7.7, 5.3, 1.2 Hz, IH), 7.24 (t, J= 7.5 Hz, IH), 7.03 (d,J =
1.5 Hz, IH), 6.96 (dd, 9.0, 0.8 Hz, IH), 6.58 (d, 1.5 Hz, IH), 3.20 (s, 6H), 2.30 (s,
3H), 2.13 (s, 3H).
Example 184
6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(pyridin-2-yl)(3(trifluoromethyl)phenyl)methyl)-lH-benzo[d]imidazol-2(3H)-one
[00510] A procedure analogous to 6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(6methylpyridin-2-yl)(pyridin-2-yl)methyl)-lH-benzo[d]imidazol-2(3H)-one was used to synthesize the intermediate (C32H31F3N4O5, 609.2 (M+l)) which was immediately taken on to the deprotection step to yield a yellow solid.
189
[00511] C25H19F3N4O3. 481.1 (M+l). ’HNMR (400 MHz, Methanol-A) δ 8.77 -
8.69 (m, IH), 8.22 (td, J= 7.9, 1.7 Hz, IH), 7.76 (s, IH), 7.72 (ddt, J= 9.2, 6.6, 3.1 Hz, 3H), 7.59 (t, J= 7.8 Hz, IH), 7.51 (d, J= 8.1 Hz, IH), 7.05 (d, .7 = 1.5 Hz, IH), 6.43 (d, J= 1.5 Hz, IH), 2.27 (s, 3H), 2.10 (s, 3H).
Example 185
4-((4-chlorophenyl)(hydroxy)(pyridin-2-yl)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo [d] imidazol-2(3H)-one
[00512] A procedure similar to 6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(6methylpyridin-2-yl)(pyridin-2-yl)methyl)-lH-benzo[d]imidazol-2(3H)-one was used to synthesize the intermediate (C31H31CIN4O5, 575.2 (M+l)) which was taken directly to the deprotection step to yield a yellow solid (9.8 mg).
[00513] C24H19CIN4O3. 447.1(M+1). ’H NMR (400 MHz, Methanol^) δ 8.71 (ddd,
J= 5.3, 1.7, 0.9 Hz, IH), 8.19 (td, J = 7.9, 1.7 Hz, IH), 7.74 - 7.66 (m, 2H), 7.44 - 7.38 (m,
2H), 7.33 - 7.28 (m, 2H), 7.03 (d, J= 1.5 Hz, IH), 6.48 (d, J= 1.5 Hz, IH), 2.29 (s, 3H),
2.12 (s, 3H).
190
Example 186
4-((6-aminopyridin-2-yl)(hydroxy)(pyridin-2-yl)methyl)-6-(3,5-dimethylisoxazol-4-yl)lH-benzo[d]imidazol-2(3H)-one
In a 2-neck, 50-mL round-bottom flask, a solution of 2-amino-6-bromopyridine (265.5 mg, 1.535 mmol) and l,2-bis(chlorodimethylsilyl)ethane (329.9 mg, 1.532 mmol) in 2methyltetrahydrofuran (12 mL) were cooled to -78°C while stirring under a nitrogen atmosphère. A solution of «-butyHithium (1.42 M in hexanes, 3.26 mL, 2.30 mmol) was added dropwise in 4 equal fractions (waiting five minutes in between) and the reaction mixture was stirred for 30 minutes after the final addition. A solution of tert-butyl 6-(3,5dimethylisoxazol-4-yl)-2-ethoxy-4-picolinoyl- lH-benzo[d]imidazole-1 -carboxylate (3 00.8 mg, 0.6504 mmol) in 2-methyltetrahydrofiiran (1.5 mL) was added dropwise. The reaction mixture was stirred for 45 minutes while warming to room température or until reaction completion. The reaction mixture was quenched with brine and diluted with ethyl acetate. The organic layer was separated and saved and the aqueous layer was extracted with ethyl acetate (three times, 40 mL each). The organic fractions were combined, dried over MgSO4, filtered and concentrated. The crude product was taken directly to the deprotection step. C25H24N6O3. 457.2 (M+l).
[00514] The crude material was dissolved in éthanol (15 mL) and transferred to a micro wave vial. Hydrochloric acid was added (4M in dioxane, 1.6 mL, 6.4 mmol) and the reaction vial was sealed and heated at 70°C for 2 hours. The reaction mixture was cooled to room température and concentrated to yield a brown oil, which was triturated with dichloromethane. The remaining oil was taken up in acetonitrile and concentrated to yield a yellow-white solid, which was further purified by preparatory HPLC to yield a yellow oil.
[00515] C23H20N6O3. 429.1 (M+l). Rf = 0.2 in 20% MeOH:DCM. Ή NMR (400
MHz, MethanoW4) δ 8.67 (ddd, 5.0, 1.8, 0.9 Hz, IH), 7.96 (td, J= 7.8, 1.8 Hz, IH), 7.85 (dd, J= 9.0, 7.4 Hz, IH), 7.70 (dt, J= 8.0, 1.0 Hz, IH), 7.47 (ddd, J= 7.6, 4.8, 1.1 Hz, IH),
191
7.04 (d, J= 1.5 Hz, IH), 6.97 (dd, J= 9.0, 1.0 Hz, IH), 6.66 (dd, J= ΊΑ, 1.0 Hz, IH), 6.42 (d, J= 1.5 Hz, IH), 2.28 (s, 3H), 2.11 (s, 3H).
Example 187 l-acetyI-4-((6-aminopyridin-2-yl)(hydroxy)(pyridin-2-yl)methyl)-6-(3,5dimethyIisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one
O O
eq.
4-(dimethylamino)pyridine (2 eq.) triethylamine (3 eq.)
DMF, OC, 30 min
[00516] To a microwave vial capped with a septum, 4-(dimethylamino)pyridine (5.8 mg, 0.047 mmol) and triethylamine (9 pL, 0.07 mmol) in N,N-dimethylformamide (0.5 mL) were cooled to 0°C in a nitrogen atmosphère. Acetic anhydride (4.4 pL, 0.047 mmol) was added and the reaction mixture was stirred for 15 minutes at 0°C before a solution of 4-((6aminopyridin-2-yl)(hydroxy)(pyridin-2-yl)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lHbenzo[d]imidazol-2(3H)-one (10 mg, 0.023 mmol) in N,N-dimethylformamide (0.25 mL) was added dropwise to the reaction mixture. The reaction was allowed to warm to room température and stirred for thirty minutes (or until completion). The reaction was quenched with water and diluted with ethyl acetate. The organic layer was separated and saved and the organic layer was extracted with ethyl acetate (three times, 20 mL each). The organic fractions were collected, dried over MgSCU, filtered and concentrated. The product was isolated by preparatory HPLC to yield a clear oil.
[00517] C25H22N6O4. 471.1 (M+l). ’HNMR (400 MHz, Methanolé) δ 8.68 (d, J=
4.8 Hz, IH), 8.18 (d,J= 1.6 Hz, IH), 8.02-7.93 (m, IH), 7.85 (dd,J=9.0, 7.4 Hz, IH),
7.72-7.65 (m, IH), 7.52-7.43 (m, IH), 6.98 (dd,J=9.2, 1.0 Hz, IH), 6.68 - 6.61 (m, IH),
6.57 (d, J= 1.6 Hz, IH), 2.70 (s, 3H), 2.30 (s, 3H), 2.11 (s, 3H).
192
Example 188
4-((6-aminopyridin-2-yl)(hydroxy)(pyridin-2-yI)methyl)-l-(cyclopropanecarbonyl)-6(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one
[00518] A procedure similar to l-acetyl-4-((6-aminopyridin-2-yl)(hydroxy)(pyridin-2yl)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one was used.
[00519] C27H24N6O4. 497.2 (M+l). ‘H NMR (400 MHz, Methanol-A) δ 8.68 (ddd, J = 4.9, 1.8, 0.9 Hz, IH), 8.13 (d, J= 1.6 Hz, IH), 7.97 (td, J= 7.8, 1.8 Hz, IH), 7.85 (dd, J =
9.0,7.4 Hz, IH), 7.69 (dt, J= 8.0, 1.0 Hz, IH), 7.48 (ddd, J= 7.6, 4.8, 1.1 Hz, IH), 7.25 7.08 (m, 2H), 6.98 (dd, J= 8.9, 1.0 Hz, IH), 6.65 (dd, J= 7 A, 1.0 Hz, IH), 6.56 (d, J= 1.6 Hz, IH), 3.48 (ddd, J= 8.0, 4.6, 3.2 Hz, IH), 2.29 (s, 3H), 2.10 (s, 3H), 1.21 (dt, J= 5.2, 3.4 Hz, 2H), 1.15-1.06 (m, 2H).
Example 189
6-(3,5-dimethylisoxazol-4-yl)-4-(hydroxy(6-(methylamino)pyridin-2-yl)(pyridin-2yl)methyl)-lH-benzo[d]imidazol-2(3H)-one
193
[00520] To a 50-mL, 2-neck round-bottom flask, 6-bromo-N-methylpyridin-2-amine (41.5 mg, 0.222 mmol) and chlorotrimethylsilane (29 pL, 0.23 mmol) were dissolved in tetrahydrofuran (2 mL). The cloudy white suspension was stirred under nitrogen for thirty minutes at room température. The reaction mixture was then cooled to -78°C before a 1.6 M π-butyllithium solution in hexanes (0.23 mL, 0.37 mmol) was added dropwise and the solution was stirred for thirty minutes. A solution of tert-butyl 6-(3,5-dimethylisoxazol-4yl)-2-ethoxy-4-picolinoyl-12/-benzo[</]imidazole-l-carboxylate in tetrahydrofuran (1 mL) was added dropwise and the reaction was warmed to ambient température and stirred for twenty minutes or until reaction completion. The reaction mixture was quenched with brine and diluted with ethyl acetate. The organic layer was separated and saved and the aqueous layer was neutralized and subsequently extracted with ethyl acetate twice. The combined organic fractions were dried over sodium sulfate, decanted and concentrated. The crude intermediate was taken directly to the deprotection step. C31H34N6O5. 611.3 (M+l).
[00521] In a microwave vial, the crude intermediate was dissolved in éthanol (3 mL) and 4M hydrochloric acid in dioxane (1 mL) was added. The vial was sealed and heated at 65°C for 1 hour. The reaction mixture was concentrated, filtered and the title compounds was purified via preparatory HPLC to yield a yellow solid.
[00522] C24H22N6O3. 443.1 (M+l). ’H NMR (400 MHz, Methanol-^) δ 8.70 (ddd, J = 5.0, 1.8, 0.9 Hz, IH), 8.03 (td, ./=7.8, 1.7 Hz, IH), 7.90 (dd, J= 9.0, 7.4 Hz, IH), 7.81 (d, J=8.0Hz, IH), 7.53 (ddd, J = 7.6, 4.9, 1.1Hz, IH), 7.02 (d, J= 1.5 Hz, IH), 7.00 (d,J=8.8 Hz, IH), 6.87 (d, J= 7.4 Hz, IH), 6.48 (d, J= 1.5 Hz, IH), 3.06 (s, 3H), 2.28 (s, 3H), 2.10 (s, 3H).
194
Example 190
4-((6-bromo-3-fluoro-2-methylpyridin-4-yI)(hydroxy)(pyridin-2-yl)methyl)-6-(3,5dimethylisoxazol-4-yl)- ΙΗ-benzo [d] imidazoI-2(3H)-one
[00523] To a solution of 2-bromo-5-fluoro-6-methyl-2-pyridine (411 mg, 2.16 mmol) in THF (10 mL) was added BuLi (0.86 mL, 2.16 mmol, 2.5 M in THF) and the solution was stirred at -78 °C for lh. To the solution of tert-butyl 6-(3,5-dimethylisoxazol-4-yl)-2-ethoxy4-picolinoyl-lH-benzo[d]imidazole-l-carboxylate (200 mg, 0.43 mmol) in THF (5 mL) was added the solution of the lithiate and the solution was stirred at -78 °C for lh. Aq NH4CI was 10 added and the solution was extracted with EtOAc (200 mL). The organic solution was washed with brine and dried over Na2ÛS4. Solvent was removed and the residue was dissolved in EtOH (6 mL) with 0.8 mL of 4N HCl in dioxane. The solution was heated at micro wave at 70 °C for lh. Solvent was removed and the residue was purified by HPLC to give 4-((6-bromo-3-fluoro-2-methylpyridin-4-yl)(hydroxy)(pyridin-2-yl)methyl)-6-(3,515 dimethylisoxazol-4-yl)- lH-benzo[d]imidazol-2(3H)-one
[00524] C24Hi9BrFN5O3. MS m/z 523.9 (M+l).
195
Example 191
6-(3,5-dimethylisoxazol-4-yI)-4-((3-fluoro-2-methylpyridin-4-yl)(hydroxy)(pyridin-2yl)methyl)-lH-benzo[d]imidazol-2(3H)-one
[00525] A mixture of 4-((6-bromo-3-fluoro-2-methylpyridin-4-yl)(hydroxy)(pyridin-2yl)methyl)-6-(3,5-dimethylisoxazol-4-yl)-lH-benzo[d]imidazol-2(3H)-one obtained above and Pd/C (5 % 100 mg) in MeOH (10 mL) was stirred under H2 balloon for lh. Reaction mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by HPLC to give 6-(3,5-dimethylisoxazol-4-yl)-4-((3-fluoro-2-methylpyridin-410 yl)(hydroxy)(pyridin-2-yl)methyl)-lH-benzo[d]imidazo 1-2(3 H)-one.
[00526] C24H20FN5O3. MS m/z 446.02 (M+l). !H NMR (400 MHz, Methanol-^) δ
8.56 (ddd, J= 5.1, 1.8, 0.9 Hz, IH), 8.42 (d, J=5.6Hz, IH), 8.00 (td, J= 7.8, 1.7 Hz, IH), 7.76 - 7.64 (m, 2H), 7.49 (ddd, J= 7.6, 5.0, 1.1 Hz, IH), 7.02 (d, J= 1.5 Hz, IH), 6.59 (t, J= 1.8 Hz, IH), 2.53 (d, J= 3.0 Hz, 3H), 2.30 (s, 3H), 2.13 (s, 3H).
Example 192
4-(3,5-dimethyIisoxazol-4-yl)-2-nitroaniline
Br
NH2
196
[00527] To a mixture of 4-bromo-2-nitro-phenylamine (150 g, 0.691 mol, 1.0 eq) and
3,5-dimethylisoxazole-4-boronic acid pinacol ester (169 g, 0.725 mol, 1.05 eq) in 1,2dimethoxyethane (1.5 L) and water (700 mL) were added PdCh(dppf) (56 g, 69 mmol, 0.1 eq) and K2CO3 (190 g, 1.38 mol, 2.0 eq). The reaction mixture was heated at 95 °C ovemight. The reaction mixture was diluted with EtOAc (3 L), washed with brine (2 x 500 mL). The organic solvent was evaporated and the residue was purified with flash chromatography on silica (PE/EA = 10:1 - 1:1) to give 150 g 4-(3,5-dimethylisoxazol-4-yl)-2-nitroaniline as a red solid.
[00528] C11H11N3O3. 234.2 (M+l)
Example 193
4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6-nitroaniIine
N-O AK | n-o JA | |
l2/AgNO3 | A | |
EtOH | || J | |
o2n γ | O2N | |
nh2 | nh2 |
[00529] To a solution of compound 4-(3,5-dimethylisoxazol-4-yl)-2-nitroaniline (334 g, 1.43 mol, 1.0 eq) in éthanol (3.3 L) were added iodine (726 g, 2.8 mol, 2.0 eq) and silver nitrate (485 g, 2.8 mol, 2.0 eq). The reaction mixture was stirred at rt ovemight, filtered, and the filtrate was evaporated to dryness. The residue was dissolved in EtOAc (5 L) and washed with water and brine, and dried over sodium sulfate. The organic solvent was evaporated to give a residue, which was purified by flash column chromatography on silica gel (PE/EA = 4:1-3:1) to give compound 393g of 4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6-nitroaniline as an orange solid.
[00530] C11H10IN3O3. 360.1 (M+l)
197
Example 194
5-(3,5-dimethylisoxazoI-4-yl)-3-iodobenzene-l,2-diamine
N-O
NH2
[00531] To a solution of 4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6-nitroaniline (393 g,
1.09 mol, 1.0 eq) in éthanol (4 L) was added tin (II) chloride (1.03 kg, 5.46 mol, 5.0 eq). The reaction mixture was stirred at 75 °C for 10 h. The solvent was evaporated and the residue was dissolved in EtOAc (5 L), washed with 1 N sodium hydroxide (3 x 1 L) (the solid precipitated out should be filtered). The organic phase was dried over Na2SO4 and the solvent was removed to give a residue. The residue was purified by flash chromatography on silica (PE/EA = 2:1-3:2) to give 253g of 5-(3,5-dimethylisoxazol-4-yl)-3-iodobenzene-l,2-diamine as a slightly brown solid.
[00532] Ci 1H12IN3O. 330.1 (M+l)
Example 195
6-(3,5-dimethylisoxazol-4-yl)-4-iodo-lH-benzo[d]imidazol-2(3H)-one
N-O
[00533] 5-(3,5-dimethylisoxazol-4-yl)-3-iodobenzene-l,2-diamine (253 g, 0.77 mol,
1.0 eq) was treated with carbonyl diimidazole (187 g, 1.15 mol, 1.5 eq) and DMAP (47 g,
384 mmol, 0.5 eq) in THF (2.5 L) at 80 °C for 16 h. The precipitate was obtained by
198 filtration. The solid was triturated with EA/PE (1/1) to give 197g of 6-(3,5-dimethylisoxazol4-yl)-4-iodo-lH-benzo[d]imidazol-2(3H)-one as a white solid.
[00534] Ci2HioIN302 356.1 (M+l)· Ή NMR (400 MHz, DMSO-J6) δ 10.97 (s, IH),
10.91 (s, IH), 7.23 (s, IH), 5.86 (s, IH), 2.35 (s, 3H), 2.17 (s, 3H).
Example 196
6-(3,5-dimethylisoxazol-4-yl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH· benzo[d]imidazol-2(3H)-one
KOAc/Pd(dppf)CI2 dioxane/120 °C/16h
[00535] A mixture of 6-(3,5-dimethylisoxazol-4-yl)-4-iodo-lH-benzo[d]imidazol2(3H)-one (166 g, 468 mmol 1.0 eq), Pd(dppf)C12 (19 g, 5% mol), KOAc (92 g, 935 mmol, 2 eq) and bispinacolato diboron (237 g, 935 mmol, 2.0 eq) in degassed dioxane (3.5 L) was flushed with nitrogen. The reaction mixture was heated at 120 °C under N2 ovemight. Then the reaction mixture was concentrated and dry-loaded onto silica gel and purified by flash chromatography (PE/EA= 10:l-3:l)to give 72g of 6-(3,5-dimethylisoxazol-4-yl)-4-(4,4,5,5tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-benzo[d]imidazol-2(3H)-one.
[00536] Ci8H22BN3O4. 356.0 (M+l) NMR (400 MHz, DMSO-îZ6) δ 10.78 (s, IH), 9.84 (s, IH), 7.04 (s, IH), 6.97 (s, IH), 2.34 (s, 3H), 2.16 (s, 3H).
199
Example 197
4-(3,5-dimethylisoxazol-4-yl)-2-nitroaniline
Br
NH2
N-O
PEPPSI-Ipr,
Cs2CO3, DME/H2O
120°C
N-O
NH2
[00537] 4-bromo-2-nitroaniline (lg ,4.6 mmol) and 3,5-Dimethylisoxazole-4-boronic acid pinacol ester (2g, 9.2mmol) was added to a solvent mixture of 1,2-dimethoxymethane (12 ml) and water (6 ml). To the above mixture were added PEPPSI-Ipr (312mg, 0.46 mmol) and CsCO.3 (4.5g, 13.8 mmol). The reaction mixture was heated at 120°C for 30 min. The reaction mixture was then diluted with EtOAc (100 ml), washed with bring (50 ml x 2). The organic solvent was evaporated and the residue was dissolved in DCM and purified with flash column chromatography (50% EtOAc/Hexane) to afford 4-(3,5-dimethylisoxazol-4-yl)-2nitroaniline.
Example 198
4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6-nitroaniline
200
[00538] 4-(3,5-dimethylisoxazol-4-yl)-2-nitroaniline (lg, 4.6 mmol) was added to
EtOH (50 ml), to the mixture was added h (l-4g, 5.5 mmol) and AgNCh (0.94g, 5.5 mmol). The reaction mixture was stirred at room température ovemight. The solvent was evaporated and then the residue was dissolved in EtOAc (50 ml) and washed with brine (30 ml x 2). The organic solvent was evaporated and the residue was dissolved in DCM and purified with flash column chromatography (product came out at 35% EtOAc/Hexane) to afford 4-(3,5dimethylisoxazol-4-yl)-2-iodo-6-nitroaniline.
Example 199
5-(3,5-dimethylisoxazoI-4-yI)-3-iodobenzene-l,2-diamine
SnCI2
---------------SsEtOH, 75°C
[00539] 4-(3,5-dimethylisoxazol-4-yl)-2-iodo-6-nitroaniline (0.9g, 2.5 mmol) was added to EtOH (50 ml), to the mixture were added SnCh (2.4g, 12.5 mmol). The reaction mixture was stirred at 75°C for 7h. The solvent was evaporated and then the residue was dissolved in EtOAc (100 ml) and washed with IN NaOH (100mlX3). The organic solvent was evaporated and the residue was dissolved in DCM and purified with combi-flash column chromatography (product came out at 60% EtOAc/Hexane) to afford 5-(3,5dimethylisoxazol-4-yl)-3-iodobenzene-l,2-diamine. LCMS m/z [M+H]+ CIIHI2IN3O requires: 330.00. Found 330.03 'H NMR (400 MHz, CD3OD) δ 2.21 (s, 3H), 2.39 (s, 3H), 7.16 (d, IH), 7.62 (d, IH).
201
Example 200
6-(3,5-dimethylisoxazol-4-yl)-4-iodo-lH-benzo[d]imidazoI-2(3H)-one
O
[00540] A mixture of 5-(3,5-dimethylisoxazol-4-yl)-3-iodobenzene-l,2-diamine (15 g,
45.6 mmol, 1.0 eq), DMAP (2.9 g, 22.7 mmol, 0.5 eq) and carbonyl diimidazole (11.0 g, 68.4 mmol, 1.5 eq) in THF (200 mL) was refluxed for 3 h. The reaction was cooled to room température, purified by flash column chromatography to give a solid, which contained some imidazole and DMAP. The solid was triturated with THF (2x) and filtered to afford 6-(3,5dimethylisoxazol-4-yl)-4-iodo-lH-benzo[d]imidazol-2(3H)-one. LC-MS: 354.0 [M-H]’ ’H NMR (400 MHz, DMSO-î/6) δ 10.9 (br s, 2H), 7.24 (d, J = 1.6 Hz, IH), 6.97 (d, J = 1.6 Hz, IH), 2.37 (s, 3H), 1.78 (s, 3H).
Example 201
Biochemical Alpha Assay
[00541] Binding of the bromodomain BRD4 I to an acetylated histone H4 peptide was measured using a bead based Amplified Luminescent Proximity Homogeneous Assay (ALPHA). The synthetic peptide containing amino acids 1-18 of histone H4 was acetylated at lysine 5, 8, 12, 16 and conjugated to biotin (SGRGACKGGACKGLGACKGGAACKRHGSGSK-biotin) was purchased from Millipore. BRD4_I was expressed and purified from Escherichici coli as an N-terminal Hisâ-tagged protein. Nickel-Chelate ALPHA acceptor beads (Perkin Elmer) were used to specifîcally bind BRD41 and ALPHA streptavidin donor beads (Perkin Elmer) were used because they specifîcally recognized the biotinylated H4 peptide. Binding of BRD41 to the peptide resulted in proximity of the donor and acceptor beads which leads to an increase in ALPHA signal whereas disruption of this protein-peptide interaction with a small molécule inhibitor resulted in a decrease in ALPHA signal. Assays
202 were performed in 50 mM Hepes (pH 7.5), 150 mM NaCl, 0. lmg/ml BSA, 0.01% (v/v) Brij, 0.5% (v/v) DMSO, 200nM H4 peptide and 15nM of BRD41 protein. After an assay reaction time of 60 minutes at 25°C, binding was measured with 20pg/ml streptavidin donor beads and 20pg/ml nickle-chelate accepter beads. ALPHA signal was detected on an Envision plate reader (Ex: 320 nm; Em: 570 nm; Ex time: 180ms). Data were normalized based on a positive (2 μΜ I-BET) and négative (DMSO) controls and IC50 values were calculated from the fit of the dose-response curves to a four-parameter équation. Ail IC50 values represent géométrie mean values of a minimum of four déterminations. These assays generally produced results within 3-fold of the reported mean.
Biochemical HTRF Assay
[00542] Binding of the two tandem bromodomains, BRD4 I and BRD4 2, to an acetylated histone H4 peptide were measured using a homogeneous time resolved fluorescence résonance energy transfer (TR-FRET) assay. The synthetic peptide containing amino acids 1-18 of histone H4 was acetylated at lysine 5, 8, 12, 16 and conjugated to biotin (SGRGACKGGACKGLGACKGGAACKRH-GSGSK-biotin) was purchased from Millipore. BRD4 I and BRD42 were expressed and purified from Escherichia coli as Nterminal Hisô-tagged proteins. An XL665 labeled anti-His antibody (Cisbio) was used to specifically bind BRD4 and a cryptate labeled streptavidin protein was used because it specifically recognized the biotinylated H4 peptide. Binding of BRD4 to the peptide resulted in an increase in FRET signal whereas disruption of this protein-peptide interaction with a small molécule inhibitor resulted in a decrease in FRET signal. Assays were performed in 50 mM Hepes (pH 7.5), 150 mM NaCl, 0.lmg/ml BSA, 0.01% (v/v) Brij, 0.5% (v/v) DMSO and 200nM H4 peptide at the following concentrations for each BRD4 isoform: 60 nM BRD41 and 120 nM BRD4 2. After an assay reaction time of 60 minutes at 25 °C, binding was measured with 2 nM crytptate labeled streptavidin and 10 nM anti-His-XL665 antibody. TRFRET signal was detected on an Envision plate reader (Ex: 320 nm; Em: 615/665 nm; lOOps delay and 200ps read window). Data were normalized based on a positive (2 μΜ I-BET) and négative (DMSO) controls and IC50 values were calculated from the fit of the dose-response curves to a four-parameter équation. Ail IC50 values represent géométrie mean values of a minimum of four déterminations. These assays generally produced results within 3-fold of the reported mean.
203
BRD4-1 Ligand Kl and BRD4-2 Ligand Kl Assays:
[00543] Binding of the two tandem bromodomains, BRD4-I and BRD4-2, to a Cy5 labeled probe/ligand (Compound 201-A) were measured using a homogeneous time resolved fluorescence résonance energy transfer (TR-FRET) assay.
[00544] The labeled ligand specifically binds BRD4-1 and BRD4-2 and can be displaced by a small molécule inhibitor that shares a similar or overlapping binding site. BRD4-I and BRD4-2 were expressed and purified from Escherichia coli as N-terminal HiS6tagged proteins. A Eu-cryptate labeled anti-His antibody (Perkin Elmer) was used to specifically bind BRD4. Binding of BRD4 to the labeled probe/ligand resulted in an increase in FRET signal whereas displacement of this labeled ligand from BRD4 with a small molécule inhibitor resulted in a decrease in FRET signal. Assays were performed in 50 mM Hepes (pH 7.5), 150 mMNaCl, O.lmg/ml BSA, 0.01% (v/v) Brij, 0.5% (v/v) DMSO and lOnM labeled ligand at the following concentrations for each BRD4 isoform: 2 nM BRD4-1 and 0.5 nM BRD4-2. After an assay reaction time of 60 minutes at 25 °C, binding was measured with 2 nM Eu-cryptate labeled anti-His antibody. TR-FRET signal was detected on an Envision plate reader (Ex: 320 nm; Em: 615/665 nm; lOOps delay and 200ps read window). Data were normalized based on a positive (2 μΜ I-BET) and négative (DMSO) controls and IC50 values were calculated from the fit ofthe dose-response curves to a fourparameter équation. Ail IC50 values represent géométrie mean values of a minimum of four déterminations. The IC50 values were converted to Ki values (dissociation constant for BRD4-inhibitor complex) using the Cheng and Prusoff équation for a compétitive inhibitor mode of action. These assays generally produced results within 3-fold of the reported mean.
204
MT-4 Prolifération Assay in 384-well Format
[00545] Compounds were tested in a standardized high-throughput 384-well assay format. Each compound was serially diluted 3-fold in 100% DMSO in polypropylene 384well plates using a Biomek FX Workstation, and 0.4 pL compound added to an assay plate containing 40 pL RPM1 media. Compounds were arranged in a horizontal pattern, with 10 concentrations per compound, and 8 compounds added per plate. Due to low DMSO tolerability, the final DMSO concentration never exceeded 0.5% (v/v). Each assay plate contained 10μΜ Puromycin and 0.5% DMSO in RPMI-1640 as positive and négative controls respectively. MT-4 cells (HTLV-1 transformed, human T lymphoblastoid cells, NIH Aids Reagent program) were added in volumes of 35 pL per well and 2,000 cells per well using a Biotek uFlow Workstation (Biotek, Winooski, VT), and the plates subsequently incubated for 5 days at 37°C in an incubator set at 5% CO2 and 90% humidity.
[00546] After 5 days, 22 pL Cell Titer Glo (Promega) was added to the assay plates with a Biotek uFlow Workstation. Plates were subsequently placed on a Perkin Elmer Envision Plate Reader for 5 minutes before the luminescence signal was read. CC50 values were calculated from the compound concentration that caused a 50% decrease in luminescence signal, a measure of toxicity, and calculated by non-linear régression using Pipeline Pilot software (Accelrys, San Diego, CA).
c-Myc Down Régulation and Viability Assays
[00547] An enzyme linked immunosorbent assay using the Meso Scale Diagnostic (MSD) technology was used to detect levels of c-Myc produced in MM1S cells (ATCC). MM1S cells were cultured in RPMI-1640 media (Coming), supplemented with 10% FBS (Hyclone), 1% penicillin-streptomycin (Cellgro), 2-mercaptoethanol (Gibco) and seeded onto 384-tissue culture treated filter binding plates (Millipore) at a density of 40K cells/well containing titrations of small molécule inhibitors or DMSO (0.4 %) in a volume of 100 pl of media. After an incubation time of 24 hrs, cells were lysed (IX lysis buffer (Thermo) supplemented with protease and phosophatase inhibitor cocktail (Thermo)) and the plates centrifuged (1000 rpm, 1min) to capture c-Myc on MSD plates coated with a monoclonal cMyc antibody (Origene). Assay wells were washed (3X Invitrogen wash buffer) and probed with a polyclonal c-Myc antibody (Abcam) and MSD détection antibody solution in order to detect levels of c-Myc on the MSD platform. c-Myc capture was reported in pg/ml based on
205 a standard curve using recombinant c-Myc protein (Prosci). EC50 values were calculated from the fit of the dose-response curves to a four-parameter équation. Ail EC50 values represent géométrie mean values of a minimum of four déterminations. These assays generally produced results within 3-fold of the reported mean.
[00548] For cell viability in the MM1S cell line, cells were seeded onto 384-tissue culture treated plates (Greiner) at a density of 60K cells/well containing titrations of small molécule inhibitors or DMSO (0.2 %). After 72 hr incubation cells were analyzed for cell viability by addition of CellTiter Glo (Promega) to the assay plates. After 15 min incubation at room température the signal from the viable cells was analyzed on an Envision plate reader (Perkin Elmer). EC50 values were calculated from the fit of the dose-response curves to a four-parameter équation. Ail EC50 values represent géométrie mean values of a minimum of four déterminations. These assays generally produced results within 3-fold of the reported mean.
[00549] Results are shown in Tables 1 and 2. An ‘n/a” indicates that assay was not performed for that compound.
206
Table 1
Compound of Example No. | Structure | BRD4 1ALPH A [nM] | ICso HTBS BRD4-1 HTRF [nM] | ICso HTBS BRD4-2 HTRF |nM] | CCso MT4 384 [nM] | |
1 | N-O Xa | n/a | 1412 | 1068 | 1123.8 | |
0 Pa hnXs2 UN ,- ° x> | ||||||
2 | N-O Xa | 30.8 | 135 | 119 | 18.951 | |
Γι] | ||||||
HN O | 'ΡΓί A\A tj | |||||
3 | N-O Xa | 119.4 | 295 | n/a | 196.26 | |
rîi | ||||||
AA HN J y-NH O | A | |||||
4 | N-O Xa | PA | 37.2 | 119 | 141 | 102.76 |
HN J rNH O | 0 |
207
5 | N-O HN / V 'N ^NH O | 233.5 | 350 | 144 | 232.94 |
6 | N-O HN / jAl ^-NH ο Γ I TN'Me o | 46.8 | 132 | 108 | 53.911 |
7 | N-O HN Γΐίη L^N | 37.3 | 121 | 101 | 17.543 |
8 | N-O JL^ÿX^N HN ΤΎ N o | 240.6 | 511 | 168 | 116.58 |
9 | N-O HM T]f^N ^N\ /Ad O | 270.3 | 497 | 227 | 203.9 |
208
10 | N-O ΗΝ^ΤγΑΐ λ-° Λ° 0 | 196.5 | 313 | 396 | 1027.6 |
11 | Ν-Ο ΗΝ'γ'^ηη )-ο Λ J Ο 1 | 222 | 438 | 174 | 420.62 |
12 | Ν-Ο HN /^ΙΙ Ο ο | 232.7 | 316 | 314 | 761.13 |
13 | Ο-Ν HN ^r-NH ο ί| 1 Ιζ^Ν | 45.2 | n/a | n/a | 51.551 |
14 | Ο-Ν X JL ΗΝ'ΤΤι^ V-NH 1· J oF [|Γ Κ^Ν | 14 | n/a | n/a | 9.543 |
209
1015.P2F
Table 2
Compound of Example No. | Structure | BRD4-1 Ligand Kl [nM] | BRD4-1 Ligand K2[nM] | CCso MT4 384 [nM] | cMYC ECso [nM] | |
23 | N-O HN /AnH AH A' O | 12.9 | 3.0 | 9.1 | 13.2 | |
33 | O-N AA i iC HN7 / X ° C | F ιΊΐ A | 14.1 | 5.3 | 29.1 | 176.5 |
36 | O-N AA c HN / +NH NJ 0 | F fil N iT H| ) | 14.1 | 5.3 | 29.1 | 176.5 |
38 | N-O aA ril hn j 0 C | ΑΊϊ ohT H J-N F ? F | 7.8 | 4.4 | 29.7 | 84.7 |
39 | N-O Al F\ 1 OH HN'/'X]—Y Af Ah An ° U F | 11.8 | 5.9 | 42.1 | 127.7 |
295287.1
210
1015.P2F
211
295287.1
1015.P2F
55 | N-O XX | 14.5 | 18.2 | 41.0 | 141.2 | ||
L II °h Ν=λ | |||||||
HNZ Ύ' A o | AJ N | —Cl | |||||
JJ | |||||||
Cl | |||||||
56 | N-O XX | 6.0 | 3.6 | 24.8 | 40.9 | ||
J- F L Ie | F | ||||||
HN^ Ά oW N<^ | ^N F | ||||||
73 | O-N x> | 34.2 | 24.0 | 61.0 | 153.6 | ||
ώ HN T ^NH O | aX X | N | |||||
133 | N-O XX | 40.3 | 15.8 | 25.5 | 44.3 | ||
|ίη OHN^ | |||||||
HnXXtX ANH An o f j) | J | ||||||
134 | N-O | 69.9 | 5.3 | 19.1 | 74.4 | ||
AA- | |||||||
fil c | N= | ||||||
HN T ° c | X_ X | J | |||||
140 | N-O χχ | 35.2 | 43.8 | 78.3 | 216.7 | ||
X hn γ VNV ° ζ | )H r J | F F |
212
295287.1
1015.P2F
143 | N-O AA | 29.3 | 8.0 | 20.4 | 118.2 | ||
A HN J aa | DH \ Si | ||||||
144 | N-O AA | 7.7 | 2.7 | n/a | n/a | ||
c HN f YNH J ° ζ. | )H r Ai | ||||||
147 | N-O ΛΑ | 81.6 | 16.0 | 56.5 | 107.3 | ||
AS hn j γ~~ J^-NH OH N- O | o | ||||||
149 | N-O AA | 17.3 | 4.6 | 17.5 | 73.8 | ||
AO | |||||||
/AxA. / HN 7 OA y-NH OH N. O | o | ||||||
169 | N-O AA | 62.0 | 33.5 | 41.4 | 128.2 | ||
A | N^ | l) | |||||
zA-î^A HN 7 YNV o | KOH S | n | |||||
A | JJ |
213
295287.1
1015.P2F
[00550] While the foregoing description describes spécifie embodiments and aspects, those with ordinary skill in the art will appreciate that various modifications and alternatives can be developed. Accordingly, the particular embodiments and aspects described above are meant to be illustrative only, and not to limit the scope of the invention, which is to be given the full breadth of the appended claims, and any and ail équivalents thereof.
Claims (20)
- We claim:A compound of Formula (I)N-O // A kxO (I) whereinRla and RIb are each independently Ci-Cô alkyl, Ci-Cé alkoxy, Ci-Cô haloalkyl, Ci-Cô haloalkoxy, Ci-Cô hydroxyalkyl, C3-C6 cycloalkyl, or CH2-C3-C6 cycloalkyl;R2a and R2b are each independently H or halogen;R3 isC5-C10 aryl, C5-C10 heteroaryl, or C5-C10 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or-S(O)2NHR4, wherein R4 is Ci-Cë alkyl or C3-C7 cycloalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or a moiety of the formula whereinR6 is H, OH, or halogen; and R7 and R8 are each independently Ci-Cô alkyl, C2-Cô alkenyl, C2-Cô alkynyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C5-C12 aryl, C5-C12 heteroaryl, or C5-C12 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; orR6 is H, Ci-Cô alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, phenyl, naphthyl, or C3-C12 heteroaryl; and R7 and R8 together form a Ci-Cô alkylidene group having a double bond with the carbon to which each of R6, R7, and R8 are bound wherein each of the Ci-Cô215295287.11015.P2F alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C3-Cô cycloalkyl, phenyl, naphthyl, or C3-C12 heteroaryl groups is optionally substituted with from 1 to 5 R20 groups;X is N-Q, or O;Q is H, C1-C3 alkyl, C1-C3 haloalkyl, benzyl or substituted benzyl;each R20 is independently Ci-Cô alkyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, C3-Cô heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, halogen, oxo, -ORa, -C(O)Ra, C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, NRaC(O)ORb, -S(0)o-2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or-NO2, wherein each Ci-Cô alkyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, C3-Cô heterocyclic, C5-C12 aryl, C5-C12 heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, -S(0)o-2Ra, S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2;each Ra and Rb is independently H; or Ci-Cô alkyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, C3-Cô heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, each of which is optionally substituted with from one to five R21; or Ra and Rb together with the atoms to which they are attached form a heterocycle, and;each R21 is independently Ci-Cô alkyl, C3-G5 cycloalkyl, Ci-Cô heteroalkyl, C3-Cô heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, or halogen;or a pharmaceutically acceptable sait thereof.
- 2. A compound of claim 1, of Formula (la)N-O whereinR3 isC5-C10 aryl, C5-C10 heteroaryl, or C5-C10 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or216295287.11015.P2F-S(O)2NHR4, wherein R4 is Ci-Cô alkyl or C3-C7 cycloalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or a moiety of the formula whereinR6 is H, OH, or halogen; and R7 and R8 are each independently Ci-Cô alkyl, C2-Cô alkenyl, C2-Cô alkynyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C5-C12 aryl, C5-C12 heteroaryl, or C5-C12 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or R6is H, Ci-Cô alkyl, C2-Cô alkenyl, C2-Cô alkynyl, C3-C6 cycloalkyl, phenyl, naphthyl, or C3-C12 heteroaryl; and R7 and R8 together form a Ci-Cô alkylidene group having a double bond with the carbon to which each of R6, R7, and R8 are bound wherein each of the Ci-Cô alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C3-C6 cycloalkyl, phenyl, naphthyl, or C3-C12 heteroaryl groups is optionally substituted with from 1 to 5 R20 groups;Q is H, C1-C3 alkyl, C1-C3 haloalkyl, benzyl or substituted benzyl;each R20 is independently Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, halogen, oxo, -ORa, -C(O)Ra, C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, NRaC(O)ORb, -S(0)o-2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2, wherein each Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, -S(0)o-2Ra, S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2;each Ra and Rb is independently H; or Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aiyl, C5-C12 heteroaryl, each of which is optionally substituted with from one to five R21; or Ra and Rb together with the atoms to which they are attached form a heterocycle, and;217295287.11015.P2F each R21 is independently Ci-Cô alkyl, Cî-Cô cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, or halogen;or a pharmaceutically acceptable sait thereof.
- 3. A compound of claim 1, of Formula (Ib)N-O 0 (Ib) whereinR3 isC5-C10 aryl, C5-C10 heteroaryl, or C5-C10 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or-S(O)2NHR4, wherein R4 is Ci-Cô alkyl or C3-C7 cycloalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; or a moiety of the formula whereinR6 is H, OH, or halogen; and R7 and R8 are each independently Ci-Cô alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C5-C12 aryl, C5-C12 heteroaryl, or C5-C12 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups; orR6is H, Ci-Cô alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cj-Cô cycloalkyl, phenyl, naphthyl, or C3-C12 heteroaryl; and R7 and R8 together form a Ci-Cô alkylidene group having a double bond with the carbon to which each of R6, R7, and R8 are bound wherein each of the Ci-Cô alkyl, C2-Cô alkenyl, C2-Cô alkynyl, C3-C6 cycloalkyl, phenyl,218295287.1 naphthyl, or C3-C12 heteroaryl groups is optionally substituted with from 1 to 5 R20 groups;1015.P2F each R20 is independently Ci-Cô alkyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, C3-Cô heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, halogen, oxo, -ORa, -C(O)Ra, C(O)ORa, -C(O)NRaRb, -OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, NRaC(O)ORb, -S(0)o.2Ra, -S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or -NO2, wherein each Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-C12 aryl, C5-C12 heteroaryl is optionally substituted with from one to five halogen, oxo, -ORa, -C(O)Ra, -C(O)ORa, -C(O)NRaRb, OC(O)NRaRb, -NRaRb, -NRaC(O)Rb, -NRaC(O)ORb, -S(O)0-2Ra, S(O)2NRaRb, -NRaS(O)2Rb, -N3, -CN, or-NO2;each Ra and Rb is independently H; or Ci-Cô alkyl, C3-C6 cycloalkyl, Ci-Cô heteroalkyl, C3-C6 heterocyclic, C5-Ci2 aryl, C5-C12 heteroaryl, each of which is optionally substituted with from one to five R21; or Ra and Rb together with the atoms to which they are attached form a heterocycle, and;each R21 is independently Ci-Cô alkyl, C3-Cô cycloalkyl, Ci-Cô heteroalkyl, C3-Cô heterocyclic, C5-C12 aryl, C5-C12 heteroaryl, or halogen;or a pharmaceutically acceptable sait thereof.
- 4. A compound of any of claims 1-3, wherein R3 is C5-C10 aryl, C5-C10 heteroaryl, or C5-C10 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups.
- 5. A compound of any of claims 1-3, wherein R3 is a moiety of the formula wherein R6 is H, OH, or halogen; andR7 and R8 are each independently Ci-Cô alkyl, C2-Cô alkenyl, C2-Cô alkynyl, C3Cô cycloalkyl, Ci-Cô heteroalkyl, C5-C12 aryl, C5-C12 heteroaryl, or C5-C12 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups.219295287.11015.P2F
- 6.A compound of claim 5, wherein R6 is OH.
- 7. A compound of claim 5, wherein R7 and R8 are each independently Ci-Cô alkyl, Cî-Cô cycloalkyl, Ci-Cô heteroalkyl, C5-C12 aryl, C5-C12 heteroaryl, or C5-C12 heteroarylalkyl, each of which is optionally substituted with from 1 to 5 R20 groups.
- 8. A compound of claim 5, wherein R7 and R8 are each independently Ci-Cô alkyl, Cô aryl or Cô heteroaryl, each of which is optionally substituted with from 1 to 5 R20 groups.
- 9. A compound of claim 5, wherein R7 and R8 are each independently Cô aryl or Cô heteroaryl, each of which is optionally substituted with from 1 to 5 R20 groups.
- 10. A compound of claim 5, wherein R7 and R8 are each independently Ci-Cô alkyl, each of which is optionally substituted with from 1 to 5 R20 groups.
- 11. A compound chosen from the following list:N-O220295287.11015.P2F5 5 5 5
- 12. A compound chosen from the following list:221295287.11015.P2FN-ON-ON-OOFx OH //FFOH //N-OVN-ON-ON-OOOH //N-O //HN f NH o7N-OOH •FΟ-ΝMHN T ^NH o7N-OHN ]YNH oN-ON= //HNNH //ClClHNOHF +FFN-ONHOH N4Ά hn γ kNHO222295287.11015.P2F
- 13. A pharmaceutical composition comprising a compound of any of claims 1-12, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier.
- 14. A use of a compound of any of claims 1-12 for the treatment of a human having a disease or condition responsive to the inhibition of a bromodomain-containing protein.
- 15. A use of a compound of any of claims 1-12 for the manufacture of a médicament for the treatment of a human having a disease or condition responsive to the inhibition of a bromodomain-containing protein.
- 16. The use of any of claims 14 or 15, wherein wherein the bromodomain-containing protein is BRD4.
- 17. The use of any of claims 14 or 15, wherein the disease or condition is a solid tumor of the colon, rectum, prostate, lung, pancréas, liver, kidney, cervix, stomach, ovaries, breast, skin, brain, méningés, or central nervous system.
- 18. The use of any of claims 14 or 15, wherein the disease or condition is multiple myeloma.
- 19. The use of any of claims 14 or 15, wherein the disease or condition is a B-cell lymphoma.223295287.11015.P2F
- 20. The use of any of claims 14 or 15, wherein the disease or condition is diffuse large B-cell lymphoma or Burkitt’s lymphoma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/805,995 | 2013-03-28 | ||
US61/860,230 | 2013-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA17636A true OA17636A (en) | 2017-05-15 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9255089B2 (en) | Benzimidazolone derivatives as bromodomain inhibitors | |
JP6726677B2 (en) | Substituted 2-H-pyrazole derivatives as anticancer agents | |
DK3057959T3 (en) | INHIBITORS FOR DNA PK | |
EP2841428B1 (en) | Dna-pk inhibitors | |
JP7373992B2 (en) | Substituted pyrazole compounds and methods of their use for the treatment of hyperproliferative diseases | |
RU2615130C2 (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
JP5989805B2 (en) | Methyl group-modifying enzyme regulator, composition and use thereof | |
TWI527800B (en) | 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof | |
AU2014262622A1 (en) | Benzimidazole derivatives as bromodomain inhibitors | |
AU2014337208A1 (en) | DNA-PK inhibitors | |
AU2015369712A1 (en) | Mutant IDH1 inhibitors useful for treating cancer | |
AU2015276699B2 (en) | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor | |
JP6283688B2 (en) | Novel pyrazole-substituted imidazopyrazine as casein kinase 1D / E inhibitor | |
WO2016054807A1 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
OA17636A (en) | Benzimidazolone derivatives as bromodomain inhibitors | |
CN116143708A (en) | Polysubstituted benzazepine heteroaryl derivative and application thereof | |
JP2022549678A (en) | Heterocyclic derivative and use thereof | |
JP2024526096A (en) | Novel compounds as protein kinase inhibitors |